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Chapter 1 General Introduction 
1.1 Neuropeptide Y 
Neuropeptide Y (NPY) is one of the most abundant neuropeptides in the central and 
peripheral nervous system.1 It was first isolated by Tatemoto et al. from porcine brain 
in 1982.2 Together with the homologous peptides pancreatic polypeptide (PP) and 
peptide YY (PYY), NPY belongs to the neuropeptide Y family.3 For all these peptides, 
consisting of 36 amino acids, C-terminal amidation is essential for biological activity.4 
The sequence of NPY is highly conserved in various species.5 The tertiary structure of 
turkey PP has been elucidated by crystallography.6-7 In this crystal structure the N-
terminal residues 1-8 form a polyproline-like helix, followed by a β-turn (9-13) and an 
α-helical region (14-31). The C-terminal pentapeptide (32-36), bearing the most 
crucial residues for receptor recognition, appears rather unordered and flexible. This 
hairpin-like conformation, the so-called PP-fold, is stabilized by hydrophobic 
interactions between the polyproline-like N-terminus and the α-helix. Due to high 
sequence homology of NPY to PP (50 %) this tertiary structure was also proposed for 
NPY (cf. Figure 1.1).8 
Figure  1.1. Tertiary structure of porcine NPY 
according to Allen.8 The residues are arranged 
according to the crystal structure of the homolog 
avian PP. 
 
The tertiary structure of NPY in solution was intensively studied by several groups 
using NMR techniques and CD spectroscopy as well as FRET based approaches. These 
studies reported contradictory findings, as some confirmed the PP-fold structure9-11, 
while others did not find the PP-fold as prevalent conformation of NPY in solution, 
e.g. due to the formation of dimeric structures through α-helical contacts and 
conformations with non-helical and flexible N-termini.12-16 However, conformational 
studies in solution do not permit any definite conclusions with regard to the receptor-
bound conformation due to unphysiologically high concentrations of NPY in the 
millimolar range. Furthermore, for instance, in NMR studies the pH was adjusted to 
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values considerably lower than 7.4 in order to increase the solubility of NPY. 
Considering the results from CD spectroscopic measurements at various concentra-
tions and pH values, different conformations of NPY were observed in a dynamic 
equilibrium, and the PP-fold conformation is probably favored under physiological 
conditions.17 Furthermore, peptide-lipid interactions at the surface of the cell mem-
brane were discussed to support the formation of the active conformation of NPY (cf. 
Figure 1.2).18-20 
Figure  1.2. The structure of pNPY bound to micelles 
according to Bader et al.18 The N-terminal part is 
flexible, while the C-terminal α-helix interacts with the 
membrane surface. Structural data are obtained from 
the Protein Data Bank (PDB access code 1F8P, 
http://www.pdb.org/pdb/home/home.do). 
In the peripheral nervous system NPY is expressed in sympathetic neurons, where it 
is stored together with noradrenaline and functions as cotransmitter.21 In the central 
nervous system (CNS) NPY was found in the basal ganglia, hippocampus, amygdala 
and the hypothalamus. In the CNS, NPY also acts as cotransmitter, e.g., together with 
noradrenaline, agouti-related peptide (AGRP)22 or GABA23. 
NPY is primarily synthesized and released by neurons. The biologically active peptide 
is derived from the 97-amino acid precursor pre-pro-NPY following at least four post-
translational enzymatic events (Figure 1.3).24-27 The 69 residue containing pro-NPY is 
produced after removal of the signal-peptide (29 amino acids). Then, pro-NPY 
undergoes cleavage by several enzymes such as prohormone convertase 1 and 2 
(PC1+2) and carboxypeptidase E (CPE), thereby generating the mature peptide. 
 
 
 
Pre-pro-NPY 
 
 
 
Pro-NPY 
 
 
 
 
NPY 
Figure  1.3. Biosynthesis of neuropeptide Y, adapted from von Hörsten et al.28; aa: amino acid. The arrows 
schematically present the cleaving sites. 
Signal-peptide
29 aa
peptide
36 aa
Gly-Lys-Arg C-peptide
27 aa
peptide
36 aa
Gly-Lys-Arg C-peptide
27 aa
peptide
36 aa
C-peptide
27 aa
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NPY possesses a broad range of biological effects including stimulation of food 
intake,29 inhibition of glutamatergic excitatory synaptic transmission,30 memory 
processes,31 hypothermia,32 anxiolysis,33 etc. Moreover, NPY is considered to be 
involved in various pathological processes such as dysregulation of food intake and 
obesity,34-37 mood disorders38-39 and alcoholism.40 
1.2 Mammalian NPY Receptor Subtypes 
The diverse biological effects of NPY are mediated by the activation of different 
receptor subtypes which are all members of the larger superfamily of G-protein 
coupled receptors (GPCRs). In mammals five neuropeptide Y receptor subtypes have 
been described, denoted as Y1, Y2, Y4, Y5, and y6.41-48 The y6 receptor was found to be 
functional in mice, but is a non-functional pseudogene in most mammalian species. In 
the rat genome it is missing at all.49 In Table 1.1 an overview of the binding profiles, 
the localization and the physiological role of the mammalian NPY receptor subtypes is 
given. 
Table  1.1. Overview of binding profile, localization and physiological role of the mammalian NPY receptor 
subtypes.27, 50-53 
 Binding Profile Localization Physiological Role 
Y1 
NPY ≈ PYY ≈ [L31, P34]NPY > 
NPY2-36 > NPY3-36 ≥ PP > 
NPY13-36 
smooth vascular muscles 
(postjunctionally), cerebral 
cortex, hypothalamus, co-
lon, human adipocytes 
Involved in regulation of 
blood pressure, seizures 
and food intake, anxiety, 
pain sensitivity, depres-
sion, angiogenesis, alcohol 
consumption 
Y2 
NPY ≥ NPY2-36 ≈ NPY3-36 ≈ 
NPY13-36 >> [L31, P34]NPY 
hippocampus, hypothal-
amus, nerve ends, (pre 
and postjunctional), renal 
tubules 
Involved in regulation of 
blood pressure, seizures 
and food intake, anxiety, 
pain sensitivity, depres-
sion, angiogenesis, hypo-
thalamic regulation of 
bone formation, regula-
tion of GI motility 
Y4 PP > PYY ≥ NPY > NPY2-36 
brain, coronary arteries, 
ileum 
food intake, regulation of 
GI motility 
Y5 
NPY ≈ PYY ≈ NPY2-36 > hPP 
> NPY13-36 > rPP 
hypothalamus 
food intake, seizures, 
anxiety 
y6 
NPY ≈ PYY ≈ [L31, P34]NPY 
>> PP54 or PP > [L31, 
P34]NPY > NPY ≈ PYY43 
cardiac and skeletal 
muscles 
no function in humans 
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1.2.1 The Y1, Y4 and Y5 Receptor 
The 384 amino acids containing Y1R was the first NPY receptor to be cloned in 1992. 
The functionality of the expressed Y1R was demonstrated by inhibition of adenylyl 
cyclase (AC) and mobilization of intracellular calcium. All mammalian Y1Rs cloned thus 
far display 90-95 % homology with the human Y1R (hY1R).55 The Y1R exhibits a high 
tendency to agonist stimulated internalization, as demonstrated by means of 
radioligand binding,56 confocal microscopy57 and GFP tagged Y1R.58 Interestingly, the 
pseudopeptide Y1R antagonist GR231118 is able to induce long-lasting disappearance 
of cell surface Y1Rs through a mechanism distinct from the classical endocytot-
ic/recycling pathway.59 
 
Sequence homology screening using a Y1R probe led to the isolation of a new human 
NPY receptor cDNA, encoding for the Y4 receptor (Y4R).47, 60-61 A unique feature of the 
Y4R is a high affinity for PP, in contrast to NPY and PYY, which exhibit low affinities for 
this receptor. Therefore, the Y4R is also referred to as PP receptor. Sequence 
homology between human and other species Y4Rs is one of the lowest (less than 
75 %) reported for orthologous GPCRs of different mammalian species.49 Additionally, 
the human Y4R (hY4R) has higher homology with hY1R (43 %) than human Y2 receptor 
(hY2R; 34 %).62 Moreover, there are contrary observations in terms of receptor inter-
nalization.56, 63 
 
NPY is one of the most potent orexigenic agents and this effect was proposed to be 
mediated by an atypical Y1R or “feeding receptor”.64-65 The pharmacological profile of 
an NPY receptor cloned from human and rat tissues was found to be similar to that of 
this atypical feeding receptor and classified as the Y5 receptor subtype (Y5R).41, 45 In 
comparison with other NPY receptor subtypes, this 446 amino acid protein has a very 
long third intracellular loop with more than 130 amino acids and an unusually short 
C-terminus. Additionally, sequence homology between the Y5R and other NPY 
receptors is very low (≈ 30 %).49, 55 Lastly, rapid association of β-arrestin 2 with the 
Y5R was observed after agonist stimulation, suggesting fast internalization similar to 
the Y1R.66 
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1.2.2 The NPY Y2 Receptor 
In 1986, the Y2 subtype was pharmacologically characterized as a predominantly 
presynaptic NPY/PYY receptor.4 The cloned hY2R consists of 381 amino acids and has 
only ≈ 30 % identity to the Y1R and the Y4R, respectively.42, 48, 61, 68-69 However, high 
sequence homology (90-95 %) between species was observed for various Y2Rs.49, 55 
Activation of the Y2R leads to an inhibition of AC70 and in rat neurons to an inhibition 
of Ca2+ influx via N-type channels71-72. The human glioblastoma cell line LN319 proved 
useful in defining Y2-mediated pathways, since these cells exclusively express this NPY 
receptor subtype.73 Herein, NPY inhibits 
forskolin-induced cAMP accumulation and 
stimulates an increase in intracellular Ca2+ via 
pertussis toxin-sensitive pathways.74 Further-
more, the Y2R mediates the activation of 
protein kinase C (PKC) in human ciliated cells.75 
Finally, the Y2R was also shown to activate 
MAPK signal transduction through a Gi protein 
and via PI-3 kinase.76 The different signaling 
pathways are summarized in Figure 1.4. 
The Y2R internalization process was a matter of 
controversy over the past years. Desensitiza-
tion of the Y2R after stimulation with NPY was 
observed in LN319 cells,74 but unlike the Y1R, 
the Y2R has not been reported to internalize 
after prolonged agonist excitation56, 58 or it was 
reported to internalize very slowly.73 However, 
mutagenesis studies recently revealed that substitution of either His155 or His159 by 
Pro in the intracellular loop 2 (ICL2) can lead to an accelerated internalization.77 
Notably, the postulated regulation of the Y2R internalization by its ICL2 is inconsistent 
with the most recent findings on Y1/Y2R chimeras, revealing putative inhibitory 
interactions within the ICL3 and the C-terminal tail of the native Y2R that reduce 
internalization.78 In the meantime, several groups confirmed rapid Y2R inter-
nalization.79-82 
1.2.3 The Y2R in Health and Disease 
The high sequence homology of Y2Rs in mammals reflects the involvement of the Y2R 
in critical developmental and metabolic events. Thus, the Y2R is also involved in a 
variety of human diseases such as epilepsy, obesity and cancer. Especially, the role of 
the NPY receptor family in appetite regulation has received intense attention in 
recent years,83 as obesity has emerged as one of the most serious major human 
health concerns in the present and future84. Herein, the Y2R appeared as interesting 
Figure  1.4. The neuropeptide Y Y2 receptor 
and its intracellular signaling pathways, 
adapted from Brumovsky et al.67 
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target as numerous studies reported reduced hunger and food intake in humans after 
application of the moderately Y2R selective agonist PYY(3-36).85-86 The potential 
benefits of Y2 and Y4R agonism for the treatment of obesity resulted in Y2/Y4 dual 
agonists developed by 7TM Pharma. The most promising peptide was tested 
successfully in Phase I/II trials and is currently under further investigation proving the 
potential of the Y2R as anti-obesity drug target.37 Furthermore, Y2R agonism was 
observed to be neuroprotective, presumably, via the reduction of glutamate release. 
Thus, the Y2R is discussed as a potential drug target in seizures and epilepsy.87 
Moreover, wound healing is reduced in Y2 knock-out mice.88 Further functions of the 
Y2R which are related to pathological processes were recently summarized.69 
Besides its physiological implications and potential role in diverse dysregulated 
physiological processes, the Y2R attracted strong attendance on its involvement in 
oncogenesis and has recently been predicted as tumor marker.89 A remarkably high 
expression was found in various human brain tumors and mastocarcinoma.90 Blocking 
the Y2Rs led to an inhibition of neuroblastoma growth in vivo, emphasizing the 
possible application of selective and potent Y2R antagonists in cancer therapy.91 
Recently, a carbaborane modified NPY analog was prepared for potential application 
in cancer treatment (boron neutron capture therapy).92 Thus, the Y2R is considered to 
be a promising target in tumor therapy and imaging, respectively. 
1.3 NPY Receptor Ligands 
1.3.1 NPY Y1, Y4 and Y5 Receptor Antagonists 
In the last two decades, a multitude of highly potent and selective non-peptidic Y1R 
antagonists with affinities in the nanomolar and subnanomolar range have been 
developed, including BIBP 3226, which is potent and selective except for a moderate 
affinity for the Neuropeptide FF receptor.93 A selection of Y1R antagonists is shown in 
Figure 1.5. 
 
Recently, an analog of the C-terminus of NPY, the peptide VD-11, was reported to act 
as a competitive antagonist at the Y4R.94 However, high-affinity non-peptide Y4R 
ligands are not known so far. The acylguanidines UR-AK49 and UR-PI284 (Figure 1.6) 
which were designed as histamine H2 and H4 receptor ligands, respectively, proved to 
be weak Y4R antagonists.95-96 These compounds may serve as lead structures towards 
potent small molecule antagonists for the Y4R.53 
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Figure  1.5. Examples of non-peptidic selective Y1R antagonists. a Rudolf et al.97, b Wieland et al.98, c Kanatani et 
al.99, d Kanatani et al.100, e Antal-Zimanyi et al.101, f Kameda et al.102 
 
Figure  1.6. Structures of UR-AK49 and UR-PI284, weak Y4R antagonists; a Binding affinity determined in a flow 
cytometric competition binding assay at CHO-hY4R-Gαqi5-mtAEQ cells.103 b Antagonistic activity determined in a 
steady-state GTPase assay at hY4R containing membranes (hY4R + Gαi2 + Gβ1γ2 + RGS4).96 
In case of the Y5R, the situation is similar as for the Y1R. The search for new anti-
obesity drugs led to numerous highly potent and selective non-peptidic antagonists 
with broad structural diversity. Some of these compounds have entered into clinical 
trials for the treatment of obesity. MK-0557 (Merck & Co., Inc.) was tested in phase II 
trials for obesity, but it was withdrawn due to lacking clinically meaningful effects 
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despite its effects on weight loss.37 A selection of Y5R antagonists with affinities in the 
low nanomolar range is given in Figure 1.7. 
 
 
Figure  1.7. Exemplary structures of selective non-peptidic Y5R antagonists. a Criscione et al.104, b Kanatani et 
al.105, c Erondu et al.106, d Sato et al.107, e Walker et al.108. 
1.3.2 NPY Y2R Ligands 
Non-peptide small molecule NPY receptor agonists are severely lacking as 
pharmacological tools and potential drugs. Despite many efforts none have been 
reported to date. However, several Y2R selective peptide agonists have been 
identified in the past. Especially, truncated analogues of NPY and PYY, such as 
NPY(13-36), PYY(3-36), PYY(22-36) and AcPYY(22-36) exhibited high potency and 
moderate to high selectivity for the Y2R.109-112 Currently, the development of novel 
truncated PYY analogs, such as modified PYY(22-36) in case of BT-48113, branched 
PYY(3-36) derived ligands114 and substitution of the OH-group of the C-terminal 
tyrosinamide in PYY(3-36) with a halogen or an amine115 seems to be the most 
promising approach for further improvement of the selectivity profile of Y2R agonists. 
 
First approaches to the design of Y2R antagonists were also based on truncated NPY 
analogs.116 In 1999, the L-arginine derivative BIIE 0246 was reported as the first highly 
selective non-peptide Y2R antagonist with a one-digit nanomolar affinity.117 The 
application of BIIE 0246 for the characterization of the Y2R revealed a more detailed 
picture of the receptor´s role in pathological processes. Hence, the disclosed 
potential of the Y2R as drug target for several major diseases led to an intensified 
search for small molecules as Y2R antagonists in pharmaceutical companies, 
especially with the help of high throughput screening (HTS). The structures of the 
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“pioneer” BIIE 0246 and more recent examples for the successful development of 
small Y2R antagonists are summarized in Figure 1.8. 
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Figure  1.8. Structures of the most potent non-peptide Y2R antagonists described in literature to date. a Doods et 
al.117, b Bonaventure et al.118, c Andres et al.119, d Shoblock et al.120, e Lunniss et al.121, f Lunniss et al.122, 
g Brothers et al.123. 
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The first screening hits with moderate antagonism at the Y2R were published by 
Andres et al. (Bristol-Myers Squibb; BMS)119 and Bonaventure et al. (Johnson & 
Johnson; JNJ)118, respectively. However, it was not before 2009 that small molecules 
with Y2R binding affinities in the low nanomolar range were identified. JNJ-31020028, 
a selective brain penetrant antagonist showed an increased noradrenaline release in 
the hypothalamus in rats. Yet, the compound was found to be ineffective in a variety 
of anxiety models although it normalized food intake in stressed animals.120 An HTS 
campaign by GlaxoSmithKline (GSK) revealed spiropiperidines 1.3 and 1.4 with im-
proved physicochemical profiles. Compound 1.4 was proposed to be the most 
promising candidate for further in vivo target validation studies despite its lower 
affinity due to excellent solubility and brain tissue binding.122 Lastly, Brothers et al. 
described four structurally diverse compounds with nanomolar binding affinities at 
the Y2R (SF-11, SF-21, SF-31 and SF-41). All of them are able to cross the blood-brain-
barrier and furthermore, selectivity versus 35 GPCRs, two ion channels and three 
transporters was reported.123 
1.4 Bioisosteres 
The design of bioisosteres introduces certain structural changes that should be 
beneficial regarding various properties such as size, electronic distribution, polarity, 
lipophilicity, pKa, etc. The concept of bioisosterism is versatile in use improving 
potency, enhancing selectivity, altering physicochemical properties, or altering 
metabolization and reducing potential toxicity, respectively. The term bioisosterism is 
subdivided into two broad categories: classical and non-classical. Classical 
bioisosteres are atoms or functional groups of the same valence (e.g. -F, -OH, -NH2, 
-CH3) and ring equivalents.124 Non-classical bioisosteres extend the concept to 
structural elements that exhibit a more sophisticated form of biochemical mimicry, 
relying upon functionality. Such modifications can differ quite substantially in 
electronic, physicochemical and/or steric properties from the functionality being 
emulated. Hence, a replacement that successfully occurs in a series of compounds 
addressing a certain target will not necessarily be successful in another class of 
compounds acting through another receptor.125-126 
Recent applications of bioisosteres in drug design focus on the newer non-classical 
approach. For instance, hydroxamic acids are often exchanged in biologically active 
compounds in order to reduce the toxic potential. The CHF2 moiety proved to be well 
suited as a replacement of the hydroxy group in cyclic hydroxamic acids evaluated in 
a series of dual inhibitors of cycloxygenase-2 and 5-lipoxygenase.127 
Furthermore, isosteres of carboxylic acid have been studied extensively with the aim 
to improve membrane permeability and enhance pharmacokinetic properties (for a 
synopsis see Figure 1.9).128-131 
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Figure  1.9. Examples of carboxylic acid bioisosteres. 
Interest in identifying isosteres of the guanidine and amidine functionality has largely 
been driven by the disadvantageous physicochemical properties of these moieties, 
representing highly basic entities. Guanidines (pKa ≈ 13-14) and amidines are 
protonated at physiological pH resulting in poor membrane permeability and low oral 
bioavailability. Basicity can be reduced by 4-5 orders of magnitude (pKa ≈ 8), affording 
acylguanidines with improved pharmacokinetic properties. The guanidine-
acylguanidine bioisosteric approach was successfully established in our group for 
different GPCR ligands. Firstly, NG-acylated imidazolylpropylguanidines were reported 
to be highly potent histamine H2 receptor (H2R) agonists (Figure 1.10).132-133 The 
exchange of the imidazole by an aminothiazole ring led to an increased selectivity for 
the H2R versus the other histamine receptor subtypes (H1R, H3R, H4R). Thus, two 
bioisosteric approaches led to improved selectivity profiles and more drug-like 
properties.134 Further variations of the NG-substituent revealed compounds with H4R 
selectivity.135 
 
Figure  1.10. Guanidine-type H2R agonists impromidine and arpromidine and general structures of bioisosteric 
analogues. 
Secondly, acylation of the guanidine moiety of BIBP 3226 using various acyl- or 
carbamoyl linkers resulted in highly potent and selective Y1R antagonists with 
reduced basicity (Figure 1.11). Furthermore, this bioisosteric replacement paved the 
way for the development of radio- and fluorescence-labeled derivatives.136-137 
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Figure  1.11. General structure of Y1R antagonists 
derived from BIBP 3226. 
 
As an alternative to acylation, the basicity of the guanidine moiety can be reduced by 
the replacement of an adjacent CH2 with an oxygen atom to yield oxyguanidines (pKa 
≈ 7-7.5), as demonstrated by RWJ-671818, a thrombin inhibitor in phase I clinical 
studies (Figure 1.12).138 
 
Figure  1.12. Structure of the oxyguanidine RWJ-671818, a thrombin inhibitor. 
Lastly, the squaric acid diamide moiety has been successfully explored as a guanidine 
mimetic of 1.5 in the context of the arginine-derived peptidomimetic 1.6 (Fig-
ure 1.13), which inhibits the HIV transcription.139 
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Figure  1.13. Structures of the guanidine 1.5, an inhibitor of the interaction between the HIV-1 transcription 
regulator Tat and the Tat-responsive RNA element TAR, and the squaric acid diamide 1.6, representing a 
guanidine bioisostere. KD (1.5) = 1.8 µM, KD (1.6) = 7.7 µM. 
  
 General Introduction 13 
1.5 Pharmacological Tools 
In general, the term “pharmacological tool” defines all types of compounds, which 
are useful for a detailed pharmacological exploration of a certain target. In case of 
GPCRs, pharmacological tools are compounds, preferentially antagonists, which bind 
to a monomeric or oligomeric receptor subtype selectively and with high affinity and 
provide information about the receptor, for instance, expression, localization, 
distribution, function, as well as ligand-receptor interactions including binding mode, 
binding kinetics, etc. 
Hence, bivalent antagonists, fluorescence- and radioligands are attractive tools for 
the characterization of GPCRs and for the investigation of GPCR ligands. In the 
following, radio- and fluorescence-based techniques commonly applied for the 
investigation of ligand-receptor interactions with focus on labeled pharmacological 
tools for NPY receptors will be presented. 
1.5.1 Radioligands and Autoradiography 
[3H]- and [125I]-labeled ligands are often utilized as standard radioligands in binding 
experiments and autoradiography, respectively. Tritium is a low energy β– emitter 
(max. β energy 18.7 keV). Hence, this radionuclide is often applied in bioassays due to 
low risk of radiation exposure and simple safety precautions. Radioligand binding 
experiments are usually performed in order to characterize the binding affinities of 
novel compounds, as well as for the evaluation of binding properties of the receptor. 
Binding studies of NPY receptors were performed with variously radiolabeled 
peptides like [3H]-propionyl-NPY.140-141 However, selective ligands were needed for 
the discrimination of receptor subtypes. [3H]BIBP 3226 was reported as a highly 
potent, reversibly binding Y1R selective antagonist, useful, for instance, for 
competition binding assays or the determination of the number of binding sites 
(Bmax).142 Recently, two acylguanidine bioisosteric analogues of BIBP 3226 were 
reported as tritiated radioligands with decreased basicity and retained Y1R affinity 
and selectivity. Besides saturation experiments and kinetics, these ligands were 
successfully applied to autoradiography.137, 143 
Receptor autoradiography represents a classical technique for the in vitro/ex vivo 
detection of receptor expression and distribution. 125I (γ-emitter, 186 keV) has been 
applied especially as peptide-label in autoradiographic investigations, for instance, 
[125I]-NPY and [125I]-PYY as tools for all NPY receptor subtypes except for the Y4R,111, 
144-147 or [125I]-PYY (3-36) for the detection of the Y2R111, 145. However, there are 
limitations in the use of 125I, for instance, due to the release of 125I and 
metabolization/distribution of free iodine in certain tissues (e.g. thyroid gland, 
stomach, kidneys).148 
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1.5.2 Positron Emission Tomography (PET) 
Positron emission tomography (PET) is a powerful molecular imaging technique in 
medical diagnostics. PET is based on the use of short-lived positron emitting isotopes 
such as 18F (t1/2 = 109.7 min), 11C (t1/2 = 20.4 min) or 64Cu (t1/2 = 12.7 h). Most 
commonly 18F is employed as a substitute of a hydrogen atom. The van-der-Waals 
radii of fluorine and hydrogen are almost the same (1.35 Å vs. 1.20 Å), whereas the 
differences in electronic properties are very pronounced. 
More than 20 nuclear reactions are known for 18F production. Proton bombardment 
of 18O enriched water resulting in the 18O(p,n)18F nuclear reaction is the most 
effective method and delivers the desired radionuclide with high molar 
radioactivity.149 Nowadays, 18F-PET is routinely applied as a diagnostic imaging 
method in the field of oncology, neurology and cardiology. Most efforts were spent in 
the development of PET tracers for tumor imaging. For instance, 2-[18F]fluoro-2-
deoxy-D-glucose ([18F]FDG) is extensively used in diagnosis and therapy control. 
[18F]FDG, a substrate of glucose transporters, is accumulated in tumor tissues due to 
metabolic trapping in cancer cells.150 
As already discussed, NPY receptors are overexpressed in various tumors and 
therefore, selective PET-ligands are promising pharmacological tools for cancer 
diagnosis and receptor imaging, respectively. A synopsis of described PET-ligands for 
the Y1R and the Y5R, respectively, is presented in Figure 1.14. For instance, the [11C]-
PET ligand 1.7 was prepared as a Y5R antagonist with high affinity (IC50 = 1.5 nM), 
appropriate lipophilicity (log D7.4 = 2.79) and moderate brain penetration 
(brain/plasma ratio = 0.50). Furthermore, the cold analog proved Y5R selectivity over 
the other NPY receptors.151 The compounds 1.8 and 1.9 were synthesized in our 
group as prototypical [18F]-PET ligands for the Y1R, derived from BIBP 3226.152 2,4-
Diaminopyridine derivatives were identified as promising PET tracer candidates for 
the Y1R in terms of binding affinity and lipophilicity by Kameda et al.153 and, recently, 
one of these compounds was selected for 18F-labeling. The resulting antagonist 
[18F]Y1-973 does not bind to the Y2, Y4 or Y5 receptor but exhibits Y1R binding in the 
subnanomolar range.154 In vitro autoradiography together with in vivo PET imaging in 
rhesus monkey proved the applicability of the novel [18F]-ligand in animal models 
with potential translation to human PET studies. However, no promising candidates 
for PET imaging of the Y2R have been identified yet. Thus, there is urgent need for 
such compounds to explore the suitability of Y2R imaging. 
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Figure  1.14. PET-ligands for the Y1R and Y5R. 
1.5.3 Fluorescent Ligand-Based Assays and Fluorescence Imaging 
Fluorescence-based binding assays are preferred over radioactive assays in terms of 
safety precautions and waste disposal. Moreover, numerous fluorescent probes have 
been developed over the past two decades resulting in the design of potent 
fluorescence ligands for different GPCRs.155-162 Thus, there is a wide range of tools, 
which broaden the scope of application of fluorescence based assays and molecular 
imaging in GPCR research. 
Fluorescence polarization assays are based on the excitation of the sample with 
polarized light. Free fluorescent ligands emit non-polarized fluorescence after 
excitation, whereas the emission of receptor bound fluorescent ligands is polarized 
due to rigidization of the fluorophore in the receptor-ligand-complex. The resulting 
fluorescence anisotropy allows determination of ligand binding under equilibrium 
conditions and study of binding kinetics, respectively. As there are no washing steps 
required in contrast to radioligand binding assays this technique is simply adaptable 
to HTS.163 
Various binding assays based on fluorescence resonance energy transfer (FRET) have 
been developed. Briefly, FRET occurs between a “donor” fluorophore and an 
“acceptor” fluorophore. As prerequisite for FRET the emission spectrum of the donor 
must overlap with the excitation spectrum of the acceptor and secondly, the two 
fluorophores have to be in close proximity to each other (usually < 10 nm). 
Consequently, this phenomenon was exploited for the detection of GPCR oligomers, 
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e.g., in case of oxytocine receptors164 and dopamine D2/somatostatin sst5 receptor 
heterooligomers.165  
1.5.3.1 Flow Cytometry 
Flow cytometry provides a sensitive and quantitative method for the measurement of 
cellular fluorescence. The optical setup of the FACSCaliburTM flow cytometer used in 
this work is presented in Figure 1.15. 
The cytometer is equipped with two lasers, namely an argon laser (488 nm) and a red 
diode laser (635 nm). Fluorescence resulting from excitation at 488 nm is detected by 
the photomultipliers Fl-1, Fl-2 and Fl-3, whereas the photomultiplier Fl-4 only detects 
the red fluorescence emitted after excitation with the red diode laser. 
Flow cytometry is widely used for the investigation of numerous cellular and cell-
associated parameters, e.g. cell cycle166, apoptosis167, oxidant production168, 
membrane potential169, calcium elevation170 and pH changes171. Binding assays for 
flow cytometric devices have been described e.g. for the chemokine receptor 
CXCR4172, the EGF receptor173 or the α-factor receptor174. Recently, flow cytometric 
equilibrium binding assays for the NPY receptors were established in our group.95, 175-
177 Herein, flow cytometry was successfully applied for the simultaneous determina-
tion of binding affinities at the Y1R, Y2R and Y5R, emphasizing the applicability of this 
technique for HTS.176  
 
Figure  1.15. Optical setup of the FACSCaliburTM flow cytometer. The fluorescence emission is separated from the 
SSC light by filters and dichroic mirrors and detected by different photomultiplier tubes (adapted from Mayer178). 
The main advantage of a flow cytometric binding assay compared to a classic 
radioligand binding assay is the fact that, similar to fluorescence polarization 
techniques, the separation of bound and free ligand is not required. Moreover, the 
sample volume of only several picoliters defined by the intersection of the laser beam 
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with the sample stream is very small.179 Therefore, the background signal caused by 
free fluorophores is very low compared to the signal from the cell. Thus, binding of 
fluorescent ligands to GPCRs can be determined at equilibrium. 
1.5.3.2 Confocal Laser Scanning Microscopy (CLSM) 
The number of binding assays using CLSM is rising. For instance, fluorescent 
adenosine A1 receptor ligands were characterized by confocal microscopy binding 
studies at the single cell level.180 Moreover, quantitative imaging of the native α1-
adrenoceptor with Bodipy-labeled prazosin revealed intracellular high affinity binding 
sites.181 Recently, the fluorescence intensity distribution analysis (FIDA) was reported 
for GPCR-focussed high throughput screening.182 This technique is applicable to 
membranes of low GPCR expression levels due to a low detection limit. 
Furthermore, confocal microscopy is regarded as an indispensable tool for GPCR 
imaging. The application of confocal microscopy for the visualization of specifically 
bound fluorescent peptides, e.g. Bodipy-conjugated NPY ligands or carboxy-
fluorescein-NPY for the investigation of NPY receptors, has proven most powerful in 
studying receptor internalization and trafficking of receptor-ligand complexes into 
the cells.57, 183 Lastly, the implication of the Y1R in the regulation of intracellular Ca2+ 
within the cardiovascular system was also identified by means of confocal 
microscopy.184 
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Chapter 2 Scope of the Thesis 
Several fluorescent or radiolabeled peptides have been used extensively as 
pharmacological tools for the investigation of NPY receptor subtypes, since labeled 
small molecules were not available for routine use in the past. However, such non-
peptidic tracers are superior to peptides in terms of their physicochemical properties. 
Labeled derivatives of the endogenous ligand NPY exhibit limited selectivity and 
stability. In addition, their applicability as pharmacological tools may be hampered by 
long incubation periods accompanied with receptor internalization and desensiti-
zation due to the slow binding kinetics of peptides. Hence, there is an urgent need for 
fluorescence and radiolabeled NPY receptor subtype selective low molecular weight 
antagonists. 
The guanidine-acylguanidine bioisosteric approach was extensively studied in our 
group for the development of pharmacological tools addressing the NPY Y1 receptor 
as well as histamine receptor subtypes.1-4 Inspired by the results from the NG-acylated 
Y1R selective ligands, A. Brennauer prepared the first analogs of the argininamide-
type Y2R selective antagonist BIIE 0246 applying this bioisosterism concept.5 
The aim of this thesis was the design, synthesis and characterization of non-peptidic 
tools for the Y2R. The synthetic strategy is based on the hypothesis that a fluorescent 
or radioactive label can be attached to the guanidino moiety of BIIE 0246 by an acyl 
or carbamoyl linker. ω-Aminoacyl linkers were considered most promising, since the 
fluorophores and radionuclide containing building blocks are commercially available 
as aminoreactive electrophiles (activated carboxylic acids, pyrylium dyes). Therefore, 
the present work was focused on the identification and optimization of stable amino-
functionalized acyl- and carbamoylguanidines. The fluorescence or radiolabel should 
be introduced in the final reaction step to yield Y2R selective tracers. Moreover, the 
lipophilic pharmacophore of BIIE 0246 should be modified in order to analyze the 
structure-activity relationships of argininamide-type Y2R antagonists and additionally 
to improve the physicochemical properties. 
With respect to the synthesis of radioligands for routine use in radioligand binding 
experiments, tritiated antagonists are preferred in our laboratory, synthesized by 
acylation with the commonly used tritiated reagent [3H]-propionic acid succinimidyl 
ester. Such a Y2R selective radioligand is anticipated to serve as a standard ligand for 
the determination of binding constants at Y2R expressing cells and for the detailed 
investigation of the binding mode of Y2R selective antagonists. 
Beside tritiated compounds, the preparation of potential PET ligands was planned as 
model compounds towards Y2R selective [18F]-PET tracers. These ligands are of poten-
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tial value as medical diagnostics, since the Y2R was reported to be expressed in 
several tumors.6 
By analogy with this approach, fluorescent Y2R antagonists differing in the spacer and 
the fluorophore, respectively, had to be designed, prepared and pharmacologically 
characterized, since fluorescence labeled compounds offer several advantages 
compared to radioligands; for instance, in terms of safety precautions, waste disposal 
or versatile applicability in various fluorescence-based techniques. Thereafter, 
selected candidates should be investigated in more detail by means of confocal 
microscopy and flow cytometry. Especially, red-fluorescent Y2R selective antagonists 
are regarded promising pharmacological tools for the detection of Y2 receptors on 
cells and for the application in equilibrium binding studies. Nevertheless, a major 
challenge in this field is the preservation of receptor affinity which is usually 
considerably affected by the introduction of bulky fluorophores into small receptor 
ligands. 
Finally, ligands comprising two pharmacophoric entities are discussed to be of 
potential value as tools for the investigation of GPCR homodimerization7-9. Thus, the 
feasibility of the bivalent ligand approach was intended to be evaluated by the 
linkage of two ω-aminoacyl precursors derived from BIIE 0246 with various 
dicarboxylic acids resulting in bivalent ligands with different chemical nature and 
length of the spacer. 
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Chapter 3 Structure-Activity Relationship 
Studies of Argininamide-Type Neuropeptide Y 
Y2 Receptor Antagonists 
3.1 Introduction 
In 1999, the non-peptidic (L)-arginine derivative BIIE 0246 was disclosed by 
Boehringer Ingelheim Pharma. This compound proved to be a highly potent and 
selective neuropeptide Y (NPY) Y2 receptor (Y2R) antagonist in binding experiments 
and functional assays, respectively. Radioligand binding studies on Y2R expressing 
SMS-KAN cells revealed an IC50 value of 3.3 nM, whereas no displacement of radio-
labeled NPY was observed in Y1, Y4 and Y5 receptor assays (Y1R, Y4R, Y5R).1 Y2R 
antagonism was demonstrated, for instance, in pharmacological investigations on the 
isolated electrically stimulated rat and guinea-pig vas deferens.1-3 More detailed 
studies on the antagonistic behavior of BIIE 0246 revealed an insurmountable binding 
mode after pre-incubation of BIIE 0246 with Y2R expressing cells, whereas compet-
itive antagonism was observed upon simultaneous application of a peptide agonist 
(e.g. PYY) and BIIE 0246.4 
BIIE 0246 was among a series of peptidomimetics synthesized as putative mimics of 
the C-terminus of NPY. For some of these BIIE 0246 analogs Y2R binding data are 
given in the patent literature,5-7 stimulating the discussion of structure-activity 
relationships of argininamide-type Y2R antagonists. The 5,11-dihydrodibenzo[b,e]-
azepin-6-one group, though representing the best suited substructure, can be 
replaced by an α-diphenylmethyl residue resulting in a relatively small decrease in 
affinity by a factor of 4-5. Apparently, the “western part” of BIIE 0246 undergoes 
hydrophobic interactions with the receptor. Substitution of the piperazine by a 
piperidine led to a six times lower affinity.8 The L-arginine side-chain is supposed to 
form a crucial electrostatic interaction with an acidic residue in the receptor 
(presumably Asp2946.59);9 exchange by non-basic groups is not tolerated. Interesting-
ly, the replacement of the 4-(2-aminoethyl)-1,2-diphenyl-1,2,4-triazolidin-3,5-dione 
moiety by an (S)-tyrosinamide was accepted, whereas the corresponding (S)-phenyl-
alaninamide analog showed low affinity. This is in agreement with the assumption 
that the hydroxyl group is important for receptor binding of BIIE 0246 due to mimick-
ing the C-terminus of NPY. 
Mutagenesis studies of the human Y2R revealed novel insights into the ligand-
receptor interactions. Interestingly, BIIE 0246 does not bind to avian Y2Rs.10 Based on 
reciprocal mutations of the human (h) and chicken (ch) Y2Rs, three amino acids in the 
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hY2R were identified to be crucial for BIIE 0246 binding: Gln1353.37 in transmembrane 
domain 3 (TM 3), Leu2275.46 in TM 5, and Leu2846.49 in TM 6.11 Point mutagenesis of 
hY2R to the corresponding amino acids in chY2 (Q135H, L227Q, L284F) resulted in low 
affinity of BIIE 0246. Inversely, the introduction of the three human residues into the 
chY2R reproduced the high affinity to hY2R.11 A site-directed mutagenesis study 
revealed the importance of Tyr1102.64 in TM 2 of the hY2R for both, peptide ligands 
and BIIE 0246 binding.12 Replacement of this residue by Ala resulted in a 5-9 fold 
reduction in the affinity of the tested peptide agonists [125I]pPYY, pNPY, hPYY (3-36) 
and pNPY (13-36). BIIE 0246 displayed a 4-fold reduced affinity for this mutant.12 The 
latest site-directed mutagenesis study revealed further amino acids with direct or 
indirect effects on the interaction of BIIE 0246 with the Y2R.13 Therein, L183A ex-
change resulted in a 46-fold decrease in binding affinity suggesting a direct hydro-
phobic interaction. Further mutations (T138I, Q287A) implemented a 2.3 and 2.9-fold 
decrease in affinity, respectively. Interestingly, according to the suggested receptor 
model, Thr1383.40, Leu1834.60 and Gln2876.55 are oriented towards the cavity defined 
between TM 3, 4, 5 and 6, which has been previously proposed to accommodate 
antagonist ligands in the Y1 receptor.14-15 These results are first clues towards models 
of the Y2R binding site of BIIE 0246. 
We are aiming at pharmacological tools for further investigations on the binding 
mode of BIIE 0246 and related argininamides and for further characterization of the 
Y2R, respectively. Several substitutions in the building block of BIIE 0246 were 
performed in order to improve the physicochemical properties (cf. Figure 3.1). 
Therefore, the lipophilicity of the building block as well as the basicity of the 
guanidine should be reduced. Compared to the guanidino group the basicity of 
acylguanidines is decreased by 4-5 orders of magnitude (pKa ≈ 8) but still sufficient to 
allow for key interactions with acidic residues of the biological target, as demonstrat-
ed recently for histamine H216-17 and H418 receptor agonists, Y1R antagonists19-21 and a 
few prototypical Y2R antagonists8 from our laboratory. In this work, special attention 
was paid to further exploring the applicability of the guanidine-acylguanidine 
bioisosteric approach to Y2R ligands. Additionally, the synthesis of amino-
functionalized building blocks was taken into consideration with respect to the 
preparation of fluorescent ligands and radiotracers. 
The structural features of the synthesized argininamides presented in this chapter are 
summarized in Figure 3.1. These compounds were investigated at recombinant hY2Rs 
for affinity and antagonism, for Y2R selectivity compared to Y1R, Y4R and Y5R, and for 
chemical stability. The structure-activity relationships will be discussed. 
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Figure 3.1. Overview about the structural modifications of argininamides described in this chapter. 
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3.2 Chemistry 
3.2.1 Synthesis 
The argininamide-type NPY Y2R antagonists were synthesized from (S)- and (R)-
configured ornithine (commonly named L-Orn and D-Orn), respectively. The tert-
butoxycarbonyl and the phthaloyl group were used as orthogonal protective groups 
of Nα and Nδ (Scheme 3.1). 
 
Scheme 3.1. Preparation of orthogonally protected ornithine 3.2. Reagents and conditions: a) 1. NaOH (2 eq), 
CuSO4 × 5 H2O (0.5 eq), NaHCO3 (1.23 eq), H2O, 30 min, rt, 2. N-Carbethoxyphthalimide (1.23 eq), 90 min, rt, 3. 
6 M HCl, 90 min, rt; b) Di-tert-butyl dicarbonate (1.05 eq), NaHCO3 (2.2 eq), 1,4-dioxane, H2O, 3 h, rt. 
Most of the argininamide-type Y2R antagonists comprise a 2-(3,5-dioxo-1,2-diphenyl-
1,2-triazolidin-4-yl)ethyl group7 at the C-terminal amide nitrogen. The corresponding 
amino compound 3.4 was prepared by N-alkylation of deprotonated 1,2-diphenyl-
urazol with N-(2-bromoethyl)phthalimide, and subsequent hydrazinolysis of the 
phthaloyl protective group. 1,2-Diphenylurazol was obtained by condensation of 1,2-
diphenylhydrazine and ethyl allophanate (cf. Scheme 3.2).22 
 
Scheme 3.2. Synthesis of amine component 3.4. Reagents and conditions: a) xylene, 24 h, reflux; b) KOtBu (1.10 
eq), DMF, 5 h, reflux; c) 1. N2H5OH (2.75 eq), THF/MeOH, 16 h, rt, 2. 2 M HCl, 2 h, rt. 
The Nα position of the ornithinamide was acylated with either the carboxylic acid 3.97 
or 3.10. For the synthesis of these compounds, anthraquinone was converted into 
5H-dibenzo[b,e]azepin-6,11-dione (3.5) by Schmidt reaction. The resulting ketone 
was reduced to alcohol 3.6 by NaBH4 and afterwards converted to the 11-chloro 
compound (3.7) using thionyl chloride. Subsequently, the alkyl chloride was allowed 
to react with an excess of piperazine yielding 11-piperazin-1-yl-5,11-dihydrodibenzo-
[b,e]azepin-6-one (3.8). Finally, acylation of the piperazine with 3,3-tetramethylene 
glutaric anhydride afforded 3.9. Carboxylic acid 3.10, lacking the cycloaliphatic 
moiety, was prepared by analogy from 3.8 and glutaric anhydride (Scheme 3.3). The 
synthesis of the ornithinamide building blocks which were subjected to 
guanidinylation is outlined in Scheme 3.4 and Scheme 3.5. 
  
 SAR Studies of Argininamide-Type NPY Y2 Receptor Antagonists 39 
 
Scheme 3.3. Preparation of the carboxylic acids 3.9, 3.10. Reagents and conditions: a) NaN3 (1.2 eq), H2SO4, 
CHCl3, 10 h, reflux; b) NaBH4 (2 eq), EtOH, 1 h, reflux; c) SOCl2, CHCl3, 30 min, reflux; d) piperazine (5 eq), 1,4-
dioxane, 30 min, reflux; e) anhydride (1 eq), CH2Cl2, 18 h, rt. 
For the preparation of the phthaloyl-protected ornithine amide building blocks 3.13 
and 3.14, the Nα,Nδ-diprotected ornithine 3.2 reacted with the amine 3.4 after in situ 
activation with DCC, followed by Boc-deprotection and a second EDC/HOBt promoted 
coupling step with the carboxylic acids 3.9 or 3.10 (Scheme 3.4) yielding 3.13 and 
3.14, respectively.8 The phthaloyl group was cleaved off by hydrazinolysis, giving the 
primary amines 3.15 and 3.16. 
The BIIE 0246 analogs comprising a phenylalanine amide or a tyrosine amide in the 
“eastern part” instead of the 4-(2-aminoethyl)-1,2-diphenyl-1,2,4-triazolidin-3,5-
dione moiety were prepared starting from the (S)-configured tert-butoxycarbonyl 
protected phenylalanine, and the N-Boc,O-Bn protected (S)-tyrosine, respectively 
(Scheme 3.5). The amino acids were converted into the respective amides (3.17, 3.18) 
by ammonolysis. Therefore, the carboxylic acids were activated with isobutyl chloro-
formate (IBCF) followed by amidation with 7 M NH3 in methanol.23-24 Deprotection, 
acylation with the orthogonally protected ornithine, and a second acidic Boc-group 
elimination resulted in the dipeptides 3.23 and 3.24. Subsequent acylation with 3.9 
gave the Pht-protected building blocks 3.25 and 3.26. The free amines 3.27 and 3.28 
were obtained after hydrazinolysis of the Nδ-Pht protected compounds (Scheme 3.5). 
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Scheme 3.4. Preparation of the ornithinamide building blocks 3.15, (S)-3.16. Reagents and conditions: a) 3.4 
(1.15 eq), HOBt × H2O (1 eq), DCC (1 eq), THF, 18 h, 0 °C → rt; b) HCl in ethyl acetate, 2 h, rt; c) 3.9 or 3.10 
(1 eq), HOBt × H2O (1 eq), EDC × HCl (1 eq), DIPEA (2 eq), CH3CN, 16 h, 0 °C → rt; d) 1. N2H5OH (2.5 eq), 
MeOH, 16 h, rt, 2. 1 M KHSO4 (5 eq), 3 h, rt. 
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Scheme 3.5. Preparation of building blocks 3.27, 3.28. Reagents and conditions: a) 1. IBCF (0.7 eq), NEt3 (0.7 
eq), THF, 30 min, 0 °C → –78 °C, 2. 7 M NH3 in MeOH, 2 h, –78 °C → rt; b) TFA/CH2Cl2 1:1 (v/v), 2 h, rt; c) (S)-
3.2 (1 eq), TBTU (1 eq), DIPEA (2 eq), DMF, 16 h, rt; d) HCl in ethylacetate, 2 h, rt; e) 3.9 (1 eq), TBTU (1 eq), 
DIPEA (2 eq), DMF, 16 h, rt; f) 1. N2H5OH (2.5 eq), MeOH, 16 h, rt, 2. 1 M KHSO4 (5 eq), 3 h, rt. 
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For the preparation of the acylguanidines by guanidinylation of ornithine derivatives, 
variously substituted S-methylisothioureas were synthesized as building blocks (3.35-
3.45; Scheme 3.7). Therefore, mono Boc-protected S-methylisothiourea was acylated 
with the corresponding carboxylic acid either by in situ activation with TBTU or by 
coupling with the pertinent succinimidyl ester. The carboxylic acids 3.30-3.33 which 
were not commercially available were prepared as outlined in Scheme 3.6. In case of 
the NG-unsubstituted parent compounds BIIE 0246 ((S)-3.47), (R)-3.47, 3.46, (S)-3.59, 
and 3.61, the guanidine moiety was introduced by treating the primary amine with 
N,N’-bis(tert-butoxycarbonyl)-S-methylisothiourea 3.34. 
Finally, the NG-unsubstituted argininamides, as well as the acylguanidine analogs 
(3.47-3.62) were prepared by guanidinylation of the corresponding building block 
with the appropriate S-methylisothiourea and subsequent Boc-deprotection with 
50 % TFA in dichloromethane (Scheme 3.9).16, 20, 25 
For compound 3.46a, comprising an O-benzyl protected tyrosine, a different cleavage 
strategy had to be elaborated (Scheme 3.8). A two step reaction starting with hydro-
genolysis of the benzyl ether followed by acidic Boc deprotection failed due to 
insufficient stability of the compound under reductive conditions. Therefore, 
different non-reductive procedures were tested. Lastly, a one step cleavage of both 
protective groups was achieved by the treatment with a 1 M solution of trimethylsilyl 
triflate and thioanisole 1:1 (n/n) in TFA and m-cresole, whereby thioanisole and m-
cresole act as cation scavengers, to yield the tyrosinamide analog 3.46.26 
 
Scheme 3.6. Synthesis of the carboxylic acids 3.30-3.33. Reagents and conditions: a) Ethyl trifluoroacetate (1 
eq), CH2Cl2, 4 h, 0 °C → rt; b) 1. Di-tert-butyl dicarbonate (2 eq), CH2Cl2, 24 h, –10 °C → rt, 2. K2CO3 (10 eq), 
CH3OH, H2O, 2 h, reflux; c) for 3.30: NEt3 (1.5 eq), THF, overnight, rt; for 3.31 and 3.32: CH2Cl2, 2 h, rt; d) Di-tert-
butyl dicarbonate (1.2 eq), NaHCO3 (1.5 eq), 1,4-dioxane, H2O, 16 h, rt. 
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Scheme 3.7. Synthesis of the guanidinylating reagents 3.34-3.45. Reagents and conditions: a) Di-tert-butyl 
dicarbonate (5 eq), 1 M NaOH, H2O/1,4-dioxane 1:1 (v/v), overnight, rt; b) for R = H (3.33): TBTU (1 eq), DIPEA 
(2 eq), DMF, 16 h, rt; for R = NHS: DIPEA (2 eq), DMF, 16 h, rt. 
Scheme 3.8. Different deprotection strategies for the synthesis of compound 3.46. Reagents and conditions: a) 
3.34 (1 eq), NEt3 (2 eq), HgCl2 (1 eq), DMF, 16 h, rt; b) TMSOTf (90 eq), PhSCH3 (90 eq), m-cresole (10 eq), 
TFA, 90 min, 0 °C; c) H2, 10 % Pd/C, MeOH, 3 h-overnight, rt; d) TFA/CH2Cl2 1:1 (v/v); 2 h, rt; e) TMSI (5 eq), 
CH2Cl2, 4 h, reflux. 
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Scheme 3.9. Preparation of NG-unsubstituted Y2R antagonists 3.47, (S)-3.59, 3.61 and NG-(ω-aminoacylated) 
argininamides 3.48-3.58, (S)-3.60, 3.62. Reagents and conditions: a) NEt3 (2 eq), HgCl2 (1 eq), DMF, 16 h, rt; b) 
TFA/CH2Cl2 1:1 (v/v), 2 h, rt. 
 
Scheme 3.10. Preparation of the potential radio- and PET-ligands (S)-3.63-(S)-3.84. Reagents and conditions: a) 
NEt3 (2.5 eq), CH3CN, 4-16 h, rt. 
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Finally, NG-acylated or carbamoylated guanidines containing a terminal amino group 
were acylated using the corresponding active esters of propionic acid, 2-fluoro 
propionic acid, or 4-fluoro benzoic acid in order to obtain a small library of the “cold 
form” of potential [3H]-radio- and [18F]-PET-ligands for the Y2R (Scheme 3.10).21 In 
addition, compounds 3.86 and 3.87 which are bearing the potential radiolabeling 
group at the guanidine moiety were prepared (Scheme 3.11). Due to the high basicity 
of the guanidine moiety a direct acylation of the NG-unsubstituted Y2R antagonist 
3.47 was hardly possible. Hence, an alternative synthetic route was developed. 
Commonly, in our lab the guanidinylating reagent is introduced as a Cbz/Boc 
protected building block followed by reductive cleavage of the Cbz group, acylation 
and final Boc cleavage.21, 27 However, the ornithinamide core structure of all Y2R 
antagonists turned out to be unstable under reductive hydrogenolysis conditions. 
Thus, the commonly used orthogonal protective group strategy could not be applied. 
In principle, the guanidinylation of primary amino groups using the pertinent S-
methylisothioureas containing propionyl, 2-fluoropropionyl or 4-fluorobenzoyl 
residues is synthetically feasible. However, the application of this approach is 
restricted to non-radioactive compounds. The introduction of the radiolabel into the 
guanidinylating agent would require additional reaction steps with radioactive 
material and therefore complicate the synthesis in terms of waste disposal, safety 
precautions and reaction time. Such a synthetic strategy is especially dis-
advantageous in case of [18F]-labeled ligands due to the very short half-life of the 
radioisotope 18F (t1/2 = 109.7 min). Therefore, introduction of the radiolabel in the 
final reaction step is preferred. 
The mono-Boc protected argininamide 3.85 was synthesized by guanidinylation with 
the bis-Boc protected S-methylisothiourea 3.34 followed by acidic cleavage of only 
one tert-butoxycarbonyl substituent. The deprotection under acidic conditions using 
mixtures of CH3CN and water containing 0.1 % TFA was monitored by HPLC and was 
found to be quantitative after 3 h (Figure 3.2). The NG-propionylated, and 4-fluoro-
benzoylated analogs (3.86, 3.87) were obtained after acylation with the 
corresponding NHS-ester and a second Boc-deprotection in one pot (Scheme 3.11). 
 
Scheme 3.11. Preparation of NG-acylated analogs 3.86, 3.87. Reagents and conditions: a) CH3CN/0.1 % aq. TFA 
1:1 (v/v), 5 h, rt; b) 1. NHS-ester (1.2 eq), NEt3 (1 eq), CH3CN, 21 h, rt, 2. TFA, 2 h, rt. 
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Figure 3.2. HPLC reaction monitoring of the selective cleavage of one tert-butoxycarbonyl protective group in 
3.47a resulting in compound 3.85. Conditions: eluent: mixtures of acetonitrile + 0.025 % TFA (A) and 0.025 % aq. 
TFA (B), gradient: 0 to 30 min: A/B 20/80 to 95/5, 30 to 40 min: 95/5, tR (3.85) = 24.7 min. 
3.2.2 Stability of the NPY Y2R Antagonists 
As recently reported, Nω-acylated argininamides have to be considered critical with 
respect to the stability, depending on the structure of the acyl substituent.25, 28 
Therefore, a selection of compounds, which were considered promising candidates 
for fluorescence-labeling and the synthesis of radioligands, respectively, were 
investigated with respect to decomposition giving BIIE 0246 ((S)-3.47) under assay-
like conditions (aqueous buffer, pH 7.4, 20 °C, time scale 90 min, cf. Table 3.1). A 
release of (S)-3.47 under the conditions of the pharmacological assays has to be 
taken into account, as the high potency of in situ generated (S)-3.47 (Ki = 10.2 nM) 
might mask low activity of the (decomposing) Y2R antagonist. In case of the 
propionylated potential radioligands and most of the amine precursors only traces of 
the parent compound BIIE 0246 were detected after 90 min, whereas the decom-
position of the amine (S)-3.48 and the fluorobenzoyl derivative (S)-3.74 was much 
more pronounced. Interestingly, propionylation of the amine group in the linker of 
(S)-3.48 yielding (S)-3.63 stabilized the compound to a high degree (Figure 3.3a, b). 
Cleavage of aminoalkanoylguanidines was already observed for NG-acylated 
argininamide-type Y1R antagonists and was proven to be extremely rapid in case of 
structures favoring an intramolecular nucleophilic attack at the carbonyl group, for 
instance, (5-aminopentanoyl)guanidines.25, 28 Nevertheless, the affinity of the major-
ity of compounds examined in this study was not affected by the formation of 
BIIE 0246, as the extent of decomposition was very low. Especially noteworthy is the 
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high stability of the carbamoylated analogs (Figure 3.3c, d), which was also demon-
strated in recent studies on fluorescent Y1R antagonists.20 
Table 3.1. Decomposition of selected Y2R antagonists in buffer (pH 7.4) at 20 °C during incubation for a period of 
90 min. 
No 
% 
Decomposition 
No 
% 
Decomposition
No 
% 
Decomposition 
(S)-3.48 11.6 (S)-3.49 <0.5 (S)-3.50 2.9 
(S)-3.53 <0.5 (S)-3.54 <0.5 (S)-3.55 <0.5 
(S)-3.57 2.4 (S)-3.58 <0.5 (S)-3.63 2.7 
(S)-3.69 <0.5 (S)-3.72 2.4 (S)-3.74 5.9 
Cleavage of the acyl or carbamoyl substituent from the guanidine group resulting in BIIE 0246 ((S)-3.47) was analyzed by 
HPLC. 
Figure 3.3. HPLC analysis of the chemical stability of NG-substituted Y2R antagonists. (S)-3.47 is formed by 
decomposition of the ligands. Incubation: 15-180 min in buffer, pH 7.4, 20 °C. a) and b) illustrate the chemical 
stability of the Nω-aminoacylguanidine (S)-3.48 and the corresponding propionylated analog (S)-3.63. c) and d) 
show the HPLC analysis of the Nω-aminocarbamoylguanidine (S)-3.54 and the corresponding “cold” 
radioligand (S)-3.69. 
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3.3 Pharmacological Results and Discussion 
The Y2R antagonists were investigated for Y2R binding and antagonism as well as for 
Y2R selectivity over Y1, Y4 and Y5 receptor (Y1R, Y4R, Y5R). The Y2R binding affinities 
were determined in a flow cytometric binding assay using CHO cells, stably expressing 
the human Y2 receptor (hY2R),29 and fluorescence-labeled pNPY (Cy5-pNPY or Dy-635-
pNPY). NPY Y2R antagonistic activities were determined in a spectrofluorimetric 
Ca2+ assay (fura-2 assay) on CHO cells, stably expressing the hY2R.30 Cell clones giving 
a robust intracellular Ca2+ response upon agonistic activation were obtained by co-
transfection of the CHO-hY2 cells with the gene encoding the chimeric G-protein Gqi5. 
Recently, an aequorin-based bioluminescence assay for the Y2R was developed in our 
laboratory.29 Thus, the CHO-hY2 cells were additionally transfected with the mtAEQ 
construct, which did not affect the functional properties of the hY2R (CHO-hY2-K9-qi5-
K9-mtAEQ-A7). 
SAR Studies of Argininamide-Type NPY Y2 Receptor Antagonists: Y2R 
Antagonism, Binding Affinity and Physicochemical Properties 
The structures and pharmacological data of the investigated argininamide-type Y2R 
antagonists are summarized in Table 3.2. To get insights into the SAR, several 
modifications of the BIIE 0246 core structure were performed, both in the N-terminal 
part of the argininamide (“western part”) and at the C-terminus (“eastern part”). 
Furthermore, an inversion of the (S)-arginine into the (R)-configuration was explored. 
Surprisingly, the (R)-argininamide ((R)-3.47) only shows a 5-fold lower affinity 
compared to the parent compound BIIE 0246 ((S)-3.47). This indicates a weak 
preference of the Y2R for the (S)-configured arginine moiety, in contrast to the Y1R, 
which clearly favors the (R)-enantiomers of antagonists derived from BIBP 3226.31 
The replacement of the cyclopentan-1,1-diyl moiety by a methylene group in the 
“western part” of (S)-3.59 resulted in a moderate decrease in affinity (Ki = 96 nM), 
verifying that this hydrophobic space-filling substructure confers to some extent to 
receptor binding. The relation between binding affinity Ki and the Gibbs free energy 
(ΔG = RTlnKi) may serve as explanation. The released Gibbs free energy upon ligand 
binding results from enthalpic and entropic contributions (ΔG = ΔH – TΔS). The cyclo-
aliphatic moiety in BIIE 0246 results in a rigidization of the molecule and therefore, in 
a lower decrease in conformational entropy upon binding to the Y2R. Furthermore, 
the desolvation entropy is increased due to an additional hydrophobic effect of the 
cyclopentyl moiety.32 
In compounds 3.46 and 3.61 the 4-(2-aminoethyl)-1,2-diphenyl-1,2,4-triazolidin-3,5-
dione moiety was replaced by less lipophilic tyrosinamide and phenylalaninamide 
residues, respectively, strongly reminiscent of the C-terminus of the endogenous 
ligand NPY. As claimed in the patent literature, this exchange does not strongly alter 
the antagonistic activity (factor of 4-5).5-7 Surprisingly, the data obtained from the 
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flow cytometric binding assay and the fura-2 Ca2+ assay revealed a different picture. 
The amides exhibited significantly lower Y2R antagonistic activities and binding 
affinities than the reference compound BIIE 0246. Hence, it remains doubtful, 
whether BIIE 0246 and analogs are mimicking the C-terminus in NPY, in particular, 
because the peptide mainly interacts with extracellular parts of the Y2R, whereas the 
smaller non-peptidic antagonists – according to mutagenesis studies – get access to 
the transmembrane domains of the receptor.9, 11-13 
In previous studies, the exchange of the 5,11-dihydrodibenzo[b,e]azepin-6-one group 
by an α-diphenylmethyl residue led to a moderately decreased activity.8 Neverthe-
less, such compounds were not further examined in the present work due to similar 
physicochemical properties and lack of obvious advantages compared to BIIE 0246. 
In our laboratory the bioisosteric replacement of guanidine groups with acyl- or 
carbamoylguanidine moieties was developed and successfully applied to different 
classes of GPCR ligands.16, 18, 20-21, 27, 33 Aiming at new pharmacological tools for the 
Y2R, a small library of NG-substituted amine precursors, varying in length and 
chemical nature of the spacer, were prepared to study the impact of the linker on 
affinity and selectivity. All derivatives with unmodified argininamide core structure 
((S)-3.48-(S)-3.58) turned out to be highly potent Y2R antagonists with retained, or 
even increased antagonistic activities and binding affinities regarding the unsub-
stituted BIIE 0246. Furthermore, the acylguanidine analogs exhibited lower retention 
times (tR) compared to BIIE 0246, despite their reduced basicity in the NG-position, 
due to an additional positive charge in the linker (representative results displayed in 
Table 3.3). Hence, these bioisosteres are considered as promising amine precursors 
for the synthesis of Y2R tracers with improved physicochemical properties. 
A correlation between linker length and affinity was obvious for the series of 
carbamoylated amine precursors (S)-3.52-(S)-3.55 with linker lengths of 4-8 atoms. 
The NG-carbamoylated analog (S)-3.53 (n=5) revealed the highest binding affinity of 
all synthesized compounds (Ki = 2.1 nM). Nevertheless, length and chemical nature of 
the linker had only minor effects on Y2R binding. 
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Table 3.2. Structures, Y2R antagonistic activities (KB) and affinities (Ki) of the guanidine-type Y2R antagonists. 
 
No Y Z KB / nMa Ki / nMb 
(S)-3.47c H -- 5.6 ± 0.4 10.2 ± 1.1 
(R)-3.47 H -- 56 ± 5 55 ± 3 
(S)-3.48 CO(CH2)3CONH(CH2)2NH2 -- 3.7 ± 0.1 3.4 ± 0.1d 
(R)-3.48 CO(CH2)3CONH(CH2)2NH2 -- 17 ± 6 36 ± 7 
(S)-3.49 CO(CH2)3CONH(CH2)3NH2 -- 4.4 ± 0.5 2.3 ± 1.4 
(S)-3.50 CO(CH2)3CONH(CH2)2NH(CH2)2NH2 -- 16 ± 2 16 ± 3 
(R)-3.50 CO(CH2)3CONH(CH2)2NH(CH2)2NH2 -- 10 ± 2 42 ± 7 
(S)-3.51 CO(CH2)2CONHCH2(CH2CH2O)3(CH2)3NH2 -- 11 ± 3 16 ± 3d 
(S)-3.52 CONH(CH2)2NH2 -- 7.0 ± 5.1 7.6 ± 4.2 
(S)-3.53 CONH(CH2)3NH2 -- 2.5 ± 0.2 2.1 ± 0.3 
(S)-3.54 CONH(CH2)4NH2 -- 1.8 ± 0.2 3.2 ± 0.3 
(S)-3.55 CONH(CH2)6NH2 -- 2.1 ± 0.4 7.0 ± 1.2 
(S)-3.56 CO(CH2)5NH2 -- 1.0 ± 0.2 7.8 ± 1.0d 
(S)-3.57 COCH2(OCH2CH2)2NH2 -- 6.5 ± 0.02 18 ± 1 
(S)-3.58 CO(CH2CH2O)4(CH2)2NH2 -- 6.0 ± 0.5 8.1 ± 3.2 
(S)-3.59 H -- 28 ± 3 96 ± 13 
(S)-3.60 CO(CH2)3CONH(CH2)2NH(CH2)2NH2 -- 173 ± 27 141 ± 12 
3.61 H -- 833 ± 275 496 ± 46 
3.62 CONH(CH2)3NH2 -- 334 ± 124 191 ± 97 
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Table 3.2. (continued) 
3.46 H -- 2200 ± 774 466 ± 3 
(S)-3.63 CO(CH2)3CONH(CH2)2NH A 16 ± 8 9.9 ± 1.0d 
(S)-3.64 CO(CH2)3CONH(CH2)3NH A 8.5 ± 0.1 22 ± 6 
(S)-3.65 CO(CH2)3CONH(CH2)2NH(CH2)2NH A 16 ± 8 9.9 ± 1.1 
(S)-3.66 CO(CH2)2CONHCH2(CH2CH2O)3(CH2)3NH A 35 ± 15 37 ± 7d 
(S)-3.67 CONH(CH2)2NH A 30 ± 11 64 ± 4 
(S)-3.68 CONH(CH2)3NH A 22 ± 2 32 ± 0.1 
(S)-3.69 CONH(CH2)4NH A 9.4 ± 0.1 55 ± 15 
(S)-3.70 CONH(CH2)6NH A 12 ± 5 84 ± 64 
(S)-3.71 CO(CH2)5NH A 11 ± 4 9.0 ± 0.2d 
(S)-3.72 COCH2(OCH2CH2)2NH A 16 ± 2 15 ± 0.2 
(S)-3.73 CO(CH2CH2O)4(CH2)2NH A 50 ± 3 48 ± 14 
(S)-3.74 CO(CH2)3CONH(CH2)2NH B 9.1 ± 1.8 8.3 ± 6.4d 
(S)-3.75 CO(CH2)3CONH(CH2)3NH B 11 ± 4 37 ± 7 
(S)-3.76 CO(CH2)2CONHCH2(CH2CH2O)3(CH2)3NH B 15 ± 4 21 ± 9d 
(S)-3.77 CONH(CH2)3NH B 2.0 ± 2.0 24 ± 0.3 
(S)-3.78 CONH(CH2)4NH B 4.7 ± 0.8 68 ± 8 
(S)-3.79 CONH(CH2)6NH B 3.7 ± 0.1 82 ± 7 
(S)-3.80 CO(CH2)5NH B 8.4 ± 1.4 34 ± 6d 
(S)-3.81 COCH2(OCH2CH2)2NH B 13 ± 2 22 ± 9 
(S)-3.82 CO(CH2CH2O)4(CH2)2NH B 26 ± 6 45 ± 3 
(S)-3.83 CO(CH2)3CONH(CH2)3NH C 12 ± 2 27 ± 4 
(S)-3.84 CO(CH2)2CONHCH2(CH2CH2O)3(CH2)3NH C 27 ± 1 21 ± 1 
3.86 -- A 8.2 ± 0.4 5.2 ± 1.8 
3.87 -- B 14 ± 3 166 ± 65d 
a Inhibition of 70 nM pNPY-induced [Ca2+]i mobilization in CHO cells; mean values ± SEM (n = 2-5). 
b Flow 
cytometric binding assay using 5 nM Cy5-pNPY (KD = 5.2 nM) in CHO cells, unless otherwise indicated; mean values 
± SEM (n = 2-4). c BIIE 0246. d Dy-635-pNPY used as fluorescent ligand (10 nM) for competition binding. 
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Figure 3.4. Flow cytometric competition 
binding assay using Cy5-pNPY as 
fluorescent ligand in the presence of NG-
unsubstituted Y2R antagonists at various 
concentrations (mean values ± SEM, 
n = 2-3). 
 
Table 3.3. Retention times (tR) of the guanidine-type Y2R antagonists (first row) and representative NG-substituted 
acylguanidines (second and third row). Conditions: eluent: mixtures of acetonitrile + 0.025 % TFA (A) and 
0.025 % aq. TFA (B), gradient: 0 to 30 min: A/B 20/80 to 95/5. 
No tR / min No tR / min No tR / min No tR / min 
(S)-3.47 18.25 (S)-3.59 14.27 3.61 14.91 3.46 11.94 
(S)-3.48 14.69 (S)-3.50 12.99 (S)-3.53 14.97 (S)-3.58 15.39 
(S)-3.60 11.80 3.62 13.06 (S)-3.63 17.04 (S)-3.65 14.55 
 
All potential radioligands exhibited a decreased affinity compared to the 
corresponding amine precursors, except for compound (S)-3.65, which contains an 
additional, at physiological pH positively charged amine function in the linker 
(Figure 3.5a; highlighted in red). Acylguanidines derived from argininamides with 
lower affinity, comprising an ω-aminoacyllinker are superior in terms of binding and 
antagonism referred to their NG-unsubstituted analogs ((R)-3.48 and (R)-3.50 vs. (R)-
3.47; 3.62 vs. 3.61). One exception within this series is antagonist (S)-3.60, comprising 
a second positive charge in the linker, with a two times lower affinity compared to 
(S)-3.59. Apparently, one additional polar group in the acyl linker of the antagonists is 
preferred by the Y2R. Thus, “masking” the positive charge by acylation with propionic 
acid, 2-fluoropropionic acid, or 4-fluorobenzoic acid results in a decrease in affinity, 
especially in case of NG-carbamoylated analogs ((S)-3.67-(S)-3.70, (S)-3.77-(S)-3.79). 
Maybe, the presence of the carbamoyl NH-group implicates a different orientation of 
the NG-substituent which is less compatible with the acylation of the ω-amino 
residue. Nevertheless, most of the synthesized potential radioligands possess high 
affinities in the low nanomolar range, especially (S)-3.63, (S)-3.65 and (S)-3.71 with Ki 
values around 10 nM (Table 3.2). Direct propionylation in NG-position yielded 
antagonist 3.86 with an increased binding affinity compared to BIIE 0246, whereas 
acylation with the 4-fluorobenzoyl substituent (3.87) resulted in a drastic decrease in 
binding, suggesting that a bulky substituent in proximity to the guanidine is less 
tolerated by the receptor. However, for a few compounds this affinity-lowering effect 
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was not reflected to the same extent by data from the fura-2 assay ((S)-3.69, (S)-3.70, 
(S)-3.77-(S)-3.80, 3.87). 
For most of the investigated compounds the binding data are in good agreement with 
the results from the functional assay. Discrepancies became obvious, in particular, 
regarding data for the ω-aminoacylated Y2R antagonists consisting of a carbamoyl 
linker (cf. (S)-3.67-(S)-3.70, (S)-3.77-(S)-3.79). Depending on the structures and the 
binding kinetics of the investigated compounds, these discrepancies between Ki and 
KB values presumably result from the different periods of incubation in the used assay 
types. The functional assays were performed in a time window of a few minutes, 
sufficient to reach equilibrium of the antagonists rather than the agonist pNPY, which 
is characterized by slow binding kinetics. By contrast, the flow cytometric binding 
assay was performed after incubation for 90 minutes. 
 
Figure 3.5. a) Comparison of binding data (pKi) of the amine precursors (S)-3.48-(S)-3.58 and the corresponding 
propionylated analogs (S)-3.63-(S)-3.73 (highlighted in red: increased affinity of (S)-3.65 vs. (S)-3.50). 
b) Comparison of binding data (pKi) of the amine precursors (S)-3.48, (S)-3.49, (S)-3.51, (S)-3.53-(S)-3.58 and 
the corresponding 4-fluorobenzoylated analogs (S)-3.74-(S)-3.82. pKi values calculated from Ki values listed in 
Table 3.2. The straight dotted lines represent the theoretical correlations that would have been obtained if pKi 
values had been identical for the compared analogs. 
Figure 3.6. Displacement of Cy5-pNPY by 
NG-substituted amine precursor (S)-3.49 and 
the acylated analogs (S)-3.64, (S)-3.75, and 
(S)-3.83 (mean values ± SEM; n = 2-3). 
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The Y2R selectivity of representative examples of the argininamide-type Y2R 
antagonists was confirmed by flow cytometric binding studies using Cy5-pNPY or Cy5-
[K4]hPP, respectively, and cells expressing human Y1, Y4 and Y5 receptors (hY1R, hY4R, 
hY5R) (Table 3.4). Hence, the structural changes in the pharmacophoric core structure 
and the bioisosteric replacement of the guanidine moiety, respectively, did not affect 
Y2R selectivity. 
Table 3.4. Binding data of selected Y2R antagonists at hY1R, hY4R and hY5R. 
No 
Ki / nMa 
No 
Ki / nMa 
hY1R hY4R hY5R hY1R hY4R hY5R 
(S)-3.47 > 5000 > 7500 > 5000 (S)-3.57 > 3500 > 6500 > 5000 
(R)-3.47 > 3500 > 7500 > 5000 (S)-3.58 > 3000 > 6500 > 5000 
(R)-3.48 > 3500 > 6500 > 5000 3.61 > 3500 > 6500 > 500 
(S)-3.49 > 5000 > 6500 > 5000 3.46 > 3500 > 6500 > 500 
(S)-3.50 > 5000 > 6500 > 5000 (S)-3.63 > 5000 > 6500 > 5000 
(R)-3.50 > 3500 > 6500 > 5000 (S)-3.69 > 3500 > 6500 > 5000 
(S)-3.53 > 3000 > 6500 > 5000 (S)-3.72 > 3500 > 6500 > 5000 
(S)-3.54 > 3000 > 6500 > 5000 (S)-3.79 > 3500 > 6500 > 2500 
(S)-3.55 > 3500 > 6500 > 5000 (S)-3.80 > 3500 > 6500 > 5000 
(S)-3.56 > 5000 > 6500 > 5000 3.86 > 3500 > 6500 > 5000 
a Flow cytometric binding assays using 10 nM Cy5-pNPY (Y1R), 5 nM Cy5-pNPY (Y5R) or 3 nM Cy5-[K
4]-hPP (Y4R) in 
HEL-Y1 cells, CHO-Y4 cells, and HEC-1B-Y5 cells, respectively. 
3.4 Summary and Conclusion 
A variety of acylguanidine and guanidine-type analogs of the highly potent Y2R 
antagonist BIIE 0246 was synthesized in order to elaborate the structure-activity 
relationships. Most compounds proved to be highly potent antagonists in the low 
nanomolar range. Modifications of the core structure of BIIE 0246 were performed in 
order to distinguish important structural motives for receptor binding. Surprisingly, 
the stereochemical switch from (S)- to (R)-configuration in the arginine moiety 
resulted in diastereomeres with hardly decreased antagonistic activity and binding 
affinity (factor 3-10). However, the affinity towards the Y2R was considerably reduced 
(≈ 10-fold) when the cyclopentane-1,1-diyl substructure was replaced with a 
methylene group, proving that – to some extent – the more rigid and bulky moiety in 
the “western part” of BIIE 0246 confers to Y2R binding. Since BIIE 0246 was developed 
as a putative mimic of the C-terminal part of NPY, the 4-(2-aminoethyl)-1,2-diphenyl-
1,2,4-triazolidin-3,5-dione moiety was replaced by more hydrophilic groups, namely a 
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phenylalaninamide and a tyrosinamide moiety, respectively. These analogs showed 
drastically decreased affinities, in contrast to reported data from patent literature. 
Most likely these compounds do not mimic the endogenous peptide in terms of 
binding. 
Additionally, NG-substituted Y2R antagonists bearing a free amine group were 
designed as precursors towards radio- and fluorescence labeled pharmacological 
tools following the guanidine-acylguanidine bioisosteric approach: the guanidine 
group was substituted with different ω-aminoacyl-, or ω-aminoalkylcarbamoyllinkers. 
Such derivatives – at physiological pH positively charged – proved to be highly potent 
Y2R antagonists with retained or even increased affinity compared to the parent 
compound BIIE 0246. The NG-carbamoylated ligand (S)-3.53 is especially noteworthy 
as it represents the most potent, selective Y2R antagonist known so far. Masking the 
positive charge in the linker, e.g., by acylation, has an affinity-lowering effect. 
Presumably, an additional positive charge in the linker contributes to Y2R binding by 
electrostatic interactions. 
Sufficient stability of the acylated and carbamoylated analogs in aqueous solution 
was proven for a selection of compounds. Acylguanidines containing a free amino 
group were less stable than the corresponding acylamino analogs. Y2R antagonists 
containing a carbamoylguanidine moiety showed a very low degree of 
decomposition, demonstrating the superiority of carbamoylated compounds 
compared to acylated guanidines in terms of stability under assay conditions. 
In conclusion, the acylguanidine substructure is useful for the synthesis of arginine-
derived non-peptidic NPY Y2R antagonists with reduced basicity. In view of recent 
results on Y1R and histamine receptor ligands, our study corroborates the hypothesis 
that the guanidine-acylguanidine exchange is a promising and broadly applicable 
bioisosteric approach. As functionalization of the amine precursors is compatible with 
high Y2R affinity and selectivity, these compounds are promising building blocks for 
the preparation of versatile pharmacological tools such as fluorescent and 
radiolabeled ligands. 
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3.5 Experimental Section 
3.5.1 General Experimental Conditions 
Unless otherwise stated, chemicals and solvents were purchased from commercial 
suppliers and used without further purification. L/D-Ornithine, N-tert-
butoxycarbonyl-L-phenylalanine, and N-tert-butoxycarbonyl-O-benzyl-L-tyrosine were 
obtained from Iris Biotech (Marktredwitz, Germany). If not otherwise indicated, tert-
butoxycarbonyl protected ω-amino carboxylic acids were obtained from Sigma-
Aldrich Chemie GmbH (Munich, Germany). Deuterated solvents for NMR 
spectroscopy were from Deutero GmbH (Kastellaun, Germany). All solvents were of 
analytical grade or distilled prior to use. If moisture-free conditions were required, 
reactions were performed in dried glassware under argon atmosphere; DMF (H2O < 
0.01 %) was purchased from Sigma-Aldrich Chemie GmbH. Thin layer chromato-
graphy was performed on Merck silica gel 60 F254 TLC aluminum plates. Spots were 
visualized with UV light at 254 nm, and/or ninhydrin or ammonium 
molybdate/cerium (IV) sulfate solution. Geduran 60 (Merck, particle size 0.040-0.063 
mm) was used for flash column chromatography. Flash chromatography was 
performed on an Intelli Flash 310 Flash Chromatography Workstation from Varian 
Deutschland GmbH (Darmstadt, Germany).  
Optical rotations at 589 nm (NaD line) were determined on an Optronic P8000T 
Polarimeter from A. Krüss (Hamburg, Germany) using a quartz micro-cuvette (layer 
thickness: 100 mm, volume: 1 mL, thermostated at 20 °C) and acetonitrile/H2O 9:1 
(v/v) as solvent. IR spectra were measured on a FTS 3000MX spectrometer (Excalibur 
Series) from Bio-Rad (Hercules, CA, USA) equipped with an attenuated total 
reflectance (ATR) unit (Specac Golden Gate Diamond Single Reflection ATR System).  
NMR spectra were recorded on an Avance 300, an Avance 400 and an Avance III 600 
spectrometer from Bruker BioSpin GmbH (Rheinstetten, Germany) with TMS as 
external standard. Multiplicities are specified with the following abbreviations: s 
(singlet), d (doublet), t (triplet), quat (quartet), p (quintet), m (multiplet), br (for 
broad singulet), as well as combinations thereof. Low resolution mass spectrometry 
analysis (MS) was performed in-house on a Finnigan ThermoQuest TSQ 7000 (ES-MS) 
and a Finnigan SSQ 710A (EI-MS 70 eV, CI-MS). High resolution mass spectrometry 
was performed on a Finnigan MAT 95 (LSI-MS).  
Melting points were determined with a Büchi 510 melting point apparatus and are 
uncorrected. The melting points are defined as the transition of the solid state into an 
amorphous state. Lyophilization was done with a Christ alpha 2-4 LD equipped with a 
vacuubrand RZ 6 rotary vane vacuum pump.  
Preparative HPLC was performed with a system from Knauer (Berlin, Germany) 
consisting of two K-1800 pumps, a K-2001 detector and a RP-column (Nucleodur 100-
5 C18ec, 250 × 21 mm, 5 μm) at a flow rate of 22 mL/min. Mixtures of acetonitrile 
and 0.1 % aq. TFA were used as mobile phase. Acetonitrile was removed from the 
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eluates under reduced pressure (final pressure: 90 mbar) at 45 °C prior to 
lyophilization. Analytical HPLC analysis was performed on two different systems 
(Thermo Separation Products, Merck) which are listed in detail below. Mixtures of 
acetonitrile (A) and 0.05 % aq. TFA (B) (Thermo Separation Products), and mixtures of 
acetonitrile + 0.025 % TFA (A) and 0.025 % aq. TFA (B) (Merck), respectively, were 
used as mobile phase. Helium degassing was used throughout. 
The buffer for the Y2R binding studies on CHO cells was prepared by the addition of 
BSA (1 %) and bacitracin (100 μg/mL) to a buffer (pH 7.4) consisting of HEPES 
(25 mM), CaCl2 × 2 H2O (2.5 mM), MgCl2 × 6 H2O (1 mM). The loading buffer (pH 7.4) 
for the determination of the mobilization of intracellular Ca2+ in CHO cells was pre-
pared by dissolving NaCl (120 mM), KCl (5 mM), MgCl2 × 6 H2O (2 mM), CaCl2 × 2 H2O 
(1.5 mM), HEPES (25 mM), and glucose (10 mM). Stock solutions of all compounds 
were prepared in DMSO at concentrations of 2 or 10 mM and stored at –20 °C. 
 
Analytical HPLC systems: 
System 1: Thermo Separation Products; composed of a SN400 controller, a P4000 
pump, a degasser (Degassex DG-4400, phenomenex), an AS3000 autosampler and a 
Spectra Focus UV-VIS detector; flow rate: 0.8 mL/min; UV detection: 220 nm. 
System 2: Merck; composed of a L-5000 controller, a 655A-12 pump, a 655A-40 
autosampler and a L-4250 UV-VIS detector; flow rate: 0.7 mL/min; UV detection: 
220 nm. 
 
Applied gradients:  
Gradient 1 (Thermo Separation Products): 0 to 30 min: A/B 20/80 to 95/5, 30 to 37 
min: 95/5. 
Gradient 2 (Merck): 0 to 30 min: A/B 20/80 to 95/5, 30 to 40 min: 95/5. 
The purity of all compounds was determined with HPLC system 1 (gradient 1) on a 
Eurospher-100 C18 column (250 × 4 mm, 5 μm, Knauer, Berlin, Germany), except for 
compounds (R)-3.47, (R)-3.48, (R)-3.50, 3.85, which were analyzed with a Nucleodur 
H-Tec 100-5 C18 column (250 × 4 mm, 5 μm, Macherey-Nagel, Düren, Germany). The 
HPLC system 2 (gradient 2) was used for reaction monitoring with a Eurospher-100 
C18 column (250 × 4 mm, 5 μm, Knauer, Berlin, Germany). 
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3.5.2 Chemistry: Experimental Protocols and Analytical Data 
(R)- and (S)-Nδ-Phthaloylornithine hydrochloride ((R)-3.1, (S)-3.1).34 To a clear 
solution of (D)- or (L)-ornithine hydrochloride (21.91 g, 0.13 mol) and NaOH (10.4 g, 
0.26 mol) in 200 mL water was added CuSO4 × 5 H2O (16.25 g, 0.065 mol) in 200 mL 
water. After stirring for 15 min, NaHCO3 (13.4 g, 0.16 mol) and N-ethoxycarbonyl 
phthalimide were added and the mixture was intensely stirred for an additional hour. 
The resulting blue copper complex of 3.1 was collected on a suction filter, washed 
with water, EtOH, CHCl3 and diethyl ether, and dried in vacuum. To the finely 
grounded blue powder was added 6 M HCl (200 mL) and the green suspension was 
stirred for 1 h. The yellowish solid was separated by a suction filter, washed with 6 M 
HCl and air-dried. The crude product was dissolved in warm MeOH (450 mL) and 
filtered. The filtrate was diluted with ethyl acetate (900 mL) to obtain the product as 
a colorless crystalline precipitate. The product was collected on a filter, washed with 
ethyl acetate, and dried. A second crop of crystals was attained on concentration of 
the mother liquor (23.06 g; 60 %). Mp 223-224 °C (decomp.)34; 1H NMR (300 MHz, 
DMSO-d6): δ = 1.79 (m, 4H, CβH2CγH2), 3.59 (m, 2H, CδH2), 3.87 (s, 1H, CαH), 7.85 (m, 
4H, Pht), 8.46 (br, 2H, NH2) ppm; MS (ES, +p) m/z (%): 263 (100) [M+H]+, 217 (45) 
[M+H–CH2O2]+; C13H14N2O4 × HCl (298.08). 
 
(R)- and (S)-Nα-tert-Butoxycarbonyl-Nδ-phthaloylornithine ((R)-3.2, (S)-3.2).35 (R)- or 
(S)-3.1 (20.3 g, 68.0 mmol) was dissolved in 250 mL water and NaHCO3 (12.60 g, 0.15 
mol) was added in small portions. Subsequently, a solution of Boc2O (15.27 g, 70.0 
mmol) in 1,4-dioxane (700 mL) was introduced and the reaction mixture was stirred 
for 3 h. The solution was washed with diethyl ether (500 mL, discarded) and carefully 
adjusted to pH 2 with 2 M HCl. The product was extracted with ethyl acetate (3 × 250 
mL); the combined extracts were dried over anhydrous Na2SO4 and the solvents were 
removed under reduced pressure. Recrystallization from toluene/petroleum ether 
gave the title compound as a white solid (14.62 g, 49 %). Mp. 126-127 °C; 1H NMR 
(300 MHz, DMSO-d6): δ = 1.35 (m, 9H, Boc), 1.47-1.78 (m, 4H, CβH2CγH2), 3.57 (m, 2H, 
CδH2), 3.85 (s, 1H, CαH), 7.05 (m, 1H, NH), 7.84 (m, 4H, Pht), 12.40 (br, 1H, COOH) 
ppm; MS (ES, +p) m/z (%): 380 (100) [M+NH4]+, 363 (35) [M+H]+; C18H22N2O6 (362.15). 
 
1,2-Diphenyl-1,2,4-triazolidin-3,5-dione (3.3).7 1,2-Diphenylhydrazine (18.4 g, 0.1 
mol) and ethyl allophanate (13.2 g, 0.1 mol) were heated in xylene (300mL) under 
reflux for 24 h. The mixture was allowed to cool to ambient temperature and then 
poured into 300 mL petroleum ether. The product was collected on a filter and re-
dissolved in acetone (400 mL). Insoluble by-products were filtered off and the filtrate 
concentrated to about 200 mL. After addition of water (200 mL) crystals began to 
form. After complete crystallization the product was separated by filtration, washed 
with water, and dried in vacuum affording pale yellow crystals (14.0 g, 55 %). Mp 216-
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217 °C; 1H NMR (300 MHz, DMSO-d6): δ = 7.22 (m, 2H, Ph), 7.37 (m, 8H, Ph), 12.05 (br, 
1H, CONHCO) ppm; MS (CI, NH3) m/z (%): 271 (100) [M+NH4]+, 254 (24) [M+H]+; 
C14H11N3O2 (253.09). 
 
4-(2-Phthalimidoethyl)-1,2-diphenyl-1,2,4-triazolidin-3,5-dione.7 3.3 (10.12 g, 40 
mmol) were dissolved in 120 mL DMF and the solution was cooled in an ice-water 
bath. KOtBu (4.94 g, 44 mmol) was added under stirring. After the KOtBu was 
completely dissolved, 2-bromoethylphthalimide (11.18 g, 44 mmol) was introduced 
and the mixture heated under reflux for 5 h. The resulting mixture was concentrated 
under reduced pressure and the residue was suspended in an aq. solution of K2CO3. 
The product was collected on a sintered filter, washed with water, and dried in 
vacuum at 50 °C. Recrystallization from 2-propanol afforded the title compound as a 
colorless, crystalline solid (10.31 g, 60 %). Mp 169-170 °C; 1H NMR (300 MHz, DMSO-
d6): δ = 3.83 and 3.90 (m, 4H, CH2CH2), 7.23 (m, 2H, Ph), 7.32 (m, 8H, Ph), 7.80 (m, 4H, 
Pht) ppm; MS (CI, NH3) m/z (%): 426 (100) [M ]; C24H18N4O4 (426.13). 
 
4-(2-Aminoethyl)-1,2-diphenyl-1,2,4-triazolidin-3,5-dione (3.4).7 Phthalimide-
protected precursor (10.28 g, 24.1 mmol) was dissolved in 200 mL THF/methanol 2:1 
(v/v) and treated with hydrazine hydrate (3.31 g, 66.2 mmol). The mixture was stirred 
at ambient temperature for 16 h. 2 M HCl (45 mL) was added and stirring was 
continued for 2 h. The organic solvents were removed under reduced pressure and 
the residual suspension was diluted with water (120 mL) and alkalified with 2 M aq. 
NaOH (pH 10). The aqueous phase was extracted with CH2Cl2 (3 × 100 mL); the 
extracts were pooled, dried over K2CO3 and evaporated to dryness. The crude product 
was suspended in ethanol and treated with 1 M HCl in diethyl ether. The precipitate 
was collected on a filter, washed with petroleum ether, and dried. In order to obtain 
the free amine base, the hydrochloride was partitioned between 2 M aq. NaOH and 
CH2Cl2. The CH2Cl2 extracts were dried over anhydrous K2CO3 and concentrated. The 
residue was dried in vacuum and recrystallized from hot cyclohexane to obtain the 
title compound as a white solid (5.28 g, 74 %). 1H NMR (300 MHz, DMSO-d6): δ = 1.68 
(br, 2H, NH2), 2.79 (t, 3J = 6.5 Hz, 2H, CH2CH2NH2), 3.54 (t, 3J = 6.5 Hz, 2H, CH2CH2NH2), 
7.23 (m, 2H, Ph), 7.38 (m, 8H, Ph) ppm; MS (CI, NH3) m/z (%): 297 (100) [M+H]+; 
C16H16N4O2 (296.13). 
 
5H-Dibenzo[b,e]azepin-6,11-dione (3.5). A mechanically stirred mixture of 9,10-
anthraquinone (20.8 g, 0.1 mol), sodium azide (7.8 g, 0.12 mol) and CHCl3 (200 mL) 
was cooled in an ice-bath, while concentrated sulfuric acid (60 mL) was added 
dropwise. After completion of the addition the mixture was heated under reflux for 
10 h. The cold mixture was poured into a chilled sodium carbonate solution (10 % 
w/w, 750 mL) in small portions. The mixture was alkalized with concentrated 
ammonia solution and allowed to stand until the precipitate had settled. The 
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supernatant clear solution was decanted and replaced by methanol (300 mL). The 
raw product was collected on a suction filter, washed with methanol and ether and 
dissolved in boiling acetic acid. Insoluble by-products were removed by filtering the 
hot suspension. After cooling, the product was separated by filtration and dried in 
vacuum at 60 °C affording fine, pale yellow crystals (13.2 g, 59 %). Mp 244-245 °C; 1H 
NMR (300 MHz, DMSO-d6): δ = 7.23 (m, 1H, Har), 7.33 (m, 1H, Har), 7.60 (m, 1H, Har), 
7.71 (m, 1H, Har), 7.81 (m, 3H, Har), 8.17 (m, 1H, Har), 11.09 (br, 1H, NH) ppm; 
C14H9NO2 (223.23). 
 
11-Hydroxy-5,11-dihydrodibenzo[b,e]azepin-6-one (3.6). NaBH4 (3.0 g, 80 mmol) 
was slowly added to a suspension of 3.5 (9.0 g, 40 mmol) in ethanol (500 mL). After 
complete addition, the mixture was heated under reflux for 1 h. The mixture was 
concentrated in vacuum to about 100 mL, treated with ammonium chloride solution 
and neutralized with hydrochloric acid. The colorless precipitate was filtered, washed 
with water, methanol, and petroleum ether, and dried in vacuum (8.5 g, 94 %) 
yielding a white powder. Mp 247-248 °C; 1H NMR (300 MHz, DMSO-d6): δ = 5.65 (s, 
1H, 11-H), 6.40 (s, 1H, OH), 7.0-8.0 (m, 8H, Har), 10.5 (s, 1H, NH) ppm; C14H11NO2 
(225.24). 
 
11-Chloro-5,11-dihydrodibenzo[b,e]azepin-6-one (3.7). To a suspension of 3.6 (8.5 g, 
37.5 mmol) in CHCl3 (200 mL) was added SOCl2 (10 mL) and the reaction mixture was 
heated under reflux for 30 min. The mixture was concentrated under reduced 
pressure and treated with n-hexane (100 mL). The product was collected on a filter, 
washed with n-pentane and dried in vacuum to afford a white powder (8.8 g, 96 %). 
Mp 218-220 °C; 1H NMR (300 MHz, DMSO-d6): δ = 5.68 (s, 1H, 11-H), 7.0-8.0 (m, 8H, 
Har), 10.84 (s, 1H, NH) ppm; C14H10ClNO (243.69). 
 
11-Piperazin-1-yl-5,11-dihydrodibenzo[b,e]azepin-6-one (3.8).36 A solution of 3.7 
(7.47 g, 30.7 mmol) in 150 mL 1,4-dioxane was added slowly to a stirred solution of 
piperazine (13.22 g, 153.5) in 250 mL 1,4-dioxane. To complete the reaction, the 
mixture was heated under reflux for 30 min. After cooling, the solvent was removed 
under reduced pressure and the residue partitioned between water (150 mL) and 
CHCl3 (100 mL). The aqueous phase was extracted with two additional portions of 
CHCl3 (2 × 100 mL) and the combined extracts were washed with 5 % aq. K2CO3 
solution and dried over anhydrous Na2SO4. After evaporation of the volatiles the raw 
product was purified by flash chromatography (eluent: CH2Cl2/MeOH 3:1 + 1 Vol% 
NEt3). The purified product was collected as a white powder (8.32 g, 92 %). Mp > 
260 °C (decomp.); 1H NMR (300 MHz, DMSO-d6): δ = 1.98 (m, 4H, 2 × CH2CH2NH), 3.17 
and 3.32 (m, 4H, 2 × CH2CH2NH), 4.15 (s, 1H, ArCHAr), 7.03 (m, 2H, Har), 7.21 (m, 1H, 
Har), 7.37 (m, 3H, Har), 7.46 (m, 1H, Har), 7.67 (m, 1H, Har), 10.30 (s, 1H, NH) ppm; MS 
(CI, NH3) m/z (%): 294 (100) [M+H]+; C18H19N3O (293.15). 
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2-(1-{2-Oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-
yl]ethyl}cyclopentyl)acetic acid (3.9).7 3.8 (6.4 g, 21.8 mmol) in 80 mL anhydrous 
CH2Cl2 was slowly added to a stirred and chilled (0 °C) solution of 3,3-
tetramethyleneglutaric anhydride (4.1 g, 24.0 mmol) in 35 mL anhydrous CH2Cl2. 
After stirring overnight at ambient temperature the reaction mixture was filtered and 
the filtrates were concentrated to dryness. Purification by flash chromatography 
(eluent: CH2Cl2 (A), MeOH (B); gradient: 0 to 4 min: A/B 100/0 to 96/4, 4 to 20 min: 
96/4 to 90/10) yielded the product as a white powder (7.55 g, 75 %). Mp 153-157 °C; 
1H NMR (300 MHz, DMSO-d6): δ = 1.53 (m, 8H, cyclopentyl), 2.04 (m, 4H, 3/5-H 
piperazine), 2.41 (s, 2H, >NC(O)CH2), 2.45 (s, 2H, CH2CO2H), 3.18 (m, 4H, 2/6-H 
piperazine), 4.24 (s, 1H, dibenzazepine-11-yl), 7.06 (m, 2H, Har), 7.24 (m, 1H, Har), 7.32 
(m, 1H, Har), 7.40 (m, 2H, Har), 7.49 (m, 1H, Har), 7.72 (m, 1H, Har), 10.35 (s, 1H, NH), 
11.97 (s, 1H, CO2H) ppm; MS (ES, +p) m/z (%): 462 (100) [M+H]+; C27H31N3O4 (461.23). 
 
5-Oxo-5-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-
yl]pentanoic acid (3.10).5 Preparation by analogy with the synthesis of 3.9 from 3.8 
(1.92 g, 6.54 mmol) and glutaric anhydride (0.75 g, 6.54 mmol) in appropriate 
amounts of solvent. Purification by flash chromatography (eluent: CH2Cl2/MeOH 40/1 
to 10/1) gave the title compound as a white powder (1.35 g, 51 %). 1H NMR (300 
MHz, DMSO-d6): δ = 1.65 (m, 2H, CH2CH2CH2COOH), 2.04 (m, 4H, 3/5-H piperazine), 
2.22 (m, 4H, CH2CH2CH2COOH), 3.26 (m, 4H, 2/6-H piperazine), 4.25 (s, 1H, 11-H 
dibenzazepine-11-yl), 7.06 (m, 2H, Har), 7.24 (m, 1H, Har), 7.41 (m, 3H, Har), 7.48 (m, 
1H, Har), 7.70 (m, 1H, Har), 10.36 (s, 1H, NH lactam), 12.04 (br, 1H, COOH) ppm; 13C 
NMR (75 MHz, DMSO-d6): δ = 20.1 (CH2CH2CH2COOH), 31.2 ((CH2)2CH2COOH), 32.8 
(CH2(CH2)2COOH), 40.8 (C-2/6 piperazine), 50.7 and 51.2 (C-3/5 piperazine), 73.7 (C-
11 dibenzazepine-11-yl), 121.3 (CarH), 123.6 (CarH), 127.6 (CarH), 127.9 (CarH), 128.3 
(CarH), 129.8 (CarH), 130.3 (CarH), 131.1 (CarH), 131.2 (Car), 131.6 (Car), 136.0 (Car), 142.0 
(Car), 168.0 (>NCO), 169.9 (C=O lactam), 174.1 (COOH) ppm; MS (ES, +p) m/z (%): 815 
(34) [2M+H]+, 408 (100) [M+H]+; C23H25N3O4 (407.18). 
 
(R)- and (S)-Nα-tert-Butoxycarbonyl-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-
yl)ethyl]-Nδ-phthaloylornithinamide ((R)-3.11, (S)-3.11).8 (R)- or (S)-3.2 (5.07 g, 14.0 
mmol) and HOBt × H2O (2.22 g, 14.5 mmol) were dissolved in 50 mL THF and cooled 
to 0 °C. DCC (2.89 g, 14.0 mmol) was added in one batch, followed by 3.4 (4.80 g, 16.2 
mmol). The reaction mixture was stirred and kept at 0 °C for 2 h; the cooling bath was 
removed and stirring was continued for 20 h. Dicyclohexylurea (DCU) was removed 
by filtration and the filtrate concentrated in vacuum. The residue was redissolved in 
ethyl acetate and washed with water, 5 % aq. KHCO3, 5 % aq. KHSO4, and brine. The 
organic layer was dried over anhydrous Na2SO4 and evaporated to dryness. 
Purification by flash chromatography (eluent: CH2Cl2/MeOH 80/1 to 40/1) gave the 
product as a white powder (8.13 g, 91 %). Mp 130 °C (decomp., sintering > 90 °C); 
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1H NMR (300 MHz, DMSO-d6): δ = 1.35 (m, 9H, Boc), 1.39-1.66 (m, 4H, CβH2CγH2), 
3.23-3.34 (m, 2H, CδH2), 3.47 (m, 2H, NHCH2CH2N<), 3.59 (m, 2H, NHCH2CH2N<), 3.82 
(m, 1H, CαH), 6.78 (d, 3J = 8.0 Hz, 1H, NH), 7.22 (m, 2H, Ph), 7.38 (m, 8H, Ph), 7.85 (m, 
4H, Pht), 8.11 (t, 3J = 5.9 Hz, 1H, NH) ppm; MS (ES, +p) m/z (%): 641 (100) [M+H]+, 541 
(45) [M+H–Boc]+; C34H36N6O7 (640.69). 
 
(R)- and (S)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nδ-phthaloyl-
ornithinamide⋅hydrochloride ((R)-3.12, (S)-3.12).8 (R)- or (S)-3.11 (7.00 g, 10.9 mmol) 
was dissolved in a saturated solution of HCl in ethyl acetate (25 mL). After stirring for 
2 h the reaction mixture was poured into 300 mL of petroleum ether. The solid 
product was separated by filtration, washed with diethyl ether and n-pentane, and 
dried in vacuum to afford the title compound as a white solid (6.18 g, 98%). 1H NMR 
(300 MHz, DMSO-d6): δ = 1.54-1.77 (m, 4H, CβH2CγH2), 3.25-3.68 (m, 7H, CδH2, 
NHCH2CH2N, CαH), 7.23 (m, 2H, Ph), 7.39 (m, 8H, Ph), 7.87 (m, 4H, Pht), 8.21 (br, 3H, 
NH3+), 8.83 (m, 1H, NH) ppm; MS (ES, +p) m/z (%): 541 (100) [M+H]+; C29H28N6O5 
(540.21). 
 
Preparation of Nδ-Pht protected ornithinamides (R)- and (S)-3.13 and (S)-3.148 
 
HOBt × H2O (1 eq), the pertinent carboxylic acid (1 eq) and DIPEA (1 eq) were 
dissolved in acetonitrile and cooled to 0°C. EDC × HCl (1 eq) and subsequently a 
solution of the appropriate amine (1.15 eq) and DIPEA (1 eq) in acetonitrile were 
added. The reaction mixture was stirred for 16 h, during which time the cooling bath 
was allowed to come up to room temperature. The solvent was rotary evaporated 
and the residue was redissolved in CH2Cl2. The solution was washed with water, 5 % 
aq. KHSO4, and brine, dried over anhydrous Na2SO4, and concentrated under reduced 
pressure. The crude products were purified by flash chromatography. 
 
(2R)- and (2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-
oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-
yl]ethyl}cyclopentyl)acetyl]-Nδ-phthaloylornithinamide ((R)-3.13, (S)-3.13). From 3.9 
and amine (R)- or (S)-3.12. Purification by flash chromatography (eluent: CH2Cl2 (A), 
MeOH (B); gradient: 0 to 2 min: A/B 100/0 to 98/2, 2 to 15 min: 98/2 to 95/5, 15 to 
25 min: 95/5) to yield a white solid (62-71 %). 1H NMR (600 MHz, DMSO-d6, COSY, 
HSQC): δ = 1.38 and 1.48 (m, 4H, 2/5-H cyclopentyl), 1.39 and 1.58 (m, 2H, CβH2), 1.51 
(m, 4H, 3/4-H cyclopentyl), 1.53 (m, 2H, CγH2), 2.01 (m, 4H, 3/5-H piperazine), 2.20 
(m, 2H, CH2CONαH), 2.44 (m, 2H, >NCOCH2), 3.24 and 3.26 (m, 4H, 2/6-H piperazine), 
3.26 and 3.38 (m, 2H, NHCH2CH2N<), 3.45 (m, 2H, CδH2), 3.58 (m, 2H, NHCH2CH2N<), 
4.12 (m, 1H, CαH), 4.23 (m, 1H, 11-H dibenzazepin-11-yl), 7.03 (m, 1H, Har), 7.06 (m, 
1H, Har), 7.20 (m, 2H, Ph), 7.24 (m, 1H, Har), 7.32 (m, 1H, Har), 7.35 (m, 8H, Ph), 7.38 
(m, 1H, Har), 7.39 (m, 1H, Har), 7.46 (m, 1H, Har), 7.70 (d, 3J = 7.9 Hz, 1H, Har), 7.82 (m, 
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2H, Pht), 7.84 (m, 2H, Pht), 7.92 (d, 3J = 9.2 Hz, 1H, NαH), 8.16 (t, 3J = 6.0 Hz, 1H, 
CONH(CH2)2), 10.32 (m, 1H, CONH lactam) ppm; 13C NMR (150 MHz, DMSO-d6, HSQC): 
δ = 23.2 and 23.3 (C-3/4 cyclopentyl), 24.8 (Cγ), 29.1 (Cβ), 36.1 (NHCH2CH2N<), 37.1 
(Cδ), 37.2 (C-2/5 cyclopentyl), 38.6 (>NCOCH2-cyclopentyl), 39.6 (NHCH2CH2N<), 43.0 
(CH2CONαH), 44.0 (C-1 cyclopentyl), 45.3 and 45.5 (C-2/6 piperazine), 50.7 and 51.2 
(C-3/5 piperazine), 51.9 (Cα), 73.7 (C-11 dibenzazepine-11-yl), 121.3 (CarH), 122.6 (Ph), 
123.0 (Pht), 123.7 (CarH), 126.6 (Ph), 127.7 (CarH), 127.9 (CarH), 128.4 (CarH), 129.0 
(Ph), 129.8 (CarH), 130.4 (CarH), 131.3 (CarH), 131.7 (Car), 134.3 (Pht), 136.1 (Car), 136.6 
(Car), 142.1 (Car), 152.6 (N(CONPh)2), 167.8 (C=O Pht), 168.1 (C=O lactam), 169.9 
(CON<), 171.1 (CONαH), 171.9 (CONH(CH2)2N<) ppm; MS (ES, +p) m/z (%): 985 (100) 
[M+H]+; C56H57N9O8 (983.43). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-{5-oxo-5-[4-(6-oxo-
6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]pentanoyl}-Nδ-phthaloyl-
ornithinamide ((S)-3.14). From 3.10 and (S)-3.12. Purification by flash 
chromatography (eluent: CH2Cl2/MeOH 40/1 to 20/1) to yield a white solid (50 %). MS 
(ES, +p) m/z (%): 930 (100) [M+H]+; C52H51N9O8 (929.39). 
 
Synthesis of Nδ deprotected ornithinamides (R)- and (S)-3.15 and (S)-3.168 
 
1 eq of the corresponding phthalimide ((R)-3.13, (S)-3.13, 3.14) was dissolved in 
methanol and treated with hydrazine hydrate (2.5 eq). After stirring for 16 h a 1 M aq. 
solution of KHSO4 (5 eq) was added and stirring was continued for additional 3 h. The 
precipitated solid was filtered off and washed with methanol. The filtrates were 
pooled, and the solvent was removed under reduced pressure. The residue was made 
alkaline with 5 % aq. K2CO3 and extracted with CH2Cl2. The combined extracts were 
dried over anhydrous Na2SO4 and evaporated to dryness. The crude products were 
purified by flash chromatography (eluent: CH2Cl2 + 2 Vol% NEt3 (A), MeOH (B); 
gradient: 0 to 5 min: A/B 98/2 to 95/5, 5 to 15 min: 95/5 to 90/10, 15 to 30 min: 
90/10) yielding slightly yellowish crystalline solids. 
 
(2R)- and (2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-
oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}-
cyclopentyl)acetyl]ornithinamide ((R)-3.15, (S)-3.15). Yield: 71 %. 1H NMR (600 MHz, 
DMSO-d6, COSY, HSQC): δ = 1.20-1.31 (m, 2H, CγH2), 1.35 and 1.58 (m, 2H, CβH2), 1.38 
and 1.52 (m, 4H, 2/5-H cyclopentyl), 1.52 (m, 4H, 3/4-H cyclopentyl), 2.03 (m, 4H, 
3/5-H piperazine), 2.20 and 2.24 (m, 2H, CH2CONαH), 2.40 (m, 2H, CδH2), 2.44 and 
2.47 (m, 2H, >NCOCH2-cyclopentyl), 3.23 and 3.42 (m, 2H, NHCH2CH2N<), 3.26 and 
3.29 (m, 4H, 2/6-H piperazine), 3.58 (m, 2H, NHCH2CH2N<), 4.08 (m, 1H, CαH), 4.22 (s, 
1H, 11-H dibenzazepin-11-yl), 7.04 (m, 1H, Har), 7.06 (m, 1H, Har), 7.21 (m, 2H, Ph), 
7.22 (m, 1H, Har), 7.31 (m, 1H, Har), 7.37 (m, 8H, Ph), 7.38 (m, 2H, Har), 7.46 (m, 1H, 
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Har), 7.70 (d, 3J = 7.6 Hz, 1H, Har), 7.93 (d, 3J = 8.1 Hz, 1H, NαH), 8.18 (t, 3J = 6.0 Hz, 1H, 
CONH(CH2)2) ppm; 13C NMR (150 MHz, DMSO-d6, HSQC): δ = 23.2 and 23.3 (C-3/4 
cyclopentyl), 29.2 (Cβ), 29.3 (Cγ), 36.0 (NHCH2CH2N<), 37.1 and 37.3 (C-2/5 
cyclopentyl), 38.5 (>NCOCH2-cyclopentyl), 39.8 (NHCH2CH2N<), 41.0 (Cδ), 42.8 
(CH2CONαH), 44.1 (C-1 cyclopentyl), 45.5 (C-2/6 piperazine), 50.8 and 51.2 (C-3/5 
piperazine), 52.1 (Cα), 73.7 (C-11 dibenzazepine-11-yl), 121.3 (CarH), 122.6 (Ph), 123.7 
(CarH), 126.6 (Ph), 127.6 (CarH), 127.9 (CarH), 128.3 (CarH), 129.0 (Ph), 129.9 (CarH), 
130.4 (CarH), 131.3 (CarH), 131.7 (Car), 136.1 (Car), 136.6 (Car), 142.1 (Car), 152.6 
(N(CONPh)2), 168.1 (C=O lactam), 169.9 (CON<), 171.1 (CONαH), 172.4 
(CONH(CH2)2N<) ppm; MS (ES, +p) m/z (%): 854 (100) [M+H]+; C48H55N9O6 (853.43). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-{5-oxo-5-[4-(6-oxo-
6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]pentanoyl}ornithinamide 
((S)-3.16). Yield: 60 %. 1H NMR (400 MHz, CD3OD, COSY, HSQC, HMBC): δ = 1.41 (m, 
2H, CγH2), 1.41 and 1.66 (m, 2H, CβH2), 1.81 (m, 2H, >NCOCH2CH2CH2CO), 2.09 and 
2.13 (m, 4H, 3/5-H piperazine), 2.22 (t, 3J = 7.1 Hz, 2H, >NCO(CH2)2CH2CO), 2.31 (m, 
2H, >NCOCH2(CH2)2CO), 2.49 (t, 3J = 6.5 Hz, 2H, CδH2), 3.29 and 3.37 (m, 4H, 2/6-H 
piperazine), 3.46 and 3.57 (m, 2H, NHCH2CH2N<), 3.75 (m, 2H, NHCH2CH2N<), 4.19 (m, 
2H, CαH, 11-H dibenzazepin-11-yl), 7.11 (m, 2H, Har), 7.20 (m, 2H, Har), 7.26 (m, 1H, 
Har), 7.31-7.41 (m, 11H), 7.48 (m, 1H, Har), 7.78 (m, 1H, Har) ppm; 13C NMR (100 MHz, 
CD3OD, HSQC, HMBC): δ = 22.4 and 22.5 (>NCOCH2CH2CH2CO), 29.5 (Cγ), 30.2 (Cβ), 
33.3 (>NCOCH2(CH2)2CO), 35.8 (>NCO(CH2)2CH2CO), 38.4 (NHCH2CH2N<), 41.4 
(NHCH2CH2N<), 41.8 (Cδ), 42.8 and 46.9 (C-2/6 piperazine), 52.1 and 52.7 (C-3/5 
piperazine), 54.5 (Cα), 75.9 (C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.2 (Ph), 126.0 
(CarH), 128.1 (CarH), 129.3 (CarH), 129.8 (CarH), 130.2 (Ph), 131.1 (CarH), 131.7 (CarH), 
132.5 (Car), 133.0 (CarH), 136.9 (Car), 137.9 (Car), 144.3 (Car), 154.5 (N(CONPh)2), 172.2 
(C=O lactam), 173.2 (CON<), 175.0 (CONH(CH2)2N<), 175.5 (CONαH) ppm; MS (ES, +p) 
m/z (%): 800 (50) [M+H]+, 401 (100) [M+2H]2+; C44H49N9O6 (799.38). 
 
Synthesis of the amidated Nα-Boc protected amino acids 3.17 and 3.1823-24 
 
1 eq of the appropriate Nα-Boc protected amino acid and NEt3 (0.7 eq) were dissolved 
in anhydrous THF under argon atmosphere and cooled to 0 °C in an ice-water bath. 
IBCF was introduced dropwise and stirring at 0 °C was continued for 30 min before 
cooling to –78 °C. Then a 7 M solution of ammonia in MeOH was added and stirring 
was continued at –78 °C for 1 h and then at ambient temperature for an additional 16 
h. After evaporation of the solvents, the residue was redissolved in ethyl acetate and 
washed with water. Subsequently, the aq. phase was extracted with ethyl acetate; 
the organic fractions were pooled, washed with 5 % aq. KHCO3 and brine, dried over 
Na2SO4 and concentrated under reduced pressure. The crude products were 
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subjected to flash chromatography (eluent: ethyl acetate) yielding the corresponding 
products as a white solid. 
 
(S)-Nα-tert-Butoxycarbonylphenylalaninamide (3.17). Yield: 100 %. 1H NMR (300 
MHz, CD3OD): δ = 1.35 (s, 9H, Boc), 2.80 and 3.08 (m, 2H, CβH2), 4.29 (m, 1H, CαH), 
7.17-7.30 (m, 5H, Ph) ppm; 13C NMR (75 MHz, CD3OD): δ = 28.7 (C(CH3)3), 39.4 (Cβ), 
57.2 (Cα), 80.6 (C(CH3)3), 127.7 (C-4 aryl), 129.4 and 130.4 (C-2/3/5/6 aryl), 138.8 (C-1 
aryl), 157.6 (COOC(CH3)3), 177.2 (COOH) ppm; MS (ES, +p) m/z (%): 265 (100) [M+H]+; 
C14H20N2O3 (264.15). 
 
(S)-Nα-tert-Butoxycarbonyl-O-benzyl-tyrosinamide (3.18). Yield: 97 %. 1H NMR (300 
MHz, DMSO-d6): δ = 1.30 (s, 9H, Boc), 2.65 and 2.86 (m, 2H, CβH2), 4.02 (m, 1H, CαH), 
5.05 (s, 2H, OCH2), 6.92 (d, 3J = 8.5 Hz, 2H, Ph), 7.15 (d, 3J = 8.5 Hz, 2H, Ph), 7.38 (m, 
5H, Ph) ppm; 13C NMR (75 MHz, DMSO-d6): δ = 28.1 (C(CH3)3), 36.6 (Cβ), 55.7 (Cα), 69.0 
(OCH2), 77.8 (C(CH3)3), 114.2 (C-1 phenyl), 127.5 (Ph), 128.3 (Ph), 130.1 (Ph), 130.3 
(Ph), 137.1 (C-1 benzyl), 155.1 (COOC(CH3)3), 156.7 (C-4 phenyl), 173.6 (CONH2) ppm; 
MS (ES, +p) m/z (%): 741 (100) [2M+H]+, 371 (60) [M+H]+; C21H26N2O4 (370.19). 
 
Preparation of the Nα-Boc deprotected amidated amino acids 3.19 and 3.20 
 
Deprotection was carried out in TFA/CH2Cl2 1:1 (v/v) (approx. 5 mL/0.2 mmol 
substrate). After stirring for 2 h toluene was added and the volatiles were removed 
under reduced pressure. The products were used without further purification.  
 
(S)-Phenylalaninamide (3.19).37 Yield: 100 %. 1H NMR (300 MHz, DMSO-d6): δ = 3.02 
(m, 2H, CβH2), 3.60 (br, 2H, NH2), 3.96 (t, 3J = 6.5 Hz, 1H, CαH), 7.21-7.38 (m, 5H, Ph), 
8.18 (br, 2H, CONH2) ppm; 13C NMR (75 MHz, DMSO-d6): δ = 36.7 (Cβ), 53.3 (Cα), 127.0 
(C-4 aryl), 128.4 and 129.4 (C-2/3/5/6 aryl), 134.5 (C-1 aryl), 169.6 (CONH2) ppm; MS 
(ES, +p) m/z (%): 206 (100) [M+H+CH3CN]+, 165 (50) [M+H]+; C9H12N2O (164.09). 
 
(S)-O-Benzyl-tyrosinamide (3.20).38 Yield: 100 %. 1H NMR (300 MHz, DMSO-d6): δ = 
2.95 (m, 2H, CβH2), 3.90 (m, 1H, CαH), 5.08 (s, 2H, OCH2), 6.99 (d, 3J = 8.6 Hz, 2H, Ph), 
7.16 (d, 3J = 8.6 Hz, 2H, Ph), 7.30-7.47 (m, 5H, Ph), 8.11 (br, 2H, CONH2) ppm; 13C NMR 
(75 MHz, DMSO-d6): δ = 35.9 (Cβ), 53.4 (Cα), 69.0 (OCH2), 114.7 (C-1 phenyl), 127.0 
(Ph), 127.6 (Ph), 127.7 (Ph), 128.3 (Ph), 130.5 (Ph), 137.0 (C-1 benzyl), 157.4 (C-4 
phenyl), 169.7 (CONH2) ppm; MS (ES, +p) m/z (%): 541 (45) [2M+H]+, 271 (100) 
[M+H]+; C16H18N2O2 (270.14). 
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Preparation of Nα-Boc protected dipeptides 3.21 and 3.22 
 
To a stirred solution of (S)-3.2 (1 eq) and DIPEA (1 eq) in DMF was added TBTU (1 eq). 
The pertinent C-terminally amidated amino acid (1 eq) and DIPEA (1 eq) were 
introduced and stirring was continued for 16 h. The solution was diluted with ethyl 
acetate and washed with 5 % aq. KHSO4, 5 % aq. KHCO3 and brine, dried over Na2SO4 
and evaporated. Flash chromatography (eluent: CH2Cl2/MeOH 40/1 to 20/1) afforded 
the products as white to yellow solids. 
 
(S)-Nα-((S)-Nα-tert-Butoxycarbonyl-Nδ-phthaloylornithyl)phenylalaninamide (3.21). 
Yield: 77 %. 1H NMR (300 MHz, DMSO-d6): δ = 1.34 (s, 9H, Boc), 1.48 (m, 4H, 
CβH2CγH2), 2.82 and 2.96 (m, 2H, CβH2 Phe-amide), 3.51 (m, 2H, CδH2), 3.79 (m, 1H, 
CαH Orn), 4.40 (m, 1H, CαH Phe-amide), 7.00 (m, 1H, NH), 7.11 and 7.39 (m, 2H, 
CONH2), 7.18 (m, 5H, Ph), 7.67 (m, 1H, NH), 7.87 (m, 4H, Pht) ppm; 13C NMR (75 MHz, 
DMSO-d6): δ = 24.8 (Cγ), 28.0 (C(CH3)3), 37.0 (Cβ Phe-amide), 37.4 (Cδ), 53.1 (Cα Phe-
amide), 78.1 (C(CH3)3), 122.9 (Pht), 126.0 (C-4 aryl), 127.8 (Ph), 129.1 (Ph), 131.6 
(Pht), 134.2 (C-1 aryl), 137.5 (Pht), 155.3 (COOC(CH3)3), 167.8 (C=O Pht), 171.4 
(CONH2), 172.5 (CONαH Phe-amide) ppm; a peak for Cα and Cβ Orn could not be 
detected; MS (ES, +p) m/z (%): 509 (100) [M+H]+; C27H32N4O6 (508.23). 
 
(S)-Nα-((S)-Nα-tert-Butoxycarbonyl-Nδ-phthaloylornithyl)-O-benzyl-tyrosinamide 
(3.22). Yield: 53 %. 1H NMR (300 MHz, DMSO-d6): δ = 1.34 (s, 9H, Boc), 1.53 (m, 4H, 
CβH2CγH2), 2.76 and 2.93 (m, 2H, CβH2 Tyr(OBn)-amide), 3.52 (m, 2H, CδH2), 3.79 (m, 
1H, CαH Orn), 4.35 (m, 1H, CαH Tyr(OBn)-amide), 5.03 (s, 2H, OCH2), 6.88 (m, 2H, 
CONH2), 7.06 (m, 4H, Ph), 7.38 (m, 5H, Ph), 7.38 (m, 1H, NH), 7.62 (m, 1H, NH), 7.85 
(m, 4H, Pht) ppm; 13C NMR (75 MHz, DMSO-d6): δ = 24.9 (Cγ), 28.0 (C(CH3)3), 36.0 (Cβ 
Tyr(OBn)-amide), 37.0 (Cδ), 53.3 (Cα Orn), 54.4 (Cα Tyr(OBn)-amide), 69.0 (OCH2), 78.1 
(C(CH3)3), 114.1 (C-3/5 phenyl), 122.8 (Pht), 127.7 (C-3/5 benzyl), 128.3 (C-2/6 
benzyl), 129.6 (C-2/6 phenyl), 130.2 (Pht), 131.6 (C-1 phenyl), 134.2 (Pht), 156.8 (C-4 
phenyl), 167.9 (C=O Pht), 171.4 (CONH2), 172.5 (CONαH Tyr(OBn)-amide) ppm; a peak 
for Cβ could not be detected; MS (ES, +p) m/z (%): 615 (100) [M+H]+; C34H38N4O7 
(614.27). 
 
Preparation of the Boc-deprotected C-terminally amidated dipeptides 3.23 and 3.24 
 
The pertinent dipeptide was dissolved in a saturated solution of HCl in ethyl acetate 
(25 mL). After stirring for 2 h the precipitate was filtered off; the mother liquor was 
poured into 300 mL of petroleum ether to give additional precipitated product. The 
solids were combined, washed with diethyl ether and n-pentane, and dried in 
vacuum to afford the title compounds as white solids. 
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(S)-Nα-((S)-Nδ-Phthaloylornithyl)phenylalaninamide (3.23). Yield: 82 %. 1H NMR (300 
MHz, DMSO-d6): δ = 1.69 (m, 4H, CβH2CγH2), 2.85 and 2.96 (m, 2H, CβH2 Phe-amide), 
3.56 (m, 2H, CδH2), 3.78 (m, 1H, CαH Orn), 4.44 (m, 1H, CαH Phe-amide), 7.10 and 7.60 
(m, 2H, CONH2), 7.19 (m, 1H, Ph), 7.26 (m, 4H, Ph), 7.86 (m, 4H, Pht), 8.18 (br, 2H, 
NH2), 8.67 (m, 1H, NH) ppm; 13C NMR (75 MHz, DMSO-d6): δ = 23.6 (Cγ), 29.0 (Cβ Orn), 
37.4 (Cβ Phe-amide), 52.4 (Cα Orn), 54.2 (Cα Phe-amide), 123.0 (Pht), 126.3 (C-4 aryl), 
128.0 and 129.1 (C-2/3/5/6 aryl), 131.5 (Pht), 134.4 (C-1 aryl), 137.6 (Pht), 167.8 (C=O 
Pht), 172.1 (CONαH Phe-amide) ppm; a peak for Cδ and CONH2 could not be detected; 
MS (ES, +p) m/z (%): 409 (100) [M+H]+; C22H24N4O4 (408.18). 
 
(S)-Nα-((S)-Nδ-Phthaloylornithyl)-O-benzyl-tyrosinamide (3.24). Yield: 83 %. 1H NMR 
(300 MHz, DMSO-d6): δ = 1.69 (m, 4H, CβH2CγH2), 2.76 and 2.89 (m, 2H, CβH2 Tyr(OBn)-
amide), 3.57 (m, 2H, CδH2), 3.75 (m, 1H, CαH Orn), 4.41 (m, 1H, CαH Tyr(OBn)-amide), 
5.05 (s, 2H, OCH2), 6.90 (m, 2H, Ph), 7.00-7.45 (m, 7H, Ph), 7.56 (m, 1H, NH), 7.88 (m, 
4H, Pht), 8.05 (br, 3H, NH3+), 8.55 (m, 1H, NH) ppm; 13C NMR (75 MHz, DMSO-d6): δ = 
23.6 (Cγ), 36.8 (Cβ Tyr(OBn)-amide), 37.4 (Cδ), 51.7 (Cα Orn), 54.3 (Cα Tyr(OBn)-amide), 
69.0 (OCH2), 114.3 (C-3/5 phenyl), 123.0 (Pht), 127.5 (C-2/6 benzyl), 127.7 (C-4 
benzyl), 128.3 (C-3/5 benzyl), 129.6 (C-2/6 phenyl), 130.1 (Pht), 131.5 (C-1 phenyl), 
134.4 (Pht), 137.1 (C-1 benzyl), 156.9 (C-4 phenyl), 167.8 (C=O Pht), 172.2 (CONαH 
Tyr(OBn)-amide) ppm; a peak for Cβ could not be detected; MS (ES, +p) m/z (%): 515 
(100) [M+H]+; C29H30N4O5 (514.22). 
 
General procedure for the preparation of Nδ-Pht protected ornithinamides 3.25 and 
3.26 
 
3.9 (1 eq) and DIPEA (1 eq) were dissolved in DMF. TBTU (1 eq) and subsequently the 
appropriate amine (1 eq) and DIPEA (1 eq) were added. After stirring for 16 h the 
reaction mixture was diluted with ethyl acetate and washed with 5 % aq. KHSO4, 5 % 
aq. KHCO3 and brine, dried over anhydrous Na2SO4, and concentrated under reduced 
pressure. The crude products were purified by flash chromatography (eluent: 
CH2Cl2/MeOH, 40/1 to 20/1) yielding white solids. 
 
(2S)-Nα-[2-(1-{2-Oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-
yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]-Nδ-phthaloylornithylphenylalaninamide 
(3.25). Yield: 81 %. 1H NMR (300 MHz, DMSO-d6): δ = 1.40-1.60 (m, 12H, 2/5-H 
cyclopentyl, 3/4-H cyclopentyl, CβH2CγH2), 2.03 (m, 4H, 3/5-H piperazine), 2.19 (m, 2H, 
CH2CONαH), 2.41 (m, 2H, >NCOCH2-cyclopentyl), 2.74 and 2.98 (m, 2H, CβH2 Phe-
amide), 3.28 (m, 4H, 2/6-H piperazine), 3.49 (m, 2H, CδH2), 4.07 (m, 1H, CαH Orn), 
4.23 (br, 1H, 11-H dibenzazepine-11-yl), 4.34 (m, 1H, CαH Phe-amide), 7.06 (m, 4H, 
Ph), 7.15 (m, 4H, Ph), 7.24 (m, 1H, Har), 7.31 (m, 1H, Har), 7.39 (m, 2H, Ph), 7.46 (m, 
1H, Har), 7.46 and 7.70 (m, 2H, CONH2), 7.85 (m, 4H, Pht), 7.92 (d, 3J = 8.2 Hz, 1H, NH), 
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8.08 (m, 1H, NH), 10.36 (m, 1H, CONH lactam) ppm; 13C NMR (75 MHz, DMSO-d6): δ = 
23.1 (C-3/4 cyclopentyl), 24.6 (Cγ), 28.9 (Cβ Orn), 37.0 (Cδ), 37.0 (C-2/5 cyclopentyl), 
37.3 (Cβ Phe-amide), 38.0 (>NCOCH2-cyclopentyl), 42.6 (CH2CONαH), 43.9 (C-1 
cyclopentyl), 52.5 (Cα Orn), 53.6 (Cα Phe-amide), 73.6 (C-11 dibenzazepine-11-yl), 
121.2 (CarH), 122.9 (Pht), 123.6 (CarH), 126.0 (Ph), 126.5 (Ph), 127.6 (CarH), 127.8 
(CarH), 128.3 (CarH), 128.9 (Ph), 129.8 (CarH), 130.3 (CarH), 131.1 (Ph), 131.2 (CarH), 
131.5 (Car), 134.3 (Pht), 136.0 (Car), 137.9 (Pht), 142.0 (Car), 167.7 (C=O Pht), 168.0 
(C=O lactam), 169.9 (CON<), 171.7 (CONαH Orn), 172.7 (CONαH Phe-amide) ppm; MS 
(ES, +p) m/z (%): 852 (100) [M+H]+; C49H53N7O7 (851.40). 
 
(2S)-Nα-[2-(1-{2-Oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)-
piperazin-1-yl]ethyl}cyclopentyl)acetyl]-Nδ-phthaloylornithyl-O-benzyl-tyrosin-
amide (3.26). Yield: 59 %. 1H NMR (300 MHz, DMSO-d6): δ = 1.35-1.65 (m, 12H, 2/5-H 
cyclopentyl, 3/4-H cyclopentyl, CβH2CγH2), 2.02 (m, 4H, 3/5-H piperazine), 2.20 (m, 2H, 
CH2CONαH), 2.40 (m, 2H, >NCOCH2-cyclopentyl), 2.70 and 2.92 (m, 2H, CβH2 Tyr(OBn)-
amide), 3.26 (m, 4H, 2/6-H piperazine), 3.51 (m, 2H, CδH2), 4.11 (m, 1H, CαH Orn), 
4.21 (br, 1H, 11-H dibenzazepine-11-yl), 4.29 (m, 1H, CαH Tyr(OBn)-amide), 5.02 (s, 
2H, OCH2), 6.85 (m, 2H, Ph), 7.07 (m, 5H, Ph), 7.21-7.43 (m, 10H), 7.48 and 7.71 (m, 
2H, CONH2), 7.83 (m, 4H, Pht), 7.83 (m, 1H, NH), 8.05 (m, 1H, NH), 10.37 (m, 1H, 
CONH lactam) ppm; 13C NMR (75 MHz, DMSO-d6): δ = 23.1 (C-3/4 cyclopentyl), 24.7 
(Cγ), 29.0 (Cβ Orn), 37.0 (Cδ), 37.0 (C-2/5 cyclopentyl), 37.3 (Cβ Tyr(OBn)-amide), 38.1 
(>NCOCH2-cyclopentyl), 42.6 (CH2CONαH), 43.9 (C-1 cyclopentyl), 45.4 (C-2/6 
piperazine), 50.7 (C-3/5 piperazine), 52.4 (Cα Orn), 53.8 (Cα Tyr(OBn)-amide), 69.0 
(OCH2), 73.6 (C-11 dibenzazepine-11-yl), 114.2 (C-3/5 phenyl), 121.2 (CarH), 122.9 
(Pht), 123.6 (CarH), 127.5 (Ph), 127.7(CarH), 127.8 (CarH), 128.3 (Ph), 129.8 (CarH), 130.0 
(Ph), 130.3 (CarH), 131.1 (Ph), 131.2 (CarH), 131.5 (Car), 134.3 (Pht), 136.0 (Car), 137.1 
(Pht), 142.0 (Car), 156.8 (C-4 phenyl), 167.8 (C=O Pht), 168.1 (C=O lactam), 169.9 
(CON<), 171.3 (CONH2), 171.6 (CONαH Orn), 172.7 (CONαH Tyr(OBn)-amide) ppm; MS 
(ES, +p) m/z (%): 958 (100) [M+H]+; C56H59N7O8 (957.44). 
 
General procedure for the synthesis of Nδ-Pht deprotected ornithinamides 3.27 and 
3.288 
 
The compounds were prepared according to the experimental protocol for the 
synthesis of 3.15 and 3.16. The crude products were purified by flash 
chromatography (eluent: CH2Cl2/MeOH + 1 Vol% NEt3 10/1 to 3/1) yielding white 
solids. 
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(2S)-Nα-[2-(1-{2-Oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)-
piperazin-1-yl]ethyl}cyclopentyl)acetyl]ornithylphenylalaninamide (3.27). Yield: 84 
%. 1H NMR (600 MHz, CD3OD, COSY, HSQC, HMBC): δ = 1.37 (m, 2H, CγH2), 1.49 and 
1.64 (m, 4H, 3/4-H cyclopentyl), 1.50 and 1.64 (m, 2H, CβH2 Orn), 1.50 and 1.72 (m, 
4H, 2/5-H cyclopentyl), 2.15 and 2.19 (m, 4H, 3/5-H piperazine), 2.25 and 2.45 (m, 2H, 
CH2CONαH), 2.49 (m, 2H, >NCOCH2-cyclopentyl), 2.58 (m, 2H, CδH2), 2.87 and 3.16 (m, 
2H, CβH2 Phe-amide), 3.37-3.58 (m, 4H, 2/6-H piperazine), 4.15 (m, 1H, CαH Orn), 4.21 
(m, 1H, 11-H dibenzazepine-11-yl), 4.56 (m, 1H, CαH Phe-amide), 7.10 (m, 2H, Har), 
7.16 (m, 2H, Har), 7.23 (m, 3H, Har), 7.26 (m, 1H, Har), 7.32 (m, 1H, Har), 7.37 (m, 1H, 
Har), 7.40 (m, 1H, Har), 7.48 (m, 1H, Har), 7.79 (m, 1H, Har) ppm; 13C NMR (150 MHz, 
CD3OD, HSQC, HMBC): δ = 24.5 and 24.6 (C-3/4 cyclopentyl), 29.0 (Cγ), 29.9 (Cβ Orn), 
38.3 and 38.4 (Cβ Phe-amide), 39.4 and 39.5 (C-2/5 cyclopentyl), 39.7 (>NCOCH2-
cyclopentyl), 41.6 (Cδ), 42.8 (C-2/6 piperazine), 44.5 (CH2CONαH), 45.8 (C-1 
cyclopentyl), 52.1 and 52.6 (C-3/5 piperazine), 54.7 (Cα Orn), 55.8 (Cα Phe-amide), 
75.8 (C-11 dibenzazepine-11-yl), 122.9 (CarH), 126.0 (CarH), 127.7 (CarH), 128.8 (CarH), 
129.3 (CarH), 129.8 (CarH), 130.3 (CarH), 131.0 (CarH), 131.6 (CarH), 132.5 (Car), 133.0 
(CarH), 133.5 (Car), 136.8 (Car), 138.9 (Car), 144.3 (Car), 172.2 (C=O lactam), 172.8 
(CON<), 174.3 (CONαH Phe-amide), 175.3 (CONαH Orn), 176.2 (CONH2) ppm; MS (ES, 
+p) m/z (%): 722 (95) [M+H]+, 362 (100) [M+2H]2+; C41H51N7O5 (721.40). 
 
(2S)-Nα-[2-(1-{2-Oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)-
piperazin-1-yl]ethyl}cyclopentyl)acetyl]ornithyl-O-benzyl-tyrosinamide (3.28). Yield: 
40 %. 1H NMR (400 MHz, CD3OD, HSQC): δ = 1.37 (m, 2H, CγH2), 1.48 and 1.61 (m, 4H, 
3/4-H cyclopentyl), 1.48 and 1.72 (m, 4H, 2/5-H cyclopentyl), 1.53 and 1.64 (m, 2H, 
CβH2 Orn), 2.13 (m, 4H, 3/5-H piperazine), 2.24 and 2.45 (m, 2H, CH2CONαH), 2.36 and 
2.46 (m, 2H, >NCOCH2-cyclopentyl), 2.56 (m, 2H, CδH2), 2.82 and 3.10 (m, 2H, CβH2 
Tyr(OBn)-amide), 3.32-3.56 (m, 4H, 2/6-H piperazine), 4.17 (m, 1H, 11-H 
dibenzazepine-11-yl), 4.18 (m, 1H, CαH Orn), 4.51 (m, 1H, CαH Tyr(OBn)-amide), 4.98 
(m, 2H, OCH2), 6.80 and 6.84 (m, 2H, 3/5-H phenyl), 7.09 (m, 2H, Har), 7.14 (m, 2H, 
Har), 7.32 (m, 9H, Ph), 7.46 (m, 1H, Har), 7.79 (m, 1H, Har) ppm; 13C NMR (100 MHz, 
CD3OD, HSQC): δ = 24.5 and 24.6 (C-3/4 cyclopentyl), 29.3 (Cγ), 29.9 (Cβ Orn), 37.6 and 
37.7 (Cβ Tyr(OBn)-amide), 39.4 and 39.5 (C-2/5 cyclopentyl), 39.7 (>NCOCH2-
cyclopentyl), 41.7 (Cδ), 42.8 (C-2/6 piperazine), 44.5 (CH2CONαH), 45.8 (C-1 
cyclopentyl), 52.2 and 52.7 (C-3/5 piperazine), 54.5 and 54.8 (Cα Orn), 55.8 (Cα 
Tyr(OBn)-amide), 71.0 (OCH2), 75.8 (C-11 dibenzazepine-11-yl), 115.9 (C-3/5 phenyl), 
122.9 (CarH), 125.9 (CarH), 128.5 (Ph), 128.9 (CarH), 129.3 (CarH), 129.5 (Ph), 129.8 
(CarH), 131.0 (CarH), 131.4 (CarH), 132.4 (Car), 133.0 (CarH), 133.4 (Car), 136.8 (Car), 138.7 
(Car), 144.2 (Car), 159.0 (C-4 phenyl), 172.0 (C=O lactam), 172.7 (CON<), 174.2 (CONαH 
Tyr(OBn)-amide), 175.1 (CONαH Orn), 176.1 (CONH2) ppm; MS (ES, +p) m/z (%): 828 
(50) [M+H]+, 415 (100) [M+2H]2+; C48H57N7O6 (827.44). 
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tert-Butyl (2-aminoethyl)-{2-[(tert-butoxycarbonyl)amino]ethyl}carbamate (3.29).39-
40 A solution of ethyl trifluoroacetate (2.93 g, 20.6 mmol) in CH2Cl2 (24 mL) was added 
dropwise to a solution of diethylenetriamine (2.13 g, 20.6 mmol) in the same solvent 
(24 mL), while keeping the temperature at 0 °C. After complete addition, the mixture 
was stirred for 2 h at 0 °C and then for 2 h at rt. Removal of the solvent under 
reduced pressure yielded H2N(CH2)2NH(CH2)2NH(COCF3) as a yellow oil. This 
compound was dissolved in CH2Cl2 (40 mL) and the resulting solution was cooled to –
10 °C. Di-tert-butyl dicarbonate (9.0 g, 41.2 mmol) dissolved in CH2Cl2 (40 mL) was 
added dropwise to the cooled solution, and then the reaction mixture was stirred for 
24 h at rt. After evaporation of the solvent, (Boc)NH(CH2)2N(Boc)(CH2)2NH(COCF3) was 
obtained as a dense oil, which was dissolved in a mixture of methanol (280 mL) and 
distilled water (12 mL). Then, K2CO3 (55.28 g, 0.4 mmol) was added and the mixture 
was refluxed for 2 h. After filtration, the solvent was removed under reduced 
pressure, the residue was redissolved in distilled water and the pH adjusted to pH = 
13 with 40% aq. NaOH. Extraction with CHCl3, followed by evaporation of the organic 
phase, gave the product as a yellow oil (3.80 g; 61 %). 1H NMR (300 MHz, DMSO-d6): δ 
= 1.37 (s, 9H, Boc), 1.39 (s, 9H, Boc), 2.61 (m, 2H, CH2), 3.01 (m, 2H, CH2), 3.14 (m, 4H, 
(CH2)2), 6.88 (br, 1H, NH) ppm; MS (CI, NH3) m/z (%): 304 (61) [M+H]+, 106 (100) 
[M+H–2Boc]+; C14H29N3O4 (303.22). 
 
5-{2-[(2-tert-Butoxycarbonylaminoethyl)(tert-butoxycarbonyl)amino]ethylamino}-
5-oxopentanoic acid (3.30).25 Compound 3.29 (1.00 g, 3.30 mmol) was dissolved in 5 
mL THF and a solution of glutaric anhydride (0.38 g, 3.30 mmol) in 5 mL THF was 
added. Then NEt3 (0.69 mL, 4.95 mmol) was added to the mixture. The mixture was 
stirred overnight at rt. The solvent was removed under reduced pressure and the 
crude product was redissolved in 25 mL CH2Cl2, washed with 5 % aq. KHSO4 (40 mL), 
dried over Na2SO4 and the solvent was evaporated giving a white solid (1.19 g, 86%). 
1H NMR (300 MHz, DMSO-d6): δ = 1.37 (s, 9H, Boc), 1.39 (s, 9H, Boc), 1.68 (p, 3J = 7.3 
Hz, 2H, CH2CH2CH2COOH), 2.07 (m, 2H, (CH2)2CH2COOH), 2.19 (t, 3J = 7.3Hz, 2H, 
CH2(CH2)2COOH), 3.01 (m, 2H, BocNHCH2), 3.15 (m, 6H, BocNHCH2CH2N(Boc)(CH2)2), 
6.81 (br, 1H, NHBoc), 7.85 (br, 1H, NH), 12.02 (s, 1H, COOH) ppm; 13C NMR (75 MHz, 
DMSO-d6): δ = 20.5 (COCH2CH2CH2COOH), 25.0 (BocNHCH2) 27.9 and 28.1 (C(CH3)3), 
29.2 ((CH2)2CH2COOH), 32.9 (CH2(CH2)2COOH), 34.3 (CONHCH2), 77.4 and 78.4 
(C(CH3)3), 154.6 and 155.5 (COOC(CH3)3), 171.5 (NHCO(CH2)3COOH), 174.1 (COOH) 
ppm; MS (ES, +p) m/z (%): 853 (60) [2M+NH4]+, 418 (100) [M+H]+; C19H35N3O7 
(417.25). 
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Preparation of the carboxylic acids 3.31 and 3.3241 
 
Glutaric anhydride (1 eq) was added to a solution of mono-Boc-protected ethane-1,2-
diamine or mono-Boc-protected propane-1,3-diamine, respectively, in CH2Cl2 and the 
mixture was stirred for 2 h at rt. A 6-fold volume of CH2Cl2 was added prior to 
washing with a saturated solution of NH4Cl (2-fold volume) and brine (2-fold volume). 
Drying over Na2SO4, filtration and removal of the solvent under reduced pressure 
yielded the products as highly viscous yellowish oils (95-97 %). 
 
4-(2-tert-Butoxycarbonylaminoethyl)aminocarbonylbutanoic acid (3.31). 1H NMR 
(300 MHz, CD3OD): δ = 1.42 (s, 9H, Boc), 1.88 (m, 2H, NHCOCH2CH2CH2COOH), 2.24 (t, 
3J = 7.4 Hz, 2H, NHCOCH2CH2CH2COOH), 2.32 (t, 3J = 7.4 Hz, 2H, 
NHCOCH2CH2CH2COOH), 3.14 and 3.24 (m, 4H, NHCH2CH2NHCO) ppm; MS (CI, NH3) 
m/z (%): 275 (100) [M+H]+; C12H22N2O5 (274.31). 
 
4-(3-tert-Butoxycarbonylaminopropyl)aminocarbonylbutanoic acid (3.32). 1H NMR 
(300 MHz, DMSO-d6): δ = 1.37 (s, 9H, Boc), 1.47 (m, 2H, NHCH2CH2CH2NHCO), 1.69 
(m, 2H, NHCOCH2CH2CH2COOH), 2.07 (t, 3J = 7.4 Hz, 2H, NHCOCH2CH2CH2COOH), 2.19 
(t, 3J = 7.4 Hz, 2H, NHCOCH2CH2CH2COOH), 2.89 (quat, 2H, 3J = 6.7 Hz, 
NHCH2CH2CH2NHCO), 3.00 (quat, 2H, 3J = 6.7 Hz, NHCH2CH2CH2NHCO), 6.75 (m, 1H, 
NH), 7.76 (m, 1H, NH), 12.02 (s, 1H, COOH) ppm; 13C NMR (75 MHz, DMSO-d6): δ = 
20.6 (NHCOCH2CH2CH2CO2H), 28.1 (C(CH3)3), 29.5 (NHCH2CH2CH2NHCO), 32.9 
(NHCOCH2CH2CH2COOH), 34.3 (NHCOCH2CH2CH2COOH), 36.0 (NHCH2CH2CH2NHCO), 
37.5 (NHCH2CH2CH2NHCO), 77.3 (C(CH3)3), 155.4 (CO(O)C(CH3)3), 171.4 
(NHCOCH2CH2CH2COOH), 174.0 (NHCOCH2CH2CH2COOH) ppm; MS (CI, NH3) m/z (%): 
289 (100) [M+H]+, 233 (50) [M+H–C4H8]+; C13H24N2O5 (288.17). 
 
6-(tert-Butoxycarbonylamino)hexanoic acid (3.33).42 To a solution of 6-amino-
hexanoic acid (1.97 g, 15 mmol) and NaHCO3 (3.16 g, 37.5 mmol) in 30 mL H2O was 
added di-tert-butyl dicarbonate (3.93 g, 18 mmol) in 30 mL 1,4-dioxane and stirred 
overnight at rt. The solution was washed with diethyl ether (30 mL) and the ether 
phase was discarded. The pH of the solution was adjusted to pH = 2 with 2 M HCl, 
washed with ethyl acetate (3 × 30 mL) and the organic phase was dried over Na2SO4. 
After filtration and evaporation of the solvent the product was obtained as a colorless 
solid (3.13 g, 90 %). 1H NMR (300 MHz, CDCl3): δ = 1.44 (s, 9H, Boc), 1.32-1.55 (m, 4H, 
(CH2)2(CH2)2CH2NHBoc), 1.75 (p, 3J = 7.4 Hz, 2H, CH2CH2(CH2)3NHBoc), 2.36 (t, 3J = 7.4 
Hz, 2H, CH2(CH2)4NHBoc), 3.12 (m, 2H, (CH2)3CH2NHBoc), 4.55 (br, 1H, NHBoc) ppm; 
MS (CI, NH3) m/z (%): 232 (13) [M+H]+, 193 (100) [M+NH4–C4H8]+; C11H21NO4 (231.15). 
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Experimental details for the variously substituted S-methylisothioureas 3.34-3.45 
 
N,N’-Bis(tert-butoxycarbonyl)-S-methylisothiourea (3.34).43 S-Methylisothiouronium 
sulfate (3.02 g, 10.8 mmol) was dissolved in 60 mL water-dioxane 1:1 (v/v) and 
treated with 1 M aq. NaOH solution (20 mL) and Boc2O (12.62 g, 53.8 mmol). After 
stirring for 16 h the precipitated product was filtered off and washed with a small 
amount of water; the filtrates were concentrated under reduced pressure to half the 
volume, and additional product was collected by filtration. The combined solid 
products were dried by lyophilization. Yield: 3.02 g (96 %). 1H NMR (300 MHz, DMSO-
d6): δ = 1.44 (s, 18H, 2x Boc), 2.28 (s, 3H, SCH3), 11.06 (br, 1H, NHBoc) ppm; 13C NMR 
(75 MHz, DMSO-d6): δ = 13.7 (SCH3), 27.6 (2x C(CH3)3), 164.9 (2x C(O)OC(CH3)3) ppm; 
MS (CI, NH3) m/z (%): 291 (100) [M+H]+; C12H22N2O4S (290.13). 
 
S-Methylisothiourea and N-tert-butoxycarbonyl-S-methylisothiourea were prepared 
as previously described.16, 25 
 
N’-Substituted N-tert-butoxycarbonyl-S-methylisothioureas (3.35-3.38, 3.43-3.45) 
 
TBTU (1 eq) was added to a solution of the respective carboxylic acid (1 eq), HOBt × 
H2O (1 eq), DIPEA (1 eq) in DMF. N-tert-butoxycarbonyl-S-methylisothiourea (1 eq) 
was introduced and the solution was shaken for 16 h, diluted with ethyl acetate, 
washed with 5 % aq. KHCO3, 5 % aq. KHSO4, and brine. The crude product was dried 
over anhydrous Na2SO4 and evaporated to dryness. Purification by flash 
chromatography (eluent: CH2Cl2/ethyl acetate) afforded the title compounds. 
 
Preparation of the guanidinylating agents 3.39-3.42 
 
The succinimidyl ester of the corresponding carbamic acid (1.5 mmol) in DMF (1 mL) 
was added to a stirred solution of N-tert-butoxycarbonyl-S-methylisothiourea (0.29 g, 
1.5 mmol) and DIPEA (0.51 mL, 3.0 mmol) in DMF (2 mL), and stirring was continued 
for 16 h. The solution was diluted with ethyl acetate (30 mL) and washed with 5 % aq. 
KHSO4, 5 % aq. KHCO3 and brine, dried over anhydrous Na2SO4 and evaporated. The 
crude products were purified by flash chromatography (eluent: CH2Cl2/ethyl acetate 
20:1 v/v). 
 
N-tert-Butoxycarbonyl-N’-[4-(2-tert-butoxycarbonylaminoethyl)aminocarbonyl-
butanoyl]-S-methylisothiourea (3.35). Yield: 64 %, as colorless oil. 1H NMR (300 MHz, 
CDCl3): δ = 1.44 (s, 9H, Boc), 1.52 (s, 9H, Boc), 2.00 (quat, 3J = 7.2 Hz, 2H, 
COCH2CH2CH2CO), 2.26 (t, 3J = 7.2 Hz, 2H, CO(CH2)2CH2CO), 2.40 (s, 3H, SCH3), 2.52 (t, 
3J = 7.0 Hz, 2H, COCH2(CH2)2CO), 3.27 (m, 2H, NHCH2CH2NHBoc), 3.35 (m, 2H, 
NHCH2CH2NHBoc) ppm; MS (ES, +p) m/z (%):447 (100) [M+H]+; C19H34N4O6S (446.22). 
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N-tert-Butoxycarbonyl-N’-[4-(3-tert-butoxycarbonylaminopropyl)aminocarbonyl-
butanoyl]-S-methylisothiourea (3.36). Yield: 70 %, as yellow oil. 1H NMR (300 MHz, 
CDCl3): δ = 1.43 (s, 9H, Boc), 1.51 (s, 9H, Boc), 1.61 (m, 2H, NHCH2CH2CH2NHBoc), 2.01 
(m, 2H, COCH2CH2CH2CO), 2.27 (m, 2H, CO(CH2)2CH2CO), 2.39 (s, 3H, SCH3), 2.52 (m, 
2H, COCH2(CH2)2CO), 3.16 (m, 2H, NH(CH2)2CH2NHBoc), 3.29 (m, 2H, 
NHCH2(CH2)2NHBoc) ppm; MS (CI, NH3) m/z (%): 461 (100) [M+H]+; C20H36N4O6S 
(460.24).  
 
N-tert-Butoxycarbonyl-N’-{4-[2-(2-tert-butoxycarbonylaminoethyl)tert-butoxy-
carbonylaminoethyl]aminocarbonylbutanoyl}-S-methylisothiourea (3.37). Yield: 78 
%, as yellow oil. 1H NMR (300 MHz, DMSO-d6): δ = 1.36 (s, 9H, Boc), 1.39 (s, 9H, Boc), 
1.42 (s, 9H, Boc), 1.72 (p, 3J = 7.3 Hz, 2H, CH2CH2CH2CON=), 2.27 (s, 3H, SCH3), 2.35 
(m, 2H, (CH2)2CH2CON=), 2.69 (m, 2H, CH2(CH2)2CON=), 3.01 (m, 2H, CH2NHBoc), 3.15 
(m, 6H, BocNHCH2CH2N(Boc)(CH2)2), 6.82 (br, 1H, NHBoc), 7.86 (br, 1H, NH), 11.20 
(br, 1H, NHBoc) ppm; 13C NMR (75 MHz, DMSO-d6): δ = 14.0 (SCH3), 20.7 
(CH2CH2CH2CON=), 27.6 and 27.9 and 28.1 (C(CH3)3), 29.0 ((CH2)2CH2CON=), 29.9 
(CH2(CH2)2CON=), 34.3 (CONHCH2CH2), 39.7 (CONHCH2), 59.6 (CH2N(Boc)CH2), 77.4 
and 78.4 and 80.0 (C(CH3)3), 154.6 and 155.5 and 155.6 (C(O)OC(CH3)3) ppm; MS (ES, 
+p) m/z (%): 590 (100) [M+H]+; C26H47N5O8S (589.31). 
 
N-tert-Butoxycarbonyl-N'-(18-tert-butoxycarbonylamino-4-oxo-9,12,15-trioxa-5-
azaoctadecanoyl)-S-methylisothiourea (3.38). Yield: 58 %, as yellow oil. 1H NMR (300 
MHz, DMSO-d6): δ = 1.37 (s, 9H, Boc), 1.42 (s, 9H, Boc), 1.59 (m, 4H, 
OCH2CH2CH2NHBoc + NHCH2CH2CH2O), 2.27 (s, 3H, SCH3), 2.35 (m, 2H, 
=NCOCH2CH2CONH), 2.56 (m, 2H, =NCOCH2CH2CONH), 2.95 (m, 2H, 
OCH2CH2CH2NHBoc), 3.06 (m, 2H, NHCH2CH2CH2O), 3.38 (m, 4H, ((NH(CH2)2CH2O)2), 
3.50 (m, 8H, (O(CH2)2O)2), 5.76 (s, 1H, BocNHC(SCH3)=N), 6.75 (m, 1H, NH), 7.87 (m, 
1H, NH) ppm; MS (ES, +p) m/z (%): 593 (100) [M+H]+; C26H48N4O9S (592.31). 
 
N-tert-Butoxycarbonyl-N’-[N-(2-tert-butoxycarbonylaminoethyl)aminocarbonyl]-S-
methylisothiourea (3.39). Yield: 0.33 g (60 %, as colorless oil). 1H NMR (300 MHz, 
DMSO-d6): δ = 1.37 (s, 9H, Boc), 1.44 (s, 9H, Boc), 2.28 (s, 3H, SCH3), 3.02 (m, 4H, 
NHCH2CH2NHBoc), 6.84 (m, 1H, NH), 7.74 (m, 1H, NH), 12.33 (m, 1H, NH) ppm; 13C 
NMR (75 MHz, DMSO-d6): δ = 13.5 (SCH3), 27.5 (C(CH3)3), 28.1 (C(CH3)3), 77.5 
(C(CH3)3), 82.0 (C(CH3)3), 150.1 (C=O carbonyl), 155.5 (C=O carbonyl), 161.5 (C=N), 
164.7 (C=O carbonyl) ppm; MS (ES, +p) m/z (%): 753 (40) [2M+H]+, 377 (100) [M+H]+; 
C15H28N4O5S (376.18). 
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N-tert-Butoxycarbonyl-N’-[N-(3-tert-butoxycarbonylaminopropyl)aminocarbonyl]-S-
methylisothiourea (3.40). Yield: 0.30 g (51 %, as colorless oil). 1H NMR (300 MHz, 
DMSO-d6): δ = 1.37 (s, 9H, Boc), 1.44 (s, 9H, Boc), 1.53 (m, 2H, NHCH2CH2CH2NH), 2.28 
(s, 3H, SCH3), 2.91 and 3.03 (m, 2H, NHCH2CH2CH2NH), 6.78 (m, 1H, NH), 7.75 (m, 1H, 
NH), 12.40 (br, 1H, NH) ppm; 13C NMR (75 MHz, DMSO-d6): δ = 13.5 (SCH3), 27.5 
(C(CH3)3), 28.1 (C(CH3)3), 29.4 (NHCH2CH2CH2NH), 54.8 (NHCH2CH2CH2NH), 77.4 
(C(CH3)3), 82.0 (C(CH3)3), 150.1 (CO(O)tBu), 155.5 (CO(O)tBu), 161.3 (NC(N)SCH3), 
164.7 (NCONH) ppm; MS (ES, +p) m/z (%): 391 (100) [M+H]+; C16H30N4O5S (390.19). 
 
N-tert-Butoxycarbonyl-N’-[N-(4-tert-butoxycarbonylaminobutyl)aminocarbonyl]-S-
methylisothiourea (3.41). Yield: 0.30 g (48 %, as colorless oil); 1H NMR (300 MHz, 
DMSO-d6): δ = 1.27-1.53 (m, 22H, 2 x Boc, CH2(CH2)2CH2), 2.28 (s, 3H, SCH3), 2.89 (m, 
2H, CH2NH), 3.01 (m, 2H, CH2NH), 6.80 (t, 3J = 5.2 Hz, 1H, CH2NH), 7.79 (t, 3J = 5.8 Hz, 
1H, CH2NH), 12.44 (s, 1H, NH) ppm; MS (ES, +p) m/z (%): 405 (100) [M+H]+; 
C17H32N4O5S (404.21). 
 
N-tert-Butoxycarbonyl-N’-[N-(6-tert-butoxycarbonylaminohexyl)aminocarbonyl]-S-
methylisothiourea (3.42). Yield: 0.29 g (45 %, as yellow oil). 1H NMR (300 MHz, 
DMSO-d6): δ = 1.23 (m, 4H, NH(CH2)2(CH2)2(CH2)2NH), 1.32-1.48 (m, 22H, 2x Boc + 
NHCH2CH2(CH2)2CH2CH2NH), 2.28 (s, 3H, SCH3), 2.88 (m, 2H, NHCH2(CH2)5NH), 3.01 
(m, 2H, NHCH2(CH2)5NH), 6.77 (m, 1H, NH), 7.78 (m, 1H, NH), 12.43 (br, 1H, NH) ppm; 
MS (ES, +p) m/z (%): 433 (100) [M+H]+; C19H36N4O5S (432.24). 
 
N-tert-Butoxycarbonyl-N’-[6-(tert-butoxycarbonylamino)hexanoyl]-S-methyl-
isothiourea (3.43). Yield: 85 %, as white solid. 1H NMR (300 MHz, CDCl3): δ = 1.40-
1.60 (m, 4H, (CH2)2(CH2)2CH2NHBoc), 1.44 (s, 9H, Boc), 1.52 (s, 9H, Boc), 1.70 (m, 2H, 
CH2CH2(CH2)3NHBoc), 2.40 (s, 3H, SCH3), 2.45 (t, 3J = 7.3 Hz, 2H, CH2(CH2)4NHBoc), 
3.12 (m, 2H, (CH2)4CH2NHBoc), 4.56 (br, 1H, NH) ppm; 13C NMR (75 MHz, CDCl3): δ = 
14.5 (SCH3), 24.4 (CH2CH2(CH2)3NHBoc), 26.2 (CH2CH2CH2CH2CH2NHBoc), 28.0 (Boc), 
28.4 (Boc), 29.8 ((CH2)3CH2CH2NHBoc), 37.1 (CH2(CH2)4NHBoc), 40.4 
((CH2)4CH2NHBoc), 77.2 (Boc), 79.1 (Boc), 156.0 (Boc), 169.3 (NC(SMe)N), 171.1 (C=O) 
ppm; MS (ES, +p) m/z (%): 404 (100) [M+H]+, 304 (45) [M+H–Boc]+; C18H33N3O5S 
(403.54). 
 
N-tert-Butoxycarbonyl-N’-[8-(tert-butoxycarbonylamino-3,6-dioxa)octanoyl]-S-
methylisothiourea (3.44). Yield: 45 %, as yellow oil. 1H NMR (300 MHz, DMSO-d6): δ = 
1.37 (s, 9H, Boc), 1.45 (s, 9H, Boc), 2.30 (s, 3H, SCH3), 3.06 (quat, 3J = 5.9 Hz, 2H, 
NHCH2CH2O), 3.39 (t, 3J = 5.9 Hz, 2H, NHCH2CH2O), 3.57 and 3.65 (m, 4H, OCH2CH2O), 
4.15 (s, 2H, =NCOCH2O), 6.75 (m, 1H, NH), 12.22 (br, 1H, NH) ppm; MS (ES, +p) m/z 
(%): 436 (100) [M+H]+, 336 (25) [M+H–Boc]+; C18H33N3O7S (435.20). 
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N-tert-Butoxycarbonyl-N’-[15-(tert-butoxycarbonylamino-4,7,10,13-tetraoxa)penta-
decanoyl]-S-methylisothiourea (3.45). Yield: 80 %, as slightly yellow oil. 1H NMR (300 
MHz, DMSO-d6): δ = 1.37 and 1.43 (m, 18H, Boc), 2.28 (s, 3H, SCH3), 2.59 (t, 3J = 5.8 
Hz, 2H, NCOCH2CH2O), 3.05 (quat, 3J = 5.9 Hz, 2H, NHCH2CH2O), 3.36 (m, 2H, 
NHCH2CH2O), 3.49 (m, 12H, (OCH2CH2O)3), 3.63 (m, 2H, NCOCH2CH2O), 6.76 (m, 1H, 
NH) ppm; MS (ES, +p) m/z (%): 538 (100) [M+H]+, 438 (19) [M+H–Boc]+; C23H43N3O9S 
(537.27). 
 
General procedure for the guanidinylation with S-methylisothioureas (3.46a-
3.62a)16, 20, 25 
 
For the synthesis of 3.46a-3.62a HgCl2 (1 eq) was added to a solution of the 
corresponding ornithinamide (3.15, (S)-3.16, 3.27, 3.28) (1 eq), substituted S-
methylisothiourea (1 eq), and NEt3 (2 eq) in DMF (approx. 1 mL/0.1 mmol substrate). 
After stirring overnight the resulting mixture was diluted with ethyl acetate (10 
mL/0.1 mmol substrate). Insoluble Hg-salts were separated by vacuum filtration 
through a short bed of Celite® in a Pasteur pipette plugged with some cotton wool 
and washed with ethyl acetate. The combined filtrates were washed with 5 % aq. 
KHSO4 and brine and dried over anhydrous Na2SO4. The products were purified by 
flash chromatography (eluent: CH2Cl2/methanol 40/1 to 10/1). 
 
(2S)-Nω,Nω’-Bis(tert-butoxycarbonyl)-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-
dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]arginyl-O-benzyl-
tyrosinamide (3.46a). Yield: 84 %. MS (ES, +p) m/z (%): 1070 (25) [M+H]+, 536 (100) 
[M+2H]2+; C59H75N9O10 (1069.56). 
 
(2R)- and (2S)-Nω,Nω’-Bis-tert-butoxycarbonyl-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-tri-
azolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo-
[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((R)-3.47a, 
(S)-3.47a). Yield: 73 %. MS (ES, +p) m/z (%): 549 (100) [M+2H]2+; C59H73N11O10 
(1095.55). 
 
(2R)- and (2S)-Nω’-tert-Butoxycarbonyl-Nω-[4-(2-tert-butoxycarbonylaminoethyl)-
aminocarbonylbutanoyl]-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-
Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-
yl]ethyl}cyclopentyl)acetyl]argininamide ((R)-3.48a, (S)-3.48a). Yield: 72 %. MS (ES, 
+p) m/z (%): 627 (100) [M+2H]2+; C66H85N13O12 (1251.64). 
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(2S)-Nω’-tert-Butoxycarbonyl-Nω-[4-(3-tert-butoxycarbonylaminopropyl)amino-
carbonylbutanoyl]-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-
(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]-
ethyl}cyclopentyl)acetyl]argininamide ((S)-3.49a) Yield: 79 %. MS (ES, +p) m/z (%): 
1266 (26) [M+H]+, 634 (100) [M+2H]2+; C67H87N13O12 (1265.66). 
 
(2R)- and (2S)-Nω’-tert-Butoxycarbonyl-Nω-{4-[2-(2-tert-butoxycarbonylaminoethyl)-
tert-butoxycarbonylaminoethyl]aminocarbonylbutanoyl}-N-[2-(3,5-dioxo-1,2-di-
phenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-di-
benzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((R)-
3.50a, (S)-3.50a). Yield: 72 %. MS (ES, +p) m/z (%): 699 (100) [M+2H]2+; C73H98N14O14 
(1394.74). 
 
(2S)-Nω’-tert-Butoxycarbonyl-Nω-(18-tert-butoxycarbonylamino-4-oxo-9,12,15-tri-
oxa-5-azaoctadecanoyl)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-
Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-
yl]ethyl}cyclopentyl)acetyl]argininamide ((S)-3.51a). Yield: 69 %. MS (ES, +p) m/z 
(%): 1399 (4) [M+H]+, 700 (100) [M+2H]2+; C73H99N13O15 (1397.74). 
 
(2S)-Nω’-tert-Butoxycarbonyl-Nω-[N-(2-tert-butoxycarbonylaminoethyl)amino-
carbonyl]-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-
2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclo-
pentyl)acetyl]argininamide ((S)-3.52a). Yield: 43 %. MS (ES, +p) m/z (%): 1183 (20) 
[M+H]+, 592 (100) [M+2H]2+; C62H79N13O11 (1181.60). 
 
(2S)-Nω’-tert-Butoxycarbonyl-Nω-[N-(3-tert-butoxycarbonylaminopropyl)amino-
carbonyl]-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-
2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclo-
pentyl)acetyl]argininamide ((S)-3.53a). Yield: 65 %. MS (ES, +p) m/z (%): 1197 (20) 
[M+H]+, 599 (100) [M+2H]2+; C63H81N13O11 (1195.62). 
 
(2S)-Nω’-tert-Butoxycarbonyl-Nω-[N-(4-tert-butoxycarbonylaminobutyl)amino-
carbonyl]-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-
2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclo-
pentyl)acetyl]argininamide ((S)-3.54a). Yield: 83 %. MS (ES, +p) m/z (%): 1211 (100) 
[M+H]+, 715 (20); C64H83N13O11 (1209.63). 
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(2S)-Nω’-tert-Butoxycarbonyl-Nω-[N-(6-tert-butoxycarbonylaminohexyl)amino-
carbonyl]-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-
2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclo-
pentyl)acetyl]argininamide ((S)-3.55a). Yield: 72 %. MS (ES, +p) m/z (%): 1239 (100) 
[M+H]+, 715 (30), 620 (33) [M+2H]2+; C66H87N13O11 (1237.66).  
 
(2S)-Nω’-tert-Butoxycarbonyl-Nω-[6-(tert-butoxycarbonylamino)hexanoyl]-N-[2-(3,5-
dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-di-
hydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]arginin-
amide ((S)-3.56a). Yield: 86 %. MS (ES, +p) m/z (%): 1210 (50) [M+H]+, 606 (100) 
[M+2H]2+; C65H84N12O11 (1209.44). 
 
(2S)-Nω’-tert-Butoxycarbonyl-Nω-[8-(tert-butoxycarbonylamino-3,6-dioxa)octanoyl]-
N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-
oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]argininamide ((S)-3.57a). Yield: 83 %. MS (ES, +p) m/z (%): 1242 (7) [M+H]+, 
621 (100) [M+2H]2+; C65H84N12O13 (1240.63). 
 
(2S)-Nω’-tert-Butoxycarbonyl-Nω-[15-(tert-butoxycarbonylamino-4,7,10,13-tetra-
oxa)pentadecanoyl]-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-
(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]-
ethyl}cyclopentyl)acetyl]argininamide ((S)-3.58a). Yield: 62 %. MS (ES, +p) m/z (%): 
1366 (5) [M+Na]+, 1344 (5) [M+H]+, 683 (30) [M+H+Na]2+, 672 (100) [M+2H]2+; 
C70H94N12O15 (1342.70). 
 
(2S)-Nω,Nω’-Bis(tert-butoxycarbonyl)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-
4-yl)ethyl]-Nα-{5-oxo-5-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-
yl)piperazin1-yl]pentanoyl}argininamide ((S)-3.59a). Yield: 83 %. MS (ES, +p) m/z (%): 
1042 (20) [M+H]+; 522 (100) [M+2H]2+; C55H67N11O10 (1041.15). 
 
(2S)-Nω’-tert-Butoxycarbonyl-Nω-{4-[2-(2-tert-butoxycarbonylaminoethyl)tert-
butoxycarbonylaminoethyl]aminocarbonylbutanoyl}-N-[2-(3,5-dioxo-1,2-diphenyl-
1,2,4-triazolidin-4-yl)ethyl]-Nα-{5-oxo-5-[4-(6-oxo-6,11-dihydro-5H-dibenzo-
[b,e]azepin-11-yl)piperazin-1-yl]pentanoyl}argininamide ((S)-3.60a). Yield: 67 %. MS 
(ES, +p) m/z (%): 1342 (35) [M+H]+; 672 (100) [M+2H]2+; C69H92N14O14 (1340.69). 
 
(2S)-Nω,Nω’-Bis(tert-butoxycarbonyl)-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-
dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]arginyl-
phenylalaninamide (3.61a). Yield: 95 %. MS (ES, +p) m/z (%): 964 (35) [M+H]+, 483 
(100) [M+2H]2+; C52H69N9O9 (963.52). 
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(2S)-Nω’-tert-Butoxycarbonyl-Nω-[N-(3-tert-butoxycarbonylaminopropyl)amino-
carbonyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)-
piperazin-1-yl]ethyl}cyclopentyl)acetyl]arginylphenylalaninamide (3.62a). Yield: 83 
%. MS (ES, +p) m/z (%): 1064 (30) [M+H]+, 533 (100) [M+2H]2+; C56H77N11O10 
(1063.59). 
 
(2S)-Nα-[2-(1-{2-Oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)-
piperazin-1-yl]ethyl}cyclopentyl)acetyl]arginyltyrosinamide (3.46).26 Compound 
3.46a (0.05 g, 0.05 mmol) was treated with a 1 M solution of TMSOTf (0.87 mL, 4.5 
mmol), thioanisole (0.53 mL, 4.5 mmol), and m-cresole (0.05 mL, 0.5 mmol) in TFA for 
90 min at ice-bath temperature. After evaporation of the solvents the crude product 
was purified using preparative HPLC to obtain the title compound as a white fluffy 
solid (40 mg, 90 %). Mp 180 °C; 1H NMR (400 MHz, CD3OD, HSQC): δ = 1.50 (m, 2H, 
CγH2), 1.52 and 1.68 (m, 4H, 2/5-H cyclopentyl), 1.53 and 1.66 (m, 4H, 3/4-H 
cyclopentyl), 1.60 and 1.70 (m, 2H, CβH2 Orn), 2.26 (m, 4H, 3/5-H piperazine), 2.28 
and 2.49 (m, 2H, CH2CONαH), 2.48 (m, 2H, >NCOCH2-cyclopentyl), 2.80 and 3.07 (m, 
2H, CβH2 Tyr-amide), 3.11 (t, 3J = 6.9 Hz, 2H, CδH2), 3.41 and 3.49 and 3.63 (m, 4H, 
2/6-H piperazine), 4.22 (m, 1H, CαH Orn), 4.33 (m, 1H, 11-H dibenzazepine-11-yl), 
4.50 (m, 1H, CαH Tyr-amide), 6.60 and 6.66 (m, 2H, 3/5-H phenyl), 7.03 (m, 2H, Har), 
7.13 (m, 2H, 2/6-H phenyl), 7.29 (m, 1H, Har), 7.34 (m, 1H, Har), 7.41 (m, 2H, Har), 7.51 
(m, 1H, Har), 7.83 (m, 1H, Har) ppm; 13C NMR (100 MHz, CD3OD, HSQC): δ = 24.5 and 
24.6 (C-3/4 cyclopentyl), 26.0 (Cγ), 30.0 (Cβ Orn), 37.8 and 37.9 (Cβ Tyr-amide), 39.4 
and 39.5 (C-2/5 cyclopentyl), 39.8 (>NCOCH2-cyclopentyl), 41.9 (Cδ), 42.5 (C-2/6 
piperazine), 44.5 (CH2CONαH), 45.8 (C-1 cyclopentyl), 52.2 and 52.6 (C-3/5 
piperazine), 54.2 (Cα Orn), 55.9 (Cα Tyr-amide), 75.8 (C-11 dibenzazepine-11-yl), 116.2 
(C-3/5 phenyl), 122.9 (C-2/6 phenyl), 126.1 (CarH), 129.6 (CarH), 130.1 (CarH), 131.4 
(CarH), 131.8 (CarH), 132.4 (Car), 133.2 (CarH), 136.9 (Car), 137.4 (Car), 157.2 (C-4 
phenyl), 158.6 (NC(N)N), 171.9 (C=O lactam), 172.9 (CON<), 173.8 (CONαH Tyr-amide), 
175.2 (CONαH Orn), 176.1 (CONH2) ppm; MS (ES, +p) m/z (%): 780 (30) [M+H]+, 391 
(100) [M+2H]2+; HRMS (LSI-MS): m/z [M+H]+ calcd. for C42H54N9O6: 780.4197, found: 
780.4211; RP-HPLC: 92 % (tR = 12.2 min, k´ = 3.5); C42H53N9O6 (779.41). 
 
General procedure for the preparation of the deprotected argininamides 3.47-3.628 
 
Deprotection was carried out in TFA-CH2Cl2 1:1 (v/v) (approx. 5 mL/0.2 mmol 
substrate). After stirring for 2 h, CCl4 or toluene (10 mL) was added, and the volatiles 
were removed under reduced pressure. The crude products were purified by 
preparative HPLC. The final products were obtained as white to slightly yellowish 
powders in yields from 70 to 99 %. 
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(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-
(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]argininamide ((S)-3.47). Mp 125 °C; [ߙ]஽ଶ଴= –3.3 cm3 g-1 dm-1 (c = 0.66 in 
CH3CN/H2O 9:1); 1H NMR (600 MHz, DMSO-d6, HSQC): δ = 1.44 (m, 2H, CγH2), 1.40 and 
1.65 (m, 2H, CβH2), 1.40-1.55 (m, 4H, 2/5-H cyclopentyl), 1.55 (m, 4H, 3/4-H 
cyclopentyl), 2.11 (m, 4H, 3/5-H piperazine), 2.24 and 2.30 (m, 2H, CH2CONαH), 2.46 
and 2.52 (m, 2H, NCOCH2-cyclo-C5H8), 3.00 (m, 2H, CδH2), 3.32 (m, 4H, 2/6-H 
piperazine), 3.29 and 3.38 (m, 2H, NHCH2CH2N), 3.59 (m, 2H, NHCH2CH2N), 4.14 (m, 
1H, CαH), 4.30 (m, 1H, 11-H dibenzazepin-11-yl), 7.03 (m, 1H, Har), 7.11 (m, 1H, Har), 
7.21 (m, 2H, Ph), 7.22 (m, 1H, Har), 7.32 (m, 1H, Har), 7.37 (m, 8H, Ph), 7.38 (m, 2H, 
Har), 7.45 (m, 1H, Har), 7.73 (m, 1H, Har), 8.02 (d, 3J = 7.5 Hz, 1H, NαH), 8.32 (t, 3J = 5.6 
Hz, 1H, CONHC2H4N), 10.40 (s, 1H, C(O)NH lactam) ppm; 13C NMR (150 MHz, DMSO-
d6, HSQC): δ = 23.2 (C-3/4 cyclopentyl), 24.9 (Cγ), 28.6 (Cβ), 36.0 (NHCH2CH2N), 37.1 
(C-2/5 cyclopentyl), 38.5 (NCOCH2-cyclo-C5H8), 39.6 (NHCH2CH2N), 40.1 (Cδ), 41.9 and 
45.5 (C-2/6 piperazine), 42.7 (CH2CONαH), 43.9 (C-1 cyclopentyl), 50.7 (C-3/5 
piperazine), 51.9 (Cα), 73.7 (C-11 dibenzazepin-11-yl), 121.3 (CarH), 122.7 (Ph), 123.8 
(CarH), 126.6 (Ph), 127.8 (2 CarH), 128.3 (CarH), 128.9 (Ph), 129.7 (CarH), 130.4 (CarH), 
131.1 (CarH), 131.4 (Car), 136.3 (Car), 136.4 (Car), 143.4 (Car), 152.5 (NCONPh), 156.9 
(NC(N)N), 168.2 (C=O lactam), 169.9 (CON), 171.2 (CONαH), 171.9 (CONHC2H4N) ppm; 
IR (neat): υ´ = 3281, 2963, 1649, 1446, 1176, 1132 cm-1; MS (ES, +p) m/z (%): 897 
(100) [M+H]+; HRMS (LSI-MS): m/z [M+H]+ calcd for C49H58N11O6: 896.4572, found: 
896.4550; RP-HPLC: 100 % (tR = 18.3 min, k’ = 5.7); anal. calcd. for C49H57N11O6⋅4 
H2O⋅5 HCl: C 51.16, H 6.13, N 13.40 %, found: C 51.12, H 6.25, N 13.08 %; C49H57N11O6 
(896.05). 
 
(2R)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-
(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]argininamide ((R)-3.47). Mp 125 °C; [ߙ]஽ଶ଴= +4.1 cm3 g-1 dm-1 (c = 0.88 in 
CH3CN/H2O 9:1); 1H NMR (600 MHz, CD3OD, HSQC, HMBC): δ = 1.48 and 1.72 (m, 2H, 
CβH2), 1.51 and 1.70 (m, 4H, 2/5-H cyclopentyl), 1.51 (m, 2H, CγH2), 1.63 (m, 4H, 3/4-H 
cyclopentyl), 2.21 and 2.29 (m, 4H, 3/5-H piperazine), 2.26 and 2.42 (m, 2H, 
CH2CONαH), 2.47 (m, 2H, >NCOCH2-cyclopentyl), 3.02 (m, 2H, CδH2), 3.41-3.46 (m, 4H, 
2/6-H piperazine), 3.47 and 3.53 (m, 2H, NHCH2CH2N<), 3.78 (m, 2H, NHCH2CH2N<), 
4.23 (m, 1H, CαH), 4.41 (br, 1H, 11-H dibenzazepine-11-yl), 7.15 (m, 2H, Har), 7.20 (m, 
2H, Har), 7.32 (m, 5H, Ph), 7.37 (m, 5H, Ph), 7.41 (m, 1H, Har), 7.45 (m, 1H, Har), 7.52 
(m, 1H, Har), 7.84 (d, 3J = 7.7 Hz, 1H, Har) ppm; 13C NMR (150 MHz, CD3OD, HSQC, 
HMBC): δ = 24.5 and 24.6 (C-3/4 cyclopentyl), 26.3 (Cγ), 30.0 (Cβ), 38.4 (NHCH2CH2N<), 
39.3 and 39.4 (C-2/5 cyclopentyl), 39.7 (>NCOCH2-cyclopentyl), 41.2 (NHCH2CH2N<), 
41.9 (Cδ), 44.7 (CH2CONαH), 45.8 (C-1 cyclopentyl), 47.0 (C-2/6 piperazine), 52.2 and 
52.7 (C-3/5 piperazine), 53.9 (Cα), 75.8 (C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.2 
(Ph), 126.1 (CarH), 128.2 (CarH), 129.4 (CarH), 129.7 (CarH), 130.2 (Ph), 131.4 (CarH), 
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131.9 (CarH), 132.4 (Car), 133.3 (CarH), 136.9 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 158.6 
(NC(N)N), 171.7 (C=O lactam), 172.8 (CON<), 174.6 (CONH(CH2)2N<), 174.7 (CONαH) 
ppm; MS (ES, +p) m/z (%): 897 (60) [M+H]+, 449 (100) [M+2H]2+; HRMS (LSI-MS): m/z 
[M+H]+ calcd. for C49H58N11O6: 896.4572, found: 896.4603; RP-HPLC: 98 % (tR = 18.3 
min, k’ = 5.8); C49H57N11O6 (895.45). 
 
(2S)-Nω-[4-(2-Aminoethyl)aminocarbonylbutanoyl]-N-[2-(3,5-dioxo-1,2-diphenyl-
1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo-
[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((S)-3.48). 
Mp 138 °C; [ߙ]஽ଶ଴= –7.6 cm3 g-1 dm-1 (c = 0.98 in CH3CN/H2O 9:1); 1H NMR (600 MHz, 
CD3OD, HSQC): δ = 1.51 and 1.75 (m, 2H, CβH2), 1.52 and 1.70 (m, 4H, 2/5-H 
cyclopentyl), 1.53 and 1.63 (m, 4H, 3/4-H cyclopentyl), 1.61 (m, 2H, CγH2), 1.93 (p, 3J = 
7.4 Hz, 2H, COCH2CH2CH2CO), 2.28 and 2.36 (m, 4H, 3/5-H piperazine), 2.29 and 2.44 
(m, 2H, CH2CONαH), 2.30 (m, 2H, COCH2(CH2)2CONH), 2.49 (m, 2H, >NCOCH2-
cyclopentyl), 2.51 (m, 2H, CO(CH2)2CH2CONH), 3.04 (t, 3J = 5.9 Hz, 2H, NHCH2CH2NH2), 
3.17 (m, 2H, CδH2), 3.34-3.55 (m, 4H, 2/6-H piperazine), 3.44 (t, 3J = 5.9 Hz, 2H, 
NHCH2CH2NH2), 3.45 and 3.54 (m, 2H, NHCH2CH2N<), 3.78 (m, 2H, NHCH2CH2N<), 4.25 
(m, 1H, CαH), 4.51 (br, 1H, 11-H dibenzazepine-11-yl), 7.16 (m, 2H, Har), 7.20 (m, 2H, 
Har), 7.32 (m, 5H, Ph), 7.37 (m, 5H, Ph), 7.43 (m, 1H, Har), 7.47 (m, 1H, Har), 7.54 (m, 
1H, Har), 7.87 (m, 1H, Har) ppm; 13C NMR (150 MHz, CD3OD, HSQC): δ = 21.0 
(COCH2CH2CH2CO), 24.5 and 24.6 (C-3/4 cyclopentyl), 25.4 (Cγ), 30.0 (Cβ), 35.4 
(COCH2(CH2)2CONH), 36.8 (CO(CH2)2CH2CONH), 38.2 (NHCH2CH2NH2), 38.4 
(NHCH2CH2N<), 39.3 and 39.4 (C-2/5 cyclopentyl), 39.7 (>NCOCH2-cyclopentyl), 40.9 
(NHCH2CH2NH2), 41.2 (NHCH2CH2N<), 41.9 (Cδ), 44.6 (CH2CONαH), 45.8 (C-1 
cyclopentyl), 46.7 (C-2/6 piperazine), 52.3 and 52.7 (C-3/5 piperazine), 53.8 (Cα), 75.8 
(C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.1 (Ph), 126.2 (CarH), 128.1 (CarH), 129.6 
(CarH), 130.0 (CarH), 130.2 (Ph), 131.6 (CarH), 132.2 (CarH), 132.4 (Car), 133.5 (CarH), 
137.0 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 155.1 (NC(N)N), 171.2 (C=O lactam), 172.8 
(CON<), 174.6 (CONH(CH2)2N<), 174.7 (CONαH), 176.4 (CO(CH2)3CONH), 176.7 
(CO(CH2)3CONH) ppm; MS (LSI, MeOH/gly) m/z (%): 1052 (100) [M+H]+; HRMS (LSI-
MS): m/z [M+H]+ calcd. for C56H70N13O8: 1052.5470, found: 1052.5462; RP-HPLC: 100 
% (tR = 14.7 min, k´ = 4.4); C56H69N13O8 (1051.54). 
 
(2R)-Nω-[4-(2-Aminoethyl)aminocarbonylbutanoyl]-N-[2-(3,5-dioxo-1,2-diphenyl-
1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo-
[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((R)-3.48). 
Mp 138 °C; [ߙ]஽ଶ଴= +5.6 cm3 g-1 dm-1 (c = 0.57 in CH3CN/H2O 9:1); 1H NMR (600 MHz, 
CD3OD, HSQC): δ = 1.51 and 1.75 (m, 2H, CβH2), 1.52 and 1.70 (m, 4H, 2/5-H 
cyclopentyl), 1.53 and 1.63 (m, 4H, 3/4-H cyclopentyl), 1.61 (m, 2H, CγH2), 1.93 (p, 3J = 
7.4 Hz, 2H, COCH2CH2CH2CO), 2.28 and 2.36 (m, 4H, 3/5-H piperazine), 2.29 and 2.44 
(m, 2H, CH2CONαH), 2.30 (m, 2H, COCH2(CH2)2CONH), 2.49 (m, 2H, >NCOCH2-
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cyclopentyl), 2.51 (m, 2H, CO(CH2)2CH2CONH), 3.04 (t, 3J = 5.9 Hz, 2H, NHCH2CH2NH2), 
3.17 (m, 2H, CδH2), 3.34-3.55 (m, 4H, 2/6-H piperazine), 3.44 (t, 3J = 5.9 Hz, 2H, 
NHCH2CH2NH2), 3.45 and 3.54 (m, 2H, NHCH2CH2N<), 3.78 (m, 2H, NHCH2CH2N<), 4.25 
(m, 1H, CαH), 4.51 (br, 1H, 11-H dibenzazepine-11-yl), 7.16 (m, 2H, Har), 7.20 (m, 2H, 
Har), 7.32 (m, 5H, Ph), 7.37 (m, 5H, Ph), 7.43 (m, 1H, Har), 7.47 (m, 1H, Har), 7.54 (m, 
1H, Har), 7.87 (m, 1H, Har) ppm; 13C NMR (150 MHz, CD3OD, HSQC): δ = 21.0 
(COCH2CH2CH2CO), 24.5 and 24.6 (C-3/4 cyclopentyl), 25.4 (Cγ), 30.0 (Cβ), 35.4 
(COCH2(CH2)2CONH), 36.8 (CO(CH2)2CH2CONH), 38.2 (NHCH2CH2NH2), 38.4 
(NHCH2CH2N<), 39.3 and 39.4 (C-2/5 cyclopentyl), 39.7 (>NCOCH2-cyclopentyl), 40.9 
(NHCH2CH2NH2), 41.2 (NHCH2CH2N<), 41.9 (Cδ), 44.6 (CH2CONαH), 45.8 (C-1 
cyclopentyl), 46.7 (C-2/6 piperazine), 52.3 and 52.7 (C-3/5 piperazine), 53.8 (Cα), 75.8 
(C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.1 (Ph), 126.2 (CarH), 128.1 (CarH), 129.6 
(CarH), 130.0 (CarH), 130.2 (Ph), 131.6 (CarH), 132.2 (CarH), 132.4 (Car), 133.5 (CarH), 
137.0 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 155.1 (NC(N)N), 171.2 (C=O lactam), 172.8 
(CON<), 174.6 (CONH(CH2)2N<), 174.7 (CONαH), 176.4 (CO(CH2)3CONH), 176.7 
(CO(CH2)3CONH) ppm; MS (LSI, MeOH/gly) m/z (%): 1052 (100) [M+H]+; HRMS (LSI-
MS): m/z [M+H]+ calcd. for C56H70N13O8: 1052.5470, found: 1052.5462; RP-HPLC: 100 
% (tR = 10.3 min, k´ = 2.9);C56H69N13O8 (1051.54). 
 
(2S)-Nω-[4-(3-Aminopropyl)aminocarbonylbutanoyl]-N-[2-(3,5-dioxo-1,2-diphenyl-
1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo-
[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((S)-3.49). 
Mp 129 °C; 1H NMR (600 MHz, CD3OD): δ = 1.51 and 1.74 (m, 2H, CβH2), 1.50 und 1.66 
(m, 4H, 2/5-H cyclopentyl), 1.51 und 1.63 (m, 4H, 3/4-H cyclopentyl), 1.62 (m, 2H, 
CγH2), 1.83 (p, 3J = 7.0 Hz, 2H, CONHCH2CH2CH2NH2), 1.92 (p, 3J = 7.3 Hz, 2H, 
COCH2CH2CH2CONH), 2.17 und 2.24 (m, 4H, 3/5-H piperazine), 2.27 (m, 2H, 
COCH2(CH2)2CONH), 2.50 (m, 2H, CO(CH2)2CH2CONH), 2.93 (t, 3J = 7.2 Hz, 2H, 
CONH(CH2)2CH2NH2), 3.18 (m, 2H, CδH2), 3.27 (t, 3J = 6.6 Hz, 2H, CONHCH2(CH2)2NH2), 
3.37 und 3.54 (m, 4H, 2/6-H piperazine), 3.54 (m, 2H, NHCH2CH2N), 3.77 (m, 2H, 
NHCH2CH2N), 4.25 (m, 1H, CαH), 4.33 (br, 1H, 11-H dibenzazepine-11-yl), 7.12 (m, 1H, 
Har), 7.13 (m, 1H, Har), 7.20 (m, 1H, Har), 7.31 (m, 2H, Ph), 7.34 (m, 1H, Har), 7.37 (m, 
8H, Ph), 7.39 (m, 1H, Har), 7.43 (m, 1H, Har), 7.51 (m, 1H, Har), 7.82 (m, 1H, Har) ppm; 
13C NMR (150 MHz, CD3OD): δ = 21.3 (NCOCH2CH2CH2CONH), 24.5 und 24.6 (C-3/4 
cyclopentyl), 25.4 (Cγ), 28.8 (CONHCH2CH2CH2NH2), 30.0 (Cβ), 35.5 
(NCOCH2(CH2)2CONH), 36.8 (NCO(CH2)2CH2CONH), 38.2 (CONHCH2(CH2)2NH2), 38.5 
(NHCH2CH2N), 39.2 und 39.3 (C-2/5 cyclopentyl), 39.4 und 39.7 (NCOCH2-cyclopentyl), 
40.9 (CONH(CH2)2CH2NH2), 41.2 (NHCH2CH2N), 41.9 (Cδ), 42.4 und 47.3 (C-2/6 
piperazine), 44.7 (CH2CONαH), 45.8 (C-1 cyclopentyl), 52.2 und 52.6 (C-3/5 
piperazine), 53.7 (Cα), 75.8 (C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.1 (Ph), 126.1 
(CarH), 128.1 (CarH), 129.2 (CarH), 129.6 (CarH), 130.1 (Car), 130.2 (Ph), 131.2 (CarH), 
131.8 (CarH), 132.4 (Car), 133.2 (CarH), 136.9 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 155.1 
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(NC(N)N), 171.8 (C=O lactam), 172.7 (CONαH), 174.5 (CONHC2H4N), 174.7 (CON), 
175.9 (NCO(CH2)3CONH), 176.6 (NCO(CH2)3CONH) ppm; IR (neat): υ´ = 3277, 2948, 
1648, 1442, 1192, 1130 cm-1; MS (ES, +p) m/z (%): 1066 (100) [M+H]+; HRMS (LSI-MS): 
m/z [M+H]+ calcd for C57H72N13O8: 1066.5621, found: 1066.5642; RP-HPLC: 100 % (tR = 
14.8 min, k´ = 4.5); anal. calcd. for C57H71N13O8⋅1.75 H2O⋅3.25 TFA: C 51.95, H 5.32, N 
12.40 %, found: C 51.86, H 5.10, N 12.44 %; C57H71N13O8 (1065.55). 
 
(2S)-Nω-{4-[2-(2-Aminoethyl)aminoethyl]aminocarbonylbutanoyl}-N-[2-(3,5-dioxo-
1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-
5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide 
((S)-3.50). Mp 108-110 °C; [ߙ]஽ଶ଴= –10.4 cm3 g-1 dm-1 (c = 0.52 in CH3CN/H2O 9:1); 1H 
NMR (600 MHz, CD3OD, COSY, HSQC, HMBC): δ = 1.51 and 1.63 (m, 4H, 3/4-H 
cyclopentyl), 1.51 and 1.67 (m, 4H, 2/5-H cyclopentyl), 1.51 and 1.74 (m, 2H, CβH2), 
1.59 (m, 2H, CγH2), 1.93 (p, 3J = 7.4 Hz, 2H, COCH2CH2CH2CO), 2.19 and 2.26 (m, 4H, 
3/5-H piperazine), 2.28 and 2.42 (m, 2H, CH2CONαH), 2.31 (t, 3J = 7.4 Hz, 2H, 
COCH2(CH2)2CONH), 2.48 (m, 2H, >NCOCH2-cyclopentyl), 2.50 (t, 3J = 7.4 Hz, 2H, 
CO(CH2)2CH2CONH), 3.17 (m, 2H, CδH2), 3.22 (t, 3J = 5.7 Hz, 2H, NHCH2CH2NH), 3.33 (t, 
3J = 6.5 Hz, 2H, NHCH2CH2NH2), 3.36-3.50 (m, 4H, 2/6-H piperazine), 3.40 (t, 3J = 6.5 
Hz, 2H, NHCH2CH2NH2), 3.45 and 3.54 (m, 2H, NHCH2CH2N<), 3.51 (t, 3J = 5.7 Hz, 2H, 
NHCH2CH2NH), 3.78 (m, 2H, NHCH2CH2N<), 4.25 (m, 1H, CαH), 4.37 (br, 1H, 11-H 
dibenzazepine-11-yl), 7.14 (m, 2H, Har), 7.20 (m, 2H, Har), 7.32 (m, 5H, Ph), 7.37 (m, 
5H, Ph), 7.40 (m, 1H, Har), 7.44 (m, 1H, Har), 7.51 (m, 1H, Har), 7.83 (d, 3J = 7.7 Hz, 1H, 
Har) ppm; 13C NMR (150 MHz, CD3OD, HSQC, HMBC): δ = 21.0 (COCH2CH2CH2CO), 24.5 
and 24.6 (C-3/4 cyclopentyl), 25.4 (Cγ), 30.0 (Cβ), 35.3 (COCH2(CH2)2CONH), 36.8 
(CO(CH2)2CH2CONH), 36.9 (NHCH2CH2NH2), 37.1 (CONHCH2CH2NH), 38.4 
(NHCH2CH2N<), 39.3 and 39.4 (C-2/5 cyclopentyl), 39.7 (>NCOCH2-cyclopentyl), 41.1 
(NHCH2CH2N<), 42.0 (Cδ), 44.7 (CH2CONαH), 45.7 (NHCH2CH2NH2), 45.8 (C-1 
cyclopentyl), 47.2 (C-2/6 piperazine), 49.5 (CONHCH2CH2NH), 52.2 and 52.6 (C-3/5 
piperazine), 53.8 (Cα), 75.8 (C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.1 (Ph), 126.1 
(CarH), 128.1 (CarH), 129.2 (CarH), 129.6 (CarH), 130.2 (Ph), 131.3 (CarH), 131.9 (CarH), 
132.4 (Car), 133.2 (CarH), 136.9 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 155.0 (NC(N)N), 
171.7 (C=O lactam), 172.8 (CON<), 174.6 (CONH(CH2)2N<), 174.7 (CONαH), 176.6 
(CO(CH2)3CONH), 176.7 (CO(CH2)3CONH) ppm; MS (ES, +p) m/z (%): 549 (100) 
[M+2H]2+; HRMS (LSI-MS): m/z [M+H]+ calcd. for C58H75N14O8: 1095.5892, found: 
1095.5912; RP-HPLC: 99 % (tR = 13.0 min, k´ = 3.8); C58H74N14O8 (1094.58). 
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(2R)-Nω-{4-[2-(2-Aminoethyl)aminoethyl]aminocarbonylbutanoyl}-N-[2-(3,5-dioxo-
1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-
5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide 
((R)-3.50). Mp 108-110 °C; [ߙ]஽ଶ଴= +2.5 cm3 g-1 dm-1 (c = 0.63 in CH3CN/H2O 9:1); 1H 
NMR (600 MHz, CD3OD, HSQC): δ = 1.51 and 1.63 (m, 4H, 3/4-H cyclopentyl), 1.51 and 
1.67 (m, 4H, 2/5-H cyclopentyl), 1.51 and 1.74 (m, 2H, CβH2), 1.59 (m, 2H, CγH2), 1.93 
(p, 3J = 7.4 Hz, 2H, COCH2CH2CH2CO), 2.19 and 2.26 (m, 4H, 3/5-H piperazine), 2.28 
and 2.42 (m, 2H, CH2CONαH), 2.31 (t, 3J = 7.4 Hz, 2H, COCH2(CH2)2CONH), 2.48 (m, 2H, 
>NCOCH2-cyclopentyl), 2.50 (t, 3J = 7.4 Hz, 2H, CO(CH2)2CH2CONH), 3.17 (m, 2H, CδH2), 
3.22 (t, 3J = 5.7 Hz, 2H, NHCH2CH2NH), 3.33 (t, 3J = 6.5 Hz, 2H, NHCH2CH2NH2), 3.36-
3.50 (m, 4H, 2/6-H piperazine), 3.40 (t, 3J = 6.5 Hz, 2H, NHCH2CH2NH2), 3.45 and 3.54 
(m, 2H, NHCH2CH2N<), 3.51 (t, 3J = 5.7 Hz, 2H, NHCH2CH2NH), 3.78 (m, 2H, 
NHCH2CH2N<), 4.25 (m, 1H, CαH), 4.48 (br, 1H, 11-H dibenzazepine-11-yl), 7.15 (m, 
2H, Har), 7.20 (m, 2H, Har), 7.32 (m, 5H, Ph), 7.37 (m, 5H, Ph), 7.42 (m, 1H, Har), 7.46 
(m, 1H, Har), 7.53 (m, 1H, Har), 7.86 (d, 3J = 7.7 Hz, 1H, Har) ppm; 13C NMR (150 MHz, 
CD3OD, HSQC): δ = 21.0 (COCH2CH2CH2CO), 24.5 and 24.6 (C-3/4 cyclopentyl), 25.4 
(Cγ), 30.0 (Cβ), 35.3 (COCH2(CH2)2CONH), 36.8 (CO(CH2)2CH2CONH), 36.9 
(NHCH2CH2NH2), 37.1 (CONHCH2CH2NH), 38.4 (NHCH2CH2N<), 39.3 and 39.4 (C-2/5 
cyclopentyl), 39.7 (>NCOCH2-cyclopentyl), 41.1 (NHCH2CH2N<), 42.0 (Cδ), 44.7 
(CH2CONαH), 45.7 (NHCH2CH2NH2), 45.8 (C-1 cyclopentyl), 46.8 (C-2/6 piperazine), 
49.5 (CONHCH2CH2NH), 52.2 and 52.6 (C-3/5 piperazine), 53.8 (Cα), 75.8 (C-11 
dibenzazepine-11-yl), 123.0 (CarH), 124.1 (Ph), 126.2 (CarH), 128.1 (CarH), 129.6 (CarH), 
129.9 (CarH), 130.2 (Ph), 130.4 (CarH), 131.5 (CarH), 132.1 (CarH), 132.4 (Car), 133.4 
(CarH), 137.0 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 155.0 (NC(N)N), 171.3 (C=O lactam), 
172.8 (CON<), 174.6 (CONH(CH2)2N<), 174.7 (CONαH), 176.6 (CO(CH2)3CONH) ppm; 
MS (ES, +p) m/z (%): 549 (100) [M+2H]2+; HRMS (LSI-MS): m/z [M+H]+ calcd. for 
C58H75N14O8: 1095.5892, found: 1095.5912; RP-HPLC: 97 % (tR = 13.6 min, k´ = 4.1), 
gradient: 0 to 20 min: A/B 10/90 to 60/40, 20 to 21 min: 95/5, 21 to 29 min: 95/5; 
C58H74N14O8 (1094.58). 
 
(2S)-Nω-(18-Amino-4-oxo-9,12,15-trioxa-5-azaoctadecanoyl)-N-[2-(3,5-dioxo-1,2-di-
phenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-di-
benzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((S)-
3.51). 1H NMR (600 MHz, CD3OD, COSY, HSQC, HMBC): δ = 1.52 and 1.63 (m, 4H, 3/4-
H cyclopentyl), 1.52 and 1.69 (m, 4H, 2/5-H cyclopentyl), 1.52 and 1.74 (m, 2H, CβH2), 
1.63 (m, 2H, CγH2), 1.74 (m, 2H, NHCH2CH2CH2O), 1.90 (m, 2H, H2NCH2CH2CH2O), 2.26 
and 2.43 (m, 2H, CH2CONαH), 2.28 and 2.41 (m, 4H, 3/5-H piperazine), 2.49 (m, 2H, 
>NCOCH2-cyclopentyl), 2.55 and 2.73 (m, 4H, =NCO(CH2)2CONH), 3.08 (m, 2H, 
H2NCH2(CH2)2O), 3.16 (m, 2H, CδH2), 3.23 (m, 2H, NHCH2(CH2)2O), 3.37-3.51 (m, 4H, 
2/6-H piperazine), 3.44 and 3.56 (m, 2H, NHCH2CH2N<), 3.49 (m, 2H, NH(CH2)2CH2O), 
3.56 and 3.61 (m, 8H, (O(CH2)2O)2), 3.64 (m, 2H, H2N(CH2)2CH2O), 3.78 (m, 2H, 
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NHCH2CH2N<), 4.25 (m, 1H, CαH), 4.53 (br, 1H, 11-H dibenzazepine-11-yl), 7.16 (m, 
1H, Har), 7.17 (m, 1H, Har), 7.20 (m, 2H, Har), 7.32 (m, 5H, Ph), 7.37 (m, 5H, Ph), 7.43 
(m, 1H, Har), 7.47 (m, 1H, Har), 7.54 (m, 1H, Har), 7.88 (m, 1H, Har) ppm; 13C NMR (150 
MHz, CD3OD, HSQC, HMBC): δ = 24.5 and 24.6 (C-3/4 cyclopentyl), 25.4 (Cγ), 28.0 
(NHCH2CH2CH2O), 30.0 (Cβ), 30.4 (H2NCH2CH2CH2O), 30.5 (=NCOCH2CH2CO), 32.9 
(=NCOCH2CH2CO), 37.8 (NHCH2(CH2)2O), 38.4 (NHCH2CH2N<), 39.3 and 39.4 (C-2/5 
cyclopentyl), 39.7 (>NCOCH2-cyclopentyl), 40.1 (H2NCH2(CH2)2O), 41.2 (NHCH2CH2N<), 
41.9 (Cδ), 44.6 (CH2CONαH), 45.8 (C-1 cyclopentyl), 46.7 (C-2/6 piperazine), 52.3 and 
52.7 (C-3/5 piperazine), 53.8 (Cα), 69.6 (NH(CH2)2CH2O), 70.4 (H2N(CH2)2CH2O), 71.0 
and 71.4 ((O(CH2)2O)2), 75.9 (C-11 dibenzazepine-11-yl), 123.1 (CarH), 124.2 (Ph), 
126.2 (CarH), 128.2 (CarH), 129.7 (CarH), 130.0 (Car), 130.2 (Ph), 130.5 (CarH), 131.6 
(CarH), 132.2 (CarH), 132.4 (Car), 133.5 (CarH), 137.0 (Car), 137.8 (Car), 154.5 
(N(CONPh)2), 155.0 (NC(N)N), 171.1 (C=O lactam), 172.8 (CONαH), 173.8 
(=NCO(CH2)2CO), 174.5 (CONH(CH2)2N<), 174.7 (CON<), 176.4 (=NCO(CH2)2CO) ppm; 
MS (ES, +p) m/z (%): 1199 (4) [M+H]+, 600 (100) [M+2H]2+; HRMS (LSI-MS): m/z 
[M+2H]2+ calcd. for C63H84N13O11: 599.8246, found: 599.8261; HRMS (FAB): m/z 
[M+H]+ calcd. for C63H84N13O11: 1198.6413, found: 1198.6423; RP-HPLC: 99 % (tR = 
15.1 min, k´ = 4.6); C63H83N13O11 (1197.63). 
 
(2S)-Nω-[(2-Aminoethyl)aminocarbonyl]-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-tri-
azolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo-
[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((S)-3.52). 
1H NMR (600 MHz, CD3OD, COSY, HSQC, HMBC): δ = 1.51 and 1.63 (m, 4H, 3/4-H 
cyclopentyl), 1.51 and 1.67 (m, 4H, 2/5-H cyclopentyl), 1.51 and 1.74 (m, 2H, CβH2), 
1.59 (m, 2H, CγH2), 2.21 and 2.30 (m, 4H, 3/5-H piperazine), 2.28 and 2.43 (m, 2H, 
CH2CONαH), 2.48 (m, 2H, >NCOCH2-cyclopentyl), 3.08 (t, 3J = 5.7 Hz, 2H, 
NHCH2CH2NH2), 3.15 (m, 2H, CδH2), 3.36-3.53 (m, 4H, 2/6-H piperazine), 3.40-3.58 (m, 
2H, NHCH2CH2N<), 3.48 (m, 2H, NHCH2CH2NH2), 3.78 (m, 2H, NHCH2CH2N<), 4.25 (m, 
1H, CαH), 4.41 (br, 1H, 11-H dibenzazepine-11-yl), 7.15 (m, 2H, Har), 7.19 (m, 2H, Har), 
7.32 (m, 5H, Ph), 7.37 (m, 5H, Ph), 7.41 (m, 1H, Har), 7.45 (m, 1H, Har), 7.52 (m, 1H, 
Har), 7.85 (d, 3J = 7.7 Hz, 1H, Har) ppm; 13C NMR (150 MHz, CD3OD, HSQC, HMBC): δ = 
24.5 and 24.6 (C-3/4 cyclopentyl), 25.6 (Cγ), 30.0 (Cβ), 38.4 (NHCH2CH2N<), 38.5 
(NHCH2CH2NH2), 39.3 and 39.4 (C-2/5 cyclopentyl), 39.7 (>NCOCH2-cyclopentyl), 40.8 
(NHCH2CH2NH2), 41.2 (NHCH2CH2N<), 41.9 (Cδ), 44.7 (CH2CONαH), 45.8 (C-1 
cyclopentyl), 47.0 (C-2/6 piperazine), 52.2 and 52.6 (C-3/5 piperazine), 53.8 (Cα), 75.8 
(C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.1 (Ph), 126.2 (CarH), 128.1 (CarH), 129.5 
(CarH), 129.8 (CarH), 130.2 (Ph), 130.3 (Car), 131.4 (CarH), 132.0 (CarH), 132.4 (Car), 133.3 
(CarH), 137.0 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 155.7 (NC(N)N), 156.5 (=NCONH), 
171.5 (C=O lactam), 172.8 (CON<), 174.6 (CONH(CH2)2N<), 174.7 (CONαH) ppm; MS 
(ES, +p) m/z (%): 492 (100) [M+2H]2+; HRMS (LSI-MS): m/z [M+H]+ calcd. for 
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C52H64N13O7: 982.5052, found: 982.5071; RP-HPLC: 100 % (tR = 14.3 min, k´ = 4.3); 
C52H63N13O7 (981.50). 
 
(2S)-Nω-[(3-Aminopropyl)aminocarbonyl]-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-tri-
azolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo-
[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((S)-3.53). 
Mp 146 °C; 1H NMR (600 MHz, CD3OD, COSY, HSQC, HMBC): δ = 1.51 and 1.63 (m, 4H, 
3/4-H cyclopentyl), 1.51 and 1.66 (m, 4H, 2/5-H cyclopentyl), 1.51 and 1.74 (m, 2H, 
CβH2), 1.59 (m, 2H, CγH2), 1.86 (p, 3J = 7.4 Hz, 2H, NHCH2CH2CH2NH2), 2.24 and 2.31 
(m, 4H, 3/5-H piperazine), 2.28 and 2.43 (m, 2H, CH2CONαH), 2.49 (m, 2H, >NCOCH2-
cyclopentyl), 2.96 (t, 3J = 7.4 Hz, 2H, NH(CH2)2CH2NH2), 3.14 (m, 2H, CδH2), 3.29 (m, 
2H, NHCH2(CH2)2NH2), 3.39-3.58 (m, 4H, 2/6-H piperazine), 3.46 and 3.54 (m, 2H, 
NHCH2CH2N<), 3.78 (m, 2H, NHCH2CH2N<), 4.25 (m, 1H, CαH), 4.44 (br, 1H, 11-H 
dibenzazepine-11-yl), 7.16 (m, 2H, Har), 7.19 (m, 2H, Har), 7.32 (m, 5H, Ph), 7.37 (m, 
5H, Ph), 7.42 (m, 1H, Har), 7.45 (m, 1H, Har), 7.52 (m, 1H, Har), 7.85 (m, 1H, Har) ppm; 
13C NMR (150 MHz, CD3OD, HSQC, HMBC): δ = 24.5 and 24.6 (C-3/4 cyclopentyl), 25.7 
(Cγ), 28.7 (NHCH2CH2CH2NH2), 30.0 (Cβ), 37.6 (NHCH2(CH2)2NH2), 38.3 
(NH(CH2)2CH2NH2), 38.4 (NHCH2CH2N<), 39.3 and 39.4 (C-2/5 cyclopentyl), 39.7 
(>NCOCH2-cyclopentyl), 41.2 (NHCH2CH2N<), 41.8 (Cδ), 44.7 (CH2CONαH), 45.8 (C-1 
cyclopentyl), 47.0 (C-2/6 piperazine), 52.2 and 52.7 (C-3/5 piperazine), 53.8 (Cα), 75.8 
(C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.1 (Ph), 126.2 (CarH), 128.1 (CarH), 129.5 
(CarH), 129.8 (CarH), 130.2 (Ph), 130.3 (Car), 131.4 (CarH), 132.0 (CarH), 132.4 (Car), 133.4 
(CarH), 137.0 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 155.7 (NC(N)N), 156.1 (=NCONH), 
171.4 (C=O lactam), 172.8 (CON<), 174.6 (CONH(CH2)2N<), 174.7 (CONαH) ppm; IR 
(neat): υ´ = 3252, 2949, 1650, 1443, 1180, 1129 cm-1; MS (LSI, MeOH/gly) m/z (%): 
997 (100) [M+H]+; HRMS (LSI-MS): m/z [M+H]+ calcd. for C53H66N13O7: 996.5208, 
found: 996.5200; RP-HPLC: 98 % (tR = 15.0 min, k´ = 4.5); anal. calcd. for 
C53H65N13O7⋅1.75 H2O⋅2.75 TFA: C 52.38, H 5.37, N 13.57  %, found: C 52.36, H 5.32, N 
13.56 %; C53H65N13O7 (995.51). 
 
(2S)-Nω-[(4-Aminobutyl)aminocarbonyl]-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-tri-
azolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo-
[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((S)-3.54). 
Mp 146 °C; [ߙ]஽ଶ଴= –1.7 cm3 g-1 dm-1 (c = 0.98 in CH3CN/H2O 9:1); 1H NMR (600 MHz, 
CD3OD, COSY, HSQC, HMBC): δ = 1.51 and 1.62 (m, 4H, 3/4-H cyclopentyl), 1.51 and 
1.66 (m, 4H, 2/5-H cyclopentyl), 1.51 and 1.74 (m, 2H, CβH2), 1.59 (m, 2H, 
NH(CH2)2CH2CH2NH2), 1.66 (m, 2H, CγH2), 1.66 (m, 2H, NHCH2CH2(CH2)2NH2), 2.28 and 
2.43 (m, 2H, CH2CONαH), 2.26 and 2.34 (m, 4H, 3/5-H piperazine), 2.49 (m, 2H, 
>NCOCH2-cyclopentyl), 2.93 (t, 3J = 7.5 Hz, 2H, NH(CH2)3CH2NH2), 3.14 (m, 2H, CδH2), 
3.21 (t, 3J = 6.6 Hz, 2H, NHCH2(CH2)3NH2), 3.37-3.58 (m, 4H, 2/6-H piperazine), 3.45 
and 3.55 (m, 2H, NHCH2CH2N<), 3.78 (m, 2H, NHCH2CH2N<), 4.25 (m, 1H, CαH), 4.47 
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(br, 1H, 11-H dibenzazepine-11-yl), 7.16 (m, 2H, Har), 7.19 (m, 2H, Har), 7.32 (m, 5H, 
Ph), 7.37 (m, 5H, Ph), 7.42 (m, 1H, Har), 7.45 (m, 1H, Har), 7.53 (m, 1H, Har), 7.86 (m, 
1H, Har) ppm; 13C NMR (150 MHz, CD3OD, HSQC, HMBC): δ = 24.5 and 24.6 (C-3/4 
cyclopentyl), 25.7 (Cγ + NH(CH2)2CH2CH2NH2), 27.4 (NHCH2CH2(CH2)2NH2), 30.0 (Cβ), 
38.4 (NHCH2CH2N<), 39.3 and 39.4 (C-2/5 cyclopentyl), 39.7 (>NCOCH2-cyclopentyl), 
39.9 (NHCH2(CH2)3NH2), 39.9 (NH(CH2)3CH2NH2), 41.2 (NHCH2CH2N<), 41.8 (Cδ), 44.6 
(CH2CONαH), 45.8 (C-1 cyclopentyl), 46.8 (C-2/6 piperazine), 52.3 and 52.6 (C-3/5 
piperazine), 53.8 (Cα), 75.8 (C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.1 (Ph), 126.2 
(CarH), 128.1 (CarH), 129.6 (CarH), 129.9 (CarH), 130.2 (Ph), 130.4 (Car), 131.5 (CarH), 
132.1 (CarH), 132.4 (Car), 133.4 (CarH), 137.0 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 155.8 
(NC(N)N), 155.9 (=NCONH), 171.3 (C=O lactam), 172.7 (CON<), 174.6 (CONH(CH2)2N<), 
174.7 (CONαH) ppm; IR (neat): υ´ = 3284, 2958, 1652, 1445, 1175, 1131 cm-1;  MS (LSI, 
MeOH/gly) m/z (%): 1011 (100) [M+H]+; HRMS (LSI-MS): m/z [M+H]+ calcd. for 
C54H68N13O7: 1010.5365, found: 1010.5361; RP-HPLC: 98 % (tR = 15.0 min, k´ = 4.5); 
anal. calcd. for C54H67N13O7⋅ 2 H2O⋅ 2.5 TFA: C 53.21, H 5.60, N 13.67  %, found: C 
53.24, H 5.87, N 13.77 %; C54H67N13O7 (1009.53). 
 
(2S)-Nω-[(6-Aminohexyl)aminocarbonyl]-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-tri-
azolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo-
[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((S)-3.55). 1H 
NMR (600 MHz, CD3OD, COSY, HSQC): δ = 1.37 (m, 4H, NH(CH2)2(CH2)2(CH2)2NH2), 1.51 
and 1.63 (m, 4H, 3/4-H cyclopentyl), 1.51 and 1.66 (m, 4H, 2/5-H cyclopentyl), 1.52 
(m, 2H, NHCH2CH2(CH2)4NH2), 1.63 (m, 2H, CγH2), 1.64 (m, 2H, NH(CH2)4CH2CH2NH2), 
1.74 (m, 2H, CβH2), 2.20 and 2.28 (m, 4H, 3/5-H piperazine), 2.27 and 2.42 (m, 2H, 
CH2CONαH), 2.49 (m, 2H, >NCOCH2-cyclopentyl), 2.90 (t, 3J = 7.6 Hz, 2H, 
NH(CH2)5CH2NH2), 3.14 (m, 2H, CδH2), 3.17 (m, 2H, NHCH2(CH2)5NH2), 3.37-3.51 (m, 
4H, 2/6-H piperazine), 3.45 and 3.55 (m, 2H, NHCH2CH2N<), 3.78 (m, 2H, 
NHCH2CH2N<), 4.25 (m, 1H, CαH), 4.38 (br, 1H, 11-H dibenzazepine-11-yl), 7.15 (m, 
2H, Har), 7.19 (m, 2H, Har), 7.31 (m, 5H, Ph), 7.37 (m, 5H, Ph), 7.40 (m, 1H, Har), 7.44 
(m, 1H, Har), 7.51 (m, 1H, Har), 7.83 (m, 1H, Har) ppm; 13C NMR (150 MHz, CD3OD, 
HSQC): δ = 24.5 and 24.6 (C-3/4 cyclopentyl), 25.7 (Cγ), 27.0 and 27.2 
(NH(CH2)2(CH2)2(CH2)2NH2), 28.4 (NH(CH2)4CH2CH2NH2), 30.0 (Cβ), 30.2 
(NHCH2CH2(CH2)4NH2), 38.4 (NHCH2CH2N<), 39.3 and 39.4 (C-2/5 cyclopentyl), 39.7 
(>NCOCH2-cyclopentyl), 40.5 (NHCH2(CH2)5NH2), 40.6 (NH(CH2)5CH2NH2), 41.2 
(NHCH2CH2N<), 41.8 (Cδ), 44.6 (CH2CONαH), 45.8 (C-1 cyclopentyl), 47.1 (C-2/6 
piperazine), 52.3 and 52.6 (C-3/5 piperazine), 53.8 (Cα), 75.8 (C-11 dibenzazepine-11-
yl), 123.0 (CarH), 124.1 (Ph), 126.1 (CarH), 128.1 (CarH), 129.3 (CarH), 129.7 (CarH), 130.2 
(Ph), 130.2 (Car), 131.3 (CarH), 131.9 (CarH), 132.4 (Car), 133.3 (CarH), 136.9 (Car), 137.8 
(Car), 154.5 (N(CONPh)2), 155.6 (=NCONH), 155.8 (NC(N)N), 171.6 (C=O lactam), 172.7 
(CON<), 174.5 (CONH(CH2)2N<), 174.7 (CONαH) ppm; MS (LSI, MeOH/gly) m/z (%): 
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1039 (100) [M+H]+; HRMS (LSI-MS): m/z [M+H]+ calcd. for C56H72N13O7: 1038.5678, 
found: 1038.5667; RP-HPLC: 93 % (tR = 15.5 min, k´ = 4.7); C56H72N13O7 (1037.56). 
 
(2S)-Nω-(6-Aminohexanoyl)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-
yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-
yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((S)-3.56). [ߙ]஽ଶ଴= +12.0 cm3 
g-1 dm-1 (c = 0.49 in CH3CN/H2O 9:1); 1H NMR (600 MHz, DMSO-d6, HSQC): δ = 1.31 (m, 
2H, CO(CH2)2CH2(CH2)2NH2), 1.49 (m, 2H, CγH2), 1.45 and 1.64 (m, 2H, CβH2), 1.39-1.56 
(m, 4H, 2/5-H cyclopentyl), 1.53 (m, 2H, CH2CH2NH2), 1.54 (m, 2H, COCH2CH2), 1.54 
(m, 4H, 3/4-H cyclopentyl), 2.08 and 2.10 (m, 4H, 3/5-H piperazine), 2.21 and 2.30 (m, 
2H, CH2CONαH), 2.41 (t, 3J = 7.3 Hz, 2H, C(O)CH2CH2), 2.41 and 2.49 (m, 2H, NCOCH2-
cyclopentyl), 2.77 (m, 2H, CH2NH2), 3.18 (m, 2H, CδH2), 3.31-3.33 (m, 4H, 2/6-H 
piperazine), 3.31 and 3.38 (m, 2H, NHCH2CH2N), 3.60 (t, 3J = 6.0 Hz, 2H, NHCH2CH2N), 
4.16 (m, 1H, CαH), 4.32 (br, 1H, 11-H dibenzazepine-11-yl), 7.06 (m, 1H, Har), 7.10 (m, 
1H, Har), 7.22 (m, 2H, Ph), 7.25 (m, 1H, Har), 7.33 (m, 1H, Har), 7.37 (m, 8H, Ph), 7.39 
(m, 1H, Har), 7.41 (m, 1H, Har), 7.49 (m, 1H, Har), 7.75 (m, 1H, Har), 7.84 (br, 3H, NH3+), 
7.99 (d, 3J = 8.0 Hz, 1H, NαH), 8.25 (t, 3J = 5.8 Hz, 1H, CONHC2H4N), 8.61 and 9.15 (br, 
2H, NωH2), 9.47 (t, 3J = 5.4 Hz, 1H, NδH), 10.36 (s, 1H, C(O)NH lactam), 12.30 (s, 1H, 
Nω’H) ppm; 13C NMR (150 MHz, DMSO-d6, HSQC): δ = 23.2 (COCH2CH3), 23.2 (C-3/4 
cyclopentyl), 24.2 (Cγ), 25.2 (CH2(CH2)2NH2), 26.6 (CH2CH2NH2), 28.7 (Cβ), 35.9 
(C(O)CH2), 36.1 (NHCH2CH2N), 37.2 (C-2/5 cyclopentyl), 38.5 (NCOCH2-cyclopentyl), 
38.5 (CH2NH2), 39.6 (NHCH2CH2N), 40.5 (Cδ), 40.5 and 45.3 (C-2/6 piperazine), 42.8 
(CH2CONαH), 44.0 (C-1 cyclopentyl), 50.6 and 51.2 (C-3/5 piperazine), 51.8 (Cα), 73.6 
(C-11 dibenzazepine-11-yl), 121.3 (CarH), 122.6 (Ph), 123.7 (CarH), 126.6 (Ph), 127.8 
(CarH), 128.1 (CarH), 128.4 (CarH), 128.9 (Ph), 129.9 (CarH), 130.5 (CarH), 131.3 (CarH), 
131.6 (Car), 136.1 (Car), 136.5 (Car), 141.5 (Car), 152.5 (N(CONPh)2), 153.1 (NC(N)N), 
167.9 (C=O lactam), 169.9 (CON), 171.2 (CONαH), 171.9 (CONHC2H4N), 175.3 
(CO(CH2)5) ppm; IR (neat): υ´ = 3298, 2954, 1665, 1447, 1179, 1130 cm-1; MS (ES, +p) 
m/z (%): 1010 (32) [M+H]+, 803 (70) [MH–207]+; RP-HPLC: 100 % (tR = 15.2 min, k´ = 
4.6); anal. calcd. for C55H68N12O7⋅5 H2O⋅5 HCl: C 51.54, H 6.53, N 13.12 %, found: C 
51.23, H 6.53, N 13.00%; C55H68N12O7 (1009.20). 
 
(2S)-Nω-(8-Amino-3,6-dioxaoctanoyl)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-
4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)-
piperazin-1-yl]ethyl}cyclopentyl)-acetyl]argininamide ((S)-3.57). Mp 142-145 °C; 1H 
NMR (600 MHz, CD3OD, COSY, HSQC, HMBC): δ = 1.51 and 1.63 (m, 4H, 3/4-H 
cyclopentyl), 1.51 and 1.70 (m, 4H, 2/5-H cyclopentyl), 1.53 and 1.77 (m, 2H, CβH2), 
1.63 (m, 2H, CγH2), 2.20 and 2.29 (m, 4H, 3/5-H piperazine), 2.27 and 2.43 (m, 2H, 
CH2CONαH), 2.47 (m, 2H, >NCOCH2-cyclopentyl), 3.12 (t, 3J = 5.0 Hz, 2H, 
OCH2CH2NH2), 3.20 (m, 2H, CδH2), 3.37-3.51 (m, 4H, 2/6-H piperazine), 3.45 and 3.54 
(m, 2H, NHCH2CH2N<), 3.70 (m, 2H, OCH2CH2NH2), 3.72 and 3.78 (m, 4H, O(CH2)2O), 
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3.78 (m, 2H, NHCH2CH2N<), 4.25 (m, 1H, CαH), 4.25 (s, 2H, =NCOCH2O), 4.40 (br, 1H, 
11-H dibenzazepine-11-yl), 7.15 (m, 2H, Har), 7.19 (m, 2H, Har), 7.32 (m, 5H, Ph), 7.37 
(m, 5H, Ph), 7.41 (m, 1H, Har), 7.45 (m, 1H, Har), 7.52 (m, 1H, Har), 7.84 (m, 1H, Har) 
ppm; 13C NMR (150 MHz, CD3OD, HSQC, HMBC): δ = 24.5 and 24.6 (C-3/4 cyclopentyl), 
25.4 (Cγ), 30.0 (Cβ), 38.4 (NHCH2CH2N<), 39.3 and 39.4 (C-2/5 cyclopentyl), 39.7 
(>NCOCH2-cyclopentyl), 40.6 (OCH2CH2NH2), 41.1 (NHCH2CH2N<), 42.1 (Cδ), 44.6 
(CH2CONαH), 45.8 (C-1 cyclopentyl), 47.1 (C-2/6 piperazine), 52.2 and 52.6 (C-3/5 
piperazine), 53.7 (Cα), 67.9 (OCH2CH2NH2), 71.1 (=NCOCH2O), 71.3 and 72.1 
(O(CH2)2O), 75.8 (C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.1 (Ph), 126.1 (CarH), 
128.1 (CarH), 129.4 (CarH), 129.7 (CarH), 130.2 (Ph), 130.2 (Car), 131.3 (CarH), 131.9 
(CarH), 132.4 (Car), 133.3 (CarH), 136.9 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 154.8 
(NC(N)N), 171.6 (C=O lactam), 172.8 (CON<), 174.0 (=NCOCH2O), 174.5 
(CONH(CH2)2N<), 174.7 (CONαH) ppm; MS (LSI, MeOH/gly) m/z (%): 1042 (100) 
[M+H]+; HRMS (LSI-MS): m/z [M+H]+ calcd. for C55H69N12O9: 1041.5310, found: 
1041.5272; RP-HPLC: 93 % (tR = 15.2 min, k´ = 4.6); C55H68N12O9 (1040.52). 
 
(2S)-Nω-(15-Amino-4,7,10,13-tetraoxapentadecanoyl)-N-[2-(3,5-dioxo-1,2-diphenyl-
1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo-
[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((S)-3.58). 1H 
NMR (600 MHz, CD3OD, COSY, HSQC): δ = 1.51 and 1.63 (m, 4H, 3/4-H cyclopentyl), 
1.52 and 1.74 (m, 4H, 2/5-H cyclopentyl), 1.50 and 1.69 (m, 2H, CβH2), 1.60 (m, 2H, 
CγH2), 2.18 and 2.25 (m, 4H, 3/5-H piperazine), 2.27 and 2.43 (m, 2H, CH2CONαH), 
2.47 (m, 2H, >NCOCH2-cyclopentyl), 2.72 (t, 3J = 5.9 Hz, 2H, =NCOCH2CH2O), 3.12 (t, 3J 
= 5.0 Hz, 2H, OCH2CH2NH2), 3.17 (m, 2H, CδH2), 3.35-3.51 (m, 4H, 2/6-H piperazine), 
3.44 and 3.53 (m, 2H, NHCH2CH2N<), 3.62 and 3.64 (m, 12H, (O(CH2)2O)3), 3.70 (t, 3J = 
5.0 Hz, 2H, OCH2CH2NH2), 3.78 (t, 3J = 5.9 Hz, 2H, =NCOCH2CH2O), 3.78 (m, 2H, 
NHCH2CH2N<), 4.25 (m, 1H, CαH), 4.36 (br, 1H, 11-H dibenzazepine-11-yl), 7.14 (m, 
2H, Har), 7.20 (m, 2H, Har), 7.32 (m, 5H, Ph), 7.37 (m, 5H, Ph), 7.40 (m, 1H, Har), 7.44 
(m, 1H, Har), 7.52 (m, 1H, Har), 7.83 (m, 1H, Har) ppm; 13C NMR (150 MHz, CD3OD, 
HSQC): δ = 24.5 and 24.6 (C-3/4 cyclopentyl), 25.4 (Cγ), 29.9 (Cβ), 38.4 (NHCH2CH2N<), 
38.4 (=NCOCH2CH2O), 39.3 and 39.4 (C-2/5 cyclopentyl), 39.7 (>NCOCH2-cyclopentyl), 
40.6 (OCH2CH2NH2), 41.1 (NHCH2CH2N<), 42.0 (Cδ), 44.7 (CH2CONαH), 45.8 (C-1 
cyclopentyl), 47.2 (C-2/6 piperazine), 52.2 and 52.6 (C-3/5 piperazine), 53.7 (Cα), 66.9 
(=NCOCH2CH2O), 67.8 (OCH2CH2NH2), 71.1 and 71.3 and 71.5 ((O(CH2)2O)3), 75.8 (C-11 
dibenzazepine-11-yl), 123.0 (CarH), 124.1 (Ph), 126.1 (CarH), 128.1 (CarH), 129.2 (CarH), 
129.6 (CarH), 130.2 (Ph), 131.3 (CarH), 131.9 (CarH), 132.4 (Car), 133.2 (CarH), 136.9 (Car), 
137.8 (Car), 154.5 (N(CONPh)2), 155.0 (NC(N)N), 171.7 (C=O lactam), 172.7 (CON<), 
174.5 (CONH(CH2)2N<), 174.7 (CONαH), 175.4 (=NCO(CH2)2O) ppm; MS (LSI, 
MeOH/gly) m/z (%): 1144 (100) [M+H]+; HRMS (LSI-MS): m/z [M+H]+ calcd for : , 
found: ; RP-HPLC: 93 % (tR = 15.4 min, k´ = 4.7); C60H78N12O11 (1142.59). 
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(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-{5-oxo-5-[4-(6-oxo-
6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]pentanoyl}argininamide 
((S)-3.59). 1H NMR (600 MHz, CD3OD, COSY, HSQC, HMBC): δ = 1.51 (m, 2H, CγH2), 
1.51 and 1.72 (m, 2H, CβH2), 1.81 (m, 2H, >NCOCH2CH2CH2CO), 2.23 (t, 3J = 7.1 Hz, 2H, 
>NCO(CH2)2CH2CO), 2.28 and 2.33 (m, 4H, 3/5-H piperazine), 2.34 (m, 2H, 
>NCOCH2(CH2)2CO), 3.02 (m, 2H, CδH2), 3.37 and 3.43 (m, 4H, 2/6-H piperazine), 3.46 
and 3.57 (m, 2H, NHCH2CH2N<), 3.77 (m, 2H, NHCH2CH2N<), 4.24 (m, 1H, CαH), 4.48 
(br, 1H, 11-H dibenzazepin-11-yl), 7.15 (m, 2H, Har), 7.21 (m, 2H, Har), 7.33 (m, 5H, 
Ph), 7.38 (m, 5H, Ph), 7.42 (m, 1H, Har), 7.46 (m, 1H, Har), 7.53 (m, 1H, Har), 7.86 (d, 3J 
= 7.6 Hz, 1H, Har) ppm; 13C NMR (150 MHz, CD3OD, HSQC, HMBC): δ = 22.2 
(>NCOCH2CH2CH2CO), 26.2 (Cγ), 30.0 (Cβ), 33.1 (>NCOCH2(CH2)2CO), 35.7 
(>NCO(CH2)2CH2CO), 38.4 (NHCH2CH2N<), 41.3 (NHCH2CH2N<), 41.9 (Cδ), 46.0 (C-2/6 
piperazine), 52.2 and 52.6 (C-3/5 piperazine), 54.1 (Cα), 75.9 (C-11 dibenzazepine-11-
yl), 123.0 (CarH), 124.2 (Ph), 126.2 (CarH), 128.2 (CarH), 129.6 (CarH), 129.9 (CarH), 130.2 
(Ph), 130.5 (CarH), 131.5 (CarH), 132.1 (CarH), 132.4 (Car), 133.4 (CarH), 137.0 (Car), 137.8 
(Car), 154.5 (N(CONPh)2), 158.6 (NC(N)N), 171.2 (C=O lactam), 173.2 (CON<), 174.6 
(CONH(CH2)2N<), 175.5 (CONαH) ppm; MS (ES, +p) m/z (%): 842 (50) [M+H]+, 422 
(100) [M+2H]2+; HRMS (LSI-MS): m/z [M+H]+ calcd. for C45H52N11O6: 842.4102, found: 
842.4089; RP-HPLC: 99 % (tR = 14.3 min, k´ = 4.3); C45H51N11O6 (841.40). 
 
(2S)-Nω-{4-[2-(2-Aminoethyl)aminoethyl]aminocarbonylbutanoyl}-N-[2-(3,5-dioxo-
1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-{5-oxo-5-[4-(6-oxo-6,11-dihydro-5H-di-
benzo[b,e]azepin-11-yl)piperazin-1-yl]pentanoyl}argininamide ((S)-3.60). 1H NMR 
(600 MHz, CD3OD, COSY, HSQC, HMBC): δ =  1.52 and 1.74 (m, 2H, CβH2), 1.59 (m, 2H, 
CγH2), 1.81 (m, 2H, >NCOCH2CH2CH2CO), 1.93 (p, 3J = 7.4 Hz, 2H, =NCOCH2CH2CH2CO), 
2.23 (t, 3J = 7.0 Hz, 2H, >NCO(CH2)2CH2CO), 2.23 and 2.29 (m, 4H, 3/5-H piperazine), 
2.29 and 2.35 (m, 2H, >NCOCH2(CH2)2CO), 2.31 and 2.51 (m, 2H, t, 3J = 7.4 Hz, 2H, 
=NCOCH2CH2CH2CO), 3.16 (m, 2H, CδH2), 3.22 (t, 3J = 5.7 Hz, 2H, NHCH2CH2NH), 3.33 
(t, 3J = 6.0 Hz, 2H, NHCH2CH2NH2), 3.36 (m, 4H, 2/6-H piperazine), 3.40 (t, 3J = 6.0 Hz, 
2H, NHCH2CH2NH2), 3.47 and 3.53 (m, 2H, NHCH2CH2N<), 3.51 (t, 3J = 5.7 Hz, 2H, 
NHCH2CH2NH), 3.77 (m, 2H, NHCH2CH2N<), 4.25 (m, 1H, CαH), 4.42 (br, 1H, 11-H 
dibenzazepin-11-yl), 7.15 (m, 2H, Har), 7.21 (m, 2H, Har), 7.33 (m, 5H, Ph), 7.38 (m, 5H, 
Ph), 7.41 (m, 1H, Har), 7.45 (m, 1H, Har), 7.53 (m, 1H, Har), 7.86 (d, 3J = 7.7 Hz, 1H, Har) 
ppm; 13C NMR (150 MHz, CD3OD, HSQC, HMBC): δ = 20.9 (=NCOCH2CH2CH2CONH), 
22.2 (>NCOCH2CH2CH2CO), 25.4 (Cγ), 29.9 (Cβ), 33.1 (>NCOCH2(CH2)2CO), 35.3 and 
36.8 (=NCOCH2CH2CH2CONH), 35.7 (>NCO(CH2)2CH2CO), 36.9 (NHCH2CH2NH2), 37.1 
(CONHCH2CH2NH), 38.4 (NHCH2CH2N<), 41.3 (NHCH2CH2N<), 41.9 (Cδ), 45.7 
(NHCH2CH2NH2), 46.2 (C-2/6 piperazine), 49.5 (CONHCH2CH2NH), 52.2 and 52.6 (C-3/5 
piperazine), 54.0 (Cα), 75.9 (C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.2 (Ph), 126.2 
(CarH), 128.2 (CarH), 129.4 (CarH), 129.8 (CarH), 130.2 (Ph), 130.3 (CarH), 131.4 (CarH), 
132.0 (CarH), 132.4 (Car), 133.3 (CarH), 137.0 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 155.1 
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(NC(N)N), 171.5 (C=O lactam), 173.2 (CON<), 174.5 (CONH(CH2)2N<), 175.5 (CONαH), 
176.6 and 176.7 (=NCO(CH2)3CONH) ppm; MS (ES, +p) m/z (%): 1041 (10) [M+H]+, 521 
(80) [M+2H]2+, 348 (100) [M+3H]3+; HRMS (LSI-MS): m/z [M+H]+ calcd. for C54H69N14O8: 
1041.5423, found: 1041.5410; RP-HPLC: 99 % (tR = 11.8 min, k´ = 3.4); C54H68N14O8 
(1040.53). 
 
(2S)-Nα-[2-(1-{2-Oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)-
piperazin-1-yl]ethyl}cyclopentyl)acetyl]arginylphenylalaninamide (3.61). Mp 148 °C; 
1H NMR (400 MHz, CD3OD, HSQC): δ = 1.47 (m, 2H, CγH2), 1.50 and 1.70 (m, 4H, 2/5-H 
cyclopentyl), 1.51 and 1.63 (m, 4H, 3/4-H cyclopentyl), 1.57 and 1.65 (m, 2H, CβH2 
Orn), 2.28 and 2.47 (m, 2H, CH2CONαH), 2.30 (m, 4H, 3/5-H piperazine), 2.45 and 2.50 
(m, 2H, >NCOCH2-cyclopentyl), 2.87 and 3.17 (m, 2H, CβH2 Phe-amide), 3.09 (t, 3J = 6.9 
Hz, 2H, CδH2), 3.34-3.55 (m, 4H, 2/6-H piperazine), 4.21 (m, 1H, CαH Orn), 4.43 (m, 1H, 
11-H dibenzazepine-11-yl), 4.58 (m, 1H, CαH Phe-amide), 7.15 (m, 4H, Ph), 7.22 (m, 
3H), 7.30 (m, 1H, Har), 7.43 (m, 3H), 7.52 (m, 1H, Har), 7.85 (m, 1H, Har) ppm; 13C NMR 
(100 MHz, CD3OD, HSQC): δ = 23.2 (C-3/4 cyclopentyl), 24.6 (Cγ), 28.4 (Cβ Orn), 37.2 
(Cβ Phe-amide), 38.1 and 38.2 (C-2/5 cyclopentyl), 38.4 (>NCOCH2-cyclopentyl), 40.5 
(Cδ), 43.1 (CH2CONαH), 44.3 (C-1 cyclopentyl), 45.5 (C-2/6 piperazine), 50.8 and 51.2 
(C-3/5 piperazine), 53.0 (Cα Orn), 54.3 (Cα Phe-amide), 74.4 (C-11 dibenzazepine-11-
yl), 121.6 (CarH), 124.8 (CarH), 126.3 (Ph), 128.0 (Ph), 128.4 (CarH), 129.0 (Ph), 130.0 
(CarH), 130.6 (CarH), 131.0 (Car), 132.0 (CarH), 135.5 (Car), 137.4 (Car), 157.2 (NC(N)N), 
170.1 (C=O lactam), 171.5 (CON<), 172.5 (CONαH Phe-amide), 173.8 (CONαH Orn), 
174.7 (CONH2) ppm; MS (LSI, MeOH/gly) m/z (%): 765 (100) [M+H]+; HRMS (LSI-MS): 
m/z [M+H]+ calcd. for C42H54N9O5: 764.4248, found: 764.4247; RP-HPLC: 98 % (tR = 
14.9 min, k´ = 4.5); C42H53N9O5 (763.42). 
 
(2S)-Nω-[(3-Aminopropyl)aminocarbonyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-
5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]arginyl-
phenylalaninamide (3.62). 1H NMR (400 MHz, CD3OD, HSQC): δ = 1.50 (m, 2H, CγH2), 
1.50 and 1.65 (m, 2H, CβH2 Orn), 1.50 and 1.71 (m, 4H, 2/5-H cyclopentyl), 1.64 (m, 
4H, 3/4-H cyclopentyl), 1.88 (p, 3J = 7.2 Hz, 2H, NHCH2CH2CH2NH2), 2.28 and 2.47 (m, 
2H, CH2CONαH), 2.28 (m, 4H, 3/5-H piperazine), 2.46 (m, 2H, >NCOCH2-cyclopentyl), 
2.87 and 3.17 (m, 2H, CβH2 Phe-amide), 2.98 (t, 3J = 7.5 Hz, 2H, NH(CH2)2CH2NH2), 3.20 
(m, 2H, CδH2), 3.30 (m, 2H, NHCH2(CH2)2NH2), 3.35-3.54 (m, 4H, 2/6-H piperazine), 
4.19 (m, 1H, CαH Orn), 4.40 (m, 1H, 11-H dibenzazepine-11-yl), 4.59 (m, 1H, CαH Phe-
amide), 7.11-7.26 (m, 7H), 7.30 (m, 1H, Har), 7.35 (m, 1H, Har), 7.43 (m, 2H, Har), 7.52 
(m, 1H, Har), 7.85 (m, 1H, Har) ppm; 13C NMR (100 MHz, CD3OD, HSQC): δ = 24.5 and 
24.6 (C-3/4 cyclopentyl), 25.5 (Cγ), 28.7 (NHCH2CH2CH2NH2), 29.6 and 29.7 (Cβ Orn), 
37.6 (NHCH2(CH2)2NH2), 38.3 (NH(CH2)2CH2NH2), 38.4 and 38.5 (Cβ Phe-amide), 39.4 
and 39.5 (C-2/5 cyclopentyl), 39.7 (>NCOCH2-cyclopentyl), 41.8 (Cδ), 44.4 (CH2CONαH), 
45.8 (C-1 cyclopentyl), 47.0 (C-2/6 piperazine), 52.2 and 52.7 (C-3/5 piperazine), 54.3 
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and 54.4 (Cα Orn), 55.7 (Cα Phe-amide), 75.8 (C-11 dibenzazepine-11-yl), 123.0 (CarH), 
126.2 (CarH), 127.7 (CarH), 128.8 (CarH), 129.4 (Ph), 129.7 (CarH), 130.3 (Ph), 131.4 (Car), 
132.0 (CarH), 132.4 (Car), 133.3 (CarH), 136.9 (Car), 138.8 (Car), 155.8 (NC(N)N), 156.1 
(=NCONH), 171.6 (C=O lactam), 172.8 (CON<), 173.9 (CONαH Phe-amide), 175.3 
(CONαH Orn), 176.0 (CONH2) ppm; MS (LSI, MeOH/gly) m/z (%): 865 (100) [M+H]+; 
HRMS (LSI-MS): m/z [M+H]+ calcd. for C46H62N11O6: 864.4885, found: 864.4899; RP-
HPLC: 97 % (tR = 13.1 min, k´ = 3.9); C46H61N11O6 (863.48). 
 
General procedure for the preparation of the potential radioligands (S)-3.63-(S)-
3.84:21 
 
The pertinent amine precursor (1 eq) and NEt3 (2.5 eq) were dissolved in CH3CN (1 
mL/20 µmol) followed by the addition of the corresponding active ester (1 eq) in 
CH3CN (0.5 mL/20 µmol). The reaction was stopped by addition of 10 % aq. TFA 
(corresponding to 2-3 eq of TFA) after an incubation period of 16 h at rt. Purification 
with preparative HPLC and lyophilization afforded the products as white fluffy solids 
in yields from 65 to 90 %. 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-
(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]-Nω-[4-(2-propanoylaminoethyl)aminocarbonylbutanoyl]argininamide ((S)-
3.63). Mp 127 °C; 1H NMR (600 MHz, CD3OD, HSQC): δ = 1.10 (t, 3J = 7.6 Hz, 3H, 
COCH2CH3), 1.51 and 1.63 (m, 4H, 3/4-H cyclopentyl), 1.51 and 1.67 (m, 4H, 2/5-H 
cyclopentyl), 1.52 and 1.75 (m, 2H, CβH2), 1.59 (m, 2H, CγH2), 1.91 (p, 3J = 7.3 Hz, 2H, 
COCH2CH2CH2CO), 2.18 and 2.25 (m, 4H, 3/5-H piperazine), 2.19 (quat, 3J = 7.6 Hz, 2H, 
COCH2CH3), 2.24 (t, 3J = 7.3 Hz, 2H, COCH2(CH2)2CONH), 2.25 and 2.42 (m, 2H, 
CH2CONαH), 2.47 (m, 2H, >NCOCH2-cyclopentyl), 2.47 (m, 2H, CO(CH2)2CH2CONH), 
3.17 (m, 2H, CδH2), 3.27 (m, 4H, CONH(CH2)2NH), 3.33-3.53 (m, 4H, 2/6-H piperazine), 
3.46 and 3.54 (m, 2H, NHCH2CH2N<), 3.78 (m, 2H, NHCH2CH2N<), 4.25 (m, 1H, CαH), 
4.34 (br, 1H, 11-H dibenzazepine-11-yl), 7.14 (m, 2H, Har), 7.20 (m, 2H, Har), 7.32 (m, 
5H, Ph), 7.37 (m, 6H, Ph), 7.44 (m, 1H, Har), 7.51 (m, 1H, Har), 7.83 (d, 3J = 7.6 Hz, 1H, 
Har) ppm; 13C NMR (150 MHz, CD3OD, HSQC): δ = 10.4 (COCH2CH3), 21.4 
(COCH2CH2CH2CO), 24.5 and 24.6 (C-3/4 cyclopentyl), 25.4 (Cγ), 30.0 (Cβ), 30.2 
(COCH2CH3), 35.6 (COCH2(CH2)2CONH), 36.9 (CO(CH2)2CH2CONH), 38.5 (NHCH2CH2N<), 
39.3 and 39.4 (C-2/5 cyclopentyl), 39.6 (>NCOCH2-cyclopentyl), 40.0 and 40.2 
(CONH(CH2)2NH), 41.2 (NHCH2CH2N<), 42.0 (Cδ), 44.7 (CH2CONαH), 45.9 (C-1 
cyclopentyl), 47.1 (C-2/6 piperazine), 52.2 and 52.6 (C-3/5 piperazine), 53.7 (Cα), 75.8 
(C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.1 (Ph), 126.1 (CarH), 128.1 (CarH), 129.3 
(CarH), 129.7 (CarH), 130.2 (Ph), 131.3 (CarH), 131.8 (CarH), 132.4 (Car), 133.2 (CarH), 
136.9 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 154.9 (NC(N)N), 172.8 (CON<), 174.5 
(CONH(CH2)2N<), 174.7 (CONαH), 176.4 (CO(CH2)3CONH), 177.4 (COCH2CH3) ppm; MS 
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(ES, +p) m/z (%): 1108 (100) [M+H]+; HRMS (LSI-MS): m/z [M+H]+ calcd. for 
C59H74N13O9: 1108.5732, found: 1108.5712; RP-HPLC: 95 % (tR = 17.0 min, k´ = 5.3); 
C59H73N13O9 (1107.57). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-
(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]-Nω-[4-(3-propanoylaminopropyl)aminocarbonylbutanoyl]argininamide ((S)-
3.64). 1H NMR (600 MHz, CD3OD): δ = 1.11 (COCH2CH3), 1.51 and 1.74 (m, 2H, CβH2), 
1.51 and 1.66 (m, 4H, 2/5-H cyclopentyl), 1.51 and 1.63 (m, 4H, 3/4-H cyclopentyl), 
1.62 (m, 2H, CγH2), 1.66 (m, 2H, CONHCH2CH2CH2NH), 1.92 (p, 3J = 7.3 Hz, 2H, 
COCH2CH2CH2CONH(CH2)3NH), 2.18 and 2.25 (m, 4H, 3/5-H piperazine), 2.20 (m, 2H, 
COCH2CH3), 2.27 (m, 2H, COCH2(CH2)2CONH(CH2)3NH), 2.48 (m, 2H, 
CO(CH2)2CH2CONH(CH2)3NH), 3.18 (m, 6H, CONHCH2CH2CH2NH3, CδH2), 3.34-3.48 (m, 
4H, 2/6-H piperazine), 3.54 (m, 2H, NHCH2CH2N), 3.78 (m, 2H, NHCH2CH2N), 4.25 (m, 
1H, CαH2), 4.41 (br, 1H, 11-H dibenzazepine-11-yl), 7.14 (m, 1H, Har), 7.15 (m, 1H, Har), 
7.20 (m, 2H, Har), 7.32 (m, 5H, Ph), 7.37 (m, 5H, Ph), 7.41 (m, 1H, Har), 7.45 (m, 1H, 
Har), 7.52 (m, 1H, Har), 7.85 (m, 1H, Har) ppm; 13C NMR (150 MHz, CD3OD): δ = 10.5 
(COCH2CH3), 21.4 (=NCOCH2CH2CH2CONH), 24.5 and 24.6 (C-3/4 cyclopentyl), 25.4 
(Cγ), 28.8 (CONHCH2CH2CH2NH), 30.0 (Cβ), 30.2 (COCH2CH3), 35.6 
(=NCOCH2(CH2)2CONH(CH2)3NH), 36.8 (=NCO(CH2)2CH2CONH(CH2)3NH), 37.7 
(CONHCH2CH2CH2NH), 38.2 (CONHCH2CH2CH2NH), 38.5 (NHCH2CH2N<), 39.3 and 39.4 
(C-2/5 cyclopentyl), 39.5 and 39.7 (>NCOCH2-cyclopentyl), 41.2 (NHCH2CH2N<), 42.0 
(Cδ), 44.7 (CH2CONαH), 45.8 (C-1 cyclopentyl), 47.0 (C-2/6 piperazine), 52.2 and 52.7 
(C-3/5 piperazine), 53.7 (Cα), 75.8 (C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.2 (Ph), 
126.1 (CarH), 128.2 (CarH), 129.3 (CarH), 129.7 (CarH), 130.2 (Ph), 131.4 (CarH), 132.0 
(CarH), 132.4 (Car), 133.3 (CarH), 137.0 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 155.0 
(NC(N)N), 172.8 (CONαH), 174.5 (CONHC2H4N<), 174.7 (CON<), 175.9 
(=NCO(CH2)3CONH), 176.4 (=NCO(CH2)3CONH), 177.2 (NHCOCH2CH3) ppm; MS (ES, +p) 
m/z (%): 1122 (100) [M+H]+; HRMS (LSI-MS): m/z [M+H]+ calcd for C60H76N13O9: 
1122.5889, found: 1122.5834; RP-HPLC: 99 % (tR = 14.7 min, k´ = 4.4); C60H75N13O9 
(1121.58). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-
(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]-Nω-{4-[2-(2-propanoylaminoethyl)aminoethyl]aminocarbonylbutanoyl}-
argininamide ((S)-3.65). 1H NMR (600 MHz, CD3OD, COSY, HSQC, HMBC): δ = 1.12 (t, 
3J = 7.6 Hz, 3H, COCH2CH3), 1.51 and 1.63 (m, 4H, 3/4-H cyclopentyl), 1.51 and 1.67 
(m, 4H, 2/5-H cyclopentyl), 1.52 and 1.75 (m, 2H, CβH2), 1.60 (m, 2H, CγH2), 1.93 (p, 3J 
= 7.4 Hz, 2H, COCH2CH2CH2CO), 2.20 and 2.28 (m, 4H, 3/5-H piperazine), 2.25 (m, 2H, 
COCH2CH3), 2.26 and 2.43 (m, 2H, CH2CONαH), 2.32 (t, 3J = 7.4 Hz, 2H, 
COCH2(CH2)2CONH), 2.48 (m, 2H, >NCOCH2-cyclopentyl), 2.51 (m, 2H, 
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CO(CH2)2CH2CONH), 3.16 (m, 4H, 2 x CONHCH2CH2NH), 3.18 (m, 2H, CδH2), 3.35-3.52 
(m, 4H, 2/6-H piperazine), 3.45 and 3.54 (m, 2H, NHCH2CH2N<), 3.46 (m, 4H, 
CONHCH2CH2NH), 3.78 (m, 2H, NHCH2CH2N<), 4.25 (m, 1H, CαH), 4.39 (br, 1H, 11-H 
dibenzazepine-11-yl), 7.14 (m, 2H, Har), 7.20 (m, 2H, Har), 7.32 (m, 5H, Ph), 7.37 (m, 
5H, Ph), 7.41 (m, 1H, Har), 7.45 (m, 1H, Har), 7.52 (m, 1H, Har), 7.84 (d, 3J = 7.7 Hz, 1H, 
Har) ppm; 13C NMR (150 MHz, CD3OD, HSQC, HMBC): δ = 10.0 (COCH2CH3), 21.0 
(COCH2CH2CH2CO), 24.5 and 24.6 (C-3/4 cyclopentyl), 25.4 (Cγ), 29.8 (COCH2CH3), 30.0 
(Cβ), 35.3 (COCH2(CH2)2CONH), 36.8 (CO(CH2)2CH2CONH), 37.3 (2 x CONHCH2CH2NH), 
38.4 (NHCH2CH2N<), 39.3 and 39.4 (C-2/5 cyclopentyl), 39.7 (>NCOCH2-cyclopentyl), 
41.2 (NHCH2CH2N<), 42.0 (Cδ), 44.7 (CH2CONαH), 45.8 (C-1 cyclopentyl), 47.1 (C-2/6 
piperazine), 49.3 (2 x CONHCH2CH2NH), 52.2 and 52.6 (C-3/5 piperazine), 53.8 (Cα), 
75.8 (C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.1 (Ph), 126.1 (CarH), 128.1 (CarH), 
129.3 (CarH), 129.7 (CarH), 130.2 (Ph), 131.3 (CarH), 131.9 (CarH), 132.4 (Car), 133.3 
(CarH), 136.9 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 155.0 (NC(N)N), 171.6 (C=O lactam), 
172.8 (CON<), 174.6 (CONH(CH2)2N<), 174.7 (CONαH), 176.6 (CO(CH2)3CONH), 176.7 
(CO(CH2)3CONH), 178.7 (COCH2CH3) ppm; MS (ES, +p) m/z (%): 576 (65) [M+2H]2+, 385 
(100) [M+3H]3+; HRMS (ESI-MS): m/z [M+H]+ calcd. for C61H79N14O9: 1151.6149, found: 
1151.6144; RP-HPLC: 98 % (tR = 14.5 min, k´ = 4.4); C61H78N14O9 (1150.61). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-
(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]-Nω-(18-propanoylamino-4-oxo-9,12,15-trioxa-5-azaoctadecanoyl)arginin-
amide ((S)-3.66). 1H NMR (600 MHz, CD3OD, COSY, HSQC): δ = 1.10 (t, 3J = 7.6 Hz, 3H, 
COCH2CH3), 1.51 and 1.63 (m, 4H, 3/4-H cyclopentyl), 1.51 and 1.66 (m, 4H, 2/5-H 
cyclopentyl), 1.52 (m, 2H, CβH2), 1.58 (m, 2H, CγH2), 1.73 (m, 4H, (NHCH2(CH2CH2O)2), 
2.25 and 2.42 (m, 2H, CH2CONαH), 2.16-2.28 (m, 4H, 3/5-H piperazine), 2.17 (quat, 3J 
= 7.6 Hz, 2H, COCH2CH3), 2.48 (m, 2H, >NCOCH2-cyclopentyl), 2.55 and 2.69 (m, 4H, 
=NCO(CH2)2CONH), 3.16 (m, 2H, CδH2), 3.23 (m, 4H, (NHCH2(CH2)2O)2), 3.37-3.51 (m, 
4H, 2/6-H piperazine), 3.44 and 3.56 (m, 2H, NHCH2CH2N<), 3.50 (m, 4H, 
(NH(CH2)2CH2O)2), 3.56 and 3.62 (m, 8H, (O(CH2)2O)2), 3.78 (m, 2H, NHCH2CH2N<), 
4.25 (m, 1H, CαH), 4.37 (br, 1H, 11-H dibenzazepine-11-yl), 7.14 (m, 2H, Har), 7.20 (m, 
2H, Har), 7.32 (m, 5H, Ph), 7.37 (m, 5H, Ph), 7.41 (m, 1H, Har), 7.44 (m, 1H, Har), 7.51 
(m, 1H, Har), 7.83 (m, 1H, Har) ppm; 13C NMR (150 MHz, CD3OD, HSQC): δ = 10.6 
(COCH2CH3), 24.6 and 24.7 (C-3/4 cyclopentyl), 25.4 (Cγ), 30.0 (Cβ), 30.3 (COCH2CH3), 
30.4 (NHCH2CH2CH2O), 30.4 (=NCOCH2CH2CO), 33.0 (=NCOCH2CH2CO), 37.9 
(NHCH2(CH2)2O), 38.5 (NHCH2CH2N<), 39.3 and 39.4 (C-2/5 cyclopentyl), 39.7 
(>NCOCH2-cyclopentyl), 41.2 (NHCH2CH2N<), 42.1 (Cδ), 44.7 (CH2CONαH), 45.9 (C-1 
cyclopentyl), 47.2 (C-2/6 piperazine), 52.3 and 52.7 (C-3/5 piperazine), 53.7 (Cα), 54.8 
(CH3CH2CONHCH2(CH2)2O), 69.9 ((NH(CH2)2CH2O)2), 71.2 and 71.5 ((O(CH2)2O)2), 75.8 
(C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.2 (Ph), 126.1 (CarH), 128.2 (CarH), 129.2 
(Car), 129.7 (CarH), 130.2 (Ph), 131.3 (CarH), 131.9 (CarH), 132.4 (Car), 133.2 (CarH), 136.9 
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(Car), 137.8 (Car), 154.5 (N(CONPh)2), 154.9 (NC(N)N), 172.8 (CONαH), 173.7 
(=NCO(CH2)2CO), 174.5 (CONH(CH2)2N<), 174.7 (CON<), 176.3 (=NCO(CH2)2CO), 177.0 
(COCH2CH3) ppm; MS (ES, +p) m/z (%): 628 (100) [M+2H]2+; HRMS (ESI-MS): m/z 
[M+H]+ calcd. for C66H88N13O12: 1254.6670, found: 1254.6670; RP-HPLC: 99 % (tR = 
17.7 min, k´ = 5.6); C66H87N13O12 (1253.66). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-
(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]-Nω-[(2-propanoylaminoethyl)aminocarbonyl]argininamide ((S)-3.67). 1H 
NMR (600 MHz, CD3OD, COSY, HSQC, HMBC): δ = 1.10 (t, 3J = 7.6 Hz, 3H, COCH2CH3), 
1.51 and 1.63 (m, 4H, 3/4-H cyclopentyl), 1.51 and 1.68 (m, 4H, 2/5-H cyclopentyl), 
1.51 and 1.73 (m, 2H, CβH2), 1.57 (m, 2H, CγH2), 2.19 (quat, 3J = 7.6 Hz, 2H, COCH2CH3), 
2.22 and 2.29 (m, 4H, 3/5-H piperazine), 2.28 and 2.43 (m, 2H, CH2CONαH), 2.48 (m, 
2H, >NCOCH2-cyclopentyl), 3.14 (m, 2H, CδH2), 3.27 (m, 2H, NHCH2CH2NHCOCH2CH3), 
3.29 (m, 2H, NHCH2CH2NHCOCH2CH3), 3.44 (br, 4H, 2/6-H piperazine), 3.45 and 3.55 
(m, 2H, NHCH2CH2N<), 3.78 (m, 2H, NHCH2CH2N<), 4.25 (m, 1H, CαH), 4.40 (br, 1H, 11-
H dibenzazepine-11-yl), 7.15 (m, 2H, Har), 7.20 (m, 2H, Har), 7.32 (m, 5H, Ph), 7.37 (m, 
5H, Ph), 7.41 (m, 1H, Har), 7.45 (m, 1H, Har), 7.52 (m, 1H, Har), 7.85 (d, 3J = 7.5 Hz, 1H, 
Har) ppm; 13C NMR (150 MHz, CD3OD, HSQC, HMBC): δ = 10.4 (COCH2CH3), 24.5 and 
24.6 (C-3/4 cyclopentyl), 25.6 (Cγ), 30.1 (Cβ), 30.2 (COCH2CH3), 38.4 (NHCH2CH2N<), 
39.3 and 39.4 (C-2/5 cyclopentyl), 39.7 (>NCOCH2-cyclopentyl), 39.9 
(NHCH2CH2COCH2CH3), 40.7 (NHCH2CH2NHCOCH2CH3), 41.2 (NHCH2CH2N<), 41.9 (Cδ), 
44.7 (CH2CONαH), 45.9 (C-1 cyclopentyl), 47.0 (C-2/6 piperazine), 52.2 and 52.6 (C-3/5 
piperazine), 53.8 (Cα), 75.8 (C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.1 (Ph), 126.2 
(CarH), 128.1 (CarH), 129.5 (CarH), 129.8 (CarH), 130.2 (Ph), 130.3 (Car), 131.4 (CarH), 
132.0 (CarH), 132.4 (Car), 133.3 (CarH), 137.0 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 155.6 
(=NCONH), 155.7 (NC(N)N), 171.6 (C=O lactam), 172.8 (CON<), 174.5 (CONH(CH2)2N<), 
174.7 (CONαH), 177.5 (COCH2CH3) ppm; MS (ES, +p) m/z (%): 1039 (45) [M+H]+, 520 
(100) [M+2H]2+; HRMS (LSI-MS): m/z [M+H]+ calcd. for C55H68N13O8: 1038.5314, found: 
1038.5273; RP-HPLC: 100 % (tR = 17.1 min, k´ = 5.3); C55H67N13O8 (1037.52). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-
(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]-Nω-[(3-propanoylaminopropyl)aminocarbonyl]argininamide ((S)-3.68). 1H 
NMR (600 MHz, CD3OD): δ = 1.11 (t, 3J = 7.6 Hz, 3H, COCH2CH3), 1.51 and 1.62 (m, 4H, 
3/4-H cyclopentyl), 1.52 and 1.68 (m, 4H, 2/5-H cyclopentyl), 1.53 and 1.74 (m, 2H, 
CβH2), 1.59 (m, 2H, CγH2), 1.67 (m, 2H, NHCH2CH2CH2NH), 2.18 (quat, 3J = 7.6 Hz, 2H, 
COCH2CH3), 2.26 and 2.44 (m, 2H, CH2CONαH), 2.26 and 2.35 (m, 4H, 3/5-H 
piperazine), 2.49 (m, 2H, >NCOCH2-cyclopentyl), 3.14 (m, 2H, CδH2), 3.19 (m, 4H, 
NHCH2CH2CH2NH), 3.38-3.59 (m, 4H, 2/6-H piperazine), 3.45 and 3.55 (m, 2H, 
NHCH2CH2N<), 3.78 (m, 2H, NHCH2CH2N<), 4.25 (m, 1H, CαH), 4.47 (br, 1H, 11-H 
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dibenzazepine-11-yl), 7.15 (m, 2H, Har), 7.20 (m, 2H, Har), 7.32 (m, 5H, Ph), 7.37 (m, 
5H, Ph), 7.42 (m, 1H, Har), 7.46 (m, 1H, Har), 7.53 (m, 1H, Har), 7.86 (m, 1H, Har) ppm; 
13C NMR (150 MHz, CD3OD): δ = 10.5 (COCH2CH3), 24.6 (C-3/4 cyclopentyl), 25.7 (Cγ), 
30.1 (Cβ), 30.2 (COCH2CH3), 30.4 (NHCH2CH2CH2NH), 38.2 and 39.4 (NHCH2CH2CH2NH), 
38.4 (NHCH2CH2N<), 39.3 and 39.4 (C-2/5 cyclopentyl), 39.7 (>NCOCH2-cyclopentyl), 
41.2 (NHCH2CH2N<), 41.8 (Cδ), 44.6 (CH2CONαH), 45.8 (C-1 cyclopentyl), 46.9 (C-2/6 
piperazine), 52.3 and 52.7 (C-3/5 piperazine), 53.8 (Cα), 75.8 (C-11 dibenzazepine-11-
yl), 123.0 (CarH), 124.2 (Ph), 126.2 (CarH), 128.2 (CarH), 129.5 (CarH), 129.9 (CarH), 130.2 
(Ph), 130.4 (Car), 131.5 (CarH), 132.0 (CarH), 132.4 (Car), 133.4 (CarH), 137.0 (Car), 137.8 
(Car), 154.5 (N(CONPh)2), 155.4 (=NCONH), 155.7 (NC(N)N), 171.4 (C=O lactam), 172.8 
(CON<), 174.5 (CONH(CH2)2N<), 174.7 (CONαH), 177.2 (COCH2CH3) ppm; MS (LSI, 
MeOH/gly) m/z (%): 1053 (100) [M+H]+, 846 (30); HRMS (LSI-MS): m/z [M+H]+ calcd. 
for C56H70N13O8: 1053.5477, found: 1053.5430; RP-HPLC: 98 % (tR = 18.3 min, k´ = 5.8); 
C56H69N13O8 (1051.54). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-
(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]-Nω-[(4-propanoylaminobutyl)aminocarbonyl]argininamide ((S)-3.69). Mp 
127-130 °C; 1H NMR (600 MHz, CD3OD, COSY, HSQC, HMBC): δ = 1.10 (t, 3J = 7.6 Hz, 
3H, COCH2CH3), 1.51 and 1.62 (m, 4H, 3/4-H cyclopentyl), 1.51 (m, 4H, 
NHCH2(CH2)2CH2NH), 1.52 and 1.68 (m, 4H, 2/5-H cyclopentyl), 1.53 and 1.74 (m, 2H, 
CβH2), 1.59 (m, 2H, CγH2), 2.17 (quat, 3J = 7.6 Hz, 2H, COCH2CH3), 2.26 and 2.44 (m, 2H, 
CH2CONαH), 2.26 and 2.35 (m, 4H, 3/5-H piperazine), 2.49 (m, 2H, >NCOCH2-
cyclopentyl), 3.15 (m, 2H, CδH2), 3.16 (m, 4H, NHCH2(CH2)2CH2NH), 3.38-3.55 (m, 4H, 
2/6-H piperazine), 3.45 and 3.55 (m, 2H, NHCH2CH2N<), 3.78 (m, 2H, NHCH2CH2N<), 
4.25 (m, 1H, CαH), 4.50 (br, 1H, 11-H dibenzazepine-11-yl), 7.16 (m, 2H, Har), 7.19 (m, 
2H, Har), 7.32 (m, 5H, Ph), 7.36 (m, 5H, Ph), 7.43 (m, 1H, Har), 7.47 (m, 1H, Har), 7.53 
(m, 1H, Har), 7.87 (m, 1H, Har) ppm; 13C NMR (150 MHz, CD3OD, HSQC, HMBC): δ = 
10.6 (COCH2CH3), 24.6 (C-3/4 cyclopentyl), 25.7 (Cγ), 27.7 and 27.8 
(NHCH2(CH2)2CH2NH), 30.0 (Cβ), 30.2 (COCH2CH3), 38.4 (NHCH2CH2N<), 39.3 and 39.4 
(C-2/5 cyclopentyl), 39.7 (>NCOCH2-cyclopentyl), 39.9 and 40.4 (NHCH2(CH2)2CH2NH), 
41.2 (NHCH2CH2N<), 41.8 (Cδ), 44.6 (CH2CONαH), 45.8 (C-1 cyclopentyl), 46.8 (C-2/6 
piperazine), 52.3 and 52.6 (C-3/5 piperazine), 53.8 (Cα), 75.8 (C-11 dibenzazepine-11-
yl), 123.0 (CarH), 124.1 (Ph), 126.2 (CarH), 128.1 (CarH), 129.6 (CarH), 130.0 (CarH), 130.2 
(Ph), 130.4 (Car), 131.5 (CarH), 132.1 (CarH), 132.4 (Car), 133.4 (CarH), 137.0 (Car), 137.8 
(Car), 154.5 (N(CONPh)2), 155.4 (=NCONH), 155.8 (NC(N)N), 171.2 (C=O lactam), 172.8 
(CON<), 174.5 (CONH(CH2)2N<), 174.7 (CONαH), 177.1 (COCH2CH3) ppm; MS (LSI, 
MeOH/gly) m/z (%): 1067 (100) [M+H]+; HRMS (LSI-MS): m/z [M+H]+ calcd. for 
C57H72N13O8: 1066.5627, found: 1066.5602; RP-HPLC: 99 % (tR = 18.3 min, k´ = 5.8); 
C57H71N13O8 (1065.55). 
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(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-
(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]-Nω-[6-(propanoylaminohexyl)aminocarbonyl]argininamide ((S)-3.70). 1H 
NMR (600 MHz, CD3OD, COSY, HSQC): δ = 1.10 (t, 3J = 7.6 Hz, 3H, COCH2CH3), 1.31 (m, 
4H, NH(CH2)2(CH2)2(CH2)2NH), 1.48 (m, 4H, NHCH2CH2(CH2)2CH2CH2NH), 1.52 and 1.69 
(m, 4H, 2/5-H cyclopentyl), 1.53 and 1.63 (m, 4H, 3/4-H cyclopentyl), 1.54 and 1.75 
(m, 2H, CβH2), 1.60 (m, 2H, CγH2), 2.16 (quat, 3J = 7.6 Hz, 2H, COCH2CH3), 2.26 and 2.45 
(m, 2H, CH2CONαH), 2.35 and 2.44 (m, 4H, 3/5-H piperazine), 2.49 (m, 2H, >NCOCH2-
cyclopentyl), 3.13 and 3.15 (m, 4H, NHCH2(CH2)4CH2NH), 3.15 (m, 2H, CδH2), 3.42-3.57 
(m, 4H, 2/6-H piperazine), 3.45 and 3.56 (m, 2H, NHCH2CH2N<), 3.78 (m, 2H, 
NHCH2CH2N<), 4.25 (m, 1H, CαH), 4.63 (br, 1H, 11-H dibenzazepine-11-yl), 7.19 (m, 
4H, Har), 7.32 (m, 5H, Ph), 7.36 (m, 5H, Ph), 7.45 (m, 1H, Har), 7.48 (m, 1H, Har), 7.56 
(m, 1H, Har), 7.91 (m, 1H, Har) ppm; 13C NMR (150 MHz, CD3OD, HSQC): δ = 10.6 
(COCH2CH3), 24.6 (C-3/4 cyclopentyl), 25.7 (Cγ), 27.4 and 27.5 
(NH(CH2)2(CH2)2(CH2)2NH), 30.1 (Cβ), 30.2 and 30.4 (NHCH2CH2(CH2)2CH2CH2NH), 30.3 
(COCH2CH3), 38.4 (NHCH2CH2N<), 39.3 and 39.4 (C-2/5 cyclopentyl), 39.8 (>NCOCH2-
cyclopentyl), 40.2 and 40.7 (NHCH2(CH2)4CH2NH), 41.2 (NHCH2CH2N<), 41.8 (Cδ), 44.6 
(CH2CONαH), 45.8 (C-1 cyclopentyl), 46.3 (C-2/6 piperazine), 52.3 and 52.7 (C-3/5 
piperazine), 53.8 (Cα), 75.9 (C-11 dibenzazepine-11-yl), 123.1 (CarH), 124.2 (Ph), 126.3 
(CarH), 128.2 (CarH), 129.9 (CarH), 130.2 (Ph), 130.8 (CarH), 131.7 (CarH), 132.3 (CarH), 
133.6 (CarH), 137.1 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 155.4 (=NCONH), 155.8 
(NC(N)N), 170.9 (C=O lactam), 172.8 (CON<), 174.6 (CONH(CH2)2N<), 174.7 (CONαH), 
177.0 (COCH2CH3) ppm; MS (LSI, MeOH/gly) m/z (%): 1095 (100) [M+H]+; HRMS (LSI-
MS): m/z [M+H]+ calcd. for C59H76N13O8: 1094.5940, found: 1094.5925; RP-HPLC: 99 % 
(tR = 19.6 min, k´ = 6.3); C59H75N13O8 (1093.59). 
 
(2S)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-
(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]-Nω-(6-propanoylaminohexanoyl)argininamide ((S)-3.71). MS (ES, +p) m/z (%): 
1065 (100) [M+H]+; HRMS(LSI-MS): m/z [M+H]+ calcd. for C58H73N12O8: 1065.5674, 
found: 1065.5694; RP-HPLC: 88 % (tR = 18.9 min, k´ = 6.0); C58H72N12O8 (1064.56). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-
(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]-Nω-(8-propanoylamino-3,6-dioxaoctanoyl)argininamide ((S)-3.72). 1H NMR 
(600 MHz, CD3OD, COSY, HSQC): δ = 1.10 (t, 3J = 7.6 Hz, 3H, COCH2CH3), 1.51 and 1.63 
(m, 4H, 3/4-H cyclopentyl), 1.51 and 1.70 (m, 4H, 2/5-H cyclopentyl), 1.53 and 1.76 
(m, 2H, CβH2), 1.63 (m, 2H, CγH2), 2.18 (quat, 3J = 7.6 Hz, 2H, COCH2CH3), 2.25 and 2.34 
(m, 4H, 3/5-H piperazine), 2.26 and 2.44 (m, 2H, CH2CONαH), 2.48 (m, 2H, >NCOCH2-
cyclopentyl), 3.21 (m, 2H, CδH2), 3.35 (t, 3J = 5.6 Hz, 2H, OCH2CH2NH), 3.38-3.53 (m, 
4H, 2/6-H piperazine), 3.46 and 3.55 (m, 2H, NHCH2CH2N<), 3.54 (t, 3J = 5.6 Hz, 2H, 
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OCH2CH2NH), 3.66 and 3.73 (m, 4H, O(CH2)2O), 3.78 (m, 2H, NHCH2CH2N<), 4.20 (s, 
2H, =NCOCH2O), 4.26 (m, 1H, CαH), 4.48 (br, 1H, 11-H dibenzazepine-11-yl), 7.16 (m, 
2H, Har), 7.20 (m, 2H, Har), 7.32 (m, 5H, Ph), 7.37 (m, 5H, Ph), 7.42 (m, 1H, Har), 7.46 
(m, 1H, Har), 7.54 (m, 1H, Har), 7.87 (m, 1H, Har) ppm; 13C NMR (150 MHz, CD3OD, 
HSQC): δ = 10.5 (COCH2CH3), 24.6 (C-3/4 cyclopentyl), 25.5 (Cγ), 30.0 (Cβ), 30.2 
(COCH2CH3), 38.4 (NHCH2CH2N<), 39.3 and 39.5 (C-2/5 cyclopentyl), 39.7 (>NCOCH2-
cyclopentyl), 40.2 and 42.0 (OCH2CH2NH), 41.2 (NHCH2CH2N<), 42.1 (Cδ), 44.7 
(CH2CONαH), 45.8 (C-1 cyclopentyl), 46.8 (C-2/6 piperazine), 52.3 and 52.6 (C-3/5 
piperazine), 53.7 and 53.8 (Cα), 70.7 (OCH2CH2NH), 71.2 (=NCOCH2O), 71.2 and 72.2 
(O(CH2)2O), 75.8 (C-11 dibenzazepine-11-yl), 123.1 (CarH), 124.2 (Ph), 126.2 (CarH), 
128.2 (CarH), 129.5 (CarH), 129.9 (CarH), 130.2 (Ph), 130.4 (Car), 131.5 (CarH), 132.1 
(CarH), 132.4 (Car), 133.4 (CarH), 137.0 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 154.7 
(NC(N)N), 171.3 (C=O lactam), 172.8 (CON<), 173.9 (=NCOCH2O), 174.5 
(CONH(CH2)2N<), 174.7 (CONαH), 177.4 (COCH2CH3) ppm; MS (LSI, MeOH/gly) m/z 
(%): 1098 (100) [M+H]+; HRMS (LSI-MS): m/z [M+H]+ calcd. for C58H73N12O10: 
1097.5573, found: 1097.5531; RP-HPLC: 94 % (tR = 18.4 min, k´ = 5.8); C58H72N12O10 
(1096.55). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-
(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]-Nω-(15-propanoylamino-4,7,10,13-tetraoxapentadecanoyl)argininamide ((S)-
3.73). 1H NMR (600 MHz, CD3OD, COSY, HSQC): δ = 1.10 (t, 3J = 7.6 Hz, 3H, COCH2CH3), 
1.51 and 1.63 (m, 4H, 3/4-H cyclopentyl), 1.51 and 1.70 (m, 4H, 2/5-H cyclopentyl), 
1.52 and 1.75 (m, 2H, CβH2), 1.60 (m, 2H, CγH2), 2.18 (quat, 3J = 7.6 Hz, 2H, COCH2CH3), 
2.21 and 2.29 (m, 4H, 3/5-H piperazine), 2.25 and 2.43 (m, 2H, CH2CONαH), 2.48 (m, 
2H, >NCOCH2-cyclopentyl), 2.69 (t, 3J = 5.7 Hz, 2H, =NCOCH2CH2O), 3.17 (m, 2H, CδH2), 
3.33 (t, 3J = 5.6 Hz, 2H, OCH2CH2NH), 3.37-3.51 (m, 4H, 2/6-H piperazine), 3.44 and 
3.55 (m, 2H, NHCH2CH2N<), 3.51 (t, 3J = 5.6 Hz, 2H, OCH2CH2NH), 3.60 (m, 12H, 
(O(CH2)2O)3), 3.77 (m, 2H, =NCOCH2CH2O), 3.78 (m, 2H, NHCH2CH2N<), 4.25 (m, 1H, 
CαH), 4.41 (br, 1H, 11-H dibenzazepine-11-yl), 7.15 (m, 2H, Har), 7.20 (m, 2H, Har), 7.32 
(m, 5H, Ph), 7.37 (m, 5H, Ph), 7.41 (m, 1H, Har), 7.45 (m, 1H, Har), 7.53 (m, 1H, Har), 
7.85 (m, 1H, Har) ppm; 13C NMR (150 MHz, CD3OD, HSQC): δ = 10.5 (COCH2CH3), 24.5 
and 24.6 (C-3/4 cyclopentyl), 25.4 (Cγ), 30.0 (Cβ), 30.1 (COCH2CH3), 38.4 and 38.5 
(NHCH2CH2N<), 38.6 (=NCOCH2CH2O), 39.4 and 39.5 (C-2/5 cyclopentyl), 39.7 
(>NCOCH2-cyclopentyl), 40.3 and 42.2 (OCH2CH2NH), 41.2 (NHCH2CH2N<), 42.0 (Cδ), 
44.7 (CH2CONαH), 45.8 and 45.9 (C-1 cyclopentyl), 47.0 (C-2/6 piperazine), 52.2 and 
52.7 (C-3/5 piperazine), 53.7 and 53.8 (Cα), 66.9 (=NCOCH2CH2O), 70.6 (OCH2CH2NH), 
71.3 and 71.4 and 71.5 ((O(CH2)2O)3), 75.8 (C-11 dibenzazepine-11-yl), 123.0 (CarH), 
124.1 (Ph), 126.1 (CarH), 128.2 (CarH), 129.4 (CarH), 129.8 (CarH), 130.2 (Ph), 130.3 (Car), 
131.4 (CarH), 132.0 (CarH), 132.4 (Car), 133.3 (CarH), 137.0 (Car), 137.8 (Car), 154.5 
(N(CONPh)2), 154.9 (NC(N)N), 171.5 (C=O lactam), 172.8 (CON<), 174.5 
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(CONH(CH2)2N<), 174.7 (CONαH), 175.3 (=NCO(CH2)2O), 177.1 (COCH2CH3) ppm; MS 
(LSI, MeOH/gly) m/z (%): 1200 (100) [M+H]+; HRMS (LSI-MS): m/z [M+H]+ calcd. for 
C63H83N12O12: 1199.6253, found: 1199.6267; RP-HPLC: 100 % (tR = 18.2 min, k´ = 5.7); 
C63H82N12O12 (1198.62). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nω-{4-[2-(4-fluoro-
benzoylamino)ethyl]aminocarbonylbutanoyl}-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-
dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]-
argininamide ((S)-3.74). 1H NMR (300 MHz, CD3OD): δ = 1.51 and 1.72 (m, 2H, CβH2), 
1.51 and 1.66 (m, 4H, 2/5-H cyclopentyl), 1.51 and 1.63 (m, 4H, 3/4-H cyclopentyl), 
1.62 (m, 2H, CγH2), 1.90 (p, 3J = 7.2 Hz, 2H, COCH2CH2CH2CONH(CH2)2NH), 2.20-2.37 
(m, 6H, 3/5-H piperazine, COCH2(CH2)2CONH(CH2)2NH), 2.40-2.53 (m, 4H, >NCOCH2-
cyclopentyl, CO(CH2)2CH2CONH(CH2)2NH), 3.18 (m, 2H, CδH2), 3.35-3.62 (m, 10H, 
CONHCH2CH2NH, 2/6-H piperazine, NHCH2CH2N<), 3.78 (m, 2H, NHCH2CH2N<), 4.25 
(m, 1H, CαH2), 4.46 (br, 1H, 11-H dibenzazepine-11-yl), 7.13-7.23 (m, 6H, Har, Ph), 7.32 
(m, 5H, Ph), 7.36 (m, 7H, Ph, Har), 7.51 (m, 1H, Har), 7.85 (m, 3H, Ph, Har) ppm; 13C 
NMR (75 MHz, CD3OD): δ = 21.4 (NCOCH2CH2CH2CONH), 24.6 and 24.7 (C-3/4 
cyclopentyl), 25.5 (Cγ), 30.1 (Cβ), 35.7 (=NCOCH2(CH2)2CONH), 36.9 
(NCO(CH2)2CH2CONH(CH2)2NH), 37.8 (CONHCH2CH2NH), 38.5 (NHCH2CH2N<), 39.2 and 
39.3 (C-2/5 cyclopentyl), 39.5 and 39.7 (>NCOCH2-cyclopentyl), 40.1 
(CONHCH2CH2NH), 41.0 (NHCH2CH2N<), 42.0 (Cδ), 44.7 (CH2CONαH), 45.9 (C-1 
cyclopentyl), 52.3 and 52.7 (C-3/5 piperazine), 53.8 (Cα), 75.9 (C-11 dibenzazepine-11-
yl), 116.3 (CarH), 116.6 (CarH), 123.1 (CarH), 124.2 (Ph), 126.2 (CarH), 128.2 (Ph), 129.4 
(CarH), 129.9 (CarH), 130.3 (Ph), 132.0 (CarH), 132.4 (Car), 133.4 (CarH), 137.0 (Car), 137.8 
(Car), 154.5 (N(CONPh)2), 169.4 (COC6H4F), 172.8 (CONαH), 174.6 (CONHC2H4N<), 
174.8 (CON<), 175.6 (=NCO(CH2)3CONH), 176.5 (=NCO(CH2)3CONH) ppm; MS (ES, +p) 
m/z (%): 1174 (100) [M+H]+; HRMS (LSI-MS): m/z [M+H]+ calcd. for C63H73FN13O9: 
1174.5638, found: 1174.5636; RP-HPLC: 95 % (tR = 19.3 min, k´ = 6.1); C63H72FN13O9 
(1173.56). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nω-{4-[3-(4-fluoro-
benzoylamino)propyl]aminocarbonylbutanoyl}-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-
dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]-
argininamide ((S)-3.75). 1H NMR (400 MHz, CD3OD): δ = 1.50 and 1.70 (m, 2H, CβH2), 
1.50 and 1.66 (m, 4H, 2/5-H cyclopentyl), 1.51 and 1.63 (m, 4H, 3/4-H cyclopentyl), 
1.62 (m, 2H, CγH2), 1.78 (p, 3J = 6.8 Hz, 2H, CONHCH2CH2CH2NH), 1.93 (p, 3J = 7.3 Hz, 
2H, COCH2CH2CH2CONH(CH2)3NH), 2.24 and 2.29 (m, 4H, 3/5-H piperazine), 2.27 (m, 
2H, COCH2(CH2)2CONH(CH2)3NH), 2.49 (m, 2H, >NCOCH2-cyclopentyl), 2.50 (m, 2H, 
CO(CH2)2CH2CONH(CH2)3NH), 3.18 (m, 2H, CδH2), 3.25 (t, 3J = 6.7 Hz, 2H, 
CONHCH2CH2CH2NH), 3.34 and 3.50 (m, 4H, 2/6-H piperazine), 3.39 (t, 3J = 6.9 Hz, 2H, 
CONHCH2CH2CH2NH), 3.54 (m, 2H, NHCH2CH2N<), 3.78 (m, 2H, NHCH2CH2N<), 4.25 
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(m, 1H, CαH2), 4.40 (br, 1H, 11-H dibenzazepine-11-yl), 7.13 (m, 1H, Har), 7.14 (m, 1H, 
Har), 7.16 (m, 1H, Har), 7.19 (m, 2H, Ph), 7.31 (m, 5H, Ph), 7.35 (m, 1H, Har), 7.36 (m, 
5H, Ph), 7.41 (m, 1H, Har), 7.44 (m, 1H, Har), 7.52 (m, 1H, Har), 7.84 (m, 1H, Har), 7.86 
(m, 2H, Ph) ppm; 13C NMR (100 MHz, CD3OD): δ = 21.4 (NCOCH2CH2CH2CONH), 24.5 
and 24.6 (C-3/4 cyclopentyl), 25.4 (Cγ), 30.0 (Cβ), 30.3 (CONHCH2CH2CH2NH), 35.6 
(=NCOCH2(CH2)2CONH), 36.9 (=NCO(CH2)2CH2CONH), 37.8 (CONHCH2CH2CH2NH), 38.4 
(CONHCH2CH2CH2NH), 38.5 (NHCH2CH2N<), 39.2 and 39.3 (C-2/5 cyclopentyl), 39.5 
and 39.7 (>NCOCH2-cyclopentyl), 41.2 (NHCH2CH2N<), 42.0 (Cδ), 42.2 und 47.0 (C-2/6 
piperazine), 44.7 (CH2CONαH), 45.9 (C-1 cyclopentyl), 52.2 and 52.7 (C-3/5 
piperazine), 53.7 (Cα), 75.8 (C-11 dibenzazepine-11-yl), 116.3 (CarH), 116.5 (CarH), 
123.0 (CarH), 124.2 (Ph), 126.1 (CarH), 128.2 (Ph), 129.3 (CarH), 129.7 (CarH), 130.2 (Ph), 
131.3 (CarH), 131.9 (CarH), 132.4 (Car), 133.3 (CarH), 136.9 (Car), 137.8 (Car), 142.8 (Car), 
154.5 (N(CONPh)2), 155.0 (NC(N)N), 167.4 (CarF), 169.1 (COC6H4F), 171.6 (C=O lactam), 
172.8 (CONαH), 174.5 (CONHC2H4N<), 174.7 (CON<), 175.2 (=NCO(CH2)3CONH), 176.5 
(=NCO(CH2)3CONH) ppm; MS (ES, +p) m/z (%): 1188 (100) [M+H]+; HRMS (LSI-MS): 
m/z [M+H]+ calcd. for C64H75FN13O9: 1188.5795, found: 1188.5807; RP-HPLC: 100 % (tR 
= 19.6 min, k´ = 6.3); C64H74FN13O9 (1187.57). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nω-[18-(4-fluoro-
benzoylamino)-4-oxo-9,12,15-trioxa-5-azaoctadecanoyl]-Nα-[2-(1-{2-oxo-2-[4-(6-
oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]argininamide ((S)-3.76). 1H NMR (600 MHz, CD3OD, HSQC): δ = 1.50 and 1.62 
(m, 4H, 3/4-H cyclopentyl), 1.50 and 1.66 (m, 4H, 2/5-H cyclopentyl), 1.50 (m, 2H, 
CβH2), 1.58 (m, 2H, CγH2), 1.71 (m, 2H, NHCH2CH2CH2O), 1.86 (m, 2H, 
OCH2CH2CH2NHCOC6H4F), 2.26 and 2.42 (m, 2H, CH2CONαH), 2.19 and 2.26 (m, 4H, 
3/5-H piperazine), 2.47 (m, 2H, >NCOCH2-cyclopentyl), 2.55 (m, 2H, 
=NCOCH2CH2CONH), 2.68 (m, 2H, =NCOCH2CH2CONH), 3.16 (m, 2H, CδH2), 3.22 (m, 
2H, NHCH2(CH2)2O), 3.35-3.49 (m, 4H, 2/6-H piperazine), 3.43 and 3.57 (m, 2H, 
NHCH2CH2N<), 3.46 (m, 2H, O(CH2)2CH2NHCOC6H4F), 3.46 and 3.57 (m, 4H, 
(NH(CH2)2CH2O)2) 3.53 and 3.59 (m, 8H, (O(CH2)2O)2), 3.78 (m, 2H, NHCH2CH2N<), 4.25 
(m, 1H, CαH), 4.36 (br, 1H, 11-H dibenzazepine-11-yl), 7.16 (m, 6H, Har), 7.32 (m, 5H, 
Ph), 7.36 (m, 5H, Ph), 7.40 (m, 1H, Har), 7.44 (m, 1H, Har), 7.51 (m, 1H, Har), 7.84 (m, 
3H, Har) ppm; 13C NMR (150 MHz, CD3OD, HSQC): δ = 24.6 and 24.7 (C-3/4 
cyclopentyl), 25.4 (Cγ), 30.0 (Cβ), 30.4 ((NHCH2CH2CH2O)2), 30.4 (=NCOCH2CH2CO), 
33.0 (=NCOCH2CH2CO), 38.0 (NHCH2(CH2)2O), 38.5 (NHCH2CH2N<), 38.8 
(O(CH2)2CH2NHCOC6H4F), 39.3 and 39.5 (C-2/5 cyclopentyl), 39.7 (>NCOCH2-
cyclopentyl), 41.2 (NHCH2CH2N<), 42.1 (Cδ), 44.7 (CH2CONαH), 45.9 (C-1 cyclopentyl), 
47.2 (C-2/6 piperazine), 52.3 and 52.7 (C-3/5 piperazine), 53.7 (Cα), 69.9 and 70.2 
((NH(CH2)2CH2O)2), 71.3 and 71.5 ((O(CH2)2O)2), 75.8 (C-11 dibenzazepine-11-yl), 
116.3 (CarH), 116.5 (CarH), 123.0 (CarH), 124.2 (Ph), 126.1 (CarH), 128.2 (CarH), 129.2 
(CarH), 129.7 (CarH), 130.2 (Ph), 130.9 (CarH), 131.3 (CarH), 131.9 (CarH), 132.2 (Car), 
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132.4 (Car), 133.2 (CarH), 136.9 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 154.9 (NC(N)N), 
165.3 (CarF), 167.0 (COC6H4F), 171.7 (C=O lactam), 172.8 (CONαH), 173.7 
(=NCO(CH2)2CO), 174.5 (CONH(CH2)2N<), 174.7 (CON<), 176.2 (=NCO(CH2)2CO) ppm; 
MS (ES, +p) m/z (%): 1321 (5) [M+H]+, 661 (100) [M+2H]2+; HRMS (ESI-MS): m/z 
[M+H]+ calcd. for C70H87FN13O12: 1320.6576, found: 1320.6572; RP-HPLC: 96 % (tR = 
20.1 min, k´ = 6.4); C70H86FN13O12 (1319.65). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nω-{[3-(4-fluoro-
benzoylamino)propyl]aminocarbonyl}-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-
dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((S)-
3.77). 1H NMR (600 MHz, CD3OD): δ = 1.50 and 1.62 (m, 4H, 3/4-H cyclopentyl), 1.52 
and 1.66 (m, 4H, 2/5-H cyclopentyl), 1.53 and 1.73 (m, 2H, CβH2), 1.61 (m, 2H, CγH2), 
1.80 (p, 3J = 6.6 Hz, 2H, NHCH2CH2CH2NH), 2.25 and 2.35 (m, 4H, 3/5-H piperazine), 
2.26 and 2.44 (m, 2H, CH2CONαH), 2.47 (m, 2H, >NCOCH2-cyclopentyl), 3.14 (m, 2H, 
CδH2), 3.26 and 3.40 (t, 3J = 6.4 Hz, 2H, t, 3J = 6.8 Hz, 2H, NHCH2CH2CH2NH), 3.38-3.58 
(m, 4H, 2/6-H piperazine), 3.45 and 3.55 (m, 2H, NHCH2CH2N<), 3.78 (m, 2H, 
NHCH2CH2N<), 4.25 (m, 1H, CαH),4.44 (br, 1H, 11-H dibenzazepine-11-yl), 7.14 (m, 2H, 
4/5-H 4-fluorobenzoyl), 7.17 (m, 2H, Har), 7.19 (m, 2H, Har), 7.32 (m, 5H, Ph), 7.36 (m, 
5H, Ph), 7.41 (m, 1H, Har), 7.45 (m, 1H, Har), 7.52 (m, 1H, Har), 7.86 (m, 3H, Har, 2/6-H 
4-fluorobenzoyl) ppm; 13C NMR (150 MHz, CD3OD): δ = 24.5 and 24.6 (C-3/4 
cyclopentyl), 25.7 (Cγ), 30.0 (Cβ), 30.4 (NHCH2CH2CH2NH), 38.2 and 38.3 
(NHCH2CH2CH2NH), 38.5 (NHCH2CH2N<), 39.3 and 39.4 (C-2/5 cyclopentyl), 39.7 
(>NCOCH2-cyclopentyl), 41.2 (NHCH2CH2N<), 41.9 (Cδ), 44.7 (CH2CONαH), 45.9 (C-1 
cyclopentyl), 46.9 (C-2/6 piperazine), 52.3 and 52.6 (C-3/5 piperazine), 53.7 (Cα), 75.8 
(C-11 dibenzazepine-11-yl), 116.3 and 116.5 (C-3/5 4-fluorobenzoyl), 123.0 (CarH), 
124.1 (Ph), 126.2 (CarH), 128.1 (CarH), 129.4 (C-2/6 4-fluorobenzoyl), 129.8 (CarH), 
130.2 (Ph), 130.8 (Car), 131.4 (C-1 4-fluorobenzoyl), 132.0 (CarH), 132.4 (Car), 133.4 
(CarH), 137.0 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 155.5 (=NCONH), 155.7 (NC(N)N), 
167.0 (C-4 4-fluorobenzoyl), 169.2 (C=O 4-fluorobenzoyl), 171.5 (C=O lactam), 172.8 
(CON<), 174.5 (CONH(CH2)2N<), 174.7 (CONαH) ppm; MS (LSI, MeOH/gly) m/z (%): 
1119 (100) [M+H]+, 912 (50); HRMS (LSI-MS): m/z [M+H]+ calcd. for C60H69FN13O8: 
1118.5376, found: 1118.5348; RP-HPLC: 98 % (tR = 20.7 min, k´ = 6.7); C60H68FN13O8 
(1117.53). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nω-{[4-(4-fluoro-
benzoylamino)butyl]aminocarbonyl}-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-
dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((S)-
3.78). 1H NMR (600 MHz, CD3OD): δ = 1.50 and 1.62 (m, 4H, 3/4-H cyclopentyl), 1.50 
(m, 4H, NHCH2(CH2)2CH2NH), 1.52 and 1.68 (m, 4H, 2/5-H cyclopentyl), 1.53 and 1.73 
(m, 2H, CβH2), 1.59 (m, 2H, CγH2), 2.10 and 2.19 (m, 4H, 3/5-H piperazine), 2.19 and 
2.40 (m, 2H, CH2CONαH), 2.47 (m, 2H, >NCOCH2-cyclopentyl), 3.12 (m, 2H, CδH2), 3.22 
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and 3.37 (t, 3J = 6.3 Hz, 2H, t, 3J = 6.7 Hz, 2H, NHCH2(CH2)2CH2NH), 3.34-3.58 (m, 4H, 
2/6-H piperazine), 3.45 and 3.55 (m, 2H, NHCH2CH2N<), 3.78 (m, 2H, NHCH2CH2N<), 
4.25 (m, 2H, CαH, 11-H dibenzazepine-11-yl), 7.13 (m, 2H, 4/5-H 4-fluorobenzoyl), 
7.16 (m, 2H, Har), 7.19 (m, 2H, Har), 7.32 (m, 6H, Ph), 7.36 (m, 5H, Ph), 7.41 (m, 1H, 
Har), 7.49 (m, 1H, Har), 7.80 (d, 3J = 7.5 Hz, 1H, Har), 7.85 (m, 2H, 2/6-H 4-
fluorobenzoyl) ppm; 13C NMR (150 MHz, CD3OD): δ = 24.5 and 24.6 (C-3/4 
cyclopentyl), 25.7 (Cγ), 27.8 and 27.9 (NHCH2(CH2)2CH2NH), 30.0 (Cβ), 38.5 
(NHCH2CH2N<), 39.3 and 39.4 (C-2/5 cyclopentyl), 39.7 (>NCOCH2-cyclopentyl), 40.5 
and 42.6 (NHCH2(CH2)2CH2NH), 41.2 (NHCH2CH2N<), 41.9 (Cδ), 44.7 (CH2CONαH), 45.9 
(C-1 cyclopentyl), 47.5 (C-2/6 piperazine), 52.2 and 52.6 (C-3/5 piperazine), 53.7 (Cα), 
75.8 (C-11 dibenzazepine-11-yl), 116.3 and 116.4 (C-3/5 4-fluorobenzoyl), 122.8 (Ph), 
123.0 (CarH), 124.1 (Ph), 126.0 (CarH), 128.1 (CarH), 129.0 and 129.4 (C-2/6 4-
fluorobenzoyl), 129.9 (CarH), 130.0 (CarH), 130.2 (Ph), 130.8 (Car), 131.1 (C-1 4-
fluorobenzoyl), 131.7 (CarH), 132.1 (CarH), 132.4 (Car), 133.1 (CarH), 136.8 (Car), 137.8 
(Car), 154.5 (N(CONPh)2), 155.4 (=NCONH), 155.7 (NC(N)N), 167.0 (C-4 4-
fluorobenzoyl), 169.0 (C=O 4-fluorobenzoyl), 172.0 (C=O lactam), 172.7 (CON<), 174.5 
(CONH(CH2)2N<), 174.7 (CONαH) ppm; MS (LSI, MeOH/gly) m/z (%): 1133 (100) 
[M+H]+, 928 (50); HRMS (LSI-MS): m/z [M+H]+ calcd. for C61H71FN13O8: 1132.5533, 
found: 1132.5541; RP-HPLC: 98 % (tR = 20.8 min, k´ = 6.7); C61H70FN13O8 (1131.55). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nω-{[6-(4-fluoro-
benzoylamino)hexyl]aminocarbonyl}-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-
dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((S)-
3.79). 1H NMR (600 MHz, CD3OD): δ = 1.36 (m, 4H, NH(CH2)2(CH2)2(CH2)2NH), 1.49 (m, 
4H, NHCH2CH2(CH2)2CH2CH2NH), 1.50 and 1.62 (m, 4H, 3/4-H cyclopentyl), 1.50 and 
1.68 (m, 4H, 2/5-H cyclopentyl), 1.52 and 1.73 (m, 2H, CβH2), 1.61 (m, 2H, CγH2), 2.23 
and 2.46 (m, 2H, CH2CONαH), 2.28 and 2.41 (m, 4H, 3/5-H piperazine), 2.49 (m, 2H, 
>NCOCH2-cyclopentyl), 3.15 and 3.35 (m, 4H, NHCH2(CH2)4CH2NH), 3.16 (m, 2H, CδH2), 
3.36-3.59 (m, 4H, 2/6-H piperazine), 3.45 and 3.55 (m, 2H, NHCH2CH2N<), 3.77 (m, 
2H, NHCH2CH2N<), 4.25 (m, 1H, CαH), 4.32 (br, 1H, 11-H dibenzazepine-11-yl), 7.14 
(m, 2H, 4/5-H 4-fluorobenzoyl), 7.15 (m, 1H, Har), 7.17 (m, 1H, Har), 7.18 (m, 2H, Har), 
7.28-7.40 (m, 11H), 7.42 (m, 1H, Har), 7.50 (m, 1H, Har), 7.84 (m, 3H, 2/6-H 4-
fluorobenzoyl, Har) ppm; 13C NMR (150 MHz, CD3OD): δ = 24.5 and 24.6 (C-3/4 
cyclopentyl), 25.7 (Cγ), 27.4 and 27.6 (NH(CH2)2(CH2)2(CH2)2NH), 30.0 (Cβ), 30.4 
(NHCH2CH2(CH2)2CH2CH2NH), 38.5 (NHCH2CH2N<), 39.3 and 39.4 (C-2/5 cyclopentyl), 
39.7 (>NCOCH2-cyclopentyl), 40.7 and 42.4 (NHCH2(CH2)4CH2NH), 41.2 (NHCH2CH2N<), 
41.8 (Cδ), 44.7 (CH2CONαH), 45.9 (C-1 cyclopentyl), 47.2 (C-2/6 piperazine), 52.2 and 
52.6 (C-3/5 piperazine), 53.7 (Cα), 75.8 (C-11 dibenzazepine-11-yl), 116.3 and 116.4 
(C-3/5 4-fluorobenzoyl), 122.6 (Ph), 123.0 (CarH), 124.1 (Ph), 126.1 (CarH), 128.1 (CarH), 
129.2 and 129.6 (C-2/6 4-fluorobenzoyl), 130.2 (Ph), 130.8 (Car), 131.2 (C-1 4-
fluorobenzoyl), 131.8 (CarH), 132.2 (CarH), 132.4 (Car), 133.2 (CarH), 136.9 (Car), 137.8 
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(Car), 154.5 (N(CONPh)2), 155.4 (=NCONH), 155.7 (NC(N)N), 167.0 (C-4 4-
fluorobenzoyl), 169.0 (C=O 4-fluorobenzoyl), 171.8 (C=O lactam), 172.7 (CON<), 174.5 
(CONH(CH2)2N<), 174.7 (CONαH) ppm; MS (LSI, MeOH/gly) m/z (%): 1161 (100) 
[M+H]+, 954 (40); HRMS (LSI-MS): m/z [M+H]+ calcd. for C63H75FN13O8: 1160.5846, 
found: 1160.5816; RP-HPLC: 98 % (tR = 22.1 min, k´ = 7.2); C63H74FN13O8 (1159.58). 
 
(2S)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nω-[6-(4-fluoro-
benzoylamino)hexanoyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo-
[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((S)-3.80). 
[ߙ]஽ଶ଴= –4.7 cm3 g-1 dm-1 (c = 0.71 in CH3CN/H2O 10:1); 1H NMR (600 MHz, DMSO-d6, 
HSQC): δ = 1.32 (m, 2H, CH2(CH2)2NH), 1.48 (m, 2H, CγH2), 1.44 and 1.63 (m, 2H, CβH2), 
1.41-1.63 (m, 4H, 2/5-H cyclopentyl), 1.52 (m, 2H, CH2CH2NHBz(4F)), 1.55 (m, 4H, 3/4-
H cyclopentyl), 1.57 (m, 2H, COCH2CH2), 2.16 and 2.18 (m, 4H, 3/5-H piperazine), 2.21 
and 2.32 (m, 2H, CH2CONαH), 2.41 (t, 3J = 7.3 Hz, 2H, C(O)CH2CH2), 2.42 and 2.50 (m, 
2H, NCOCH2-cyclopentyl), 3.17 (m, 2H, CδH2), 3.25 (m, 2H, CH2NHBz(4F)), 3.33-3.37 
(m, 4H, 2/6-H piperazine), 3.31 and 3.40 (m, 2H, NHCH2CH2N), 3.60 (t, 3J = 6.0 Hz, 2H, 
NHCH2CH2N), 4.17 (m, 1H, CαH), 4.43 (br, 1H, 11-H dibenzazepine-11-yl), 7.08 (m, 1H, 
Har), 7.14 (m, 1H, Har), 7.22 (m, 2H, Ph), 7.28 (m, 1H, Har), 7.35 (m, 1H, Har), 7.37 (m, 
8H, Ph), 7.41 (m, 1H, Har), 7.43 (m, 1H, Har), 7.52 (m, 1H, Har), 7.78 (m, 1H, Har), 7.98 
(d, 3J = 8.0 Hz, 1H, NαH), 8.24 (t, 3J = 5.7 Hz, 1H, CONHC2H4N), 8.48 (t, 3J = 5.5 Hz, 1H, 
NHBz(4F)), 8.68 and 8.81 (br, 2H, NωH2), 9.20 (t, 3J = 5.6 Hz, 1H, NδH), 10.40 (s, 1H, 
C(O)NH lactam), 11.83 (s, 1H, Nω’H) ppm; 13C NMR (150 MHz, DMSO-d6, HSQC): δ = 
23.3 (C-3/4 cyclopentyl), 23.6 (COCH2CH3), 24.1 (Cγ), 25.7 (CH2(CH2)2NH), 28.7 (Cβ), 
28.8 (CH2CH2CH2NH), 36.0 (C(O)CH2), 36.1 (NHCH2CH2N), 37.2 (C-2/5 cyclopentyl), 
38.5 (NCOCH2-cyclopentyl), 39.0 (CH2NHBz(4F)), 39.6 (NHCH2CH2N), 40.5 (Cδ), 40.4 
and 44.9 (C-2/6 piperazine), 42.8 (CH2CONαH), 44.0 (C-1 cyclopentyl), 50.7 and 51.2 
(C-3/5 piperazine), 51.7 (Cα), 73.6 (C-11 dibenzazepine-11-yl), 115.0 (d, 2JC,F = 21.6 
Hz), 121.3 (CarH), 122.6 (Ph), 123.8 (CarH), 126.5 (Ph), 128.1 (CarH), 128.4 (CarH), 128.7 
(CarH), 128.9 (Ph), 129.7 (d, 3JC,F = 8.9 Hz), 130.2 (CarH), 130.7 (CarH), 131.1 (d, 4JC,F = 
2.9 Hz), 131.5 (CarH), 131.1 (Car), 136.2 (Car), 136.5 (Car), 141.5 (Car), 152.5 
(N(CONPh)2), 152.9 (NC(N)N), 163.7 (d, 1JC,F = 248.0 Hz), 165.0 (COC6H4F), 167.9 (C=O 
lactam), 170.0 (CON), 171.2 (CONαH), 171.9 (CONHC2H4N), 175.2 (CO(CH2)5) ppm; IR 
(neat): υ´ = 3300, 2943, 1641, 1443, 1289, 1172 cm-1; MS (ES, +p) m/z (%): 1132 (100) 
[M+H]+; RP-HPLC: 98 % (tR = 22.1 min, k´ = 7.8); anal. calcd. for C62H71FN12O8⋅2 H2O⋅2 
HCl: C 60.04, H 6.26, N 13.56 %, found: C 60.27, H 6.55, N 13.51 %; C62H71FN12O8 
(1131.30). 
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(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nω-[8-(4-fluoro-
benzoylamino)-3,6-dioxaoctanoyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-
dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide ((S)-
3.81). 1H NMR (600 MHz, CD3OD): δ = 1.50 and 1.63 (m, 4H, 3/4-H cyclopentyl), 1.51 
and 1.70 (m, 4H, 2/5-H cyclopentyl), 1.53 and 1.75 (m, 2H, CβH2), 1.63 (m, 2H, CγH2), 
2.12 and 2.39 (m, 4H, 3/5-H piperazine), 2.26 and 2.44 (m, 2H, CH2CONαH), 2.48 (m, 
2H, >NCOCH2-cyclopentyl), 3.18 (m, 2H, CδH2), 3.34-3.49 (m, 4H, 2/6-H piperazine), 
3.43 and 3.53 (m, 2H, NHCH2CH2N<), 3.57 (t, 3J = 5.6 Hz, 2H, OCH2CH2NH), 3.66 (t, 3J = 
5.6 Hz, 2H, OCH2CH2NH), 3.70 and 3.75 (m, 4H, O(CH2)2O), 3.78 (m, 2H, NHCH2CH2N<), 
4.19 (s, 2H, COCH2O), 4.26 (m, 1H, CαH), 4.28 (br, 1H, 11-H dibenzazepine-11-yl), 7.13 
(m, 2H, 4/5-H 4-fluorobenzoyl), 7.15 (m, 1H, Har), 7.16 (m, 1H, Har), 7.19 (m, 2H, Har), 
7.27-7.40 (m, 11H), 7.42 (m, 1H, Har), 7.50 (m, 1H, Har), 7.81 (d, 3J = 7.6 Hz, 1H, Har), 
7.85 (m, 2H, 2/6-H 4-fluorobenzoyl) ppm; 13C NMR (150 MHz, CD3OD): δ = 24.5 and 
24.6 (C-3/4 cyclopentyl), 25.4 (Cγ), 30.0 (Cβ), 38.5 (NHCH2CH2N<), 39.3 and 39.5 (C-2/5 
cyclopentyl), 39.6 (>NCOCH2-cyclopentyl), 40.8 and 42.5 (OCH2CH2NH), 41.2 
(NHCH2CH2N<), 42.1 (Cδ), 44.7 (CH2CONαH), 45.9 (C-1 cyclopentyl), 47.4 (C-2/6 
piperazine), 52.2 and 52.6 (C-3/5 piperazine), 53.7 (Cα), 70.6 (OCH2CH2NH), 71.2 
(=NCOCH2O), 71.2 and 72.2 (O(CH2)2O), 75.8 (C-11 dibenzazepine-11-yl), 116.4 and 
116.5 (C-3/5 4-fluorobenzoyl), 122.9 (CarH), 124.1 (Ph), 126.1 (CarH), 128.1 (CarH), 
129.0 (C-2/6 4-fluorobenzoyl), 130.2 (Ph), 130.9 (Car), 131.2 (C-1 4-fluorobenzoyl), 
131.7 (CarH), 132.0 (CarH), 132.4 (Car), 133.1 (CarH), 136.9 (Car), 137.8 (Car), 154.5 
(N(CONPh)2), 154.6 (NC(N)N), 167.0 (C-4 4-fluorobenzoyl), 169.3 (C=O 4-
fluorobenzoyl), 171.9 (C=O lactam), 172.7 (CON<), 173.8 (=NCOCH2O), 174.5 
(CONH(CH2)2N<), 174.7 (CONαH) ppm; MS (ES, +p) m/z (%): 1164 (50) [M+H]+, 582 
(100) [M+2H]2+; HRMS (ESI-MS): m/z [M+H]+ calcd. for C62H72FN12O10: 1163.5473, 
found: 1163.5492; RP-HPLC: 97 % (tR = 20.7 min, k´ = 6.7); C62H71FN12O10 (1162.54). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nω-[15-(4-fluoro-
benzoylamino)-4,7,10,13-tetraoxapentadecanoyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-
dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]-
argininamide ((S)-3.82). Mp 112-115 °C; 1H NMR (600 MHz, CD3OD): δ = 1.50 and 1.63 
(m, 4H, 3/4-H cyclopentyl), 1.51 and 1.70 (m, 4H, 2/5-H cyclopentyl), 1.53 and 1.75 
(m, 2H, CβH2), 1.63 (m, 2H, CγH2), 2.12 and 2.39 (m, 4H, 3/5-H piperazine), 2.26 and 
2.44 (m, 2H, CH2CONαH), 2.48 (m, 2H, >NCOCH2-cyclopentyl), 2.66 (t, 3J = 5.7 Hz, 2H, 
=NCOCH2CH2O), 3.17 (m, 2H, CδH2), 3.34-3.49 (m, 4H, 2/6-H piperazine), 3.43 and 
3.53 (m, 2H, NHCH2CH2N<), 3.56 (m, 2H, OCH2CH2NH), 3.56 and 3.63 (m, 12H, 
(O(CH2)2O)3), 3.59 (m, 2H, OCH2CH2NH), 3.74 (t, 3J = 5.7 Hz, 2H, =NCOCH2CH2O), 3.78 
(m, 2H, NHCH2CH2N<), 4.26 (m, 2H, CαH, 11-H dibenzazepine-11-yl), 7.13 (m, 2H, 4/5-
H 4-fluorobenzoyl), 7.15 (m, 1H, Har), 7.16 (m, 1H, Har), 7.19 (m, 2H, Har), 7.27-7.40 (m, 
11H), 7.42 (m, 1H, Har), 7.50 (m, 1H, Har), 7.81 (d, 3J = 7.6 Hz, 1H, Har),7.87 (m, 2H, 2/6-
H 4-fluorobenzoyl) ppm; 13C NMR (150 MHz, CD3OD): δ = 24.5 and 24.6 (C-3/4 
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cyclopentyl), 25.4 (Cγ), 30.0 (Cβ), 38.5 (NHCH2CH2N<), 38.6 (=NCOCH2CH2O), 39.3 and 
39.5 (C-2/5 cyclopentyl), 39.6 (>NCOCH2-cyclopentyl), 41.0 and 42.5 (OCH2CH2NH), 
41.2 (NHCH2CH2N<), 42.1 (Cδ), 44.7 (CH2CONαH), 45.9 (C-1 cyclopentyl), 47.4 (C-2/6 
piperazine), 52.2 and 52.6 (C-3/5 piperazine), 53.7 (Cα), 66.9 (=NCOCH2CH2O), 70.5 
(OCH2CH2NH), 71.3 and 71.4 and 71.5 ((O(CH2)2O)3), 75.8 (C-11 dibenzazepine-11-yl), 
116.3 and 116.5 (C-3/5 4-fluorobenzoyl), 122.9 (CarH), 124.1 (Ph), 126.0 (CarH), 128.1 
(CarH), 129.0 (C-2/6 4-fluorobenzoyl), 129.5 (CarH), 130.0 (CarH), 130.2 (Ph), 130.9 (Car), 
131.2 (C-1 4-fluorobenzoyl), 131.7 (CarH), 132.0 (CarH), 132.4 (Car), 133.1 (CarH), 136.9 
(Car), 137.8 (Car), 154.5 (N(CONPh)2), 154.8 (NC(N)N), 167.0 (C-4 4-fluorobenzoyl), 
169.1 (C=O 4-fluorobenzoyl), 171.9 (C=O lactam), 172.7 (CON<), 174.5 
(CONH(CH2)2N<), 174.7 (CONαH), 175.2 (=NCOCH2CH2O) ppm; MS (ES, +p) m/z (%): 
1266 (25) [M+H]+, 633 (100) [M+2H]2+; HRMS (ESI-MS): m/z [M+H]+ calcd. for 
C67H82FN12O12: 1265.6154, found: 1265.6171; RP-HPLC: 99 % (tR = 20.7 min, k´ = 6.7); 
C67H81FN12O12 (1264.61). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nω-{4-[3-(2-fluoro-
propanoylamino)propyl]aminocarbonylbutanoyl}-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-
dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]-
argininamide ((S)-3.83). Mp 129 °C; 1H NMR (600 MHz, CD3OD, COSY, HSQC): δ = 1.50 
(d, 3J = 6.8 Hz, 3H, COCHFCH3), 1.51 and 1.74 (m, 2H, CβH2), 1.50 and 1.69 (m, 4H, 2/5-
H cyclopentyl), 1.51 and 1.63 (m, 4H, 3/4-H cyclopentyl), 1.60 (m, 2H, CγH2), 1.69 (p, 3J 
= 6.8 Hz, 2H, CONHCH2CH2CH2NH), 1.92 (p, 3J = 7.3 Hz, 2H, =NCOCH2CH2CH2CONH), 
2.24 and 2.31 (m, 4H, 3/5-H piperazine), 2.25 (m, 2H, =NCOCH2(CH2)2CONH), 2.26 and 
2.43 (m, 2H, CH2CONαH), 2.48 (m, 2H, =NCO(CH2)2CH2CONH), 2.49 (m, 2H, >NCOCH2-
cyclopentyl), 3.17 (m, 2H, CδH2), 3.20 (t, 3J = 6.7 Hz, 2H, CONHCH2(CH2)2NH), 3.25 (t, 3J 
= 6.9 Hz, 2H, CONH(CH2)2CH2NH), 3.45 and 3.54 (m, 4H, 2/6-H piperazine), 3.45 and 
3.56 (m, 2H, NHCH2CH2N<), 3.78 (m, 2H, NHCH2CH2N<), 4.25 (m, 1H, CαH2), 4.43 (br, 
1H, 11-H dibenzazepine-11-yl), 4.96 (quat, 3J = 6.8 Hz, 1H, COCHFCH3), 7.15 (m, 2H, 
Har), 7.20 (m, 2H, Har), 7.32 (m, 5H, Ph), 7.37 (m, 5H, Ph), 7.42 (m, 1H, Har), 7.46 (m, 
1H, Har), 7.53 (m, 1H, Har), 7.85 (m, 1H, Har) ppm; 13C NMR (150 MHz, CD3OD, HCQC): δ 
= 18.9 and 19.0 (COCHFCH3), 21.4 (=NCOCH2CH2CH2CONH), 24.5 und 24.6 (C-3/4 
cyclopentyl), 25.4 (Cγ), 30.0 (Cβ), 30.2 (CONHCH2CH2CH2NH), 35.6 
(=NCOCH2(CH2)2CONH), 36.9 (=NCO(CH2)2CH2CONH), 37.4 (CONH(CH2)2CH2NH), 37.6 
(CONHCH2(CH2)2NH), 38.4 (NHCH2CH2N<), 39.3 (C-2/5 cyclopentyl), 39.5 and 39.7 
(>NCOCH2cyclopentyl), 41.2 (NHCH2CH2N<), 42.0 (Cδ), 44.6 (CH2CONαH), 47.0 (C-2/6 
piperazine), 45.8 (C-1 cyclopentyl), 52.2 und 52.6 (C-3/5 piperazine), 53.7 (Cα), 75.8 
(C-11 dibenzazepine-11-yl), 88.8 and 90.0 (COCHFCH3), 123.0 (CarH), 124.2 (Ph), 126.2 
(CarH), 128.2 (CarH), 129.4 (CarH), 129.8 (CarH), 130.2 (Ph), 130.3 (Car), 131.4 (CarH), 
132.0 (CarH), 132.4 (Car), 133.3 (CarH), 137.0 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 155.0 
(NC(N)N), 172.8 (CONαH), 173.4 and 173.5 (COCHFCH3), 174.5 (CONHC2H4N<), 174.7 
(CON<), 175.2 (=NCO(CH2)3CONH), 176.4 (=NCO(CH2)3CONH) ppm; MS (ES, +p) m/z 
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(%): 1141 (30) [M+H]+, 571 (100) [M+2H]2+; HRMS (LSI-MS): m/z [M+H]+ calcd. for 
C60H75FN13O9: 1140.5795, found: 1140.5799; RP-HPLC: 99 % (tR = 17.7 min, k´ = 5.6); 
C60H74FN13O9 (1139.57). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nω-[18-(2-fluoro-
propanoylamino)-4-oxo-9,12,15-trioxa-5-azaoctadecanoyl]-Nα-[2-(1-{2-oxo-2-[4-(6-
oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]argininamide ((S)-3.84). 1H NMR (600 MHz, CD3OD, COSY, HSQC): δ = 1.47 and 
1.50, (2x d, 3J = 6.8 Hz, 3H, CFHCH3), 1.50 and 1.63 (m, 4H, 3/4-H cyclopentyl), 1.50 
and 1.67 (m, 4H, 2/5-H cyclopentyl), 1.50 (m, 2H, CβH2), 1.58 (m, 2H, CγH2), 1.73 (m, 
2H, NHCH2CH2CH2O), 1.77 (m, 2H, NHCH2CH2CH2O), 2.14 and 2.21 (m, 4H, 3/5-H 
piperazine), 2.23 and 2.41 (m, 2H, CH2CONαH), 2.47 and 2.49 (m, 2H, >NCOCH2-
cyclopentyl), 2.55 and 2.70 (2x m, 4H, =NCO(CH2)2CONH), 3.16 (m, 2H, CδH2), 3.24 (t, 
3J = 6.8 Hz, 2H, NHCH2(CH2)2O), 3.31 (m, 2H, NHCH2(CH2)2), 3.32-3.49 (m, 4H, 2/6-H 
piperazine), 3.44 and 3.53 (m, 2H, NHCH2CH2N<), 3.49 (m, 2H, NH(CH2)2CH2O), 3.51 
(m, 2H, NH(CH2)2CH2O), 3.56 and 3.61 (m, 8H, (O(CH2)2O)2), 3.78 (m, 2H, 
NHCH2CH2N<), 4.25 (m, 1H, CαH), 4.28 (br, 1H, 11-H dibenzazepine-11-yl), 4.90 and 
4.98 (2x quat, 3J = 6.8 Hz, 1H, CHFCH3), 7.12 (m, 1H, Har), 7.13 (m, 1H, Har), 7.20 (m, 
2H, Har), 7.32 (m, 5H, Ph), 7.33 (m, 1H, Har), 7.38 (m, 5H, Ph), 7.42 (m, 1H, Har), 7.50 
(m, 1H, Har), 7.81 (m, 1H, Har) ppm; 13C NMR (150 MHz, CD3OD, HSQC): δ = 18.9 
(COCHFCH3), 24.5 and 24.6 (C-3/4 cyclopentyl), 25.4 (Cγ), 30.0 (Cβ), 30.3 and 30.4 (2x 
NHCH2CH2CH2O), 30.3 (=NCOCH2CH2CO), 33.0 (=NCOCH2CH2CO), 37.8 and 38.0 (2x 
NHCH2(CH2)2O), 38.5 (NHCH2CH2N<), 39.3 (C-2/5 cyclopentyl), 39.6 (>NCOCH2-
cyclopentyl), 41.2 (NHCH2CH2N<), 42.0 (Cδ), 44.7 (CH2CONαH), 45.9 (C-1 cyclopentyl), 
47.5 (C-2/6 piperazine), 52.2 and 52.6 (C-3/5 piperazine), 53.7 (Cα), 69.9 and 70.1 (2x 
HN(CH2)2CH2O), 71.2 and 71.3 ((O(CH2)2O)2), 75.8 (C-11 dibenzazepine-11-yl), 88.8 
and 90.0 (COCHFCH3), 122.9 (CarH), 124.1 (Ph), 126.0 (CarH), 128.1 (CarH), 129.0 (CarH), 
129.4 (CarH), 130.0 (Car), 130.2 (Ph), 131.2 (CarH), 131.7 (CarH), 132.4 (Car), 133.1 (CarH), 
136.9 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 154.9 (NC(N)N), 172.0 (C=O lactam), 172.7 
(CONαH), 173.1 (COCHFCH3), 173.7 (=NCO(CH2)2CO), 174.5 (CONH(CH2)2N<), 174.7 
(CON<), 176.4 (=NCO(CH2)2CO) ppm; MS (ES, +p) m/z (%): 1273 (12) [M+H]+, 637 (100) 
[M+2H]2+; HRMS (LSI-MS): m/z [M+H]+ calcd. for C66H87FN13O9: 1272.6581, found: 
1272.6562; RP-HPLC: 97 % (tR = 18.2 min, k´ = 5.7); C66H86FN13O12 (1271.65). 
 
(2S)-Nω-tert-Butoxycarbonyl-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)-
ethyl]-Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)-
piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide (3.85). A solution of (S)-3.47a 
(0.10g, 0.09 mmol) in CH3CN (6 mL) and 0.1 % aq. TFA (3 mL) was stirred for 2 h at rt. 
Subsequently, 4 mL of 0.1 % aq. TFA was added and stirring was continued for 
another 24 h. The deprotection was aborted with a few drops of NEt3 (pH 9-10) and 
the solvent was removed under reduced pressure. The aqueous phase was washed 
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twice with CH2Cl2 (20 mL). Then the organic phase was dried over Na2SO4, 
evaporated, and the crude product was purified with the Varian flash 
chromatography workstation (eluent: CH2Cl2 (A), MeOH (B); gradient: 0 to 20 min: 
A/B 100/0 to 75/25) yielding the title compound as a yellow solid (0.05 g, 60 %). MS 
(ES, +p) m/z (%): 997 (15) [M+H]+, 499 (100) [M+2H]2+; C54H65N11O8 (995.50). 
 
Preparation of the NG-acylated analogs 3.86, 3.87:21 
 
3.85 (50 mg, 45 µmol) and NEt3 (6.2 µL, 45 µmol) was dissolved in CH3CN (2 mL). The 
active ester (1.2 eq) was added and the mixture was stirred for 16 h prior to the 
addition of TFA (1.5 mL). After 2 h the deprotection mixtures were subjected to 
preparative HPLC to obtain the products as white solids (53-63 %). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-
(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]-Nω-(propanoyl)argininamide (3.86). Mp 125 °C; 1H NMR (600 MHz, CD3OD, 
COSY, HSQC, HMBC): δ = 1.12 (t, 3J = 7.4 Hz, 3H, COCH2CH3), 1.50 and 1.63 (m, 4H, 
3/4-H cyclopentyl), 1.50 and 1.70 (m, 4H, 2/5-H cyclopentyl), 1.51 and 1.75 (m, 2H, 
CβH2), 1.60 (m, 2H, CγH2), 2.19 and 2.26 (m, 4H, 3/5-H piperazine), 2.25 and 2.43 (m, 
2H, CH2CONαH), 2.44 (m, 2H, COCH2CH3), 2.47 (m, 2H, >NCOCH2-cyclopentyl), 3.18 
(m, 2H, CδH2), 3.43 (br, 4H, 2/6-H piperazine), 3.44 and 3.54 (m, 2H, NHCH2CH2N<), 
3.78 (m, 2H, NHCH2CH2N<), 4.25 (m, 1H, CαH), 4.35 (br, 1H, 11-H dibenzazepine-11-
yl), 7.14 (m, 2H, Har), 7.19 (m, 2H, Har), 7.32 (m, 5H, Ph), 7.37 (m, 5H, Ph), 7.40 (m, 1H, 
Har), 7.44 (m, 1H, Har), 7.52 (m, 1H, Har), 7.83 (d, 3J = 7.7 Hz, 1H, Har) ppm; 13C NMR 
(150 MHz, CD3OD, HSQC, HMBC): δ = 8.5 (COCH2CH3), 24.5 and 24.6 (C-3/4 
cyclopentyl), 25.5 (Cγ), 30.0 (Cβ), 31.1 (COCH2CH3), 38.4 (NHCH2CH2N<), 39.3 and 39.4 
(C-2/5 cyclopentyl), 39.7 (>NCOCH2-cyclopentyl), 41.2 (NHCH2CH2N<), 42.0 (Cδ), 44.7 
(CH2CONαH), 45.8 (C-1 cyclopentyl), 47.2 (C-2/6 piperazine), 52.2 and 52.7 (C-3/5 
piperazine), 53.7 (Cα), 75.8 (C-11 dibenzazepine-11-yl), 123.0 (CarH), 124.1 (Ph), 126.1 
(CarH), 128.1 (CarH), 129.2 (CarH), 129.7 (CarH), 130.2 (Ph), 131.3 (CarH), 131.9 (CarH), 
132.4 (Car), 133.2 (CarH), 136.9 (Car), 137.8 (Car), 154.5 (N(CONPh)2), 155.0 (NC(N)N), 
171.7 (C=O lactam), 172.8 (CON<), 174.5 (CONH(CH2)2N<), 174.7 (CONαH), 177.7 
(COCH2CH3) ppm; MS (ES, +p) m/z (%): 477 (100) [M+2H]2+; HRMS (LSI-MS): m/z 
[M+H]+ calcd. for C52H62N11O7: 952.4834, found: 952.4845; RP-HPLC: 99 % (tR = 13.5 
min, k´ = 4.0); C52H61N11O7 (951.48). 
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(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nω-(4-fluorobenzoyl)-
Nα-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-
yl]ethyl}cyclopentyl)acetyl]argininamide (3.87). 1H NMR (600 MHz, CD3OD): δ = 1.51 
and 1.79 (m, 2H, CβH2), 1.50 and 1.64 (m, 4H, 2/5-H cyclopentyl), 1.51 and 1.63 (m, 
4H, 3/4-H cyclopentyl), 1.66 (m, 2H, CγH2), 2.12 and 2.18 (m, 4H, 3/5-H piperazine), 
3.26 (m, 2H, CδH2), 3.39 and 3.46 (m, 4H, 2/6-H piperazine), 3.54 (m, 2H, 
NHCH2CH2N<), 3.78 (m, 2H, NHCH2CH2N<), 4.24 (br, 1H, 11-H dibenzazepine-11-yl), 
4.28 (m, 1H, CαH2), 7.10 (m, 1H, Har), 7.12 (m, 1H, Har), 7.18 (m, 2H, Ph), 7.28 (m, 1H, 
Har), 7.30 (m, 8H, Ph), 7.37 (m, 4H, Ph), 7.41 (m, 1H, Har), 7.49 (m, 1H, Har), 7.80 (m, 
1H, Har), 8.00 (m, 2H, Ph) ppm; 13C NMR (150 MHz, CD3OD): δ = 24.5 and 24.6 (C-3/4 
cyclopentyl), 25.4 (Cγ), 30.0 (Cβ), 38.5 (NHCH2CH2N<), 39.3 (C-2/5 cyclopentyl), 39.4 
and 39.6 (>NCOCH2-cyclopentyl), 41.2 (NHCH2CH2N<), 42.3 (Cδ), 42.6 and 47.6 (C-2/6 
piperazine), 44.7 (CH2CONαH), 45.9 (C-1 cyclopentyl), 52.1 and 52.6 (C-3/5 
piperazine), 53.7 (Cα), 75.8 (C-11 dibenzazepin-11-yl), 117.2 (CarH), 117.3 (CarH), 123.0 
(CarH), 124.1 (Ph), 126.0 (CarH), 128.1 (CarH), 128.9 (CarH), 129.4 (CarH), 129.9 (Car), 
130.2 (Ph), 131.1 (CarH), 131.6 (CarH), 132.2 (Ph), 132.4 (Car), 133.1 (CarH), 136.8 (Car), 
137.8 (Car), 154.5 (N(CONPh)2), 155.5 (NC(N)N), 168.6 (COC6H4F), 172.1 (C=O lactam), 
172.7 (CONαH), 174.5 (CONHC2H4N<), 174.7 (CON<) ppm; MS (ES, +p) m/z (%):1018 
(100) [M+H]+; HRMS (LSI-MS): m/z [M+H]+ calcd. for C56H61FN11O7: 1018.4739, found: 
1018.4742; RP-HPLC: 98 % (tR = 21.5 min, k´ = 7.0); C56H60FN11O7 (1017.47). 
3.5.3 Investigation of the Chemical Stability 
The stability of the Y2R antagonists (S)-3.48-(S)-3.50, (S)-3.53-(S)-3.55, (S)-3.57, 
(S)-3.58, (S)-3.63, (S)-3.69, (S)-3.72 and (S)-3.74 regarding the formation of BIIE 0246 
((S)-3.47) was investigated at neutral pH in FACS-buffer (cf. section 3.5.1). Incubation 
was started by addition of 10 µL of a 1 mM solution of the compounds in DMSO to 
190 µL of buffer to give a final concentration of 50 µM. After incubation times 
between 15 and 180 min a 80 µL aliquot was taken and diluted with a mixture of 
acetonitrile, H2O and 1 % aq. TFA (5:1:4, 80 µL). 100 µL of the resulting solution (pH = 
2-3) was analyzed by HPLC on a RP-column (Eurospher-100 C18, 250 × 4 mm, 5 µm, 
Knauer, Berlin, Germany) using a system from Thermo Separation Products 
(composed of a SN400 controller, a P4000 pump, a degasser (Degassex DG-4400, 
phenomenex), an AS3000 autosampler and a Spectra Focus UV-VIS detector. 
Mixtures of acetonitrile (A) and 0.05 % aq. TFA (B) were used as mobile phase 
(gradient: 0-30 min: A/B 20/80 to 95/5, 30 to 37 min: A/B 95/5). The flow rate was set 
to 0.8 mL/min, the column temperature to 30 °C and the detection wavelength to 
220 nm. The quantity of decomposition product (S)-3.47 was estimated from the 
peak integrals of the incubation sample and a reference chromatogram of the 
analyzed compound. 
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3.5.4 Pharmacology: Cell Culture, Fura-2 Assay and Flow Cytometry 
Cell culture. CHO cells were cultured as described elsewhere.29 
 
Fura-2 assay on CHO cells. The fura-2 assay was performed as previously described30 
using a LS50 B spectrofluorimeter from Perkin Elmer (Überlingen, Germany). 
 
Flow cytometric competition binding assay. The binding assay was performed as 
described elsewhere29 with the following adaptations. Samples were measured 
without further processing using a FACSCaliburTM flow cytometer from Becton 
Dickinson (Heidelberg, Germany), equipped with an argon laser (488 nm) and a red 
diode laser (635 nm); instrument settings were: FSC: E-1, SSC: 350 V, FL4: 800 V, 
Flow: HI; measurement stopped when 10000 gated events were counted. The 
experiments were performed using 490 µL of cell suspension, 5 µL of Cy5-pNPY (final 
concentration 5 nM) and 5 µL of test compound (100-fold concentrated). If indicated, 
5 µL of Dy-635-pNPY (final concentration 10 nM) was used as fluorescent ligand. 
Incubation time was 90 min at room temperature. Ki values were obtained from 2-3 
independent experiments. 
 
Flow cytometric selectivity assay. The selectivity of the new Y2R antagonists for 
human NPY Y2 over Y1, Y4 and Y5 receptors was proven by flow cytometric binding 
assays on Cy5-pNPY (Y1R, Y5R), and Cy5-[K4]-hPP (Y4R) according to previously 
described methods.29, 44-45 All flow cytometric measurements were performed on a 
FACSCaliburTM flow cytometer from Beckton Dickinson (Heidelberg, Germany), 
equipped with an argon laser (488 nm) and a red diode laser (635 nm). The 
compounds were tested at two concentrations (1 µM and 10 µM) in duplicates. 
3.6 References 
1. Doods, H.; Gaida, W.; Wieland, H. A.; Dollinger, H.; Schnorrenberg, G.; Esser, F.; 
Engel, W.; Eberlein, W.; Rudolf, K. BIIE0246: a selective and high affinity neuropeptide 
Y Y(2) receptor antagonist. Eur. J. Pharmacol. 1999, 384, R3-5. 
2. Dumont, Y.; Cadieux, A.; Doods, H.; Pheng, L. H.; Abounader, R.; Hamel, E.; Jacques, 
D.; Regoli, D.; Quirion, R. BIIE0246, a potent and highly selective non-peptide 
neuropeptide Y Y(2) receptor antagonist. Br. J. Pharmacol. 2000, 129, 1075-88. 
3. Smith-White, M. A.; Hardy, T. A.; Brock, J. A.; Potter, E. K. Effects of a selective 
neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral 
neuroeffector junctions. Br. J. Pharmacol. 2001, 132, 861-8. 
4. Dautzenberg, F. M.; Neysari, S. Irreversible binding kinetics of neuropeptide Y ligands 
to Y2 but not to Y1 and Y5 receptors. Pharmacology 2005, 75, 21-9. 
5. Rudolf, K.; Eberlein, W.; Engel, W.; Mihm, G.; Doods, H. N.; Willim, K. D.; Krause, J.; 
Wieland, H. A.; Schnorrenberg, G.; Esser, F.; Dollinger, H. Preparation of piperazine-
containing peptidomimetics for use as NPY antagonists. DE 19816929, 1999. 
108 Chapter 3  
6. Esser, F.; Schnorrenberg, G.; Dollinger, H.; Gaida, W. Preparation of novel peptides for 
use as NPY antagonists. DE19816932, 1999. 
7. Dollinger, H.; Esser, F.; Mihm, G.; Rudolf, K.; Schnorrenberg, G.; Gaida, W.; Doods, H. 
N. Preparation of novel peptides for use as NPY antagonists. DE 19816929, 1999. 
8. Brennauer, A. Acylguanidines as bioisosteric groups in argininamide-type neuropeptide 
Y Y1 and Y2 receptor antagonists: synthesis, stability and pharmacological activity. 
Doctoral thesis, Universität Regensburg, Regensburg, 2006. 
9. Merten, N.; Lindner, D.; Rabe, N.; Rompler, H.; Mörl, K.; Schöneberg, T.; Beck-
Sickinger, A. G. Receptor subtype-specific docking of Asp6.59 with C-terminal arginine 
residues in Y receptor ligands. J. Biol. Chem. 2007, 282, 7543-51. 
10. Salaneck, E.; Holmberg, S. K.; Berglund, M. M.; Boswell, T.; Larhammar, D. Chicken 
neuropeptide Y receptor Y2: structural and pharmacological differences to mammalian 
Y2(1). FEBS Lett. 2000, 484, 229-34. 
11. Berglund, M. M.; Fredriksson, R.; Salaneck, E.; Larhammar, D. Reciprocal mutations of 
neuropeptide Y receptor Y2 in human and chicken identify amino acids important for 
antagonist binding. FEBS Lett. 2002, 518, 5-9. 
12. Akerberg, H.; Fallmar, H.; Sjodin, P.; Boukharta, L.; Gutierrez-de-Teran, H.; Lundell, I.; 
Mohell, N.; Larhammar, D. Mutagenesis of human neuropeptide Y/peptide YY receptor 
Y2 reveals additional differences to Y1 in interactions with highly conserved ligand 
positions. Regul. Pept. 2010, 163, 120-9. 
13. Fallmar, H.; Kerberg, H.; Gutierrez-de-Teran, H.; Lundell, I.; Mohell, N.; Larhammar, D. 
Identification of positions in the human neuropeptide Y/peptide YY receptor Y2 that 
contribute to pharmacological differences between receptor subtypes. Neuropeptides 
2011. 
14. Kanno, T.; Kanatani, A.; Keen, S. L.; Arai-Otsuki, S.; Haga, Y.; Iwama, T.; Ishihara, A.; 
Sakuraba, A.; Iwaasa, H.; Hirose, M.; Morishima, H.; Fukami, T.; Ihara, M. Different 
binding sites for the neuropeptide Y Y1 antagonists 1229U91 and J-104870 on human 
Y1 receptors. Peptides 2001, 22, 405-13. 
15. Sautel, M.; Rudolf, K.; Wittneben, H.; Herzog, H.; Martinez, R.; Munoz, M.; Eberlein, 
W.; Engel, W.; Walker, P.; Beck-Sickinger, A. G. Neuropeptide Y and the nonpeptide 
antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor. Mol. 
Pharmacol. 1996, 50, 285-92. 
16. Kraus, A.; Ghorai, P.; Birnkammer, T.; Schnell, D.; Elz, S.; Seifert, R.; Dove, S.; 
Bernhardt, G.; Buschauer, A. N(G)-acylated aminothiazolylpropylguanidines as potent 
and selective histamine H(2) receptor agonists. ChemMedChem 2009, 4, 232-40. 
17. Xie, S. X.; Ghorai, P.; Ye, Q. Z.; Buschauer, A.; Seifert, R. Probing ligand-specific 
histamine H1- and H2-receptor conformations with NG-acylated 
Imidazolylpropylguanidines. J. Pharmacol. Exp. Ther. 2006, 317, 139-46. 
18. Igel, P.; Schneider, E.; Schnell, D.; Elz, S.; Seifert, R.; Buschauer, A. N(G)-acylated 
imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by 
variation of the N(G)-substituent. J. Med. Chem. 2009, 52, 2623-7. 
19. Keller, M.; Bernhardt, G.; Buschauer, A. [3H]UR-MK136: a highly potent and selective 
radioligand for neuropeptide Y Y1 receptors. ChemMedChem 2011, 6, 1566-71. 
 SAR Studies of Argininamide-Type NPY Y2 Receptor Antagonists 109 
20. Keller, M.; Erdmann, D.; Pop, N.; Pluym, N.; Teng, S.; Bernhardt, G.; Buschauer, A. 
Red-fluorescent argininamide-type NPY Y(1) receptor antagonists as pharmacological 
tools. Bioorg. Med. Chem. 2011, 19, 2859-78. 
21. Keller, M.; Pop, N.; Hutzler, C.; Beck-Sickinger, A. G.; Bernhardt, G.; Buschauer, A. 
Guanidine-acylguanidine bioisosteric approach in the design of radioligands: synthesis 
of a tritium-labeled N(G)-propionylargininamide ([3H]-UR-MK114) as a highly potent 
and selective neuropeptide Y Y1 receptor antagonist. J. Med. Chem. 2008, 51, 8168-
72. 
22. Dains, F. B.; Wertheim, E. The action of ammonia and amines on the substituted ureas 
and urethanes. II. Allophanic ester. J. Am. Chem. Soc. 1920, 42, 2303-2309. 
23. Altmann, E.; Aichholz, R.; Betschart, C.; Buhl, T.; Green, J.; Lattmann, R.; Missbach, 
M. Dipeptide nitrile inhibitors of cathepsin K. Bioorg. Med. Chem. Lett. 2006, 16, 2549-
54. 
24. Jacobi, P. A.; DeSimone, R. W.; Ghosh, I.; Guo, J.; Leung, S. H.; Pippin, D. New 
syntheses of the C,D-ring pyrromethenones of phytochrome and phycocyanin. J. Org. 
Chem. 2000, 65, 8478-89. 
25. Weiss, S.; Keller, M.; Bernhardt, G.; Buschauer, A.; König, B. N(G)-Acyl-argininamides 
as NPY Y(1) receptor antagonists: Influence of structurally diverse acyl substituents on 
stability and affinity. Bioorg. Med. Chem. 2010, 18, 6292-304. 
26. Fujii, N.; Otaka, A.; Ikemura, O.; Akaji, K.; Funakoshi, S.; Hayashi, Y.; Kuroda, Y.; 
Yajima, H. Trimethylsilyl Trifluoromethanesulfonate as a Useful Deprotecting Reagent 
in Both Solution and Solid-Phase Peptide Syntheses. J. Chem. Soc., Chem. Commun. 
1987, 274-275. 
27. Igel, P.; Schnell, D.; Bernhardt, G.; Seifert, R.; Buschauer, A. Tritium-labeled N(1)-[3-
(1H-imidazol-4-yl)propyl]-N(2)-propionylguanidine ([(3)H]UR-PI294), a high-affinity 
histamine H(3) and H(4) receptor radioligand. ChemMedChem 2009, 4, 225-31. 
28. Brennauer, A.; Keller, M.; Freund, M.; Bernhardt, G.; Buschauer, A. Decomposition of 
1-(w-aminoalkanoyl)guanidines under alkaline conditions. Tetrahedron Lett. 2007, 48, 
6996-9. 
29. Ziemek, R.; Brennauer, A.; Schneider, E.; Cabrele, C.; Beck-Sickinger, A. G.; 
Bernhardt, G.; Buschauer, A. Fluorescence- and luminescence-based methods for the 
determination of affinity and activity of neuropeptide Y2 receptor ligands. Eur. J. 
Pharmacol. 2006, 551, 10-8. 
30. Müller, M.; Knieps, S.; Gessele, K.; Dove, S.; Bernhardt, G.; Buschauer, A. Synthesis 
and neuropeptide Y Y1 receptor antagonistic activity of N,N-disubstituted w-guanidino- 
and w-aminoalkanoic acid amides. Arch. Pharm. 1997, 330, 333-42. 
31. Keller, M.; Teng, S.; Bernhardt, G.; Buschauer, A. Bivalent argininamide-type 
neuropeptide y y(1) antagonists do not support the hypothesis of receptor dimerisation. 
ChemMedChem 2009, 4, 1733-45. 
32. Velazquez-Campoy, A.; Todd, M. J.; Freire, E. HIV-1 protease inhibitors: enthalpic 
versus entropic optimization of the binding affinity. Biochemistry 2000, 39, 2201-7. 
33. Ghorai, P.; Kraus, A.; Keller, M.; Gotte, C.; Igel, P.; Schneider, E.; Schnell, D.; 
Bernhardt, G.; Dove, S.; Zabel, M.; Elz, S.; Seifert, R.; Buschauer, A. Acylguanidines 
as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of 
histamine H2 receptor agonists. J. Med. Chem. 2008, 51, 7193-204. 
110 Chapter 3  
34. Bodanszky, M.; Ondetti, M. A.; Birkhimer, C. A.; Thomas, P. L. Synthesis of arginine-
containing peptides through their omithine analogs. Synthesis of arginine vasopressin, 
arginine vasotocin, and L-histidyl-L-phenylalanyl-L-arginyl-L-tryptoph-ylglycine. J. Am. 
Chem. Soc. 1964, 86, 4452-9. 
35. Leschke, C.; Storm, R.; BreitwegLehmann, E.; Exner, T.; Nurnberg, B.; Schunack, W. 
Alkyl-substituted amino acid amides and analogous di- and triamines: New non-peptide 
G protein activators. J. Med. Chem. 1997, 40, 3130-3139. 
36. Waring, W. S.; Whittle, B. A. Basic dihydromorphanthridinones with anticonvulsant 
activity. J. Pharm. Pharmacol. 1969, 21, 520-30. 
37. Tadros, Z.; Lagriffoul, P. H.; Mion, L.; Taillades, J.; Commeyras, A. Enantioselective 
Hydration of Alpha-Aminonitriles Using Chiral Carbonyl Catalysts. J. Chem. Soc., 
Chem. Commun. 1991, 1373-1375. 
38. Moriguchi, T.; Yanagi, T.; Kunimori, M.; Wada, T.; Sekine, M. Synthesis and properties 
of aminoacylamido-AMP: chemical optimization for the construction of an N-acyl 
phosphoramidate linkage. J. Org. Chem. 2000, 65, 8229-38. 
39. Moura, C.; Vitor, R. F.; Maria, L.; Paulo, A.; Santos, I. C.; Santos, I. Rhenium(V) 
oxocomplexes with novel pyrazolyl-based N4- and N3S-donor chelators. Dalton Trans. 
2006, 5630-40. 
40. Bergeron, R. J.; McManis, J. S. Reagents for the Stepwise Functionalization of 
Spermine J. Org. Chem. 1988, 53, 3108-3111. 
41. Imming, P.; Yang, X.-G. On the reaction of dicarboxylic anhydrides with 1,w-diamines. 
Arch. Pharm. (Weinheim, Ger.) 1994, 327, 747-750. 
42. Quelever, G.; Kachidian, P.; Melon, C.; Garino, C.; Laras, Y.; Pietrancosta, N.; Sheha, 
M.; Louis Kraus, J. Enhanced delivery of gamma-secretase inhibitor DAPT into the 
brain via an ascorbic acid mediated strategy. Org. Biomol. Chem. 2005, 3, 2450-7. 
43. Gers, T.; Kunce, D.; Markowski, P.; Izdebski, J. Reagents for efficient conversion of 
amines to protected guanidines. Synthesis 2004, 1, 37-42. 
44. Schneider, E.; Mayer, M.; Ziemek, R.; Li, L.; Hutzler, C.; Bernhardt, G.; Buschauer, A. 
A simple and powerful flow cytometric method for the simultaneous determination of 
multiple parameters at G protein-coupled receptor subtypes. Chembiochem 2006, 7, 
1400-9. 
45. Ziemek, R.; Schneider, E.; Kraus, A.; Cabrele, C.; Beck-Sickinger, A. G.; Bernhardt, G.; 
Buschauer, A. Determination of affinity and activity of ligands at the human 
neuropeptide Y Y4 receptor by flow cytometry and aequorin luminescence. J. Recept. 
Signal Transduct. Res. 2007, 27, 217-33. 
 
 
Chapter 4 Bivalent Argininamide-Type NPY Y2 
Receptor Antagonists 
4.1 Introduction 
For many years G protein-coupled receptors (GPCRs) were thought to exist and 
function exclusively as monomers. However, there is a growing number of reports 
that suggest homo- and hetero-dimerization of numerous GPCRs, e.g. adrenergic 
receptors,1 GABAB receptors,2-3 opioid receptors,4-6 muscarinic receptors,7-9 
vasopressin receptors,10-11 chemokine receptors,12-13 dopamine receptors,14-15 
histamine receptors,16-17 etc.18-21 FRET experiments clearly proved the ability of 
human neuropeptide Y receptors Y1, Y2 and Y5 (hY1R, hY2R, hY5R) to form homo-
dimers, whereas the hY2R is less prone to dimerization than the hY1R and the hY5R, 
respectively.22 More detailed investigations on the localization, formation and 
composition of Y2R dimers were performed by Parker et al. on different tissues of the 
rabbit.23-24 Therein, the Y2R was observed to be largely dimeric in the kidney, but 
monomeric in the forebrain, possibly due to variable levels of G-proteins containing 
the Gαi subunit in different tissues.24 Furthermore, in the renal cortex a protein-
complex of about 300 kDa was detected, which was postulated to result from the 
association of both Y2R protomers of the homo-dimer with two G-protein αβγ hetero-
trimers.23 The dimerization might be enabled by a tryptophan-tryptophan H-bonding 
in TM4,24 as suggested for dopamine D2 receptor dimers.25 Commonly applied 
techniques for the identification of GPCR oligomers include co-immuno-
precipitation,26 functional studies (e.g. measurement of GPCR-β-arrestin interactions 
with β-galactosidase enzyme complementation technique27), mutation studies of 
putative dimerization motives,28 bioluminescence resonance energy transfer (BRET)1 
and molecular modeling.29 However, all experiments demonstrating a physical 
interaction between GPCRs have up to now been performed ex vivo in transfected 
cells, which implies non-physiological cellular environments and – in most cases – 
unrealistically high concentrations of receptors in the membranes. In this context, the 
in vivo demonstration of GPCR dimers of the luteinizing hormone receptor (LHR) by 
Rivero-Müller et al. constitutes a major contribution to the proof of GPCR oligo-
merization.30 Co-transfection with a binding-deficient and a signaling-deficient LHR 
resulted in a quasi wild-type phenotype after activation with LH. Thus, functional 
activity could only be generated by the dimerization of the loss-of-function LHR 
mutants.31 
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The use of bivalent ligands as an alternative to the aforementioned methods offers 
the possibility to investigate native GPCRs, expressed endogenously by normal wild-
type cells. Such compounds, defined as two pharmacophoric moieties linked through 
a spacer, should bring more insight into the phenomenon of GPCR dimerization. 
Moreover, the bivalent ligand approach is discussed as an alternative drug design 
strategy. On the one hand, bivalent ligands can interact with the orthosteric and an 
additional allosteric binding site (cf. Figure 4.1). Such key interactions may be formed 
with residues that reside within extracellular loop domains,33 which often display 
lower homology between receptor subtypes in comparison to transmembrane 
domains. Thus, a higher degree of receptor-subtype selectivity may be achieved by 
this approach. On the other hand, bivalent ligands addressing two protomers should 
enhance tissue specificity, as receptor oligomers (especially hetero-oligomers) are co-
expressed in certain tissues with a distinct pharmacology and function.27 Hence, 
concerning side-effects, ligands combining two distinct pharmacophoric moieties in 
one molecule should be superior to combined administration of two monomeric 
drugs. This renders the bivalent ligand approach a very interesting topic in drug 
design. 
However, there are a few spatial requirements to be fulfilled for a successful 
application of bivalent ligands: firstly, the spacer length must be sufficient to address 
the binding sites of both protomers. Secondly, flexibility and appropriate chemical 
nature of the linker are essential for the correct positioning of each pharmacophore. 
Studies on bivalent based drug design applied to opioid and serotonin receptors 
suggested a distance between the binding sites of 22-32 Å (corresponding to 16-24 
atoms).32, 34-35 
The distance between the two binding sites is difficult to predict as there are several 
variants of contact dimers discussed in the literature.25, 32, 34 Molecular modeling stu-
dies revealed a distance of about 27 Å in 
case of a TM5,6 interface, while a TM4,5 
interface leads to a substantially longer 
distance of approximately 32 Å.32 Also, the 
linker might span the transmembrane do-
mains or it may bridge the two binding 
sites on the extracellular side, complicating 
the prediction of an optimal spacer length. 
Moreover, an affinity-enhancing effect 
might occur due to cooperativity by inter-
action with an allosteric site, rather than 
bridging the orthosteric pockets of two 
protomers (Figure 4.1). Thus, length and 
chemical nature of the spacer must be 
optimized for each GPCR dimer empirically 
Figure  4.1. Illustration of the bivalent ligand concept 
for bridging of a hypothetical GPCR dimer. a) Occu-
pation of an allosteric binding site by the second 
pharmacophore of a bivalent ligand. b) The unoc-
cupied dimer undergoes univalent binding followed 
by either bridging of the bivalent ligand, or binding of 
a second ligand to give the dimer with both sides 
occupied. Adopted from Portoghese.32 
bivalent 
ligand
a)
b)
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by screening several ligands.36 To date, besides the aforementioned opioid and 
serotonin receptors, a variety of successful applications of the bivalent ligand 
approach to GPCRs is reported in the literature.36-39 In case of NPY receptors, the first 
studies focused on the preparation of peptidic bivalent antagonists derived from 
porcine NPY (pNPY). The first dimeric ligands, consisting of two nonapeptides 
mimicking the C-terminal part, were bridged by either disulfide bonds, 2,6-
diaminopimelic acid and 2,3-diaminopropionic acid, respectively. These antagonists 
showed high affinity for both the Y1R and the Y2R (Ki (Y1R) = 0.2-2.9 nM; Ki (Y2R) = 
0.02-8.8 nM).40 Balasubramaniam et al. constructed the first highly potent and 
selective Y1R bivalent antagonist based on the C-terminal hexapeptide of NPY.41 The 
only non-peptidic bivalent ligands for the Y1R known so far were prepared in our 
laboratory as analogs of BIBP 322642 linked by a spacer attached to the guanidino 
group.43 
This chapter presents the first non-peptide bivalent Y2R antagonists, derived from 
BIIE 024644 by application of the guanidine-acylguanidine bioisosteric approach in 
analogy to the recently developed Y1R bivalent ligands. The amine precursors used 
for the linkage with dicarboxylic acids are presented in Figure 4.2. 
 
Figure  4.2. Argininamide-type amine precursors derived from BIIE 0246 used for the preparation of bivalent Y2R 
antagonists. 
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4.2 Chemistry 
The synthesis of the amine precursors ((S)-3.48-(S)-3.50, (S)-3.52 and (S)-3.54), which 
were used for the preparation of bivalent Y2R antagonists is described in chapter 3 
(for structures cf. Figure 4.2). These building blocks contain two amino groups prone 
to acylation, namely the free Nω´H2 and the terminal amine in the acyl- or carbamoyl 
linker. The terminal amino function is more reactive than the acylguanidine due to 
higher basicity and less sterical hindrance. Hence, the guanidino function was not 
protected as the synthetic strategy aimed at a minimum number of reaction steps 
and maximal purity on the low mg scale rather than at optimization of yields and 
synthetic routes. Various alkanedioic acids and amine precursors, respectively, were 
employed to synthesize bivalent ligands with spacer lengths between 16 and 35 
atoms linking the two pharmacophoric moieties. Furthermore, the aforementioned 
building blocks (Figure 4.2) were chosen for linkage in order to obtain compounds 
differing in the chemical nature of the spacer. 
For the preparation of the bivalent ligands 4.1-4.9 the amine precursors were 
acylated with the corresponding alkanedioic acid in an EDC/DMAP-mediated coupling 
step under microwave irradiation followed by purification with preparative HPLC 
(Scheme 4.1; for structures of the bivalent ligands 4.1-4.11 cf. Table 4.1). In case of 
the antagonists 4.10 and 4.11, the terminal amino group of the branched linker was 
Boc-protected to avoid side reactions. Thus, acidic deprotection was necessary prior 
to the purification of the product (Scheme 4.1). The branched linkers were kindly 
provided by Dr. M. Keller from our laboratory.43 
 
Scheme  4.1. Synthesis of the bivalent ligands 4.1-4.11. Reagents and conditions: a) alkanedioic acid (1 eq), 
amine precursor (2.4 eq), EDC × HCl (2.1 eq), NEt3 (6 eq), DMAP (cat.), CH2Cl2, DMF, MW, 35 min, 65 °C; b) 
TFA/CH2Cl2 1:1 (v/v), 2 h, rt. 
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The title compounds were obtained in low yields (10-30 %). HPLC reaction monitoring 
revealed four major peaks (Figure 4.3 shows a representative chromatogram for the 
synthesis of 4.6). After HPLC purification several compounds were identified by MS 
analysis. Peak A corresponds to non-reacted amine precursor which was used in 
excess. Peak B is assigned to a trifluoroacetylated by-product. This side reaction 
resulted from the application of the amine precursors as TFA salts. As these salts 
proved to be highly stable, they were not converted into the less stable free amines 
before coupling (see also Chapter 3.2.2). The monoacylated compound corresponds 
to peak C, whereas peak D with the longest retention time was identified as the 
respective bivalent ligand. 
 
Figure  4.3. HPLC reaction monitoring of the preparation of bivalent ligands exemplified by the synthesis of 4.6. 
Conditions: eluent: mixtures of acetonitrile + 0.025 % TFA (A) and 0.025 % aq. TFA (B), gradient: 0 to 30 min: A/B 
20/80 to 95/5, 30 to 40 min: 95/5. Chromatogram cut after 30 min as there were no further peaks. Peak A: starting 
material (S)-3.50 (tR = 17.2 min), peak B: TFA-acylated compound (tR = 18.6 min), peak C: monoacylated by-
product (tR = 19.8 min), peak D: product 4.6 (tR = 19.8 min). 
4.3 Pharmacological Results and Discussion 
The synthesized bivalent ligands were investigated for Y2R binding in a flow 
cytometric binding assay using CHO cells, stably expressing the hY2R,45 and 
fluorescence-labeled Cy5-pNPY. NPY Y2R antagonistic activities were determined in a 
spectrofluorimetric Ca2+ assay (fura-2 assay) on CHO cells, stably expressing the 
hY2R.46 The selectivity for the Y2R over Y1R, Y4R and Y5R was examined by means of 
flow cytometry.47 
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Table  4.1. Structures, Y2R antagonistic activities (KB) and binding affinities (Ki) of the bivalent Y2R antagonists. 
 
No Spacer 
No of 
atomsa KB / nM
b Ki / nMc 
4.1 22 82 ± 2 161 ± 10 
    
 n m    
4.2 2 2 22 5 ± 3 69 ± 7 
4.3 2 4 24 61 ± 2 103 ± 57 
4.4 2 6 26 44 ± 27 300 ± 81 
4.5 3 8 30 241 ± 68 61 ± 4 
4.6 30 15 ± 3 21 ± 6 
    
 n m    
4.7 2 4 16 4.5 ± 1.9 74 ± 13 
4.8 2 6 18 119 ± 41 83 ± 7 
4.9 4 4 20 30 ± 12 171 ± 18 
4.10 35 11 ± 2 62 ± 34 
4.11 31 20 ± 4 97 ± 15 
(S)-
3.47d 
-- -- 5.6 ± 0.4 
10.2 ± 
1.1 
a Number of atoms between the two guanidine functions (“length” of the spacer). b Inhibition of 70 nM pNPY-induced 
[Ca2+]i mobilization in CHO cells; mean values ± SEM (n = 2-3). 
c Flow cytometric binding assay using Cy5-pNPY (KD = 5.2 
nM; c = 5.0 nM) in CHO cells; mean values ± SEM (n = 2-3). d BIIE 0246. 
HN
O
N
N
O
N
H
O H
N
O
N
NH
N
N
NH2N
O
O
spacer
NH
O
N
N
O
H
N
O
N
H
O
N
HN
N
N
N NH2
O
O
 Bivalent Argininamide-Type Y2R Antagonists 117 
 
 
Figure  4.4. Displacement of 5 nM Cy5-pNPY 
by (S)-3.47 (BIIE 0246) and the acyl-
guanidine-type bivalent ligands 4.1, 4.2, 4.6, 
4.10, respectively (mean values ± SEM; n = 
2). 
 
Functional and binding data as well as the structures of the prepared bivalent 
compounds are summarized in Table 4.1. All bivalent NPY Y2R antagonists showed 
binding affinities in the two to three-digit nM range. In most cases, the KB values 
determined in the calcium assay were even lower. Rigidization by introduction of a 
double-bond in the spacer is moderately tolerated by the receptor as shown for 
compound 4.1 in comparison with the flexible analog 4.2 (Ki (4.1) = 161 nM vs. Ki (4.2) 
= 69 nM; Figure 4.4). The acylguanidine-bridged ligands 4.2-4.5 showed the highest 
affinities with linker lengths of 22 and 30 atoms, respectively, bridging the two 
pharmacophoric moieties (Ki (4.2) = 61 nM; Ki (4.5) = 69 nM), whereas Y2R anta-
gonistic activities decreased with increasing spacer lengths. The introduction of a 
second positively charged amino group in the linker of antagonist 4.6 led to a gain in 
affinity. With a Ki value of 21 nM 4.6 (spacer length: 30 atoms) was the most potent 
bivalent ligand of this small series (Figure 4.4), confirming a possible additional 
electrostatic interaction with the receptor, as already discussed for the monovalent 
ligands (cf. Chapter 3). 
The affinity of carbamoylguanidine 4.9 (spacer length: 20 atoms) corresponds to 
about half of that of the lower homologs 4.7 and 4.8 with spacer lengths of 16 and 18 
atoms, respectively. The Ki values of the latter are in the same range of those of 4.2 
and 4.5. Unfortunately, acylguanidine analogs of 4.7-4.9 have not been available, yet, 
in order to compare the impact of alkanoyl- and carbamoyl-linkage on binding. As 
already observed for argininamide-type Y2R antagonists (cf. Chapter 3), the presence 
of the carbamoyl NH-group might implicate a different orientation of the NG-
substituent. Moreover, carbamoylguanidines are slightly more basic than acyl-
guanidines. This should be affinity-enhancing, as the guanidino group is supposed to 
undergo an ionic interaction with an acidic residue of the Y2R. 
All bivalent Y2R ligands show mono-phasic competition binding curves with Hill slopes 
not statistically significantly different from unity. Furthermore, the binding affinities 
of the bivalent antagonists are lower than that of the parent compound BIIE 0246. 
Thus, bridging of a Y2R dimer, or an allosteric modulation by these bivalent ligands is 
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very unlikely. Nevertheless, a larger library of structurally diverse bivalent Y2R ligands 
is necessary for more detailed structure-activity investigations. 
The bivalent ligands 4.10 and 4.11 with a terminal positively charged amino function 
in the branched part of the linker revealed Ki values below 100 nM. These compounds 
are considered appropriate precursors for the synthesis of radio- or fluorescence-
labeled bivalent Y2R antagonists. 
The introduction of a second pharmacophoric entity into the bivalent ligands might 
change the selectivity profile, as observed for several argininamide-type bivalent Y1R 
antagonists. A few eutomeric (R,R)-configured compounds appeared to be highly 
potent ligands43 with a decreased selectivity against Y4R, and some of the distomeric 
(S,S)-configured antagonists43 turned out to bind at the Y4R, rather than at the Y1R.48 
Thus, the high selectivity of monovalent antagonists used as building blocks is not 
necessarily retained with the corresponding bivalent ligands. Nevertheless, in the 
case of the bivalent Y2R antagonists presented in this thesis, the Y2R selectivity was 
not compromised compared to the monovalent parent compounds, as confirmed by 
flow cytometric binding studies (Table 4.2). 
Table  4.2. NPY receptor subtype selectivity of the bivalent Y2R antagonists. 
No 
Ki / nMa 
No 
Ki / nMa 
Y1R Y4R Y5R Y1R Y4R Y5R 
4.1 > 3500 > 6500 > 5000 4.7 > 3500 > 6500 > 5000 
4.2 > 3500 > 6500 > 5000 4.8 > 3500 > 6500 > 5000 
4.3 > 3500 > 6500 > 5000 4.9 > 2000 > 6500 > 5000 
4.4 > 3500 > 6500 > 5000 4.10 > 1500 > 3200 > 5000 
4.5 > 3500 > 6500 > 5000 4.11 > 800 > 7500 > 5000 
4.6 > 2000 > 650 > 5000     
a Flow cytometric binding assays using 10 nM Cy5-pNPY (Y1R), 5 nM Cy5-pNPY (Y5R) or 3 nM Cy5-[K
4]-hPP (Y4R) in 
HEL-Y1 cells, CHO-Y4 cells, and HEC-1B-Y5 cells, respectively. 
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4.4 Summary and Conclusion 
A small set of bivalent argininamide-type Y2R antagonists was synthesized by linkage 
of various monomeric amine precursors derived from the reference compound 
BIIE 0246, using aliphatic dicarboxylic acids or a branched dicarboxylic acid compris-
ing a primary amine. These bivalent ligands cover a wide range of linker lengths 
(number of atoms: 16-35). Flow cytometric determination of binding data revealed 
high Y2R affinities (Ki values in the range of 61 to 300 nM) and high selectivity for the 
Y2R compared to Y1R, Y4R and Y5R. Interestingly, compound 4.6, bearing two 
additional positively charged amines in the acyl linker was the only compound that 
exhibited a binding affinity (Ki = 21 nM) and potency (KB = 15 nM) in the same range 
as the corresponding monovalent NG-(ω-aminoalkylacylated) and NG-(ω-aminoalkyl-
carbamoylated) antagonists. This is in agreement with the affinity-enhancing effect of 
a positively charged amino group in the NG-substituent of monovalent acylguanidine-
type Y2R antagonists (cf. Chapter 3), suggesting an additional electrostatic interaction 
with the receptor. The prepared bivalent ligands exhibited monophasic competition 
binding curves with Hill slopes close to unity and decreased binding affinities com-
pared to the monovalent analogs. Hence, positive cooperativity due to interactions 
with an allosteric site, or even by bridging two monomers of the Y2R could not be 
observed. 
Lastly, the identification of receptor oligomers by non-labeled bivalent ligands is very 
challenging as there are only competition binding data available. Thus, a larger library 
of compounds and more detailed pharmacological studies would be indispensable to 
draw reliable conclusions from competition binding curves (bi-phasic curves, Hill 
slope with statistically high significance). Therefore, radio- and fluorescent-labeled 
bivalent ligands could serve as pharmacological tools for the identification and 
investigation of putative receptor oligomers. In particular, radiolabeled bivalent 
ligands could be useful to determine the ligand-receptor stoichiometry in order to 
distinguish between binding to monomeric or dimeric Y2Rs. The compounds 4.10 and 
4.11 can be regarded the first amine precursors allowing for the synthesis of labeled 
”twin compounds”. Of course, additional branched analogs with various linker 
lengths have to be prepared and checked for stability under assay conditions in order 
to select an appropriate candidate for labeling. 
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4.5 Experimental Section 
4.5.1 General Experimental Conditions 
Unless otherwise stated, chemicals and solvents were purchased from commercial 
suppliers and used without further purification. The dicarboxylic acids were obtained 
from Sigma-Aldrich Chemie GmbH (Munich, Germany) and from Merck KGaA 
(Darmstadt, Germany). Deuterated solvents for NMR spectroscopy were from 
Deutero GmbH (Kastellaun, Germany). All solvents were of analytical grade or 
distilled prior to use. If moisture-free conditions were required, reactions were 
performed in dried glassware under argon atmosphere; DMF (H2O < 0.01 %) was 
purchased from Sigma-Aldrich Chemie GmbH. Thin layer chromatography was 
performed on Merck silica gel 60 F254 TLC aluminum plates. Spots were visualized 
with UV light at 254 nm, and/or ninhydrin or ammonium molybdate/cerium (IV) 
sulfate solution. 
NMR spectra were recorded on an Avance 300, an Avance 400 and an Avance III 600 
spectrometer from Bruker BioSpin GmbH (Rheinstetten, Germany) with TMS as 
external standard. Multiplicities are specified with the following abbreviations: s 
(singlet), d (doublet), t (triplet), quat (quartet), q (quintet), m (multiplet), br (for 
broad singulet), as well as combinations thereof. Low resolution mass spectrometry 
analysis (MS) was performed in-house on a Finnigan ThermoQuest TSQ 7000 (ES-MS) 
and a Finnigan SSQ 710A (EI-MS 70 eV, CI-MS). High resolution mass spectrometry 
was performed on a Finnigan MAT 95 (LSI-MS). Lyophilization was done with a Christ 
alpha 2-4 LD equipped with a vacuubrand RZ 6 rotary vane vacuum pump. 
Preparation of the bivalent ligands was performed on the Microwave Synthesizer 
Initiator from Biotage (Uppsala, Sweden). 
Preparative HPLC was performed with a system from Knauer (Berlin, Germany) 
consisting of two K-1800 pumps, a K-2001 detector and a RP-column (Nucleodur 100-
5 C18ec, 250 × 21 mm, 5 μm) at a flow rate of 22 mL/min. Mixtures of acetonitrile 
and 0.1 % aq. TFA were used as mobile phase. Acetonitrile was removed from the 
eluates under reduced pressure (final pressure: 90 mbar) at 45 °C prior to 
lyophilization. Analytical HPLC analysis was performed on two different systems 
(Thermo Separation Products, Merck) which are listed in detail below. Mixtures of 
acetonitrile (A) and 0.05 % aq. TFA (B) (Thermo Separation Products), and mixtures of 
acetonitrile + 0.025 % TFA (A) and 0.025 % aq. TFA (B) (Merck) respectively were used 
as mobile phase. Helium degassing was used throughout. 
The buffer for the Y2R binding studies on CHO cells was prepared by the addition of 
BSA (1 %) and bacitracin (100 μg/mL) to a buffer (pH 7.4) consisting of HEPES 
(25 mM), CaCl2 × 2 H2O (2.5 mM), MgCl2 × 6 H2O (1 mM). The loading buffer (pH 7.4) 
for the determination of the mobilization of intracellular Ca2+ in CHO cells was 
prepared by dissolving NaCl (120 mM), KCl (5 mM), MgCl2 × 6 H2O (2 mM), CaCl2 × 2 
H2O (1.5 mM), HEPES (25 mM), and glucose (10 mM). Stock solutions of all 
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compounds were prepared in DMSO at concentrations of 2 or 10 mM and stored at –
20 °C. 
 
Analytical HPLC systems: 
System 1: Thermo Separation Products; composed of a SN400 controller, a P4000 
pump, a degasser (Degassex DG-4400, phenomenex), an AS3000 autosampler and a 
Spectra Focus UV-VIS detector; flow rate: 0.8 mL/min; UV detection: 220 nm. 
System 2: Merck; composed of a L-5000 controller, a 655A-12 pump, a 655A-40 
autosampler and a L-4250 UV-VIS detector; flow rate: 0.7 mL/min; UV detection: 220 
nm. 
 
Applied gradients:  
Gradient 1 (Thermo Separation Products): 0 to 30 min: A/B 20/80 to 95/5, 30 to 37 
min: 95/5. 
Gradient 2 (Merck): 0 to 30 min: A/B 20/80 to 95/5, 30 to 40 min: 95/5. 
The purity of all compounds was determined with HPLC system 1 (gradient 1) on a 
Eurospher-100 C18 column (250 × 4 mm, 5 μm, Knauer, Berlin, Germany) for 
compounds 4.1-4.4, 4.6, 4.9-4.11 and a Nucleodur H-Tec 100-5 C18 column (250 × 4 
mm, 5 μm, Macherey-Nagel, Düren, Germany) for compounds 4.5, 4.8, 4.9 respec-
tively. The HPLC system 2 (gradient 2) was used for reaction monitoring with a 
Eurospher-100 C18 column (250 × 4 mm, 5 μm, Knauer, Berlin, Germany). 
 
4.5.2 Chemistry: Experimental Protocols and Analytical Data 
General procedure for the preparation of the bivalent ligands 4.1-4.11: 
NEt3 (6 eq) and DMAP (0.1 eq) were added to a stirred solution of the pertinent 
amine precursor (2.4 eq) and the corresponding alkanedioic acid (1 eq) in CH2Cl2. EDC 
× HCl (2.1 eq) was added and the mixture was stirred in a microwave synthesizer for 
35 min at 65 °C. The reaction was stopped by addition of 10 % aq. TFA (corresponding 
to 2-3 eq of TFA) and the solvents were removed under reduced pressure. 
Purification with preparative HPLC and lyophilization afforded the products as white 
fluffy solids in yields from 10 to 30 %. 
 
(11E)-N1,N22-Bis(amino{(4S)-5-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-
yl)ethylamino]-5-oxo-4-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]-
azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetamido]pentylamino}methylene)-
5,10,13,18-tetroxo-6,9,14,17-tetraazadocosa-11-enediamide (4.1). MS (ES, +p) m/z 
(%): 1093 (40) [M+2H]2+, 729 (100) [M+3H]3+; RP-HPLC: 99 % (tR = 20.1 min, k´ = 6.4); 
C116H138N26O18 (2138.07). 
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N1,N22-Bis(amino{(4S)-5-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl-
amino]-5-oxo-4-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-
yl)piperazin-1-yl]ethyl}cyclopentyl)acetamido]pentylamino}methylene)-5,10,13,18-
tetroxo-6,9,14,17-tetraazadocosanediamide (4.2). 1H NMR (300 MHz, CD3OD): δ = 
1.42-1.80 (m, 24H, 2 x 3/4-H cyclopentyl, 2 x 2/5-H cyclopentyl, 2 x CβH2CγH2), 1.93 
(m, 4H, 2 x COCH2CH2CH2CO), 2.00-2.30 (m, 16H, 2 x 3/5-H piperazine, 2 x 
COCH2CH2CH2CO), 2.28 and 2.46 (m, 4H, 2 x CH2CONαH), 2.46 (m, 8H, CO(CH2)2CO, 2 x 
>NCOCH2-cyclopentyl), 3.18 (m, 4H, 2 x CδH2), 3.26 (m, 8H, 2 x NH(CH2)2NH), 3.35-
3.57 (m, 12H, 2 x 2/6-H piperazine, 2 x NHCH2CH2N<), 3.78 (br, 4H, 2 x NHCH2CH2N<), 
4.25 (br, 4H, 2 x 11-H dibenzazepine-11-yl, 2 x CαH), 7.13 (m, 4H, HAr), 7.20 (m, 4H, 
HAr), 7.36 (m, 20H, Ph), 7.36 (m, 2H, HAr), 7.42 (m, 2H, HAr), 7.51 (m, 2H, HAr), 7.80 (m, 
2H, HAr) ppm; MS (ES, +p) m/z (%): 1094 (10) [M+2H]2+, 730 (75) [M+3H]3+, 548 (100) 
[M+4H]4+; RP-HPLC: 97 % (tR = 19.6 min, k´ = 6.3); C116H140N26O18 (2185.08). 
 
N1,N24-Bis(amino{(4S)-5-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl-
amino]-5-oxo-4-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)-
piperazin-1-yl]ethyl}cyclopentyl)acetamido]pentylamino}methylene)-5,10,15,20-
tetroxo-6,9,16,19-tetraazatetracosanediamide (4.3). MS (ES, +p) m/z (%): 1108 (20) 
[M+2H]2+, 739 (80) [M+3H]3+, 555 (100) [M+4H]4+; RP-HPLC: 97 % (tR = 19.5 min, k´ = 
6.2); C118H144N26O18 (2213.12). 
 
N1,N26-Bis(amino{(4S)-5-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl-
amino]-5-oxo-4-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)-
piperazin-1-yl]ethyl}cyclopentyl)acetamido]pentylamino}methylene)-5,10,17,22-
tetroxo-6,9,18,21-tetraazahexacosanediamide (4.4). 1H NMR (600 MHz, CD3OD): δ = 
1.31 (m, 4H, CO(CH2)2(CH2)2(CH2)2CO), 1.49-1.80 (m, 28H, 2 x 3/4-H cyclopentyl, 2 x 
2/5-H cyclopentyl, 2 x CβH2CγH2, COCH2CH2(CH2)2CH2CH2CO), 1.91 (p, 3J = 7.3 Hz, 4H, 2 
x COCH2CH2CH2CO), 2.02-2.13 (m, 8H, 2 x 3/5-H piperazine), 2.16 and 2.24 (2 x m, 8H, 
2 x COCH2CH2CH2CO), 2.16 and 2.46 (m, 4H, COCH2(CH2)4CH2CO), 2.27 and 2.41 (m, 
4H, 2 x CH2CONαH), 2.48 (m, 4H, 2 x >NCOCH2-cyclopentyl), 3.18 (m, 4H, 2 x CδH2), 
3.26 (m, 8H, 2 x NH(CH2)2NH), 3.35-3.57 (m, 8H, 2 x 2/6-H piperazine), 3.46 and 3.51 
(m, 4H, 2 x NHCH2CH2N<), 3.77 (m, 4H, 2 x NHCH2CH2N<), 4.22 (br, 2H, 2 x 11-H 
dibenzazepine-11-yl), 4.25 (m, 2H, 2 x CαH), 7.12 (m, 4H, HAr), 7.20 (m, 4H, HAr), 7.28 
(m, 2H, HAr), 7.32 (m, 10H, Ph), 7.37 (m, 10H, Ph), 7.41 (m, 2H, HAr), 7.49 (m, 2H, HAr), 
7.79 (m, 2H, HAr) ppm; MS (ES, +p) m/z (%): 1122 (10) [M+2H]2+, 749 (75) [M+3H]3+, 
562 (100) [M+4H]4+; RP-HPLC: 100 % (tR = 20.2 min, k´ = 6.5); C120H148N26O18 (2241.15). 
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N1,N30-Bis(amino{(4S)-5-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl-
amino]-5-oxo-4-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)-
piperazin-1-yl]ethyl}cyclopentyl)acetamido]pentylamino}methylene)-5,11,20,26-
tetroxo-6,10,21,25-tetraazatriacontanediamide (4.5). 1H NMR (600 MHz, CD3OD, 
COSY, HSQC, HMBC): δ = 1.29 (m, 8H, CO(CH2)2(CH2)4(CH2)2CO), 1.51 and 1.64 (m, 8H, 
2 x 3/4-H cyclopentyl), 1.51 and 1.67 (m, 8H, 2 x 2/5-H cyclopentyl), 1.51 and 1.76 (m, 
4H, 2 x CβH2), 1.57 (m, 4H, COCH2CH2(CH2)4CH2CH2CO), 1.59 (m, 4H, 2 x 
NHCH2CH2CH2NH), 1.60 (m, 4H, 2 x CγH2), 1.92 (p, 3J = 7.2 Hz, 4H, 2 x 
COCH2CH2CH2CO), 2.16 (m, 4H, COCH2(CH2)6CH2CO), 2.11 and 2.17 (m, 8H, 2 x 3/5-H 
piperazine), 2.26 and 2.48 (m, 8H, 2 x COCH2CH2CH2CO), 2.28 and 2.43 (m, 4H, 2 x 
CH2CONαH), 2.49 (m, 4H, 2 x >NCOCH2-cyclopentyl), 3.19 (m, 4H, 2 x CδH2), 3.20 (m, 
8H, 2 x NHCH2CH2CH2NH), 3.39 (br, 8H, 2 x 2/6-H piperazine), 3.45 and 3.55 (m, 4H, 2 
x NHCH2CH2N<), 3.78 (m, 4H, 2 x NHCH2CH2N<), 4.25 (br, 4H, 2 x CαH, 2 x 11-H 
dibenzazepine-11-yl), 7.12 (m, 4H, HAr), 7.20 (m, 4H, HAr), 7.28 (m, 2H, HAr), 7.32 (m, 
10H, Ph), 7.37 (m, 10H, Ph), 7.41 (m, 2H, HAr), 7.49 (m, 2H, HAr), 7.79 (m, 2H, HAr) 
ppm; 13C NMR (150 MHz, CD3OD, HSQC, HMBC): δ = 21.5 (2 x COCH2CH2CH2CO), 24.5 
and 24.6 (2 x C-3/4 cyclopentyl), 25.5 (2 x Cγ), 27.0 (2 x NHCH2CH2CH2NH), 27.1 
(COCH2CH2(CH2)4CH2CH2CO), 30.0 (2 x Cβ), 30.3 (CO(CH2)2(CH2)4(CH2)2CO), 35.5 (2 x 
COCH2CH2CH2CO), 36.9 and 37.2 (COCH2(CH2)6CH2CO), 37.8 (2 x NHCH2CH2CH2NH), 
38.4 (2 x NHCH2CH2N<), 39.4 and 39.5 (2 x C-2/5 cyclopentyl), 39.7 (2 x >NCOCH2-
cyclopentyl), 41.2 (2 x NHCH2CH2N<), 42.1 (2 x Cδ), 44.8 (2 x CH2CONαH), 45.9 (2 x C-1 
cyclopentyl), 47.6 (2 x C-2/6 piperazine), 52.2 and 52.6 (2 x C-3/5 piperazine), 53.7 (2 
x Cα), 75.8 (2 x C-11 dibenzazepine-11-yl), 123.0 (2 x CArH), 124.1 (2 x Ph), 126.1 (2 x 
CArH), 128.1 (2 x CArH), 129.0 (2 x CArH), 129.4 (2 x CArH), 129.9 (2 x CArH), 130.2 (2 x 
Ph), 131.1 (2 x CArH), 131.7 (CArH), 133.1 (CArH), 137.8 (2 x CAr), 154.5 (2 x N(CONPh)2), 
154.8 (2 x NC(N)N), 172.7 (2 x CON<), 174.5 (2 x CONH(CH2)2N<), 174.7 (2 x CONαH), 
175.0 (2 x =NCO(CH2)3CO), 176.3 (2 x =NCO(CH2)3CO), 176.4 (CO(CH2)8CO) ppm; a 
peak for C=O lactam could not be detected; MS (ES, +p) m/z (%): 1151 (25) [M+2H]2+, 
767 (95) [M+3H]3+, 576 (100) [M+4H]4+; RP-HPLC: 94 % (tR = 14.3 min, k´ = 4.3); 
C124H156N26O18 (2297.21). 
 
N1,N30-Bis(amino{(4S)-5-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl-
amino]-5-oxo-4-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)-
piperazin-1-yl]ethyl}cyclopentyl)acetamido]pentylamino}methylene)-5,13,18,26-
tetroxo-6,9,12,19,22,25-hexaazatriacontanediamide (4.6). 1H NMR (600 MHz, 
CD3OD): δ = 1.49-1.80 (m, 28H, 2 x 3/4-H cyclopentyl, 2 x 2/5-H cyclopentyl, 2 x 
CβH2CγH2, COCH2(CH2)2CH2CO), 1.93 (p, 3J = 7.4 Hz, 4H, 2 x COCH2CH2CH2CO), 2.00-
2.20 (m, 8H, 2 x 3/5-H piperazine), 2.16 and 2.25 (2 x m, 4H, COCH2(CH2)CH2CO), 2.27 
and 2.41 (m, 4H, 2 x CH2CONαH), 2.31 and 2.51 (t, 3J = 7.4 Hz, 8H, 2 x 
COCH2CH2CH2CO), 2.48 (m, 4H, 2 x >NCOCH2-cyclopentyl), 3.18 (m, 4H, 2 x CδH2), 3.18 
(m, 8H, 2 x CONHCH2CH2NHCH2), 3.35-3.57 (m, 12H, 2 x 2/6-H piperazine, 2 x 
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NHCH2CH2N<), 3.47 (t, 3J = 5.6 Hz, 8H, 4 x CONHCH2), 3.77 (m, 4H, 2 x NHCH2CH2N<), 
4.22 (br, 2H, 2 x 11-H dibenzazepine-11-yl), 4.25 (m, 2H, 2 x CαH), 7.12 (m, 4H, HAr), 
7.20 (m, 4H, HAr), 7.28 (m, 2H, HAr), 7.32 (m, 10H, Ph), 7.37 (m, 10H, Ph), 7.41 (m, 2H, 
HAr), 7.49 (m, 2H, HAr), 7.79 (m, 2H, HAr) ppm; MS (ES, +p) m/z (%): 768 (30) [M+3H]3+, 
576 (100) [M+4H]4+; RP-HPLC: 91 % (tR = 16.9 min, k´ = 5.3); C122H154N28O18 (2299.20). 
 
N,N’-Bis(amino{(4S)-5-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethylamino]-
5-oxo-4-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)-
piperazin-1-yl]ethyl}cyclopentyl)acetamido]pentylamino}methylene)-6,11-dioxo-
2,5,12,15-tetraazahexadecanediamide (4.7). 1H NMR (600 MHz, CD3OD, COSY, HSQC, 
HMBC): δ = 1.49 and 1.62 (m, 8H, 2 x 3/4-H cyclopentyl), 1.49 and 1.65 (m, 8H, 2 x 
2/5-H cyclopentyl), 1.51 and 1.73 (m, 4H, 2 x CβH2), 1.57 (m, 4H, 2 x CγH2), 1.59 (m, 
4H, COCH2(CH2)2CH2CO), 2.10 and 2.15 (m, 8H, 2 x 3/5-H piperazine), 2.20 (m, 4H, 
COCH2(CH2)2CH2CO), 2.28 and 2.40 (m, 4H, 2 x CH2CONαH), 2.46 (m, 4H, 2 x >NCOCH2-
cyclopentyl), 3.15 (m, 4H, 2 x CδH2), 3.28 (m, 4H, 2 x =NCONHCH2CH2NH), 3.30 (m, 4H, 
2 x =NCONHCH2CH2NH), 3.38 (br, 8H, 2 x 2/6-H piperazine), 3.46 and 3.51 (m, 4H, 2 x 
NHCH2CH2N<), 3.77 (m, 4H, 2 x NHCH2CH2N<), 4.21 (s, 2H, 2 x 11-H dibenzazepine-11-
yl), 4.25 (m, 2H, 2 x CαH), 7.11 (m, 4H, HAr), 7.20 (m, 4H, HAr), 7.27 (m, 2H, HAr), 7.32 
(m, 10H, Ph), 7.36 (m, 10H, Ph), 7.41 (m, 2H, HAr), 7.49 (m, 2H, HAr), 7.79 (m, 2H, HAr) 
ppm; 13C NMR (150 MHz, CD3OD, HSQC, HMBC): δ = 24.5 and 24.6 (2 x C-3/4 
cyclopentyl), 25.7 (2 x Cγ), 26.2 (COCH2(CH2)2CH2CO), 30.0 (2 x Cβ), 36.7 
(COCH2(CH2)2CH2CO), 38.4 (2 x NHCH2CH2N<), 39.4 and 39.5 (2 x C-2/5 cyclopentyl), 
39.7 (2 x >NCOCH2-cyclopentyl), 39.8 (2 x =NCONHCH2CH2NH), 40.6 (2 x 
=NCONHCH2CH2NH), 41.2 (2 x NHCH2CH2N<), 41.9 (2 x Cδ), 44.8 (2 x CH2CONαH), 45.9 
(2 x C-1 cyclopentyl), 47.6 (2 x C-2/6 piperazine), 52.2 and 52.6 (2 x C-3/5 piperazine), 
53.7 (2 x Cα), 75.8 (2 x C-11 dibenzazepine-11-yl), 123.0 (2 x CArH), 124.1 (2 x Ph), 
126.0 (2 x CArH), 128.1 (2 x CArH), 128.9 (2 x CArH), 129.4 (2 x CArH), 129.9 (2 x CArH), 
130.2 (2 x Ph), 131.0 (2 x CArH), 131.6 (CArH), 132.5 (2 x CAr), 133.1 (CArH), 137.0 (2 x 
CAr), 137.9 (2 x CAr), 144.0 (2 x CAr), 154.5 (2 x N(CONPh)2), 155.5 (2 x =NCONH), 155.6 
(2 x NC(N)N), 172.2 (2 x C=O lactam), 172.6 (2 x CON<), 174.5 (2 x CONH(CH2)2N<), 
174.7 (2 x CONαH), 176.3 (CO(CH2)4CO) ppm; MS (ES, +p) m/z (%): 1038 (30) [M+2H]2+, 
692 (100) [M+3H]3+; RP-HPLC: 97 % (tR = 14.6 min, k´ = 4.4); C110H132N26O16 (2073.03). 
 
N,N’-Bis(amino{(4S)-5-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethylamino]-
5-oxo-4-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)-
piperazin-1-yl]ethyl}cyclopentyl)acetamido]pentylamino}methylene)-6,13-dioxo-
2,5,14,17-tetraazaoctadecanediamide (4.8). 1H NMR (600 MHz, CD3OD, HSQC, 
HMBC): δ = 1.29 (m, 4H, CO(CH2)2(CH2)2(CH2)2CO), 1.49 and 1.63 (m, 8H, 2 x 3/4-H 
cyclopentyl), 1.49 and 1.65 (m, 8H, 2 x 2/5-H cyclopentyl), 1.51 and 1.74 (m, 4H, 2 x 
CβH2), 1.57 (m, 4H, 2 x CγH2), 1.57 (m, 4H, COCH2CH2(CH2)2CH2CH2CO), 2.11 and 2.16 
(m, 8H, 2 x 3/5-H piperazine), 2.16 (m, 4H, COCH2(CH2)4CH2CO), 2.28 and 2.40 (m, 4H, 
 Bivalent Argininamide-Type Y2R Antagonists 125 
2 x CH2CONαH), 2.46 (m, 4H, 2 x >NCOCH2-cyclopentyl), 3.14 (m, 4H, 2 x CδH2), 3.28 
(m, 4H, 2 x =NCONHCH2CH2NH), 3.29 (m, 4H, 2 x =NCONHCH2CH2NH), 3.38 (br, 8H, 2 x 
2/6-H piperazine), 3.46 and 3.51 (m, 4H, 2 x NHCH2CH2N<), 3.77 (m, 4H, 2 x 
NHCH2CH2N<), 4.23 (s, 2H, 2 x 11-H dibenzazepine-11-yl), 4.25 (m, 2H, 2 x CαH), 7.12 
(m, 4H, HAr), 7.20 (m, 4H, HAr), 7.30 (m, 2H, HAr), 7.32 (m, 10H, Ph), 7.36 (m, 10H, Ph), 
7.41 (m, 2H, HAr), 7.49 (m, 2H, HAr), 7.79 (m, 2H, HAr) ppm; 13C NMR (150 MHz, CD3OD, 
HSQC, HMBC): δ = 24.5 and 24.6 (2 x C-3/4 cyclopentyl), 25.7 (2 x Cγ), 26.7 
(COCH2CH2(CH2)2CH2CH2CO), 29.9 (CO(CH2)2(CH2)2(CH2)2CO), 30.0 (2 x Cβ), 37.0 
(COCH2(CH2)4CH2CO), 38.5 (2 x NHCH2CH2N<), 39.4 and 39.5 (2 x C-2/5 cyclopentyl), 
39.7 (2 x >NCOCH2-cyclopentyl), 39.9 (2 x =NCONHCH2CH2NH), 40.6 (2 x 
=NCONHCH2CH2NH), 41.2 (2 x NHCH2CH2N<), 41.9 (2 x Cδ), 44.8 (2 x CH2CONαH), 46.0 
(2 x C-1 cyclopentyl), 47.6 (2 x C-2/6 piperazine), 52.2 and 52.6 (2 x C-3/5 piperazine), 
53.7 (2 x Cα), 75.8 (2 x C-11 dibenzazepine-11-yl), 123.0 (2 x CArH), 124.1 (2 x Ph), 
126.0 (2 x CArH), 128.1 (2 x CArH), 129.0 (2 x CArH), 129.4 (2 x CArH), 129.9 (2 x CArH), 
130.2 (2 x Ph), 131.0 (2 x CArH), 131.6 (CArH), 132.5 (2 x CAr), 133.1 (CArH), 136.9 (2 x 
CAr), 137.9 (2 x CAr), 154.5 (2 x N(CONPh)2), 155.5 (2 x =NCONH), 155.6 (2 x NC(N)N), 
172.1 (2 x C=O lactam), 172.6 (2 x CON<), 174.5 (2 x CONH(CH2)2N<), 174.7 (2 x 
CONαH), 176.7 (CO(CH2)6CO) ppm; MS (ES, +p) m/z (%): 1053 (15) [M+2H]2+, 702 (100) 
[M+3H]3+; RP-HPLC: 98 % (tR = 14.6 min, k´ = 4.5); C112H136N26O16 (2101.06). 
 
N,N’-Bis(amino{(4S)-5-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethylamino]-
5-oxo-4-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)-
piperazin-1-yl]ethyl}cyclopentyl)acetamido]pentylamino}methylene)-8,13-dioxo-
2,7,14,19-tetraazaicosanediamide (4.9). 1H NMR (600 MHz, CD3OD, COSY, HSQC, 
HMBC): δ = 1.49 and 1.62 (m, 8H, 2 x 3/4-H cyclopentyl), 1.50 and 1.66 (m, 8H, 2 x 
2/5-H cyclopentyl), 1.51 and 1.73 (m, 4H, 2 x CβH2), 1.50 (m, 8H, 2 x 
NHCH2(CH2)2CH2NH), 1.57 (m, 4H, 2 x CγH2), 1.59 (m, 4H, COCH2(CH2)2CH2CO), 2.17 
(m, 4H, COCH2(CH2)2CH2CO), 2.10 and 2.18 (m, 8H, 2 x 3/5-H piperazine), 2.26 and 
2.41 (m, 4H, 2 x CH2CONαH), 2.49 (m, 4H, 2 x >NCOCH2-cyclopentyl), 3.13 (m, 4H, 2 x 
CδH2), 3.16 and 3.17 (m, 8H, 2 x NHCH2(CH2)2CH2NH), 3.31-3.47 (m, 8H, 2 x 2/6-H 
piperazine), 3.45 and 3.55 (m, 4H, 2 x NHCH2CH2N<), 3.78 (m, 4H, 2 x NHCH2CH2N<), 
4.24 (br, 4H, 2 x CαH, 2 x 11-H dibenzazepine-11-yl), 7.12 (m, 4H, HAr), 7.20 (m, 4H, 
HAr), 7.27 (m, 2H, HAr), 7.32 (m, 10H, Ph), 7.37 (m, 10H, Ph), 7.42 (m, 2H, HAr), 7.50 (m, 
2H, HAr), 7.80 (m, 2H, HAr) ppm; 13C NMR (150 MHz, CD3OD, HSQC, HMBC): δ = 24.5 
and 24.6 (2 x C-3/4 cyclopentyl), 25.7 (2 x Cγ), 26.6 (COCH2(CH2)2CH2CO), 27.9 (2 x 
NHCH2(CH2)2CH2NH), 30.0 (2 x Cβ), 36.8 (COCH2(CH2)2CH2CO), 38.4 (2 x NHCH2CH2N<), 
39.3 and 39.4 (2 x C-2/5 cyclopentyl), 39.7 (2 x >NCOCH2-cyclopentyl), 39.9 and 40.4 
(2 x NHCH2(CH2)2CH2NH), 41.2 (2 x NHCH2CH2N<), 41.8 (2 x Cδ), 44.7 (2 x CH2CONαH), 
45.9 (2 x C-1 cyclopentyl), 47.5 (2 x C-2/6 piperazine), 52.2 and 52.6 (2 x C-3/5 
piperazine), 53.7 (2 x Cα), 75.8 (2 x C-11 dibenzazepine-11-yl), 123.0 (2 x CArH), 124.1 
(2 x Ph), 126.1 (2 x CArH), 128.1 (2 x CArH), 129.0 (2 x CArH), 129.4 (2 x CArH), 129.9 (2 x 
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CArH), 130.2 (2 x Ph), 131.1 (2 x CArH), 131.7 (CArH), 132.5 (2 x CAr), 133.1 (CArH), 137.0 
(2 x CAr), 137.8 (2 x CAr), 154.5 (2 x N(CONPh)2), 155.3 (2 x =NCONH), 155.7 (2 x 
NC(N)N), 172.0 (2 x C=O lactam), 172.7 (2 x CON<), 174.5 (2 x CONH(CH2)2N<), 174.7 
(2 x CONαH), 175.8 and 179.3 (CO(CH2)4CO) ppm; MS (ES, +p) m/z (%): 1066 (25) 
[M+2H]2+, 711 (100) [M+3H]3+, 534 (90) [M+4H]4+; RP-HPLC: 95 % (tR = 20.8 min, k´ = 
6.7); C114H140N26O16 (2129.09). 
 
18-(2-Aminoethyl)-N1,N35-bis(amino{(4S)-5-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-tri-
azolidin-4-yl)ethylamino]-5-oxo-4-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-di-
benzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetamido]pentylamino}-
methylene)-5,10,14,22,26,31-hexaoxo-6,9,15,18,21,27,30-heptaazapentatria-
contanediamide (4.10). 1H NMR (600 MHz, CD3OD, COSY, HSQC, HMBC): δ = 1.49 and 
1.62 (m, 8H, 2 x 3/4-H cyclopentyl), 1.49 and 1.68 (m, 8H, 2 x 2/5-H cyclopentyl), 1.51 
and 1.73 (m, 4H, 2 x CβH2), 1.60 (m, 4H, 2 x CγH2), 1.87 and 1.91 (m, 8H, 4 x 
COCH2CH2CH2CO), 2.11 and 2.18 (m, 8H, 2 x 3/5-H piperazine), 2.21 and 2.25 and 2.41 
and 2.48 (m, 16H, 4 x COCH2CH2CH2CO), 2.27 and 2.41 (m, 4H, 2 x CH2CONαH), 2.48 
(m, 4H, 2 x >NCOCH2-cyclopentyl), 2.74 (br, 4H, NHCH2CH2N(C2H4NH2)CH2CH2NH), 
3.06 (m, 4H, >N(CH2)2NH2), 3.26 and 3.83 (m, 8H, 2 x NH(CH2)2NH), 3.18 (m, 4H, 2 x 
CδH2), 3.28 (m, 4H, NHCH2CH2N(C2H4NH2)CH2CH2NH), 3.31-3.48 (m, 8H, 2 x 2/6-H 
piperazine), 3.45 and 3.53 (m, 4H, 2 x NHCH2CH2N<), 3.78 (m, 4H, 2 x NHCH2CH2N<), 
4.25 (m, 4H, 2 x CαH, 2 x 11-H dibenzazepine-11-yl), 7.12 (m, 4H, HAr), 7.20 (m, 4H, 
HAr), 7.27 (m, 2H, HAr), 7.32 (m, 10H, Ph), 7.37 (m, 10H, Ph), 7.42 (m, 2H, HAr), 7.50 (m, 
2H, HAr), 7.80 (m, 2H, HAr) ppm; 13C NMR (150 MHz, CD3OD, HSQC, HMBC): δ = 21.4 
and 23.0 (4 x COCH2CH2CH2CO), 24.5 and 24.6 (2 x C-3/4 cyclopentyl), 25.4 (2 x Cγ), 
30.0 (2 x Cβ), 35.6 and 36.2 and 36.8 (4 x COCH2CH2CH2CO), 38.1 (>NCH2CH2NH2), 38.3 
(2 x NH(CH2)2NH), 38.4 (2 x NHCH2CH2N<), 39.2 and 39.3 (2 x C-2/5 cyclopentyl), 39.5 
(2 x >NCOCH2-cyclopentyl), 39.8 (NHCH2CH2N(C2H4NH2)CH2CH2NH), 41.2 (2 x 
NHCH2CH2N<), 42.0 (2 x Cδ), 44.7 (2 x CH2CONαH), 45.9 (2 x C-1 cyclopentyl), 47.5 (2 x 
C-2/6 piperazine), 52.1 and 52.6 (2 x C-3/5 piperazine), 53.7 (2 x Cα), 55.6 
(NHCH2CH2N(C2H4NH2)CH2CH2NH), 59.5 (>NCH2CH2NH2), 75.8 (2 x C-11 
dibenzazepine-11-yl), 123.0 (2 x CArH), 124.1 (2 x Ph), 126.0 (2 x CArH), 128.1 (2 x 
CArH), 129.0 (2 x CArH), 129.4 (2 x CArH), 129.9 (2 x CArH), 130.2 (2 x Ph), 131.1 (2 x 
CArH), 131.7 (CArH), 132.3 (2 x CAr), 133.2 (CArH), 136.8 (2 x CAr), 137.8 (2 x CAr), 154.5 (2 
x N(CONPh)2), 155.0 (2 x NC(N)N), 172.7 (2 x CON<), 174.5 (2 x CONH(CH2)2N<), 174.7 
(2 x CONαH), 175.4 and 175.8 and 176.4 (2 x =NCO(CH2)3CONH, 2 x NHCO(CH2)3CONH) 
ppm; a peak for C=O lactam could not be detected; MS (ES, +p) m/z (%): 815 (35) 
[M+3H]3+, 612 (100) [M+4H]4+, 490 (40) [M+5H]5+; RP-HPLC: 98 % (tR = 16.9 min, k´ = 
5.2); C128H164N30O20 (2441.27). 
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16-(2-Aminoethyl)-N,N’-bis(amino{(4S)-5-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-tri-
azolidin-4-yl)ethylamino]-5-oxo-4-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-di-
benzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetamido]pentylamino}-
methylene)-8,12,20,24-tetroxo-2,7,13,16,19,25,30-heptaazahentriacontanediamide 
(4.11). 1H NMR (600 MHz, CD3OD, COSY, HSQC, HMBC): δ = 1.50 (m, 8H, 2 x 
NHCH2(CH2)2CH2NH), 1.50 and 1.62 (m, 8H, 2 x 3/4-H cyclopentyl), 1.50 and 1.68 (m, 
8H, 2 x 2/5-H cyclopentyl), 1.51 and 1.75 (m, 4H, 2 x CβH2), 1.57 (m, 4H, 2 x CγH2), 1.87 
(m, 4H, 2 x COCH2CH2CH2CO), 2.13 and 2.19 (m, 8H, 2 x 3/5-H piperazine), 2.19 and 
2.23 (m, 8H, 2 x COCH2CH2CH2CO), 2.27 and 2.41 (m, 4H, 2 x CH2CONαH), 2.48 (m, 4H, 
2 x >NCOCH2-cyclopentyl), 2.79 (br, 4H, NHCH2CH2N(C2H4NH2)CH2CH2NH), 3.14 (m, 
4H, 2 x CδH2), 3.16 (m, 4H, >N(CH2)2NH2), 3.17 (m, 8H, 2 x NHCH2(CH2)2CH2NH), 3.31 
(m, 4H, NHCH2CH2N(C2H4NH2)CH2CH2NH), 3.32-3.48 (m, 8H, 2 x 2/6-H piperazine), 
3.46 and 3.53 (m, 4H, 2 x NHCH2CH2N<), 3.77 (m, 4H, 2 x NHCH2CH2N<), 4.26 (m, 4H, 
2 x CαH, 2 x 11-H dibenzazepine-11-yl), 7.13 (m, 4H, HAr), 7.20 (m, 4H, HAr), 7.29 (m, 
2H, HAr), 7.32 (m, 10H, Ph), 7.36 (m, 10H, Ph), 7.42 (m, 2H, HAr), 7.50 (m, 2H, HAr), 7.80 
(m, 2H, HAr) ppm; 13C NMR (150 MHz, CD3OD, HSQC, HMBC): δ = 23.2 (2 x 
COCH2CH2CH2CO), 24.5 and 24.6 (2 x C-3/4 cyclopentyl), 25.7 (2 x Cγ), 27.7 and 27.9 (2 
x NHCH2(CH2)2CH2NH), 29.9 (2 x Cβ), 36.2 and 36.3 (2 x COCH2CH2CH2CO), 38.2 
(NHCH2CH2N(C2H4NH2)CH2CH2NH), 38.4 (2 x NHCH2CH2N<), 39.2 and 39.3 (2 x C-2/5 
cyclopentyl), 39.5 (2 x >NCOCH2-cyclopentyl), 39.9 (>NCH2CH2NH2), 40.4 (2 x 
NHCH2(CH2)2CH2NH), 41.2 (2 x NHCH2CH2N<), 41.8 (2 x Cδ), 44.7 (2 x CH2CONαH), 45.9 
(2 x C-1 cyclopentyl), 47.4 (2 x C-2/6 piperazine), 52.2 and 52.6 (2 x C-3/5 piperazine), 
53.6 (2 x Cα), 55.8 (NHCH2CH2N(C2H4NH2)CH2CH2NH), 59.5 (>NCH2CH2NH2), 75.8 (2 x 
C-11 dibenzazepine-11-yl), 123.0 (2 x CArH), 124.1 (2 x Ph), 126.0 (2 x CArH), 128.1 (2 x 
CArH), 129.0 (2 x CArH), 129.4 (2 x CArH), 129.9 (2 x CArH), 130.2 (2 x Ph), 131.1 (2 x 
CArH), 131.7 (CArH), 132.4 (2 x CAr), 133.2 (CArH), 136.9 (2 x CAr), 137.9 (2 x CAr), 154.5 (2 
x N(CONPh)2), 155.4 (2 x =NCONH), 155.7 (2 x NC(N)N), 172.7 (2 x CON<), 174.5 (2 x 
CONH(CH2)2N<), 174.7 (2 x CONαH), 175.2 and 176.2 (2 x NHCO(CH2)3CONH) ppm; a 
peak for C=O lactam could not be detected; MS (ES, +p) m/z (%): 787 (50) [M+3H]3+, 
591 (100) [M+4H]4+, 473 (40) [M+5H]5+; RP-HPLC: 95 % (tR = 17.3 min, k´ = 
5.4);C124H160N30O18 (2357.25). 
4.5.3 Pharmacology: Cell Culture, Fura-2 Assay and Flow Cytometry 
Cell culture. CHO cells were cultured as described elsewhere.45 
 
Fura-2 assay on CHO cells. The fura-2 assay was performed as previously described46 
using a LS50 B spectrofluorimeter from Perkin Elmer (Überlingen, Germany). 
 
Flow cytometric competition binding assay. The binding assay was performed as 
described elsewhere45 with the adaptations according to Chapter 3.5.4. 
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Flow cytometric selectivity assay. The selectivity was determined as described in 
Chapter 3.5.4. 
4.6 References 
1. Angers, S.; Salahpour, A.; Joly, E.; Hilairet, S.; Chelsky, D.; Dennis, M.; Bouvier, M. 
Detection of beta 2-adrenergic receptor dimerization in living cells using 
bioluminescence resonance energy transfer (BRET). Proc. Natl. Acad. Sci. U. S. A. 
2000, 97, 3684-9. 
2. Kaupmann, K.; Malitschek, B.; Schuler, V.; Heid, J.; Froestl, W.; Beck, P.; Mosbacher, 
J.; Bischoff, S.; Kulik, A.; Shigemoto, R.; Karschin, A.; Bettler, B. GABA(B)-receptor 
subtypes assemble into functional heteromeric complexes. Nature 1998, 396, 683-7. 
3. White, J. H.; Wise, A.; Main, M. J.; Green, A.; Fraser, N. J.; Disney, G. H.; Barnes, A. 
A.; Emson, P.; Foord, S. M.; Marshall, F. H. Heterodimerization is required for the 
formation of a functional GABA(B) receptor. Nature 1998, 396, 679-82. 
4. Cvejic, S.; Devi, L. A. Dimerization of the delta opioid receptor: implication for a role in 
receptor internalization. J. Biol. Chem. 1997, 272, 26959-64. 
5. George, S. R.; Fan, T.; Xie, Z.; Tse, R.; Tam, V.; Varghese, G.; O'Dowd, B. F. 
Oligomerization of mu- and delta-opioid receptors. Generation of novel functional 
properties. J. Biol. Chem. 2000, 275, 26128-35. 
6. Jordan, B. A.; Devi, L. A. G-protein-coupled receptor heterodimerization modulates 
receptor function. Nature 1999, 399, 697-700. 
7. Wreggett, K. A.; Wells, J. W. Cooperativity manifest in the binding properties of purified 
cardiac muscarinic receptors. J. Biol. Chem. 1995, 270, 22488-99. 
8. Zeng, F. Y.; Hopp, A.; Soldner, A.; Wess, J. Use of a disulfide cross-linking strategy to 
study muscarinic receptor structure and mechanisms of activation. J. Biol. Chem. 1999, 
274, 16629-40. 
9. Zeng, F. Y.; Wess, J. Identification and molecular characterization of m3 muscarinic 
receptor dimers. J. Biol. Chem. 1999, 274, 19487-97. 
10. Terrillon, S.; Barberis, C.; Bouvier, M. Heterodimerization of V1a and V2 vasopressin 
receptors determines the interaction with beta-arrestin and their trafficking patterns. 
Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 1548-53. 
11. Terrillon, S.; Bouvier, M. Receptor activity-independent recruitment of betaarrestin2 
reveals specific signalling modes. EMBO J. 2004, 23, 3950-61. 
12. Chen, C.; Li, J.; Bot, G.; Szabo, I.; Rogers, T. J.; Liu-Chen, L. Y. Heterodimerization 
and cross-desensitization between the mu-opioid receptor and the chemokine CCR5 
receptor. Eur. J. Pharmacol. 2004, 483, 175-86. 
13. Suzuki, S.; Chuang, L. F.; Yau, P.; Doi, R. H.; Chuang, R. Y. Interactions of opioid and 
chemokine receptors: oligomerization of mu, kappa, and delta with CCR5 on immune 
cells. Exp. Cell Res. 2002, 280, 192-200. 
14. Rocheville, M.; Lange, D. C.; Kumar, U.; Patel, S. C.; Patel, R. C.; Patel, Y. C. 
Receptors for dopamine and somatostatin: formation of hetero-oligomers with 
enhanced functional activity. Science 2000, 288, 154-7. 
 Bivalent Argininamide-Type Y2R Antagonists 129 
15. Zawarynski, P.; Tallerico, T.; Seeman, P.; Lee, S. P.; O'Dowd, B. F.; George, S. R. 
Dopamine D2 receptor dimers in human and rat brain. FEBS Lett. 1998, 441, 383-6. 
16. Fukushima, Y.; Asano, T.; Saitoh, T.; Anai, M.; Funaki, M.; Ogihara, T.; Katagiri, H.; 
Matsuhashi, N.; Yazaki, Y.; Sugano, K. Oligomer formation of histamine H2 receptors 
expressed in Sf9 and COS7 cells. FEBS Lett. 1997, 409, 283-6. 
17. Nguyen, T.; Shapiro, D. A.; George, S. R.; Setola, V.; Lee, D. K.; Cheng, R.; Rauser, 
L.; Lee, S. P.; Lynch, K. R.; Roth, B. L.; O'Dowd, B. F. Discovery of a novel member of 
the histamine receptor family. Mol. Pharmacol. 2001, 59, 427-33. 
18. George, S. R.; O'Dowd, B. F.; Lee, S. P. G-protein-coupled receptor oligomerization 
and its potential for drug discovery. Nat. Rev. Drug Discov. 2002, 1, 808-20. 
19. Milligan, G. G protein-coupled receptor dimerisation: molecular basis and relevance to 
function. Biochim. Biophys. Acta 2007, 1768, 825-35. 
20. Prinster, S. C.; Hague, C.; Hall, R. A. Heterodimerization of g protein-coupled 
receptors: specificity and functional significance. Pharmacol. Rev. 2005, 57, 289-98. 
21. Smith, N. J.; Milligan, G. Allostery at G protein-coupled receptor homo- and 
heteromers: uncharted pharmacological landscapes. Pharmacol. Rev. 2010, 62, 701-
25. 
22. Dinger, M. C.; Bader, J. E.; Kobor, A. D.; Kretzschmar, A. K.; Beck-Sickinger, A. G. 
Homodimerization of neuropeptide y receptors investigated by fluorescence resonance 
energy transfer in living cells. J. Biol. Chem. 2003, 278, 10562-71. 
23. Parker, M. S.; Sah, R.; Balasubramaniam, A.; Sallee, F. R.; Sweatman, T.; Park, E. A.; 
Parker, S. L. Dimers of the neuropeptide Y (NPY) Y2 receptor show asymmetry in 
agonist affinity and association with G proteins. J. Recept. Signal Transduct. Res. 
2008, 28, 437-51. 
24. Parker, S. L.; Parker, M. S.; Estes, A. M.; Wong, Y. Y.; Sah, R.; Sweatman, T.; Park, E. 
A.; Balasubramaniam, A.; Sallee, F. R. The neuropeptide Y (NPY) Y2 receptors are 
largely dimeric in the kidney, but monomeric in the forebrain. J. Recept. Signal 
Transduct. Res. 2008, 28, 245-63. 
25. Guo, W.; Shi, L.; Javitch, J. A. The fourth transmembrane segment forms the interface 
of the dopamine D2 receptor homodimer. J. Biol. Chem. 2003, 278, 4385-8. 
26. Hebert, T. E.; Moffett, S.; Morello, J. P.; Loisel, T. P.; Bichet, D. G.; Barret, C.; Bouvier, 
M. A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits 
both receptor dimerization and activation. J. Biol. Chem. 1996, 271, 16384-92. 
27. del Burgo, L. S.; Milligan, G. Heterodimerisation of G protein-coupled receptors: 
implications for drug design and ligand screening. Expert Opin. Drug. Discov. 2010, 5, 
461-474. 
28. Salahpour, A.; Angers, S.; Mercier, J. F.; Lagace, M.; Marullo, S.; Bouvier, M. 
Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface 
targeting. J. Biol. Chem. 2004, 279, 33390-7. 
29. Simpson, L. M.; Taddese, B.; Wall, I. D.; Reynolds, C. A. Bioinformatics and molecular 
modelling approaches to GPCR oligomerization. Curr. Opin. Pharmacol. 2010, 10, 30-
7. 
130 Chapter 4  
30. Vassart, G. An in vivo demonstration of functional G protein-coupled receptor dimers. 
Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 1819-20. 
31. Rivero-Müller, A.; Chou, Y. Y.; Ji, I.; Lajic, S.; Hanyaloglu, A. C.; Jonas, K.; Rahman, 
N.; Ji, T. H.; Huhtaniemi, I. Rescue of defective G protein-coupled receptor function in 
vivo by intermolecular cooperation. Proc. Natl. Acad. Sci. U. S. A. 2009, 107, 2319-
2324. 
32. Portoghese, P. S. From models to molecules: opioid receptor dimers, bivalent ligands, 
and selective opioid receptor probes. J. Med. Chem. 2001, 44, 2259-69. 
33. Jones, R. M.; Hjorth, S. A.; Schwartz, T. W.; Portoghese, P. S. Mutational evidence for 
a common kappa antagonist binding pocket in the wild-type kappa and mutant 
mu[K303E] opioid receptors. J. Med. Chem. 1998, 41, 4911-4. 
34. Lezoualc'h, F.; Jockers, R.; Berque-Bestel, I. Multivalent-based drug design applied to 
serotonin 5-HT(4) receptor oligomers. Curr. Pharm. Des. 2009, 15, 719-29. 
35. Portoghese, P. S.; Larson, D. L.; Sayre, L. M.; Yim, C. B.; Ronsisvalle, G.; Tam, S. W.; 
Takemori, A. E. Opioid agonist and antagonist bivalent ligands. The relationship 
between spacer length and selectivity at multiple opioid receptors. J. Med. Chem. 
1986, 29, 1855-61. 
36. Berque-Bestel, I.; Lezoualc'h, F.; Jockers, R. Bivalent ligands as specific 
pharmacological tools for G protein-coupled receptor dimers. Curr. Drug Discov. 
Technol. 2008, 5, 312-8. 
37. Halazy, S. G-protein coupled receptors bivalent ligands and drug design. Expert 
Opinion on Therapeutic Patents 1999, 9, 431-446. 
38. Messer, W. S., Jr. Bivalent ligands for G protein-coupled receptors. Curr. Pharm. Des. 
2004, 10, 2015-20. 
39. Shonberg, J.; Scammells, P. J.; Capuano, B. Design strategies for bivalent ligands 
targeting GPCRs. ChemMedChem 2011, 6, 963-74. 
40. Daniels, A. J.; Matthews, J. E.; Slepetis, R. J.; Jansen, M.; Viveros, O. H.; Tadepalli, A.; 
Harrington, W.; Heyer, D.; Landavazo, A.; Leban, J. J.; Spaltenstein, A. High-affinity 
neuropeptide Y receptor antagonists. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 9067-71. 
41. Balasubramaniam, A.; Zhai, W.; Sheriff, S.; Tao, Z.; Chance, W. T.; Fischer, J. E.; 
Eden, P.; Taylor, J. Bis(31/31') ([CYS(31), Trp(32), Nva(34)] NPY-(31-36)): a specific 
NPY Y-1 receptor antagonist. J. Med. Chem. 1996, 39, 811-3. 
42. Rudolf, K.; Eberlein, W.; Engel, W.; Wieland, H. A.; Willim, K. D.; Entzeroth, M.; 
Wienen, W.; Beck-Sickinger, A. G.; Doods, H. N. The first highly potent and selective 
non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur. J. Pharmacol. 
1994, 271, R11-3. 
43. Keller, M.; Teng, S.; Bernhardt, G.; Buschauer, A. Bivalent argininamide-type 
neuropeptide y y(1) antagonists do not support the hypothesis of receptor dimerisation. 
ChemMedChem 2009, 4, 1733-45. 
44. Doods, H.; Gaida, W.; Wieland, H. A.; Dollinger, H.; Schnorrenberg, G.; Esser, F.; 
Engel, W.; Eberlein, W.; Rudolf, K. BIIE0246: a selective and high affinity neuropeptide 
Y Y(2) receptor antagonist. Eur. J. Pharmacol. 1999, 384, R3-5. 
 Bivalent Argininamide-Type Y2R Antagonists 131 
45. Ziemek, R.; Brennauer, A.; Schneider, E.; Cabrele, C.; Beck-Sickinger, A. G.; 
Bernhardt, G.; Buschauer, A. Fluorescence- and luminescence-based methods for the 
determination of affinity and activity of neuropeptide Y2 receptor ligands. Eur. J. 
Pharmacol. 2006, 551, 10-8. 
46. Müller, M.; Knieps, S.; Gessele, K.; Dove, S.; Bernhardt, G.; Buschauer, A. Synthesis 
and neuropeptide Y Y1 receptor antagonistic activity of N,N-disubstituted ω-guanidino- 
and ω-aminoalkanoic acid amides. Arch. Pharm. 1997, 330, 333-42. 
47. Schneider, E.; Mayer, M.; Ziemek, R.; Li, L.; Hutzler, C.; Bernhardt, G.; Buschauer, A. 
A simple and powerful flow cytometric method for the simultaneous determination of 
multiple parameters at G protein-coupled receptor subtypes. Chembiochem 2006, 7, 
1400-9. 
48. Kaske, M.; Keller, M.; Weiß, S.; König, B.; Bernhardt, G.; Buschauer, A. Monovalent 
and bivalent argininamide-type antagonists of the human NPY Y4 receptor. In XXIst 
International Symposium on Medicinal Chemistry, Brussels (Belgium), 2010. 
 
 
 
Chapter 5 Red-Fluorescent NPY Y2 Receptor 
Antagonists 
5.1 Introduction 
There has been a remarkable growth in the use of fluorescence-based techniques for 
the investigation of ligand-receptor interactions over the past two decades. In the 
field of G-protein coupled receptor (GPCR) research, recent advances in both labeling 
methods and measuring techniques have made fluorescence assays indispensable 
tools for the exploration and visualization of GPCRs.1-2 The receptors can be labeled, 
for instance, with auto-fluorescent proteins, e. g., for direct detection in vivo, as well 
as for the investigation of protein-protein-interactions by the measurement of 
fluorescence-resonance energy transfer (FRET) of an appropriate donor-acceptor 
pair.3-5 Moreover, indirect labeling with fluorescence ligands is commonly used to 
explore ligand-receptor interactions and to visualize GPCRs without modification of 
the receptor protein. 
In the field of peptidergic GPCRs, fluorescence-labeled endogenous ligands are often 
used. In the case of peptides the decrease in affinity caused by attachment of a 
fluorophore is usually rather low, as the structures of such larger molecules are only 
moderately changed and the interactions with the receptor are hardly affected by the 
introduction of the dye. There are several examples in the literature for the 
application of NPY fluorescent probes.6-8 Such fluorescent NPY analogs can be 
utilized, e.g. for internalization studies by means of confocal microscopy or flow 
cytometry9 and as standard ligand in fluorescence-based binding experiments10, 
respectively. The synthesis of fluorescent small-molecule ligands for GPCRs is by far 
more challenging. Herein, a potential site for fluorophore conjugation is in much 
closer proximity to the pharmacophore and as a consequence, much more likely to 
affect ligand affinity and efficacy. Nevertheless, there are several examples for the 
successful development of low molecular weight fluorescent ligands and their 
application in the investigation of GPCRs.11-19 
Usually, endogenous ligands and their labeled analogues do not discriminate 
between subtypes of the GPCRs of interest. For the detection and investigation of 
receptor subtypes on cells and in tissues selective high affinity fluorescence ligands 
are required. Fluorescent non-peptide antagonists are superior to peptides 
concerning selectivity, kinetics, stability and mode of action. Antagonists do not 
induce receptor internalization, which may complicate the determination of binding 
kinetics and increase non-specific binding due to intracellular accumulation, thus, 
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leading to a high fluorescence background, e.g., in flow cytometric binding assays. 
Additionally, peptides show slower kinetics and hence longer incubation periods are 
needed. Besides, peptides are susceptible to enzymatic cleavage. 
The lack of selective non-peptide fluorescent ligands for the Y2R prompted us to 
develop fluorescent probes starting from BIIE 0246,20 the first highly potent selective 
Y2R antagonist. The guanidine-acylguanidine bioisosteric approach, which was 
successfully applied in our group for the synthesis of fluorescent Y1R antagonists,12 is 
an efficient strategy to combine labeling with lowering of the basicity of guanidine 
containing GPCR ligands. Therefore, the applicability of this concept to argininamide-
type Y2R antagonists was explored aiming at the development of potent and selective 
fluorescent ligands. 
 
Figure  5.1. Structures of the dyes used for the preparation of the red-fluorescent Y2R antagonists (5.1-5.27). 
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5.2 Chemistry 
5.2.1 Synthesis 
With respect to potential use in cellular assays red fluorescent dyes depicted in 
Figure 5.1 with a fluorescence emission wavelength over 590 nm were selected to 
reduce the background fluorescence and thus to improve the signal-to-noise ratio. 
Preferably, we used the new class of pyrylium dyes (Py-1 and Py-5)21-22 as well as the 
Cy523-related cyanine dyes S043619 and S0387. Furthermore, the Dyomics dyes 
Dy-63024 and Dy-63325-26 with an unsymmetrical hemicyanine structure consisting of 
an indol and a benzopyrane moiety, and the boron-containing Bodipy® 650/665-X 
dye27 were applied in order to expand the structural diversity of fluorescent Y2R 
antagonists. 
The (hemi-)cyanine dyes and the Bodipy dye, respectively, are excitable at 635 nm 
with a red diode laser,28 commonly used as light source in commercial flow 
cytometers. The pyrylium dyes (Py-1 and Py-5) belong to the new class of “chameleon 
labels”, which has been developed for the staining and quantification of proteins at 
picomolar concentrations.21 These dyes widen the pharmacological applicability of 
fluorescent ligands, as they are excitable at lower wavelengths by a widely used 
argon laser (λ = 488 nm). Thus, Py-labeled compounds and, e.g., cyanine fluorescent 
ligands can be applied simultaneously in cellular assays. Another advantage of pyry-
lium dyes is their lower molecular weight compared to other dye classes. In this case 
especially coupling to small molecules should be more tolerated, as the affinity-
lowering influence of the fluorophore should be less pronounced. 
The pyrylium dyes react very rapidly and regioselectively with primary amines at pH 
8-9 at room temperature to form the resonance-stabilized pyridinium compound 
with retained charge at the nitrogen. This ring transformation is accompanied by a 
hypsochromic shift of the absorption maximum by more than 100 nm (621 nm to 503 
nm for Py-1; 644 nm to 465 nm for Py-5).22 Thus, the reaction can be followed visually 
due to a change in color from blue to red. The mechanism of the pyrylium-pyridinium 
conversion has been studied extensively (Scheme 5.1a).29 Addition of the primary 
amine at position 2 yields the 2H-pyran. This intermediate is energetically unfavored 
in terms of aromaticity and hence the ring opens to form the second intermediate, a 
divinylogous amide which is usually more stable. This amide tautomerizes in the rate-
determining step into an imino-enol which rapidly cyclizes into the pyridinium 
product. 
The other dyes (S0436, S0387, Dy-630, Dy-633, Bodipy® 650/665) contain a hexanoyl 
side chain, which enables coupling to amines via the succinimidyl active esters 
(Scheme 5.1b). 
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Scheme  5.1. a) General mechanism for the reaction of pyrylium dyes with primary amines. b) Principle of the 
acylation of primary amines with fluorescent active esters; (FL: Fluorophore). 
For the preparation of fluorescent Y2R antagonists derived from BIIE 0246 the unpro-
tected amine precursors (S)-3.48-(S)-3.58 (for the preparation cf. chapter 3) were 
used. Labeling with the aforementioned amino-reactive dyes under basic conditions 
yielded compounds 5.1-5.27 (Scheme 5.2). Coupling of Py-5 and S0436-NHS, respec-
tively, to the amine precursor (S)-3.60 resulted in fluorescent ligands 5.28 and 5.29 
with reduced lipophilicity in the ornithinamide building block as well as an additional 
positive charge in the acyllinker (Scheme 5.3). The primary amine in the acyl- or 
carbamoyllinker is more reactive and sterically well accessible compared with the 
free guanidino group. Therefore, the products were obtained in satisfactory yields 
despite the lack of protection at the free Nω´H2. The labeling reactions were stopped 
with 10 % aq. TFA and the crude products were purified by preparative HPLC. 
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For structures of the fluorescent ligands 5.1-5.27 cf. Table 5.3
 
 No X n 
 
(S)-3.48 (CH2)2 1 
(S)-3.49 (CH2)3 1 
(S)-3.50 (CH2)2NH(CH2)2 1 
(S)-3.51 CH2(CH2CH2O)3(CH2)3 0 
 
(S)-3.52 NH 0 
(S)-3.53 NH 1 
(S)-3.54 NH 2 
(S)-3.55 NH 4 
(S)-3.56 CH2 2 
 No n m 
 
(S)-3.57 1 1 
(S)-3.58 2 3 
Scheme  5.2. Preparation of the fluorescent Y2R antagonists 5.1-5.27 derived from BIIE 0246. Reagents and 
conditions: a) Pyrylium dye (1 eq), amine precursor (4 eq), NEt3 (15 eq), CH3CN, DMF, 1-2 h, rt; b) pertinent dye 
succinimidyl ester (1 eq), amine precursor (2 eq), NEt3 (10-15 eq), CH3CN, DMF, 7-16 h, rt. a The succinimidyl 
ester of S0436 was purchased from FEW Chemicals (Germany) under the name S0536. b The succinimidyl ester 
of S0387 was purchased from FEW Chemicals (Germany) under the name S0586. 
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Scheme  5.3. Synthesis of the fluorescence ligands 5.28 and 5.29. Reagents and conditions: a) Py-5 (1 eq), 
(S)-3.60 (3 eq), NEt3 (15 eq), CH3CN, DMF, 1 h, rt; b) S0436-NHS (1 eq), (S)-3.60 (3 eq), NEt3 (10 eq), CH3CN, 
DMF, 16 h, rt. 
5.2.2 Fluorescence Properties of the Labeled Y2R Antagonists 
The absorption and emission spectra of the fluorescent ligands were measured in 
three different solvents: in phosphate buffered saline (PBS) at pH 7.0, in PBS with 1 % 
of bovine serum albumin (BSA) and in ethanol (EtOH). The fluorescence quantum 
yields (QY; φ) were determined with cresyl violet perchlorate as reference. PBS 
represents a commonly used standard solvent. By the addition of 1 % of BSA, assay 
conditions are simulated and the influence of proteins on the spectral properties are 
taken into account, whereas the determination in EtOH is regarded useful to observe 
the influence of the polarity of the solvent (solvatochromism). The fluorescence pro-
perties of the labeled Y2R antagonists are summarized in Table 5.1. Generally, the 
chemical structure of the linkers, connecting the fluorophore with the pharmaco-
phoric moiety, has almost no effect on the fluorescence properties. 
The majority of fluorescent ligands shows very high QYs (up to circa 50 %) in PBS + 
1 % BSA and very low QYs in pure PBS (< 6.2 %) except for compounds 5.17 and 5.23 
(11-13 % in PBS). The increase in QY by a factor of around 10 for cyanine dyes and by 
up to over 100 in case of pyrylium coupled fluorophores after the addition of BSA 
results from intermolecular interactions of the fluorophores with the protein. Binding 
of the fluorescent ligands to proteins leads to a rigidization of the molecule, which is 
 Red-Fluorescent NPY Y2R Antagonists 139 
followed by an increase in fluorescence intensity and therefore in QY.30 Thus, when 
BSA-free buffers are used for flow cytometric binding assays, the fluorescence 
intensity of these fluorescent ligands would probably increase in the receptor bound 
state. Nevertheless, an increase in fluorescence intensity could also be related to 
non-specific interactions with other proteins or with the cell membrane. 
Furthermore, the protein binding to BSA is accompanied by a hypsochromic shift of 
the emission maxima of Py-labeled ligands, presumably, due to reduced molecular 
vibrations. The Bodipy derivatives 5.26 and 5.27 have exceptionally poor quantum 
yields in PBS + 1 % BSA. Presumably, the spectroscopic properties of the Bodipy dyes 
are less affected by protein binding and rigidization. 
Table  5.1. Spectroscopic properties of the fluorescent Y2R antagonists 5.1-5.18, 5.20-5.27: Influence of the 
polarity of the solvent (PBS, pH = 7.0 vs. EtOH) and protein (BSA) on the quantum yield φ (reference: cresyl violet 
perchlorate) and on the excitation and emission maxima (λex, λem), respectively. 
No Dye 
PBS PBS + 1 % BSA EtOH 
λex / λem / nm φ / % λex / λem / nm φ / % λex / λem / nm φ / % 
5.1 Py-1 511 / 636 0.6 513 / 609 50 523 / 634 2.3 
5.2 Py-1 522 / 642 0.3 511 / 606 43 523 / 632 1.8 
5.3 Py-5 490 / 706 2.2 487 / 634 35 505 / 703 19 
5.4 Py-1 525 / 643 0.9 514 / 612 39 527 / 636 1.9 
5.5 Py-1 505 / 638 1.4 511 / 608 37 519 / 631 2.0 
5.6 Py-1 532 / 641 0.5 536 / 619 43 -- -- 
5.7 Py-1 516 / 640 0.5 519 / 608 49 525 / 634 1.9 
5.8 Py-5 489 / 702 0.5 492 / 640 27 505 / 705 18 
5.9 Py-1 515 / 641 1.2 515 / 609 47 524 / 634 2.4 
5.10 Py-5 490 / 704 1.4 485 / 641 36 502 / 705 23 
5.11 Py-1 515 / 645 0.6 516 / 608 56 522 / 634 2.1 
5.12 Py-5 485 / 705 1.1 488 / 642 44 502 / 706 24 
5.13 Py-1 516 / 641 0.6 517 / 612 44 525 / 635 2.2 
5.14 Py-5 475 / 707 5.1 490 / 644 32 502 / 705 22 
5.15 S0436 661 / 664 1.6 660 / 677 40 651 / 673 34 
5.16 S0387 657 / 667 4.9 660 / 677 34 654 / 675 37 
5.17 S0436 649 / 663 13 659 / 676 36 651 / 674 30 
5.18 S0387 654 / 667 6.2 658 / 675 47 654 / 676 35 
5.20 S0436 663 / 664 2.5 659 / 674 32 653 / 672 44 
5.21 S0387 654 / 667 3.3 659 / 675 36 654 / 675 41 
5.22 S0436 658 / 664 1.4 661 / 675 28 652 / 674 30 
5.23 Dy-633 634 / 652 11 644 / 656 55 640 / 660 24 
5.24 Dy-630 651 / 655 1.7 644 / 662 52 640 / 662 11 
5.25 Dy-633 653 / 655 0.5 647 / 659 23 639 / 660 21 
5.26 “Bodipy” 671 / -- (0.05) 667 / 670 5.6 -- -- 
5.27 “Bodipy” 673 / -- (0.1) 665 / 671 18 652 / 668 34 
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Figure  5.2. Absorption and corrected emission spectra in PBS + 1 % BSA exemplified for Py-1, Py-5, S0436, 
S0387, Dy-630, Dy-633 and Bodipy 650/665 (“Bodipy”) labeled antagonists (recorded at 22 °C). 
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In EtOH, the differences in QYs of the various fluorophores are much more pro-
nounced. Whereas the Py-1 labeled antagonists hold very low QYs in the same range 
as in PBS, the Py-5 as well as the Dy-630 and Dy-633 containing ligands, respectively, 
exhibit moderate QYs (up to 24 % for 5.12 and 5.23). The cyanine labeled ligands 
5.15-5.22 display QYs up to 44 %, which is comparable to the yields measured in PBS 
+ 1 % BSA. Lastly, the Bodipy-labeled analog 5.27 even shows a higher QY in EtOH, 
than in PBS containing BSA. Obviously, Py-1 labeled Y2R antagonists are less sensitive 
towards hydrophobic interactions compared to the ligands labeled with other dyes. 
The absorption and corrected emission spectra of various fluorescence labeled Y2R 
antagonists in PBS containing 1 % of BSA are depicted in Figure 5.2. The Py-5 labeled 
ligands show the largest Stokes shift (≈ 150 nm; in pure PBS more than 200 nm) fol-
lowed by the Py-1 derivatives (≈ 100 nm). Hence, the pyrylium coupled red-fluores-
cent ligands can be excited by the argon laser at 488 nm. The cyanine- (S0436, 
S0387), hemicyanine- (Dy-630, Dy-633), and Bodipy-labeled antagonists reveal a 
much smaller Stokes shift and are excitable at 635 nm with the red diode laser, com-
monly used in flow cytometry. 
In conclusion, the fluorescence properties of all synthesized fluorescent ligands allow 
for an application to flow cytometric equilibrium binding studies and confocal 
microscopy. It is noticeable that the pyridinium fluorophores can be investigated in 
the presence of, e.g., cyanine-labeled fluorescent probes and vice versa due to 
different excitation wavelengths. 
5.2.3 Stability of the Fluorescence Ligands 
As already discussed in Chapter 3, Nω-acylated argininamides were recently reported 
to be problematic in terms of stability of the acylguanidine side chain.31-32 However, 
HPLC analysis revealed high stability for the majority of the investigated Y2R 
antagonists under assays-like conditions over a period of (at least) 90 minutes 
(Chapter 3.2.2). Especially, the acylation of the amine precursor appeared to be 
beneficial in terms of stability. Therefore, compounds labeled with pyrylium dyes 
were of special interest in this investigation due to their preserved positive charge in 
the linker. The percentage of decomposition resulting in BIIE 0246 was determined at 
physiological pH (Table 5.2). 
The Py-5 labeled antagonists 5.10 and 5.14 comprising a positive charge in the 
fluorophore moiety proved to be stable. Even compound 5.4 including a secondary 
amine in the linker showed a very low decomposition giving BIIE 0246 (1.5 %; Fig-
ure 5.3). Interestingly, the amount of formed BIIE 0246 was even lower with respect 
to the appropriate amine precursor (S)-3.50 (2.9 %), comprising two reactive amino 
moieties in the linker. Moreover, the S0436 labeled fluorescent ligands 5.17 and 5.22 
exhibited a high stability within 90 minutes. In conclusion, the affinities examined in 
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the flow cytometric equilibrium binding assay are supposed to be not affected by the 
formation of BIIE 0246. 
Table  5.2. Chemical stability (aqueous buffer, pH 7.4, 20 °C, 90 min) of 
the fluorescent Y2R antagonists. 
No. % Decomposition No. % Decomposition 
5.4 1.5 5.17 1.0 
5.10 1.8 5.22 1.5 
5.14 1.0   
Cleavage of the acyl or carbamoyl substituent from the guanidine moiety 
resulting in BIIE 0246 was analyzed by HPLC. 
 
Figure  5.3. HPLC analysis of the Py-1 labeled fluorescent Y2R antagonist 5.4 in buffer. BIIE 0246 ((S)-3.47) is 
formed by decomposition of the ligand. Incubation: 90 min in buffer, pH 7.4, 20 °C. Conditions: eluent: mixtures of 
acetonitrile (A) and 0.05 % aq. TFA (B), gradient: 0 to 30 min: A/B 20/80 to 95/5. 
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5.3 Pharmacological Results and Discussion 
5.3.1 Pharmacology: Y2R Antagonism, Affinity and Selectivity 
The fluorescent Y2R antagonists were investigated for Y2R antagonism in a spectro-
fluorimetric Ca2+ assay (fura-2 assay) on CHO-hY2R cells. The calcium indicator dye 
fura-2 is excited at 340 and 380 nm and the fluorescence intensity is measured at 
510 nm. Hence, the spectroscopic properties of the fluorescence ligands do not 
interfere with the excitation and emission wavelengths of the fura-2-Ca2+ complex. 
Furthermore, binding of the Py-1 and Py-5 labeled antagonists 5.1-5.14 and 5.28 at 
the Y2R was determined in a flow cytometric binding assay using Cy5-pNPY or Dy-635-
pNPY. All other fluorescent ligands exhibit spectral properties similar to those of the 
applied labeled NPY derivatives. Thus, alternative standard ligands, excitable at 
wavelengths other than 635 nm (red diode laser), are needed to investigate these 
antagonists. Therefore, the Py-1 labeled compound 5.4 (excitable with an Ar laser at 
488 nm) was used for the displacement with a selection of fluorescent Y2R antago-
nists. Moreover, fluorescence ligands 5.4 and 5.16 were investigated in a radioligand 
binding assay displacing the novel Y2R selective tritiated ligand [3H]-UR-PLN196. The 
development and characterization of this radioligand is discussed in detail in 
Chapter 6. The results are summarized in Table 5.3. 
The pyrylium-labeled ligands 5.1-5.14 proved to be highly potent antagonists at the 
Y2R with Ki values in the range of the parent compound BIIE 0246. Only the Py-5 la-
beled compound 5.28 showed lower affinity than BIIE 0246 due to the alteration in 
the argininamide building block, but retained affinity referred to its guanidine analog 
(S)-3.59. In comparison to the appropriate amine precursors, the Py-labeling gave 
compounds with retained or slightly decreased affinity. Obviously, the introduction of 
the pyridinium fluorophores does not negatively affect binding and antagonistic 
activity because of the retained positive charge in the linker. Hence, a positive charge 
in the linker may contribute to Y2 receptor binding by means of an additional 
interaction with the receptor as previously discussed. Lastly, the length of the linker 
seems to have a rather low impact on binding affinity. 
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Table  5.3. Structures, Y2R antagonism and binding data of BIIE 0246 and fluorescent ligands 5.1-5.29. 
No Y Z Spacera KB / nMb Ki / nMc 
(S)-3.47d H -- -- 5.6 ± 0.4 10.2 ± 1.1 
5.1 CO(CH2)3CONH(CH2)2 A 8 4.6 ± 0.7 11 ± 1 
5.2 CO(CH2)3CONH(CH2)3 A 9 1.3 ± 0.1 9.9 ± 0.1 
5.3 CO(CH2)3CONH(CH2)3 B 9 1.9 ± 0.3 5.9 ± 0.3 
5.4 CO(CH2)3CONH(CH2)2NH(CH2)2 A 11 9.8 ± 1.6 
23 ± 4 
73 ± 6e 
5.5 CO(CH2)2CONHCH2(CH2CH2O)3(CH2)3 A 18 3.8 ± 0.2 19 ± 5 
5.6 CONH(CH2)2 A 4 3.2 ± 0.1 14 ± 7 
5.7 CONH(CH2)3 A 5 4.3 ± 0.6 12 ± 0.6 
5.8 CONH(CH2)3 B 5 4.0 ± 0.4 6.1 ± 0.2 
5.9 CONH(CH2)4 A 6 6.4 ± 1.2 6.6 ± 0.7 
5.10 CONH(CH2)6 B 8 7.2 ± 1.4 31 ± 15 
5.11 CO(CH2)5 A 6 6.4 ± 0.2 26 ± 7 
5.12 CO(CH2)5 B 6 3.3 ± 0.1 13 ± 2 
5.13 COCH2(OCH2CH2)2 A 8 14 ± 3 8.5 ± 0.4 
5.14 CO(CH2CH2O)4(CH2)2 B 15 7.3 ± 1.6 12 ± 2 
5.15 CO(CH2)3CONH(CH2)3NH C 10 35 ± 7 300f 
5.16 CO(CH2)3CONH(CH2)3NH D 10 90 ± 70 
982 ± 207f
614 ± 24e 
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Table 5.3 (continued) 
5.17 CO(CH2)3CONH(CH2)2NH(CH2)2NH C 12 14 ± 0.2 69f 
5.18 CO(CH2)3CONH(CH2)2NH(CH2)2NH D 12 12 ± 4 nd 
5.19 CO(CH2)2CONHCH2(CH2CH2O)3(CH2)3NH C 19 106 ± 34 nd 
5.20 CONH(CH2)2NH C 5 51 ± 35 nd 
5.21 CONH(CH2)3NH D 5 2714 ± 671 > 1000f 
5.22 COCH2(OCH2CH2)2NH C 9 259 ± 67 nd 
5.23 CO(CH2)3CONH(CH2)3NH F 10 663 ± 210 > 1000f 
5.24 CO(CH2)3CONH(CH2)2NH(CH2)2NH E 12 7.9 ± 3.6 nd 
5.25 CONH(CH2)6NH F 9 711 ± 203 > 1000f 
5.26 CO(CH2)3CONH(CH2)3NH G 10 nd 48f 
5.27 CO(CH2)3CONH(CH2)2NH(CH2)2NH G 12 63 ± 29 nd 
(S)-3.59 H -- -- 28 ± 3 96 ± 13 
5.28 CO(CH2)3CONH(CH2)2NH(CH2)2 B 11 11 ± 0.8 102 ± 2 
5.29 CO(CH2)3CONH(CH2)2NH(CH2)2NH C 12 70 ± 11 nd 
a Length of the linker between the argininamide and the fluorescent dye given as number of atoms. b Inhibition of 70 nM 
pNPY induced [Ca2+]i mobilization at CHO-hY2-K9-qi5-K9-mtAEQ-A7 cells expressing the human Y2R; mean values ± SEM 
(n = 2-4). c Flow cytometric binding assay using 5 nM Cy5-pNPY, or 10 nM Dy-635-pNPY as standard ligand at CHO-hY2-
K9-qi5-K9-mtAEQ-A7 cells; mean values ± SEM (n = 2-3). d BIIE 0246. e Displacement of [3H]-UR-PLN196 (KD = 65 nM; c = 
75 nM) in a radioligand binding assay at CHO-hY2-K9-qi5-K9-mtAEQ-A7 cells; mean values ± SEM (n = 2-3). 
f 5.4 (KD = 24 
nM; c = 40 nM) used as fluorescent ligand in flow cytometric competition binding; mean values ± SEM (n = 2-3). 
Insertion of the higher molecular weight (hemi-)cyanine and Bodipy dyes by acylation 
of the amine precursors yielded fluorescent ligands devoid of a positive charge in the 
linker. This modification led to a drastic decrease in both potency and binding affinity 
of most of these compounds, apparently, because of the lack of a positive charge and 
the steric demand of the bulky fluorophore in proximity to the pharmacophoric 
moiety. Furthermore, S0387 and Dy-633 labeled fluorescent ligands 5.16, 5.21, 5.23 
and 5.25 were inferior compared to the S0436 and Dy-630 coupled analogs. 
Strikingly, these ligands have one structural motif in common, namely an additional 
SO3– group in the fluorophore (for structures see Figure 5.1 and Table 5.3, respective-
ly). When the pharmacophoric moiety of the fluorescent ligand is binding to the Y2R, 
it is very likely that the fluorophores are oriented towards the extracellular region of 
the receptor protein due to lack of sufficient space between transmembrane 
domains. The extracellular loops of the Y2R contain numerous acidic (negatively 
charged) amino acids.33-34 Thus, the additional SO3– moiety could exhibit an 
electrostatic repulsion. Moreover, the sterical hindrance has to be taken into 
account. The drop in affinity proved to be less pronounced for antagonists 5.17, 5.18, 
5.24 and 5.26. Interestingly, these four fluorescent ligands have the same acyl linker, 
which includes a secondary amine function, in common. This observation once more 
underlines the affinity-enhancing effect of a positive charge in the linker. 
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The Y2R selectivity was exemplarily investigated for compound 5.9 and 5.10 in flow 
cytometric binding studies using Cy5-pNPY at cells stably expressing human Y1, Y4 or 
Y5 receptors (Table 5.4). Labeling with pyrylium dyes did not result in an alteration in 
selectivity compared to the precursors. As already discussed, the selectivity of S0436, 
S0387, Dy-630, Dy-633 and “Bodipy” labeled ligands could not be determined by flow 
cytometry due to their excitability with the red diode laser. For these compounds 
appropriate radiolabeled standard ligands have to be used. 
Table  5.4. NPY receptor subtype selectivity of the fluorescent ligands 5.9 
(Py-1 labeled) and 5.10 (Py-5 labeled). 
No 
Ki / nMa 
Y2R Y1R Y4R Y5R 
5.9 6.6 > 350 > 6500 > 4500 
5.10 31 > 3500 > 6500 > 4500 
a Flow cytometric binding assays using 10 nM Cy5-pNPY (Y1R), 5 nM Cy5-pNPY (Y2R, 
Y5R) or 3 nM Cy5-[K
4]-hPP (Y4R) in HEL-Y1 cells, CHO-Y2 cells, CHO-Y4 cells and HEC-1B-
Y5 cells, respectively. 
5.3.2 Application of Fluorescent Y2R Antagonists to Confocal Laser 
Scanning Microscopy 
Various fluorescent Y2R antagonists were screened for their applicability in confocal 
laser scanning microscopy on CHO cells expressing the hY2R. The non-specific binding 
was determined in the presence of the non-fluorescent Y2R selective antagonist 
BIIE 0246 in 100-fold excess. As shown in Figure 5.4 (panel A) the Py-1 labeled antag-
onist 5.2 is predominantly localized inside the cells. Fluorescence of the ligands was 
not detected in the nucleus. The uptake into the cells occurs within a few minutes 
even at very low concentrations (panel A2), presumably due to passive diffusion of 
the very lipophilic compound. Receptor internalization seems very unlikely, as 
antagonists have not been reported to cause internalization and down-regulation of 
GPCRs. The Py-1 labeled ligand 5.4 with an additional positive charge in the linker and 
concomitant reduced lipophilicity showed higher specific binding at the Y2R (Figure 
5.4 panel B). 
Among the Py-labeled antagonists compound 5.28, the Py-5 coupled analog of 5.4 
lacking the cyclopentyl moiety in the argininamide pharmacophore, was found most 
suitable. Thus, the lower lipophilicity resulted in reduced diffusion through the cell 
membrane (Figure 5.4 panel C). 
 
 
 Red-Fluorescent NPY Y2R Antagonists 147 
  
Total binding of 5.2 (c: 50 nM), 5 min Total binding of 5.2 (c: 1 nM), 7 min 
  
Total binding of 5.4 (c: 50 nM), 25 min Non-specific binding of 5.4 (c: 50 nM), 25 min 
   
Total binding of 5.28 (c: 50 nM), 50 min Non-specific bdg of 5.28  (c: 50 nM), 50 min autofluorescence 
Figure  5.4. Binding of the fluorescent ligands 5.2 (panel A), 5.4 (panel B), 5.28 (panel C) to Y2R expressed in 
CHO-hY2R cells, visualized by confocal microscopy. Non-specific binding was determined in the presence of 
BIIE 0246 at 100-fold excess. Cells were incubated with the fluorescent ligands at rt in Leibowitz L15 culture 
medium. All images were acquired with a Zeiss Axiovert 200 M microscope. 
 
A1 A2
B1 B2
C1 C2 C3 
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Total binding of 5.15 (c: 50 nM), 20 min Non-specific binding of 5.15 (c: 50 nM), 40 min 
 
Total binding of 5.17 (c: 50 nM), 25 min Non-specific binding of 5.17 (c: 50 nM), 33 min 
  
Total binding of 5.20 (c: 50 nM), 36 min Non-specific binding of 5.20 (c: 50 nM), 41 min 
Figure  5.5. Binding of the fluorescent ligands 5.15 (panel D), 5.17 (panel E), 5.20 (panel F) to Y2R expressed in 
CHO-hY2R cells, visualized by confocal microscopy. Non-specific binding was determined in the presence of 
BIIE 0246 at 100-fold excess. Cells were incubated with the fluorescent ligands at rt in Leibowitz L15 culture 
medium. All images were acquired with a Zeiss Axiovert 200 M microscope. 
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Total binding of 5.16            
(c: 50 nM), 15 min 
Non-specific binding of 5.16 
(c: 50 nM), 23 min 
Non-specific binding of 5.16 
(c: 50 nM), 30 min 
  
Total binding of 5.22            
(c: 50 nM), 41 min 
Non-specific binding of 5.22 
(c: 50 nM), 38 min 
Non-specific binding of 5.22 
(c: 50 nM), 50 min 
   
Total binding of 5.29            
(c: 50 nM), 36 min 
Non-specific binding of 5.29 
(c: 50 nM), 41 min 
Non-specific binding of 5.29 
(c: 50 nM), 41 min 
Figure  5.6. Binding of the fluorescent ligands 5.16 (panel G), 5.22 (panel H), 5.29 (panel I) to Y2R expressed in 
CHO-hY2R cells, visualized by confocal microscopy. 1: Total binding; 2: Displacement with pNPY at 500-fold 
excess; 3: Non-specific binding determined in the presence of BIIE 0246 at 100-fold excess. Cells were incubated 
with the fluorescent ligands at rt in Leibowitz L15 culture medium. All images were acquired with a Zeiss Axiovert 
200 M microscope. 
G3
H1 H3H2
I1 I3I2
G2G1 
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Total binding of 5.24 (c: 50 nM), 40 min Non-specific binding of 5.24 (c: 50 nM), 40 min 
  
Total binding of 5.25 (c: 500 nM), 26 min Non-specific binding of 5.25 (c: 500 nM), 28 min 
Figure  5.7. Binding of the fluorescent ligands 5.24 (panel J) and 5.25 (panel K) to Y2R expressed in CHO-hY2R 
cells, visualized by confocal microscopy. J1: Total binding merged; J2: Non-specific binding determined in the 
presence of BIIE 0246 at 100-fold excess (fluorescence image); K1: Total binding; K2: Non-specific binding 
determined in the presence of BIIE 0246 at 100-fold excess (fluorescence image). Cells were incubated with the 
fluorescent ligands at rt in Leibowitz L15 culture medium. All images were acquired with a Zeiss Axiovert 200 M 
microscope. 
The S0436 and S0387 labeled fluorescent ligands which were applied to confocal 
laser scanning microscopy showed high specific binding to the Y2R at a concentration 
as low as 50 nM (Figure 5.5 and Figure 5.6). Even compounds 5.16 and 5.22, which 
are rather weak Y2R antagonists (KB values: 90 nM and 259 nM, respectively), reveal-
ed intense fluorescence in the membrane (Figure 5.6 panel G and H). Moreover, bind-
ing to the Y2R seems to occur quite fast, as a high fluorescence signal was already 
observed after 15 min of incubation (Figure 5.6 G1). Non-specific binding was detect-
ed mainly inside the cells (cf. Figure 5.5 F2 and Figure 5.6 G3). However, penetration 
through the cell membrane was considerably reduced in comparison to the pyrylium 
labeled ligands. 
Displacement of the fluorescent ligands 5.16, 5.22 and 5.29 was performed with the 
endogenous ligand pNPY at a 500-fold excess – initially, in order to distinguish total 
and non-specific binding (Figure 5.6 panels G2, H2, I2). Surprisingly, the Y2R 
antagonists were hardly displaced by pNPY. Interestingly, BIIE 0246 was reported to 
exhibit an insurmountable antagonism against NPY after pre-incubation with the cells 
J2J1 
K2K1 
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for 20 min, whereas it behaved as a competitive antagonist when co-incubated in a 
functional Ca2+ assay.35 Nevertheless, in the case of the fluorescent ligands the poor 
displacement was observed despite co-incubation with pNPY. Thus, with respect to 
an explanation of this unusual behavior, more detailed investigations of the binding 
mode of argininamide-type Y2R antagonists are urgently needed. 
Furthermore, the Dy-630 and Dy-633 fluorophore containing antagonists 5.23-5.25 
(data shown for 5.24 and 5.25 in Figure 5.7, panel J and K) showed high specific 
binding at the Y2R with binding characteristics similar to S0436 and S0387 labeled 
fluorescent ligands. Binding was detectable at different concentrations corresponding 
to the antagonistic activities of the fluorescent ligands (cf. Table 5.3). While a 50 nM 
concentration was sufficient for the detection of the highly potent fluorescent ligand 
5.24 (Figure 5.7 panel J1), membranes could only be visualized at a 500 nM 
concentration in case of the weak antagonist 5.25 (Figure 5.7 panel K1). 
5.3.3 Fluorescent Y2R Antagonists in Flow Cytometry: Kinetics, 
Saturation and Competition Binding Experiments 
Several fluorescent Y2R antagonists were chosen for more detailed investigations in 
flow cytometric binding experiments due to suited properties in terms of binding 
affinity, antagonistic activity, fluorescence properties and applicability in confocal 
microscopy. All experiments were performed on CHO-hY2R cells. 
5.3.3.1 Saturation Binding Experiments 
To optimize the assay conditions, saturation binding experiments were performed 
with compounds 5.15 and 5.17 at different incubation periods using BSA containing 
or BSA free binding buffer. There was a significant increase in the ratio of total to 
non-specific binding when BSA free buffer was used (Table 5.5). Presumably, the 
increase in fluorescence intensity in the receptor bound state, resulting from 
rigidization, is more pronounced in the absence of BSA, compared to BSA containing 
binding buffer. Consequently, the following experiments were performed with BSA 
free binding buffer. 
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Four fluorescent Y2R antagonists were 
chosen for saturation binding experiments 
(5.4, 5.15-5.17). Besides compound 5.17, 
all investigated fluorescent ligands showed 
very low non-specific binding even at high 
concentrations (Figure 5.8 and Figure 5.9). 
The saturation binding of the Py-1 labeled 
compound 5.4 was measured in the fluo-
rescence channels Fl-2 (585 ± 21 nm) and 
Fl-3 (> 670 nm) and KD values of 25 nM and 
27 nM, respectively, were obtained (Fig-
ure 5.8). These data are in excellent 
agreement with the binding affinity 
determined by the displacement of Cy5-pNPY (Ki = 23 nM). 
Figure  5.8. Flow cytometric saturation binding experiment with fluorescent ligand 5.4 at CHO-hY2R cells (mean 
values ± SEM, n = 2, experiments performed in triplicate). Non-specific binding was determined in the presence of 
BIIE 0246 (100-fold excess); incubation time: 30 min. a) Measurement in Fl-2 (585 ± 21 nm); b) Measurement in 
Fl-3 (> 670 nm). 
Figure  5.9. Flow cytometric saturation binding experiment with fluorescent ligands 5.16 and 5.17 at CHO-hY2R 
cells (mean values ± SEM, n = 2, experiments performed in triplicate). Non-specific binding was determined in the 
presence of BIIE 0246 (100-fold excess); incubation time: 30 min; measurement in Fl-4 (661 ± 8 nm). 
a) Saturation binding of 5.16. b) Saturation binding of 5.17. 
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Table 5.5. Preliminary investigation on total (T) and 
non-specific (NS) binding of 5.15 (c = 25 nM; KB = 
35 nM). Influence of incubation time (tinc) and BSA 
on receptor binding. NS was determined with 5 µM 
BIIE 0246. 
tinc /min 
addition 
of BSAa 
Ratio T / NS 
15 + 3.9 
15 - 9.3 
30 + 3.8 
30 - 8.1 
a +: Addition of 1 % BSA to binding buffer (pH = 7.4); -: No 
BSA in the binding buffer (pH =7.4). 
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In case of the S0436 and S0387 labeled ligands 5.15-5.17 the fluorescence channel 
Fl-4 (661 ± 8 nm) was used for the determination of the dissociation constants. All 
ligands exhibited high to moderate binding affinity with KD values of 42-143 nM 
(Table 5.6). It is noteworthy, that the S0387 labeled ligand 5.16 showed much higher 
binding affinity in saturation binding than expected from competition binding studies 
with the fluorescent ligand 5.4 and the radioligand [3H]-UR-PLN196, and from the 
functional fura-2 assay, respectively (cf. Table 5.3 
and Table 5.6, respectively). 
In summary, the fluorescent ligands 5.4 and 5.15-
5.17 revealed satisfactory results in saturation 
binding experiments, and therefore, were used in 
flow cytometric competition binding studies. 
Especially the Py-1 labeled ligand 5.4, excitable by 
the argon laser (λ = 488 nm), and the S0387 labeled 
antagonist 5.16, excitable by the red diode laser (λ 
= 635nm), showed favorable properties in terms of 
specific binding and affinity. Therefore, both 
compounds were selected for more detailed 
binding studies. 
5.3.3.2 Association and Dissociation Kinetics 
The investigation of the association and the dissociation of compounds 5.4 and 5.16 
should provide more detailed information about the binding properties of 
argininamide-type Y2R antagonists. Therefore, the on- and off-rate (kon, koff), the half-
life (t1/2) and the kinetically derived equilibrium dissociation constant were 
determined.  
The data of 5.16 are summarized in Table 5.7. The association reaches 90 % of 
maximum binding within around 30 minutes (Figure 5.10a), i. e., the association rate 
is rather slow in comparison to other non-peptidic antagonists. However, the 
fluorescent antagonist showed faster association than Cy5-pNPY, which reaches 90 % 
of maximum binding after about 110 minutes36. Interestingly, the dissociation of 5.16 
remained incomplete even after 60 minutes (≈ 40 % specifically bound; Figure 5.10b). 
Table  5.7. Y2R binding characteristics of 5.16. 
koff / min-1 a kon / min-1 · nM-1 b koff/kon / nMc KD / nMd 
0.01285 0.000526 24 62 
a Dissociation rate constant determined by linear regression. b Association rate constant determined by 
linear regression. c Kinetically derived dissociation constant. d Equilibrium dissociation constant deter-
mined in saturation binding experiments. 
 
Table 5.6. Equilibrium dissociation con-
stants of the fluorescent ligands 5.4, 
5.15-5.17. 
No 
Saturation binding 
KD / nMa 
5.4 
25 ± 1.4b 
27 ± 2c 
5.15 143 ± 16 
5.16 62 ± 5 
5.17 42 ± 3 
a Equilibrium dissociation constant determi-
ned on CHO-hY2R cells, measured in Fl-4 
(mean values ± SEM, n = 2, performed in trip-
licate). b Measurement in Fl-2. c Measure-
ment in Fl-3. 
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Apparently, slow dissociation resulted in pseudo-irreversible binding. However, the 
dissociation rate of 5.16 was sufficient to calculate the kinetically derived KD (koff/kon = 
24 nM) by linearization of the association and dissociation curves (Figure 5.10c, d). 
This value is 2.5-times lower than the KD received from saturation binding 
experiments (62 nM; Figure 5.9a). Yet, both values are in the same range. Taking the 
incomplete displacement of 5.16 into account, the calculated values can only be 
considered as an approximation of the actual half-lives (t1/2) and off/on rates.37 These 
findings prompted us to investigate the dissociation of the fluorescent labeled 
endogenous ligand Cy5-pNPY, a high affinity fluorescent ligand, which has been 
characterized in our workgroup in detail.10, 38 In contrast to 5.16 the Cy5 labeled 
peptide revealed complete and relatively fast dissociation (Figure 5.11). 90 % of Cy5-
pNPY were dissociated from the receptor after 60 minutes. Thus, the calculated KD 
from kinetic studies is in good agreement with the dissociation constant from 
saturation binding (KD (kinetic) = 6.1 nM; KD (saturation) = 5.2 nM10) proving that the 
binding of the fluorescent peptide follows the law of mass action.39 
 
Figure  5.10. Binding kinetics of 5.16 at CHO-hY2R cells. a) Association of 5.16 (c = 60 nM) as a function of time. 
b) Dissociation kinetics of 5.16 (pre-incubation: 60 nM, 30 min) in the presence of BIIE 0246 (c = 6 µM), 
monophasic exponential decay, t1/2 = 11.9 min. c) Linearization of the association (ln[Beq/(Beq-B)] vs. time) for the 
determination of the on-rate (kon): slope = kob = 0.04442 min-1, kon = (kob - koff)/[L] = 0.000526 min-1 · nM-1. d) 
Linearization of the dissociation (ln(B/B0) vs. time) for the determination of the off-rate (koff): slope (-1) = koff = 
0.01285 min-1. (n = 3). 
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Figure  5.11. Dissociation of Cy5-pNPY (c = 5 nM) 
from the Y2R as a function of time in the presence of 
pNPY (c = 500 nM), monophasic exponential decay, 
t1/2 = 11.2 min. 
 
For the Py-1 labeled fluorescent ligand 5.4 a time-dependent association similar to 
that of 5.16 was observed (Figure 5.12). Surprisingly, the dissociation experiments 
failed. There was no displacement in the presence of 100-fold excess of BIIE 0246, 
although the same concentration of BIIE 0246 was sufficient to determine the non-
specific binding of 5.4 in saturation binding assays (cf. Figure 5.8). The critical 
difference between the assay procedures is the co-incubation of the fluorescent 
ligand with BIIE 0246 in case of saturation binding, whereas for dissociation 
experiments the fluorescent ligand is initially pre-incubated for 30 min with the cells, 
followed by a washing step and the addition of BIIE 0246 to the cell suspension. Thus, 
BIIE 0246 is unable to displace 5.4 when the latter has been pre-incubated with the 
cells. In principle, such a behavior could implement a distinct binding site or covalent 
binding of 5.4 to the receptor. However, both scenarios are highly unlikely. Both 
compounds share the same pharmacophoric moiety, irreversible binding of the Py-1 
labeled fluorescent ligand was not observed when 5.4 was displaced with BIIE 0246 in 
saturation and competition binding experiments, and 5.4 does not possess reactive 
groups prone to covalent binding. 
Figure  5.12. Association kinetic of 5.4 (c = 40 nM). 
Non-specific binding was determined with 100-fold 
excess of BIIE 0246. 
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5.3.3.3 Competition Binding Experiments 
The applicability of selected fluorescent ligands (5.4, 5.15-5.17) as reference 
compounds for the determination of Y2R binding affinity was explored in competition 
binding experiments using several reference Y2R ligands and new compounds 
described in this work. The fluorescent compounds were used at concentrations 
around their KD values determined by saturation, taking into consideration the large 
difference between specific and non-specific binding at the respective 
concentrations, resulting in a high signal-to-noise ratio. The standard antagonist 
BIIE 0246 was used in equilibrium competition binding experiments with all four 
fluorescent ligands. Furthermore, the endogenous ligand pNPY, the potential 
radioligand (S)-3.63, and the recently developed small molecule Y2R antagonist SF-11 
were used for the displacement of the Py-1 labeled antagonist 5.4 and the S0387 
coupled analog 5.16. Unfortunately, SF-11 exhibited low binding affinities in the µM 
range at the Y2R, despite moderate antagonism demonstrated in functional assays 
(IC50 = 199 nM40; IC50 (fura-2) = 349 nM; KB = 77 nM). The calculated Ki values are 
summarized in Table 5.8. 
As already observed in confocal microscopy, the high affinity agonist pNPY failed to 
displace the fluorescent antagonists (Figure 5.13). By contrast, the argininamide-type 
Y2R fluorescent ligands were able to displace Cy5-pNPY in flow cytometric 
competition binding with high affinities (e.g., 5.4: Ki = 23 nM). Presumably, 
interaction of pNPY with the agonist binding pocket is prevented by the antagonist 
priorly bound to the Y2R. Thus, BIIE 0246-type ligands act as insurmountable (non-
competitive) antagonists versus the endogenous agonist, probably due to distinct or 
at least not totally overlapping binding sites, or because of the stabilization of a 
ligand (antagonist)-specific receptor conformation. However, the calculated Ki values 
of BIIE 0246 and (S)-3.63 are in good agreement with data from flow cytometric 
competition binding using Cy5-pNPY as standard ligand (Table 5.8). 
Hence, the fluorescent antagonists are useful pharmacological tools in flow 
cytometric binding experiments for the characterization of non-peptidic antagonists. 
Yet, the characterization of peptide ligands could result in “false negatives” due to 
insurmountable ((pseudo)-irreversible) antagonism (Figure 5.13). 
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Figure  5.13. Flow cytometric competition binding on CHO-hY2R cells; incubation time: 30 min for non-peptidic 
antagonists; incubation time: 90 min for pNPY; non-specific binding was determined with BIIE 0246 (c = 10 µM); 
mean values ± SEM (n = 2-5). a) Displacement of 5.4 (c = 40 nM, KD = 25 nM) measured in Fl-2. b) Displacement 
of 5.16 (c = 60 nM, KD = 60 nM) measured in Fl-4. 
Table  5.8. Ki values determined in flow cytometric competition binding assays on CHO-hY2R cells. 
Compd. 
Flow cytometric competition binding assay, Ki / nM 
displacement of 
5.4a 5.16b 5.15c 5.17d Cy5-pNPYe 
BIIE 0246 22 ± 6 2.9 ± 0.3 19 ± 4 15 ± 1 10.2 ± 1.1 
pNPY 12040 ± 1009 770 ± 190 nd nd 0.8 ± 0.210 
(S)-3.63 77 ± 3 11 ± 0.6 nd nd 9.9 ± 1.0f 
SF-11 4915 ± 836 2890 ± 938 nd nd 1251 ± 348 
a KD = 25 nM (Fl-2), c = 40 nM. 
b KD = 62 nM (Fl-4), c = 60 nM. 
c KD = 143 nM (Fl-4), c = 100 nM. 
d KD = 42 nM (Fl-4), c = 
40 nM. e KD = 5.2 nM (Fl-4), c = 5 nM. 
f Determined with Dy-635-pNPY. (mean values ± SEM, n = 2-5). 
5.4 Summary and Conclusion 
The design of fluorescent Y2R ligands was based on the application of the guanidine-
acylguanidine bioisosteric approach to the argininamide-type Y2R antagonist 
BIIE 0246. Herein, the guanidine group was linked to fluorophores via ω-aminoacyl 
spacers of different lengths and chemical nature. The fluorescent label was attached 
to the primary amines by acylation with succinimidyl esters or by ring transformation 
of pyrylium dyes. The majority of the synthesized derivatives proved to be potent and 
selective fluorescence labeled Y2R antagonists. However, the binding affinity strongly 
depended on the chemical nature of the fluorescent dye. 
The low molecular weight pyrylium dyes turned out to be well suited for fluorescence 
labeling of Y2R antagonists exhibiting retained affinity compared to the parent 
compound BIIE 0246. Hence, a preserved positive charge in the ω-aminoacyl spacer 
after ring transformation is assumed to be favorable in terms of receptor binding, as 
the positively charged resonance-stabilized pyridinium may contribute to Y2R binding 
by electrostatic interactions. The attachment of bulky dyes by acylation and 
concomitant elimination of the positive charge led to a more or less pronounced 
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decrease in activity compared to the parent argininamide. As expected, a preserved 
positive charge in the linker was favorable in terms of antagonistic activity (5.17, 
5.18, 5.24). By contrast, S0387 and Dy-633 labeled compounds (5.16, 5.21, 5.23, 
5.25), comprising a SO3– moiety in the fluorophore, appeared to be inferior compared 
to their S0436 and Dy-630 coupled analogs (5.15, 5.20), presumably due to 
electrostatic repulsion with extracellular loop regions of the receptor. 
The majority of the cyanine (S0436, S0387), Dy-630 and Dy-633 labeled fluorescent 
ligands were successfully applied in confocal microscopy even at very low concentra-
tions relative to their KB and Ki values (cf. 5.16). In case of pyrylium coupled ligands, 
5.4 and 5.28 revealed suitable binding properties, whereas rapid diffusion into the 
cells was observed for the Py-1 and Py-5 fluorescent antagonists 5.1-5.3, 5.5-5.14. A 
selection of fluorescent ligands turned out to be appropriate for investigations in flow 
cytometric equilibrium binding studies. The versatility of this application makes 
fluorescence-labeled Y2R antagonists a promising alternative to the commonly used 
universal NPY receptor ligand Cy5-pNPY. 
In addition, the novel fluorescent probes were utilized in more detailed studies on 
the binding mode of argininamide-type Y2R antagonists. In contrast to Cy5-pNPY, 
kinetic experiments with the fluorescent ligand 5.16 revealed pseudo-irreversible 
binding. Furthermore, an insurmountable binding versus the natural ligand pNPY was 
observed for several fluorescent antagonists in flow cytometric competition binding 
(5.4, 5.16) and confocal microscopy (5.16, 5.22, 5.29), respectively. 
In summary, the new fluorescent probes can be regarded as useful reference 
compounds and pharmacological tools for fluorescence-based screening and detailed 
pharmacological characterization of small molecule Y2R ligands. Moreover, these 
fluorescent ligands enable the optical detection of NPY Y2 receptors in vitro as 
demonstrated on hY2R expressing CHO cells. 
5.5 Experimental Section 
5.5.1 General Experimental Conditions 
Chemicals and solvents were purchased from commercial suppliers and used without 
further purification. Pyrylium dyes Py-1 and Py-5 (tetrafluoroborate salts) were kindly 
provided by the Institute of Analytical Chemistry, Chemo- and Biosensors at the 
University of Regensburg (Prof. Dr. O. S. Wolfbeis). These dyes are also commercially 
available from Active Motif Chromeon (www.activemotif.com). The succinimidyl 
esters of fluorescent dyes S0436 and S0387 were obtained from FEW Chemicals 
(Bitterfeld-Wolfen, Germany). The succinimidyl esters of fluorescent dyes Dy-630 and 
Dy-633 were obtained from Dyomics (Jena, Germany). The Bodipy 650/665-X 
succinimidyl ester (SE) and Cy5-NHS ester were obtained from Molecular Probes 
(now Invitrogen; Darmstadt, Germany) and GE Healthcare LifeSciences (Freiburg, 
 Red-Fluorescent NPY Y2R Antagonists 159 
Germany), respectively. Porcine NPY (pNPY) was kindly provided by the Institute of 
Organic Chemistry I at the Ruhr-University Bochum (Prof. Dr. C. Cabrele). SF-11 was 
purchased from Tocris Bioscience (Bristol, United Kingdom). All solvents were of 
analytical grade or distilled prior to use. DMF (H2O < 0.01 %) was purchased from 
Sigma-Aldrich Chemie GmbH. 
Low resolution mass spectrometry analysis (MS) was performed in-house on a 
Finnigan ThermoQuest TSQ 7000 (ES-MS) and a Finnigan SSQ 710A (EI-MS 70 eV, 
CI-MS). High resolution mass spectrometry analysis (HRMS) for compound 5.5 was 
performed on a JMS-700 instrument (JOEL Ltd, Tokyo, Japan). Lyophilization was 
done with a Christ alpha 2-4 LD equipped with a vacuubrand RZ 6 rotary vane vacuum 
pump. 
Preparative HPLC was performed on a system from Knauer (Berlin, Germany) 
consisting of two K-1800 pumps, a K-2001 detector and two RP-columns (Nucleodur 
100-5 C18ec, 250 × 21 mm, 5 μm; Gemini-NX C18, 250 × 21 mm, 5 μm, AXIA Packed) 
at a flow rate of 22 mL/min. Mixtures of acetonitrile and 0.1 % aq. TFA were used as 
mobile phase. Acetonitrile was removed from the eluates under reduced pressure 
(final pressure: 90 mbar) at 45 °C prior to lyophilization. Analytical HPLC analysis was 
performed on two different systems (Thermo Separation Products, Merck) which are 
listed in detail below. Mixtures of acetonitrile (A) and 0.05 % aq. TFA (B) (Thermo 
Separation Products), and mixtures of acetonitrile + 0.025 % TFA (A) and 0.025 % aq. 
TFA (B) (Merck), respectively, were used as mobile phase. Helium degassing was used 
throughout. 
Stock solutions (2 or 10 mM) of all compounds were prepared in DMSO and stored at 
–20 °C. 
 
Analytical HPLC systems: 
System 1: Thermo Separation Products; composed of a SN400 controller, a P4000 
pump, a degasser (Degassex DG-4400, phenomenex), an AS3000 autosampler and a 
Spectra Focus UV-VIS detector; flow rate: 0.8 mL/min; UV detection: 220 nm. 
System 2: Merck; composed of a L-5000 controller, a 655A-12 pump, a 655A-40 
autosampler and a L-4250 UV-VIS detector; flow rate: 0.7 mL/min; UV detection: 220 
nm. 
 
Applied gradients:  
Gradient 1 (Thermo Separation Products): 0 to 30 min: A/B 20/80 to 95/5, 30 to 37 
min: 95/5. 
Gradient 2 (Merck): 0 to 30 min: A/B 20/80 to 95/5, 30 to 40 min: 95/5. 
The purity of all compounds was determined by HPLC using system 1 (gradient 1) on a 
Eurospher-100 C18 column (250 × 4 mm, 5 μm, Knauer, Berlin, Germany), except for 
compounds 5.18, 5.24 and 5.27, which were measured with a Nucleodur H-Tec 100-5 
C18 column (250 × 4 mm, 5 μm, Macherey-Nagel, Düren, Germany). HPLC system 2 
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(gradient 2) was used for reaction monitoring on a Eurospher-100 C18 column (250 × 
4 mm, 5 μm, Knauer, Berlin, Germany). 
5.5.2 Chemistry: Experimental Protocols and Analytical Data 
General procedure for the preparation of Py-1 and Py-5 labeled fluorescent ligands 
5.1-5.14, 5.28: 
The pertinent amine precursor (2-4 eq) and NEt3 (8-15 eq) were dissolved in a 
mixture of CH3CN and DMF (≈ 10 % DMF v/v, total volume: 400-800 µL) followed by 
the addition of the pyrylium dye × BF4– (1 eq) in DMF (≈ 50 µL). The reaction was 
stopped by addition of 10 % aq. TFA (corresponding to 6-10 eq TFA) after an 
incubation period of 1-3 h at rt. The reaction mixture was adjusted with 0.1 % aq. TFA 
to a volume of ≈ 2-4 mL resulting in a ratio of CH3CN/0.1 % aq. TFA, which 
approximately corresponds to the ratio of the solvents CH3CN/0.1 % TFA in the 
starting eluent (max. two times higher concentration of CH3CN). The reaction 
mixtures were subjected to preparative HPLC yielding the products as red solids after 
lyophilization. 
 
1-((15S)-10-Amino-19-[3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl]-4,8,16-trioxo-
15-{2-[1-(2-oxo-2-{4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-
yl}ethyl)cyclopentyl]acetamido}-3,9,11,17-tetraazanonadec-9-enyl)-4-[2-
(1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)vinyl]-2,6-dimethylpyridinium 
2,2,2-trifluoroacetate (5.1). Yield: 52 % (1.73 mg); MS (ES, +p) m/z (%): 671 (100) 
[M+H]2+; RP-HPLC: 92 % (tR = 22.7 min, k´ = 7.4); C77H91N14O8+ × C2F3O2– (1425.70). 
 
1-((5S)-10-Amino-1-[3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl]-4,12,16-trioxo-5-
{2-[1-(2-oxo-2-{4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-
yl}ethyl)cyclopentyl]acetamido}-3,9,11,17-tetraazaicos-10-en-20-yl)-4-[2-
(1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)vinyl]-2,6-dimethylpyridinium 
2,2,2-trifluoroacetate (5.2). Yield: 35 % (1.20 mg); MS (ES, +p) m/z (%): 678 (100) 
[M+H]2+; RP-HPLC: 94 % (tR = 22.9 min, k´ = 7.5); C78H93N14O8+ × C2F3O2– (1466.72). 
 
1-((5S)-10-Amino-1-[3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl]-4,12,16-trioxo-5-
{2-[1-(2-oxo-2-{4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl}-
ethyl)cyclopentyl]acetamido}-3,9,11,17-tetraazaicos-10-en-20-yl)-4-{4-[4-(dimethyl-
amino)phenyl]buta-1,3-dienyl}-2,6-dimethylpyridinium 2,2,2-trifluoroacetate (5.3). 
Yield: 36 % (1.59 mg); MS (ES, +p) m/z (%): 665 (100) [M+H]2+, 443 (32) [M+2H]3+; RP-
HPLC: 96 % (tR = 20.8 min, k´ = 6.7); C76H91N14O8+ × C2F3O2– (1440.70). 
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1-((18S)-13-Amino-22-[3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl]-7,11,19-trioxo-
18-{2-[1-(2-oxo-2-{4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-
yl}ethyl)cyclopentyl]acetamido}-3,6,12,14,20-pentaazadocos-12-enyl)-4-[2-
(1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)vinyl]-2,6-dimethylpyridinium 
2,2,2-trifluoroacetate (5.4). Yield: 39 % (1.79 mg); MS (ES, +p) m/z (%): 692 (30) 
[M+H]2+, 462 (100) [M+2H]3+; RP-HPLC: 90 % (tR = 18.3 min, k´ = 5.8); C79H96N15O8+ × 
C2F3O2– (1495.75). 
 
1-((5S)-10-Amino-1-[3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl]-4,12,15-trioxo-5-
{2-[1-(2-oxo-2-{4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-
yl}ethyl)cyclopentyl]acetamido}-20,23,26-trioxa-3,9,11,16-tetraazanonacos-10-en-
29-yl)-4-[2-(1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)vinyl]-2,6-
dimethylpyridinium 2,2,2-trifluoroacetate (5.5). Yield: 50 % (2.25 mg); MS (ES, +p) 
m/z (%): 744 (100) [M+H]2+; HRMS (LSI-MS): m/z [M+H]+ calcd. for C84H106N14O11+: 
1486.8160, found: 1486.8101; RP-HPLC: 62 % (tR = 23.9 min, k´ = 7.9); C84H105N14O11+ × 
C2F3O2– (1598.80). 
 
1-((11S)-6-Amino-15-[3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl]-4,12-dioxo-11-
{2-[1-(2-oxo-2-{4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl}-
ethyl)cyclopentyl]acetamido}-3,5,7,13-tetraazapentadec-5-enyl)-4-[2-(1,2,3,5,6,7-
hexahydropyrido[3,2,1-ij]quinolin-9-yl)vinyl]-2,6-dimethylpyridinium 2,2,2-tri-
fluoroacetate (5.6). Yield: 49 % (1.86 mg); MS (ES, +p) m/z (%): 636 (100) [M+H]2+; 
RP-HPLC: 64 % (tR = 22.8 min, k´ = 7.4); C73H85N14O7+ × C2F3O2– (1382.66). 
 
1-((5S)-10-Amino-1-[3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl]-4,12-dioxo-5-{2-
[1-(2-oxo-2-{4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl}-
ethyl)cyclopentyl]acetamido}-3,9,11,13-tetraazahexadec-10-en-16-yl)-4-[2-
(1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)vinyl]-2,6-dimethylpyridinium 
2,2,2-trifluoroacetate (5.7). Yield: 45 % (1.68 mg); MS (ES, +p) m/z (%): 643 (100) 
[M+H]2+; RP-HPLC: 61 % (tR = 24.6 min, k´ = 8.1); C74H87N14O7+ × C2F3O2– (1396.68). 
 
1-((5S)-10-Amino-1-[3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl]-4,12-dioxo-5-{2-
[1-(2-oxo-2-{4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl}-
ethyl)cyclopentyl]acetamido}-3,9,11,13-tetraazahexadec-10-en-16-yl)-4-{4-[4-(di-
methylamino)phenyl]buta-1,3-dienyl}-2,6-dimethylpyridinium 2,2,2-trifluoro-
acetate (5.8). Yield: 17 % (0.73 mg); MS (ES, +p) m/z (%): 630 (100) [M+H]2+; RP-HPLC: 
98 % (tR = 21.7 min, k´ = 7.0); C72H85N14O7+ × C2F3O2– (1370.66). 
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1-((5S)-10-Amino-1-[3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl]-4,12-dioxo-5-{2-
[1-(2-oxo-2-{4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl}-
ethyl)cyclopentyl]acetamido}-3,9,11,13-tetraazaheptadec-10-en-17-yl)-4-[2-
(1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)vinyl]-2,6-dimethylpyridinium 
2,2,2-trifluoroacetate (5.9). Yield: 35 % (1.52 mg); MS (ES, +p) m/z (%): 650 (100) 
[M+H]2+; RP-HPLC: 66 % (tR = 25.1 min, k´ = 8.3); C75H89N14O7+ × C2F3O2– (1410.69). 
 
1-((5S)-10-Amino-1-[3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl]-4,12-dioxo-5-{2-
[1-(2-oxo-2-{4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl}-
ethyl)cyclopentyl]acetamido}-3,9,11,13-tetraazanonadec-10-en-19-yl)-4-{4-[4-(di-
methylamino)phenyl]buta-1,3-dienyl}-2,6-dimethylpyridinium 2,2,2-trifluoro-
acetate (5.10). Yield: 33 % (1.88 mg); MS (ES, +p) m/z (%): 651 (100) [M+H]2+; RP-
HPLC: 78 % (tR = 23.2 min, k´ = 7.6); C75H91N14O7+ × C2F3O2– (1412.71). 
 
1-{6-[Amino((4S)-5-{2-[3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl]ethylamino}-5-
oxo-4-{2-[1-(2-oxo-2-{4-[6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl]piperazin-
1-yl}ethyl)cyclopentyl]acetamido}pentylamino)methyleneamino]-6-oxohexyl}-4-[2-
(1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)vinyl]-2,6-dimethylpyridinium 
2,2,2-trifluoroacetate (5.11). Yield: 67 % (3.31 mg); MS (ES, +p) m/z (%): 649 (100) 
[M+H]2+; RP-HPLC: 72 % (tR = 24.0 min, k´ = 7.9); C76H90N13O7+ × C2F3O2– (1409.70). 
 
1-{6-[Amino((4S)-5-{2-[3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl]ethylamino}-5-
oxo-4-{2-[1-(2-oxo-2-{4-[6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl]piperazin-
1-yl}ethyl)cyclopentyl]acetamido}pentylamino)methyleneamino]-6-oxohexyl}-4-{4-
[4-(dimethylamino)phenyl]buta-1,3-dienyl}-2,6-dimethylpyridinium 2,2,2-trifluoro-
acetate (5.12). Yield: 36 % (1.25 mg); MS (ES, +p) m/z (%): 636 (100) [M+H]2+; RP-
HPLC: 98 % (tR = 22.6 min, k´ = 7.4); C72H84N13O7+ × C2F3O2– (1355.65). 
 
1-((15S)-10-Amino-19-[3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl]-8,16-dioxo-15-
{2-[1-(2-oxo-2-{4-[6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl]piperazin-1-yl}-
ethyl)cyclopentyl]acetamido}-3,6-dioxa-9,11,17-triazanonadec-9-enyl)-4-[2-
(1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)vinyl]-2,6-dimethylpyridinium 
2,2,2-trifluoroacetate (5.13). Yield: 24 % (1.18 mg); MS (ES, +p) m/z (%): 665 (100) 
[M+H]2+; RP-HPLC: 90 % (tR = 24.1 min, k´ = 7.9); C76H90N13O9+ × C2F3O2– (1441.69). 
 
1-((22S)-17-Amino-26-[3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl]-15,23-dioxo-22-
{2-[1-(2-oxo-2-{4-[6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl]piperazin-1-
yl}ethyl)cyclopentyl]acetamido}-3,6,9,12-tetraoxa-16,18,24-triazahexacos-16-enyl)-
4-{4-[4-(dimethylamino)phenyl]buta-1,3-dienyl}-2,6-dimethylpyridinium 2,2,2-
trifluoroacetate (5.14). Yield: 23 % (0.90 mg); MS (ES, +p) m/z (%): 703 (100) [M+H]2+; 
RP-HPLC: 90 % (tR = 22.0 min, k´ = 7.1); C79H98N13O11+ × C2F3O2– (1517.74). 
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1-((18S)-13-Amino-18-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl-
carbamoyl]-7,11,20,24-tetraoxo-24-{4-[6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-
11-yl]piperazin-1-yl}-3,6,12,14,19-pentaazatetracos-12-enyl)-4-{4-[4-(dimethyl-
amino)phenyl]buta-1,3-dienyl}-2,6-dimethylpyridinium 2,2,2-trifluoroacetate 
(5.28). Yield: 15 % (0.75 mg); MS (ES, +p) m/z (%): 652 (75) [M+H]2+, 435 (100) 
[M+2H]3+; RP-HPLC: 94 % (tR = 15.2 min, k´ = 4.6); C73H88N15O8+ × C2F3O2– (1415.68). 
 
General procedure for the preparation of S0436, S0387, Dy-630, Dy-633, and 
Bodipy 650/665-X labeled fluorescent ligands 5.15-5.27, 5.29: 
The pertinent amine precursor (2 eq) and NEt3 (8 eq) were dissolved in CH3CN (200-
400 µL), followed by the addition of the dye-NHS ester (1 eq) in CH3CN (100-200 µL) 
and DMF resulting in a total volume of 300-600 µL. For the acylation with S0387-NHS 
ester ≈ 10-20 % DMF v/v was added to the CH3CN solution prior to addition to the 
stirred reaction mixture. The reaction was stopped by addition of 10 % aq. TFA 
(corresponding to 6-10 eq TFA) after an incubation period of 8-16 h at rt. The reaction 
mixture was adjusted to a volume of ≈ 2-4 mL by addition of 0.1 % aq. TFA resulting in 
a ratio of CH3CN/0.1 % aq. TFA, which approximately corresponds to the ratio of the 
solvents (CH3CN/0.1 % TFA) in the starting eluent (max. two times higher 
concentration of CH3CN). The reaction mixtures were subjected to preparative HPLC 
yielding the products as cyan or blue solids after lyophilization. 
 
4-[2-(5-{1-[(5S)-10-Amino-1-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)-
4,12,16,22-tetraoxo-5-{2-[1-(2-oxo-2-{4-[6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-
11-yl]piperazin-1-yl}ethyl)cyclopentyl]acetamido}-3,9,11,17,21-pentaazaheptacos-
10-en-27-yl]-3,3-dimethylindolin-2-ylidene}penta-1,3-dienyl)-1,1-dimethyl-1H-iso-
indolium-3-yl]butane-1-sulfonate 2,2,2-trifluoroacetate (5.15). Yield: 73 % (2.88 
mg); MS (ES, +p) m/z (%): 1654 (40) [M+H]+, 827 (100) [M+2H]2+; RP-HPLC: 92 % (tR = 
24.3 min, k´ = 8.0); C92H113N12O12S × C2HF3O2 (1765.83). 
 
Compound (S)-3.49 labeled with S0387 (5.16). Yield: 23 % (0.56 mg); MS (ES, +p) m/z 
(%): 868 (100) [M+3H]2+; RP-HPLC: 99 % (tR = 16.5 min, k´ = 5.1); C92H112N15O15S2– × 
C4H2F6O4 (1958.77). 
 
Compound (S)-3.50 labeled with S0436 (5.17). Yield: 58 % (1.54 mg); MS (ES, +p) m/z 
(%): 842 (25) [M+2H]2+, 562 (100) [M+3H]3+; RP-HPLC: 97 % (tR = 20.2 min, k´ = 6.5); 
C93H116N16O12S × C2HF3O2 (1794.86). 
 
Compound (S)-3.50 labeled with S0387 (5.18). Yield: 34 % (1.20 mg); MS (ES, +p) m/z 
(%): 882 (100) [M+3H]2+; RP-HPLC: 99 % (tR = 12.5 min, k´ = 4.4); C93H115N16O12S2– × 
C4H2F6O4 (1987.80). 
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Compound (S)-3.51 labeled with S0436 (5.19). Yield: 83 % (1.83 mg); MS (ES, +p) m/z 
(%): 1786 (30) [M+H]+, 894 (100) [M+2H]2+; RP-HPLC: 87 % (tR = 23.9 min, k´ = 7.9); 
C98H125N15O15S × C2HF3O2 (1897.91). 
 
Compound (S)-3.52 labeled with S0436 (5.20). Yield: 65 % (1.54 mg); MS (ES, +p) m/z 
(%): 785 (100) [M+2H]2+; RP-HPLC: 97 % (tR = 24.9 min, k´ = 8.2); C87H105N15O11S × 
C2HF3O2 (1681.77). 
 
Compound (S)-3.53 labeled with S0387 (5.21). Yield: 43 % (1.05 mg); MS (ES, +p) m/z 
(%): 832 (100) [M+3H]2+; RP-HPLC: 97 % (tR = 17.5 min, k´ = 5.5); C87H105N15O11S– × 
C4H2F6O4 (1795.76). 
 
Compound (S)-3.57 labeled with S0436 (5.22). Yield: 29 % (1.84 mg); MS (ES, +p) m/z 
(%): 1628 (20) [M+H]+, 815 (100) [M+2H]2+; RP-HPLC: 93 % (tR = 24.5 min, k´ = 8.1); 
C90H110N14O13S × C2HF3O2 (1740.80). 
 
Compound (S)-3.49 labeled with Dy-633 (5.23). Yield: 73 % (0.81 mg); MS (ES, +p) 
m/z (%): 889 (100) [M+3H]2+; RP-HPLC: 98 % (tR = 18.8 min, k´ = 6.0); C94H116N15O16S2– 
× C4H2F6O4 (2002.80). 
 
1-[(5S)-10-Amino-1-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)-4,12,16,24-tetra-
oxo-5-{2-[1-(2-oxo-2-{4-[6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl]piperazin-
1-yl}ethyl)cyclopentyl]acetamido}-3,9,11,17,20,23-hexaazanonacos-10-en-29-yl]-2-
{3-[2-tert-butyl-7-(diethylamino)chromenylium-4-yl]allylidene}-3,3-dimethyl-
indoline-5-sulfonate 2,2,2-trifluoroacetate (5.24). Yield: 34 % (0.93 mg); MS (ES, +p) 
m/z (%): 857 (35) [M+2H]2+, 572 (100) [M+3H]3+; RP-HPLC: 100 % (tR = 15.0 min, k´ = 
5.5); C94H118N16O13S × C2HF3O2 (1824.87). 
 
Compound (S)-3.55 labeled with Dy-633 (5.25). Yield: 23 % (0.26 mg); MS (ES, +p) 
m/z (%): 875 (100) [M+3H]2+; RP-HPLC: 93 % (tR = 22.0 min, k´ = 7.1); C93H116N15O15S2– 
× C4H2F6O4 (1974.80). 
 
3-{4-[(5S)-10-Amino-1-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)-4,12,16,22,29-
pentaoxo-5-{2-[1-(2-oxo-2-{4-[6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl]-
piperazin-1-yl}ethyl)cyclopentyl]acetamido}-3,9,11,17,21,28-hexaazatriacont-10-en-
30-yloxy]styryl}-5,5-difluoro-7-(1H-pyrrol-2-yl)-5H-dipyrrolo[1,2-c:1',2'-f]-
[1,3,2]diazaborinin-4-ium-5-uide 2,2,2-trifluoroacetate (5.26). Yield: 40 % (0.60 mg); 
MS (ES, +p) m/z (%): 798 (100) [M+2H]2+; RP-HPLC: 98 % (tR = 25.6 min, k´ = 8.5); 
C86H98BF2N17O11 (1593.77). 
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Compound (S)-3.50 labeled with Bodipy 650/665-X (5.27). Yield: 56 % (1.27 mg); MS 
(ES, +p) m/z (%): 812 (30) [M+2H]2+, 542 (100) [M+3H]3+; RP-HPLC: 87 % (tR = 15.5 
min, k´ = 5.7); C87H102BF2N18O11 (1623.80). 
 
4-{2-[5-(1-{(7S)-12-Amino-7-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl-
carbamoyl]-1,5,14,18,26-pentaoxo-1-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-
11-yl)piperazin-1-yl]-6,11,13,19,22,25-hexaazahentriacont-12-en-31-yl}-3,3-di-
methylindolin-2-ylidene)penta-1,3-dienyl]-3,3-dimethyl-3H-indolium-1-yl}butane-1-
sulfonate 2,2,2-trifluoroacetate (5.29). Yield: 57 % (1.48 mg); MS (ES, +p) m/z (%): 
815 (85) [M+2H]2+, 544 (100) [M+3H]3+; RP-HPLC: 87 % (tR = 18.0 min, k´ = 5.7); 
C89H110N16O12S × C2HF3O2 (1740.81). 
5.5.3 Synthesis and Purification of Cy5-pNPY 
Cy5-pNPY was synthesized as previously described.38 HPLC purification was 
performed by analytical HPLC using system 2 equipped with a Jupiter 300 C18 column 
(250 × 4.6 mm, 5µm, Phenomenex, Aschaffenburg, Germany). Conditions: UV 
detection: 275 nm; fluorescence detection: λex = 645 nm, λem = 670 nm; eluent: 
mixtures of acetonitrile + 0.025 % TFA (A) and 0.025 % aq. TFA (B), gradient: 0 to 30 
min: A/B 25/75 to 35/65, 30 to 32 min: 35/65 to 95/5, 32 to 47 min: 95/5, tR = 32.0 
min (UV). After evaporation the product was re-diluted in CH3CN/0.1 aq. TFA (20/80, 
v/v). The concentration was determined by UV/vis spectroscopy at 649 nm, using the 
molar extinction coefficient of cy5 for the appropriate solvent mixture determined 
previously by R. Ziemek (313568 L · mol–1 · cm–1)36. Afterwards, the labeled peptide 
was aliquoted (1 nmol) into siliconized microtubes (1.5 mL) and the solvent was 
evaporated in the vacuum concentrator at room temperature. The purified product 
was analyzed by MS (MALDI-TOF: m/z = 4927). 
5.5.4 Fluorescence Spectroscopy and Determination of Quantum Yields 
The quantum yields were determined with a Cary Eclipse spectrofluorimeter and a 
Cary 100 UV/VIS photometer (Varian Inc., Mulgrave, Victoria, Australia). The 
photomultiplier voltage of the Cary Eclipse spectrofluorimeter was set to 400 V 
throughout. Recording of excitation spectra was performed with an excitation slit of 5 
nm and an emission slit of 10 nm. Emission spectra depicted in Figure 5.2 were 
recorded with an excitation slit and an emission slit of 10 nm, respectively. The 
quantum yields were determined by analogy with a previously reported protocol12 
using cresyl violet perchlorate (Acros Organics, Geel, Belgium) as red fluorescent 
standard, for which a quantum yield of 54 % in ethanol was reported in the 
literature41. Determination of the spectra was performed in acryl cuvettes (10 × 10 
mm, Ref. 67.755, Sarstedt, Nümbrecht, Germany). For fluorescence spectroscopy, 
solutions corresponding to absorbances between 0.08 and 0.2 at the respective 
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excitation wavelength were used. The appropriate concentration of the fluorescent 
ligands was determined by UV/vis spectroscopy; absorption spectra were recorded 
within a concentration range of 3-10 µM. For the pyrylium labeled compounds 5.1-
5.14 the excitation wavelength was chosen as close to the absorption maximum as 
possible. The (hemi-)cyanine- and Bodipy-labeled ligands (5.15-5.27) were excited at 
a plateau of the absorption spectrum. It was strictly avoided to excite the fluorescent 
compounds in flank of the excitation spectrum. 
Solutions of the fluorescent ligands were freshly prepared from 2 or 10 mM stock 
solutions of the compounds in DMSO and immediately protected from light. 
Fluorescence spectra were recorded at two different slit adjustments 
(excitation/emission): 10/5 nm, 10/10 nm. For the determination of reference 
spectra, the pure solvents with the same DMSO content were measured. 
Instrument settings for the recorded emission spectra: T = 22 °C; `medium scan rate´; 
filter settings: auto (excitation filter), open (emission filter); λem = λex + 10-15 nm. 
Substraction of the corresponding reference spectrum from every emission spectrum 
yielded the net spectra, which were multiplied with the appropriate lamp correction 
spectra, resulting in the corrected emission spectra (cf. Figure 5.2). The corrected 
emission spectra were integrated up to 850 nm. 
The absorbance at the excitation wavelength was determined by recording 
absorption spectra immediately after recording the emission spectra (within 30 min 
after preparation of test solutions). Baselines were stored using reference solutions 
and substracted from the raw spectra. The quantum yield was calculated according to 
the following equation41: 
φF(X) = (As/Ax) (Fx/Fs) (nx/ns)2 φF(S) 
A: absorbance of the corrected absorption spectrum at the excitation wavelength; 
F: integral of the corrected emission spectrum; 
n: refraction index of the solvent; 
φF: quantum yield / %; 
s: cresyl violet perchlorate standard; φF(S) = 54; 
x: fluorescent ligand (sample). 
5.5.5 Investigation of the Chemical Stability 
The stability of the fluorescent Y2R antagonists 5.4, 5.10, 5.14, 5.17 and 5.22 
regarding the formation of BIIE 0246 was investigated at neutral pH in FACS binding 
buffer (cf. Chapter 5.5.6.1). Incubation was started by addition of 10 µL of a 1 mM 
solution of the compounds in DMSO to 190 µL of buffer giving a final concentration of 
50 µM. After 90 minutes incubation, a 80 µL aliquot was taken and diluted with a 
mixture of CH3CN, H2O and 1 % aq. TFA (5:1:4, 80 µL). 100 µL of the resulting solution 
(pH = 2-3) was analyzed by HPLC on a RP-column (Eurospher-100 C18, 250 × 4 mm, 
5 µm, Knauer, Berlin, Germany) using a system from Thermo Separation Products 
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(composed of a SN400 controller, a P4000 pump, a degasser (Degassex DG-4400, 
phenomenex), an AS3000 autosampler and a Spectra Focus UV/vis detector). 
Mixtures of acetonitrile (A) and 0.05 % aq. TFA (B) were used as mobile phase 
(gradient: 0 to 30 min: A/B 20/80 to 95/5, 30 to 37 min: A/B 95/5). The flow rate was 
set to 0.8 mL/min, the column temperature to 30 °C and the detection wavelength to 
220 nm. The quantity of decomposition product BIIE 0246 ((S)-3.47) was estimated 
from the peak integrals of the incubation sample and a reference chromatogram of 
the analyzed compound (incubation time: 0 min). 
5.5.6 Receptor Binding and Functional Assays 
5.5.6.1 Cell Culture and Buffers 
Cell culture. CHO cells stably expressing the hY2R were cultured as described else-
where.10 
Buffers. The buffer for the Y2R binding studies on CHO cells was prepared by the 
addition of BSA (1 %) and bacitracin (100 μg · L-1) to a buffer (pH 7.4) consisting of 
HEPES (25 mM), CaCl2 × 2 H2O (2.5 mM), MgCl2 × 6 H2O (1 mM). BSA and bacitracin 
were omitted in saturation binding, kinetic and competition binding experiments with 
non-peptide fluorescent antagonists. For the displacement of 5.4 and 5.16 with pNPY 
only BSA was omitted. The loading buffer (pH 7.4) for the determination of the 
mobilization of intracellular Ca2+ in CHO cells was prepared by dissolving NaCl (120 
mM), KCl (5 mM), MgCl2 × 6 H2O (2 mM), CaCl2 × 2 H2O (1.5 mM), HEPES (25 mM), 
and glucose (10 mM). 
 
5.5.6.2 Fura-2 Calcium Assay and Radioligand Competition Binding Experiments 
The fura-2 assay was performed as previously described using a LS50 B spectro-
fluorimeter from Perkin Elmer (Überlingen, Germany).42 Radioligand competition 
binding experiments with [3H]-UR-PLN196 were performed for the determination of 
Ki values of the fluorescent ligands 5.4 and 5.16. as described in Chapter 6. 
 
5.5.6.3 Flow Cytometry 
All flow cytometric binding assays were performed with a FACSCaliburTM flow 
cytometer (Becton Dickinson, Heidelberg, Germany), equipped with an argon laser 
(488 nm) and a red diode laser (635 nm).10, 38, 43 All binding assays were performed in 
a final volume of 500 µL containing labeled ligand and unlabeled peptide or 
antagonist as needed. 
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Selectivity assay. The selectivity of the new Y2R antagonists for human NPY Y2 over 
Y1, Y4 and Y5 receptors was investigated by flow cytometric binding assays on Cy5-
pNPY (Y1R, Y5R), and Cy5-[K4]-hPP (Y4R) according to previously described methods.10, 
38, 44 The compounds were tested at two concentrations (1 µM and 10 µM) in 
duplicate. 
Competition binding assay with Cy5-pNPY. The binding assay was performed as 
described elsewhere10 with the following adaptations. Instrument settings were: FSC: 
E-1, SSC: 350 V, Fl-4: 800 V, Flow: HI; measurement stopped when 10000 gated 
events were counted. The experiments were performed using 490 µL of cell 
suspension, 5 µL of Cy5-pNPY (final concentration 5 nM) and 5 µL of test compound 
(100-fold concentrated). If indicated, 5 µL of Dy-635-pNPY (final concentration 10 
nM) was used as fluorescent ligand. Incubation time was 90 min at room 
temperature. Ki values were obtained from 2-3 independent experiments. 
Displacement of fluorescent ligands 5.4, and 5.15-5.17. The cells were seeded three 
days prior to the experiment (90-95 % confluency), trypsinized and resuspended in 
Ham´s F12 medium, containing 10 % fetal calf serum for the inactivation of trypsin. 
After centrifugation at 1,000 rpm for 5 min, the cells were suspended in binding 
buffer without BSA to a density of 2-3 · 106 cells/mL. Bacitracin (0.1 g/L) was added in 
case of competition binding with pNPY in order to prevent protease-mediated 
degradation of the peptide. The experiments were performed with the respective 
fluorescent ligand (c (5.4) = 40 nM, c (5.15) = 100 nM, c (5.16) = 60 nM, c (5.17) = 40 
nM ) in the presence and absence of various competitors at different concentrations 
(10–10 to 10–4 M). Non-specific binding was determined in the presence of 10 µM BIIE 
0246. The samples were incubated in siliconized reaction vessels for 30 min (90 min 
for pNPY) at room temperature before flow cytometer analysis. Instrument settings 
for fluorescent ligand 5.4: FSC: E-1, SSC: 360 V, Fl-2: 550 V, Fl-3: 800 V, Flow: HI; 
measurement stopped when 10000 gated events were counted; Instrument settings 
for fluorescent ligands 5.15-5.17: FSC: E-1, SSC: 350 V, Fl-4: 600 V, Flow: HI; 
measurement stopped when 10000 gated events were counted. 
Saturation binding experiments with 5.4, and 5.15-5.17. Saturation binding 
experiments were performed by analogy with the above mentioned competition 
binding assays with following adaptations. The cells were incubated with the 
respective fluorescent ligand in  increasing concentrations (c ≈ 0.2 × KD - 10 × KD) for 
30 min. Non-specific binding was determined with 100-fold excess of BIIE 0246. 
Kinetics of Y2R binding of Cy5-pNPY, 5.4 and 5.16. The cells were treated as already 
described. Association kinetics was determined by incubation of the cells with a 
constant concentration of labeled ligand (c (Cy5-pNPY) = 5 nM, c (5.4) = 40 nM, c 
(5.16) = 60 nM). Samples were taken at different time periods and measured (For 
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instrument settings see the respective competition binding protocols). Non-specific 
binding was measured with 100-fold excess of pNPY in case of Cy5-pNPY and BIIE 
0246 for the labeled non-peptide ligands, respectively. 
For dissociation experiments cells were pre-incubated with the corresponding labeled 
ligand at the above mentioned concentrations for 30 min (Cy5-pNPY: 120 min) in 
binding buffer without BSA, bacitracin, except for Cy5-pNPY (buffer + 1 % BSA and 
0.1 g/L bacitracin). For non-specific binding, pre-incubation was performed in pre-
sence of 100-fold excess of pNPY in case of Cy5-pNPY and BIIE 0246 for the non-
peptide labeled ligands, respectively. Afterwards, cells were washed with cold 
binding buffer and resuspended in binding buffer consisting of pNPY and BIIE 0246 
(100-fold excess), respectively. Samples were taken at different time periods and 
measured. (For instrument settings see the respective competition binding 
protocols). 
 
5.5.6.4 Data Processing 
All data to be fitted were processed with GraphPad Prism 5. 
Fura-2 Assay. The ratio of fluorescence intensities at 510 nm after excitation at 340 
and 380 nm was used for the calculation of the calcium concentration according to 
the Grynkiewicz equation.45 At least two points between 20 and 80 % inhibition 
served for the calculation of IC50 values after logit-log transformation using the 
following equation: 
logit (P) = log [P/(100-P)]  
IC50 values were obtained by plotting logit (P) versus log B with the slope n according 
to logit (P) = nlog B–nlog IC50 by linear regression. The KB value was calculated using 
the Cheng-Prusoff equation46: 
KB = IC50 · [EC50/(EC50+L)] 
P: mean percent inhibition with SEM < 10 %, determined from 2-3 independent 
experiments performed on different days; 
B: antagonist concentration; 
IC50: concentration of competitor producing 50 % inhibition; 
EC50: agonist concentration that induces 50 % of the maximum response; 
L: concentration of pNPY. 
Radioligand Binding Assay. IC50 values were converted to Ki values according to the 
Cheng-Prusoff equation46 using the respective KD value of the radioligand. 
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Flow Cytometry. The geometric means of fluorescence in the corresponding 
fluorescence channel (Fl-2, Fl-3, Fl-4) of the gated cells were calculated using the 
WinMDI 2.9 software. The inhibition constant Ki was calculated using the Cheng-
Prusoff equation46: 
Ki = IC50 · [KD/(KD+L)] 
Ki: inhibition constant of the competitor; 
KD: dissociation constant of the labeled ligand; 
IC50: concentration of unlabeled competitor producing 50 % inhibition of the specific 
binding of the labeled ligand; 
L: concentration of the labeled ligand. 
 
Data from saturation binding were evaluated by one-site saturation fits. Rate 
constants (kob, koff) were analyzed by linear regressions. The association rate constant 
(kon) was calculated according to the following equation: 
kon = (kob–koff)/L 
L: concentration of the ligand; 
kob: observed/macroscopic association rate constant; 
koff: dissociation rate constant. 
5.5.7 Confocal Microscopy 
Two days prior to the experiment CHO-hY2R cells were trypsinized and seeded in 
Nunc LabTekTM II chambered coverglasses with 8 chambers (Nunc, Wiesbaden, 
Germany), or in 1 µ-Slides 8 well ibiTreat sterile glasses (ibidi GmbH; München, 
Germany) in Ham´s F12 medium, containing 10 % fetal calf serum. On the day of the 
experiment confluency of the cells was 60-90 %. The culture medium was removed, 
the cells were washed twice with Leibowitz L15 culture medium (200 µL) and covered 
with L15 medium (120 µL). L15 medium (40 µL) and 5-fold concentrated fluorescent 
probe in L15 medium (40 µL) was added for total binding. For non-specific binding 
L15 medium (40 µL) with the competing agent BIIE 0246 (5-fold concentrated) and 
L15 medium (40 µL) with the fluorescent probe (5-fold concentrated) was added. 
Images of total and non-specific binding were acquired after an incubation period of 
5-50 min. 
Confocal microscopy was performed with a Zeiss Axiovert 200 M microscope, 
equipped with the LSM 510 laser scanner. The objective was a Plan-Apochromat 
63x/1.4 with oil immersion. Table 5.9 shows the most important settings for the 
detection of the investigated fluorescent ligands. 
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Table  5.9. Conditions for the detection of the fluorescent ligands 5.2, 5.4, 5.15-5.17, 
5.20, 5.22-5.26, 5.28 and 5.29 with the Zeiss Axiovert 200 M microscope. 
No Excitation (laser transmission) Filter Pinhole / µm 
5.2 514 nm (10 %) LP 560 78 
5.4 488 nm (10 %) LP 560 276 
5.15 633 nm (10 %) LP 650 276 
5.16 633 nm (10 %) LP 650 276 
5.17 633 nm (10 %) LP 650 276 
5.20 633 nm (10 %) LP 650 276 
5.22 633 nm (10 %) LP 650 94 
5.23 633 nm (10 %) LP 650 276 
5.24 633 nm (10 %) LP 650 288 
5.25 633 nm (10 %) LP 650 276 
5.26 633 nm (10 %) LP 650 276 
5.28 488 nm (10 %) LP 650 276 
5.29 633 nm (10 %) LP 650 276 
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Chapter 6 [3H]-UR-PLN196: A Highly Potent 
and Selective Tritiated Neuropeptide Y Y2 
Receptor Antagonist 
6.1 Introduction 
Radioligands are frequently used as pharmacological tools to characterize new 
compounds with respect to their binding properties and their pharmacological 
profile. Such radioligands should be characterized by high purity (> 90 %), sufficient 
stability and high specific activity (> 10 Ci/mmol) in terms of chemical properties, as 
well as subtype selectivity, fast kinetics and appropriate mode of action (antagonism) 
with respect to the pharmacological profile. Concerning the Y2R, the commonly 
applied standard ligands like [3H]-NPY,1-2 [125I]-PYY3 or [125I]-PYY(3-36)4-5 are not 
considered suitable for labeling, especially due to lacking selectivity. For instance, in 
autoradiography utilizing [125I]-PYY(3-36), discrimination between BIIE 0246-sensitive 
and BIIE 0246-insensitive binding sites is required due to strong binding of the 
radioligand to the Y5R sites (BIIE 0246-insensitive sites).6 Hence, novel non-peptidic 
highly selective radiolabeled antagonists are required as pharmacological tools for 
more detailed investigations of the Y2 receptor subtype. 
Therefore, we prepared a series of derivatives of the highly potent and selective 
argininamide-type Y2R antagonist BIIE 0246.7 Previously, the parent compound was 
found to tolerate electron-withdrawing substituents attached to the guanidine group 
(NG), including moieties comprising a terminal amino group (Nω), in terms of Y2R 
binding regardless of the lowered basicity by 4-5 orders of magnitude.8 These findings 
prompted us to synthesize a small library of potential radioligands (“cold” versions) 
by propionylation of the terminal amino moiety, whereof an appropriate candidate 
was chosen for the development of a tritiated selective Y2R antagonist (Table 6.1). 
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Table  6.1. Structures and Y2R affinities of BIIE 0246, selected Nω-substituted 
potential radioligands and the NG-propionylated analog 3.86. 
compound R n Ki / nMa 
BIIE 0246 H -- 10.2 
(S)-3.63 2 9.9b 
(S)-3.64 3 37b 
(S)-3.65 -- 9.9 
(S)-3.68 3 32 
(S)-3.69 4 55 
(S)-3.71 -- 9.0b 
(S)-3.72 -- 15 
3.86 
 
-- 5.2 
a Displacement of Cy5-pNPY in a flow cytometric competition binding assay on CHO-hY2R 
cells. b Displacement of Dy-635-pNPY in a flow cytometric competition binding assay on 
CHO-hY2R cells. (mean values, n = 2-4) 
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6.2 Chemistry 
The majority of the highly selective potential radioligands exhibit lower Y2R binding 
affinities than the parent compound BIIE 0246 (cf. Table 6.1 for a selection of poten-
tial [3H]-radioligands; cf. Table 3.2 and Table 3.4 for binding constants and selectivity). 
Especially the carbamoyl-substituted analogs lose affinity compared to the corre-
sponding amine precursors. However, several derivatives turned out to be highly 
potent Y2R antagonists with affinities in the one-digit nM-range ((S)-3.63, (S)-3.65, (S)-
3.71, 3.86). Direct propionylation in NG-position yielded 3.86, the derivative with the 
highest Y2R antagonistic activity. 
 
Scheme  6.1. Preparation of the tritiated Y2 receptor antagonist 6.1. Reagents and conditions: a) (S)-3.48 (40 eq), 
succinimidyl [3H]-propionate (1 eq), NEt3 (80 eq), CH3CN, 20 h, rt. 
 
Figure  6.1. HPLC analysis of identity, purity and long-term stability (13 months) of [3H]-UR-PLN196 (6.1). a) 
Radiochromatogram of the synthesized radioligand 6.1 (purity control). b) UV chromatogram of unlabeled ligand 
(S)-3.63 (identity control). c) Long-term stability control of 6.1 with radiometric detection. Eluent: mixtures of 
CH3CN + 0.05 % TFA (A) and 0.05 % aq. TFA (B), gradient: 0 to 20 min: A/B 30/70 to 60/40, 20 to 22 min: 60/40 
to 95/5, 22 to 25 min: 95/5, columns: Agilent C18, 5 µm (chromatograms a) and b)), Synergi C-18, 5 µm 
(chromatogram c)). The minor difference in retention times (tR) of a) and b) results from the setup of the UV and 
the radiodetector in series. The identity of 6.1 was confirmed by spiking with the “cold” analog (S)-3.63. 
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Considering Y2R affinity, synthetic pathway, overall yield and supposed long-term 
stability, the amine precursor (S)-3.48 was considered the most attractive candidate 
for labeling. The Nω-[2,3-3H]-propionyl-substituted argininamide 6.1 ([3H]-UR-
PLN196), the “hot” form of (S)-3.63, was prepared by acylation with the commercially 
available tritiated succinimidyl propionate (Scheme 6.1). After purification by HPLC, 
the designated radioligand 6.1 was obtained in a radiochemical purity of 90 % 
(Figure 6.1a; for comparison: (S)-3.63 is obtained in 95 % chemical purity (Figure 
6.1b)) with a specific activity of 73 Ci · mmol–1. The identity of the radioligand was 
confirmed by HPLC analysis of labeled (6.1) and unlabeled UR-PLN196 ((S)-3.63), 
which have identical retention times (Figure 6.1a, b). Moreover, long-term stability in 
ethanol containing 100 µM TFA at –20 °C was proven over a period of 13 months 
(Figure 6.1c). 
6.3 Pharmacological Results and Discussion 
6.3.1 Saturation Binding 
In the first binding experiments no saturation of the Y2R with the newly developed 
radioligand 6.1 was observed, despite a binding affinity of the cold analog (S)-3.63 in 
the one-digit nM range determined in flow cytometric competition binding experi-
ments with various fluorescent ligands (cf. Figure 6.7b). Thus, the potential ad-
sorption of the compound to different reaction vessels and in various solvents was 
investigated, as a high tendency towards the adsorption to plastics was already 
observed in case of BIIE 0246 in a previous work.9 The results are presented in 
Figure 6.2. 
Figure  6.2. Fraction of total activity recovered after 
solution of 6.1 (c = 17 nM) in different solvents (water, 
binding buffer without BSA (–) and binding buffer with 
1 % BSA (+)) to variously treated reaction vessels 
(cups). Siliconized cups were obtained by coating with 
SigmacoteTM (Sigma-Aldrich, Germany). 100 % activity 
was calculated by means of the activity concentration 
aV of the radioligand stock solution (aV = 9.25 MBq · 
mL–1; V (6.1) = 2 µL). 
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BD PrimariaTM 24-well plates (Beckton Dickinson GmbH, Germany) were used to 
perform radioligand binding assays. 
Saturation experiments with 6.1 at CHO-hY2R cells afforded a KD value of 65 nM, 
which is higher than expected from previous flow cytometric binding assays (Ki = 
9.9 nM, cf. Table 6.1, cf. Figure 6.7b). Presumably, this discrepancy results from 
adsorption of small amounts of the radioligand to the surface-modified plates. 
Furthermore, the radioligand 6.1 might occupy a second low-affinity binding site. This 
is rather speculative and more data points with a higher number of repetitions within 
high concentrations would be necessary in order to detect a second binding site. 
Unfortunately, the performance of such additional assays was impossible due to the 
limited amounts of available hot ligand. Scatchard analysis revealed linearity, which is 
consistent with mass action behavior at a single site (Figure 6.3b).10 Moreover, the 
radioligand showed a high specific binding throughout proving the applicability as a 
selective radioligand in binding studies on the Y2R (Figure 6.3a). Besides the equili-
brium dissociation constant KD, saturation analysis with 6.1 revealed a maximum 
number of binding sites (Bmax) of about 175,000 sites per cell. 
Figure  6.3. a) Representative saturation binding curve of 6.1 at CHO-hY2R cells; b) Representative scatchard plot 
for the binding of 6.1 at CHO-hY2R cells, best fitted by linear regression, KD = –1/slope = 87 nM. (mean values ± 
SEM, n = 4, performed in triplicate) 
6.3.2 Association and Dissociation Kinetics 
The results from kinetic studies of 6.1 are presented in Figure 6.4. The novel Y2R 
selective radioligand exhibits rather low on- and off-rates, which was also observed 
for fluorescence-labeled Y2R antagonists (cf. Chapter 5). Association was mostly com-
pleted after 30 minutes (Figure 6.4a). Pseudo-irreversible binding was observed as a 
consequence of slow dissociation kinetics (≈ 20 % specifically bound radioligand after 
90 minutes; Figure 6.4b). There are several examples of pseudo-irreversible binding, 
originating from slow dissociation even for lower molecular weight GPCR radio-
ligands, inter alia the Histamine H2 receptor agonist [3H]-UR-DE25711, or the NPY Y5 
receptor (Y5R) selective antagonist [35S]SCH 50094612. 
0 25 50 75 100 125 150
0
3000
6000
9000
12000 specific binding
non-specific binding
a)
Radioligand Concentration / nM
Bo
un
d 
/ d
pm
0 50 100 150 200 250 300
0.001
0.002
0.003
0.004 b)
Specifically Bound / pM
Sp
ec
ifi
ca
lly
 B
ou
nd
 / 
Fr
ee
180 Chapter 6 
However, the equilibrium dissociation constant of 6.1, calculated from the 
linearization of the kinetics (KD = koff/kon = 43 nM; Figure 6.4c and d), was in good 
agreement with the KD value derived from saturation binding experiments (KD = 
65 nM) proving that the radioligand 6.1 follows the law of mass action.10 
Figure  6.4. Association and dissociation kinetics of the specific Y2R binding of 6.1 at CHO-hY2R cells. a) Radio-
ligand (c = 75 nM) association as a function of time; b) Radioligand (pre-incubation = 75 nM, 30 min) dissociation 
as a function of time, monophasic exponential decay, t1/2 = 9.3 min, dissociation performed with 100-fold excess 
of BIIE 0246; c) Linearization ln[Beq/(Beq-B)] versus time of the association kinetic for the determination of kob and 
kon, slope = kob = 0.082 min–1, kon = (kob - koff)/[L] = 6.92 · 10–4 min–1 · nM–1; d) Linearization ln(B/B0) versus time of 
the dissociation kinetic for the determination of koff = slope · (–1) = 0.030 min–1. (mean values ± SEM, n = 3) 
 
Figure  6.5. Radioligand dissociation kinetics of 6.1 on CHO-hY2R cells. a) Dissociation in the presence of 100-
fold excess of the endogenous agonist pNPY. b) Dissociation in the presence of 400-fold excess of the Y2R 
antagonistic small molecule SF-1113. (mean values ± SEM, n = 3) 
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Dissociation experiments were also performed in the presence of pNPY or the low 
molecular weight Y2R antagonist SF-1113 instead of BIIE 0246, the parent compound 
of 6.1. Displacement with structurally distinct compounds should give insights into 
the binding behavior of the novel radioligand. As already observed for the novel 
fluorescent ligands no dissociation of the argininamide-type 3H-labeled antagonist 
was observed with pNPY (Figure 6.5a), whereas the dissociation induced by the non-
peptide antagonist SF-11 was the same as in the presence of BIIE 0246 (Figure 6.5b). 
Hence, 6.1 is displaceable by non-peptide antagonists such as SF-11 or BIIE 0246, but 
not by the peptide pNPY. 
6.3.3 Y2R Antagonism of 6.1: Ca2+ Assay, Schild Analysis and 
Displacement with pNPY 
The interpretation of agonist concentration-response curves (CRCs) in the presence 
of an antagonist is indispensable for the elucidation of the antagonist´s binding 
mode. As defined by Vauquelin et al. insurmountable antagonism refers to 
experiments in which the cells are pre-incubated with the antagonist before the 
addition of the agonist and the measurement of the response. Yet, non-competitive 
antagonism can only be positively identified by co-incubation experiments.14 Thus, 
the Y2R antagonism of (S)-3.63 was investigated in a fura-2 based Ca2+ assay on CHO-
hY2R cells for co-application and after pre-incubation for 20 minutes, respectively 
(Figure 6.6a and b). CRCs were constructed in the absence and presence of the 
antagonist at different concentrations and the data were subjected to Schild 
analysis15 (Figure 6.6c). 
On the one hand, co-application with increasing concentrations of the “cold” ligand 
(S)-3.63 led to a parallel rightward shift of the CRCs of pNPY indicating competitive 
antagonism as already observed for BIIE 0246 in similar assays16-17. Unfortunately, 
pNPY concentrations >3 µM result in a depression of the Ca2+-response. Hence, the 
maximal effect was not detectable for CRCs generated in the presence of high 
antagonist concentrations (Figure 6.6a). On the other hand, pretreatment of the cells 
with (S)-3.63 for 20 minutes reduced the maximal agonist response strongly in a 
concentration-dependent manner with comparatively low effects on the EC50 values 
of pNPY (Figure 6.6b). The strong depression of the maxima after pre-incubation 
indicates an insurmountable antagonism against pNPY.14, 17 Schild regression, 
constructed with the CRCs for co-application with (S)-3.63 (Figure 6.5a), yielded a 
linear plot with a slope steeper but not significantly different from unity (Figure 6.5c). 
The pA2 value reflects the affinity of the antagonist and the resulting A2 value (43 nM) 
equals the KD value determined from the study of binding kinetics. 
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Figure  6.6. Concentration-response curves (CRCs) of pNPY obtained from a fura-2 assay on CHO-hY2R cells 
and Schild analysis. The presence of (S)-3.63 (cold form of 6.1) led to a rightward shift of the curves. a) Co-
incubation with different concentrations of antagonist (S)-3.63. b) Pretreatment with different concentrations of 
antagonist (S)-3.63 for 20 minutes. c) Schild regression: log(r–1) plotted against log antagonist concentration; 
the concentration ratios r (r = 10∆pEC50) were calculated from the rightward shifts (∆pEC50) of the CRCs when co-
incubated with (S)-3.63 as shown in Figure 6.6a. pA2 = 7.37; A2 = 43 nM. (mean values ± SEM, n = 3-8) 
Recently, a Y5R selective radioligand with similar properties in kinetic and functional 
experiments was reported as an insurmountable pseudo-irreversible non-peptide 
antagonist.12 There are several possible explanations for an apparently 
insurmountable pseudo-irreversible binding. A slow rate of receptor dissociation18, a 
slow rate of interconversion from an inactive to an active receptor conformation19-20 
and a stabilization of an inactive ligand (antagonist) specific receptor conformation21, 
respectively, or binding to a site distinct from the peptide agonist binding site22. 
Interestingly, pNPY displaced the radioligand 6.1 in competition binding only at very 
high concentrations (Figure 6.7a; Ki = 406 ± 113 nM), whereas in binding experiments 
with [3H]-pNPY the endogenous peptide showed a very high affinity with a 1000-fold 
lower dissociation constant (Ki = 0.4 ± 0.1 nM)23. Additionally, pNPY was not able to 
fully displace 6.1 in dissociation experiments (Figure 6.5a). These data suggest that 
BIIE 0246 derived antagonists bind to a different site on the Y2R than the endogenous 
peptide NPY, or at least, the binding sites overlap only partially. Apparently, 
argininamide-type Y2R antagonists are characterized by two features: firstly, slow 
dissociation from the receptor and secondly, occupation of a distinct binding site and 
– possibly – the stabilization of a ligand-specific conformation. 
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Figure  6.7. a) Displacement of the tritiated Y2R antagonist 6.1 (c = 75 nM) by the agonist pNPY. b) Flow 
cytometric competition binding assay. Displacement of Dy-635-pNPY (c = 5 nM) by the “cold” radioligand (S)-
3.63. The assays were performed on CHO cells stably expressing the Y2R with an incubation period of 120 min. 
(mean values ± SEM, n = 3) 
 
Table  6.2. Y2R binding and functional characteristics of (S)-3.63/6.1. 
koff / min–1 a kon / min–1 · nM–1 b koff/kon / nMc KD / nMd A2 / nMe
0.030 0.000692 43 65 43 
a Dissociation rate constant from linear regression. b Association rate constant from linear regression. c Kinetically derived 
dissociation constant. d Equilibrium dissociation constant determined in saturation binding experiments. e Antagonist 
dissociation constant of (S)-3.63 derived from Schild analysis. 
6.3.4 Competition Binding Experiments: Application as Standard Ligand 
Although being insurmountable against pNPY, the radioligand 6.1 was successfully 
applied as standard ligand in competition binding studies of non-peptide Y2R 
antagonists as shown in Figure 6.8. As the receptor was not completely saturable, the 
KD value received from binding kinetics was applied for the calculation of Ki values by 
means of the Cheng-Prusoff equation24. The Ki value of BIIE 0246 (Ki = 13 nM) is 
consistent with reported data from competition binding using radio-labeled agonists 
(Ki = 24 nM9 and 36 nM16, resp.). Furthermore, the dissociation constants of the other 
investigated compounds are in good agreement with data from flow cytometry 
(Table 6.3). However, structurally diverse and selective Y2R antagonists as reference 
compounds would be necessary for the verification of these results. In agreement 
with theory, the Ki value of (S)-3.63 from competition binding experiments with the 
labeled analog 6.1 corresponds, within the error range of the methods, to the KD 
value of compound 6.1: 36 nM for (S)-3.63 and 43 nM for 6.1. 
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Figure  6.8. Displacement of the [3H]-labeled 
radioligand 6.1 (c = 75 nM, KD = 43 nM) by arginin-
amide-type Y2R antagonists BIIE 0246, (S)-3.53, 
(S)-3.63 (cold form of 6.1), fluorescent Y2R antagonists 
5.4 and 5.16 and the low molecular weight Y2R selec-
tive antagonist SF-11. The assay was performed on 
CHO cells stably expressing the Y2R with an incuba-
tion period of 30 min. (mean values ± SEM, n = 2-3) 
 
Table  6.3. Ki values from radioligand competition binding experiments using 6.1 as radio-
ligand compared to data from flow cytometric competition binding assays with Cy5-pNPY 
and 5.4, respectively. 
Compd. 
Radioligand binding, Ki / nM 
displacement of 
Flow cytometry, Ki / nM 
displacement of 
6.1a Cy5-pNPYb 5.4c 
BIIE 0246 13 ± 1 10 ± 1 22 ± 6 
(S)-3.50 28 ± 5 16 ± 3 -- 
(S)-3.53 12 ± 2 2.1 ± 0.3 -- 
(S)-3.63 36 ± 14 9.9 ± 1.1d 77 ± 3 
3.86 33 ± 7 5.2 ± 1.8 -- 
5.4 57 ± 4 23 ± 4 -- 
5.16 482 ± 19 -- 982 ± 207 
SF-11 2118 ± 975 1251 ± 348 4915 ± 836 
a KD = 43 nM (kinetics), c = 75 nM. 
b KD = 5.2 nM (Fl-4), c = 5 nM. 
c KD = 25 nM (Fl-2), c = 40 nM. 
d Determined with Dy-635-pNPY. (mean values ± SEM, n = 2-5). All experiments performed at 
CHO-hY2R cells. 
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6.4 Summary and Conclusion 
The guanidine-acylguanidine bioisosteric approach was applied to the preparation of 
a tritiated Y2R selective radioligand starting from the highly potent argininamide-type 
Y2R antagonist BIIE 0246. Acyl and carbamoyl moieties, bearing a terminal primary 
amino group for radiolabeling, were attached at NG of the guanidine function in 
BIIE 0246 and optimized with respect to length and chemical nature of the linker. 
Therefore, the “cold” versions of the corresponding propionamides were investigated 
in a flow cytometric Y2R binding assay at CHO cells expressing the hY2R to select the 
most suitable candidate for radiolabeling. A one step synthesis afforded the desired 
radioligand 6.1 by acylation of the amine precursor, the NG-[5-(2-aminoethylamino)-
5-oxopentanoyl]-substituted BIIE 0246 ((S)-3.48), with succinimidyl [2,3-3H]-
propionate (specific activity: 73 Ci · mmol–1). 
The non-peptidic radioligand [3H]-UR-PLN196 is superior to Y2R-addressing radio-
labeled peptides due to selectivity, resistance against enzymatic cleavage, long-term 
stability, mode of action (antagonist vs. agonist) and costs of preparation. [3H]-UR-
PLN196 can be used for the detection and quantification of Y2R binding sites. Detailed 
investigations in binding experiments (with 6.1) and functional assays (with (S)-3.63) 
identified the novel radioligand as an insurmountable antagonist versus pNPY 
exhibiting pseudo-irreversible binding at the Y2R. Moreover, the tritiated compound 
was successfully applied as standard ligand in competition binding experiments with 
several Y2R antagonists. 
In conclusion, the prepared radioligand 6.1 proved to be a valuable pharmacological 
tool for the detection of the Y2R in vitro and for the investigation of the antagonistic 
binding mode, respectively, as well as for the characterization of non-peptidic Y2 
receptor antagonists. 
6.5 Experimental Section 
6.5.1 General Experimental Conditions 
Chemicals and solvents were purchased from commercial suppliers and used without 
further purification. Porcine NPY (pNPY) was kindly provided by the Institute of 
Organic Chemistry I at the Ruhr-University Bochum (Prof. Dr. C. Cabrele). SF-11 was 
purchased from Tocris Bioscience (Bristol, United Kingdom). All solvents were of 
analytical grade or distilled prior to use. 
Analytical HPLC analysis and purification, respectively, were performed on a Waters 
system (two pumps 510, pump control module, 486 UV detector, Packard Radiomatic 
Flow-1 beta Series A-500 detector, flow rate of liquid scintillator (RotiszintTM eco plus, 
Carl Roth GmbH & Co. KG, Karlsruhe, Germany): 4 mL/min). In general, an Agilent 
Scalar C18 column (250 × 4.6 mm, 5 µm) was used. Long-term stability control was 
performed on a Synergi C-18 column (250 × 4.6 mm, 5 µm). 
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6.5.2 Synthesis, Purification and Quantification of [3H]-UR-PLN196 (6.1) 
Succinimidyl [2,3-3H]-propionate was purchased from Hartmann Analytic GmbH 
(Braunschweig, Germany) and provided in hexane/ethyl acetate 9:1 (v/v) (specific 
activity as = 3.07 TBq mmol–1 = 83 Ci mmol–1; 185 MBq/2.5 mL). 
 
(2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-oxo-2-[4-
(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)-
acetyl]-Nω-[4-(2-[2,3-3H]propanoylaminoethyl)aminocarbonylbutanoyl]arginin-
amide (6.1). Compound (S)-3.48 (1.23 mg, 0.964 µmol) was dissolved in anhydrous 
CH3CN (140 µL) yielding a concentration of 6.9 mM, and NEt3 was diluted in CH3CN to 
a concentration of 2.7 µL NEt3/100 µL. Compound (S)-3.48 (6.9 mM in CH3CN, 50 µL, 
0.344 µmol) and NEt3 (10 µL of the above described solution in CH3CN, 1.928 µmol) 
were added to succinimidyl [2,3-3H]-propionate (4.22 µg, 0.0241 µmol) in 1 mL 
hexane/ethyl acetate 9:1 (v/v) in a 1.5 mL Eppendorf reaction vessel (screw top). The 
solvent was removed in a vacuum concentrator (40 °C) over a period of 20 min and 
(S)-3.48 (6.9 mM in CH3CN, 90 µL, 0.620 µmol) was added. Again, the solvent was 
removed in a vacuum concentrator (40 °C) over a period of 40 min. After addition of 
100 µL of CH3CN the reaction mixture was vigorously blended (vortexer) for 1 min, 
briefly centrifuged and stirred with a magnetic micro stirrer at rt overnight. 
For HPLC analysis 0.5 µL of the reaction mixture (reaction control) were diluted 
(1:200) with 97.5 µL of CH3CN/0.05 % aq. TFA (30/70) and spiked with 2 µL of “cold” 
radioligand (S)-3.63 (1 mM in CH3CN) to a total volume of 100 µL. This solution was 
completely injected into the HPLC system and analyzed by means of UV- and 
radiometric detection (Figure 6.9b). Eluent: CH3CN + 0.05 % aq. TFA (A) and 0.05 % 
aq. TFA (B), gradient: 0 to 25 min: A/B 30/70 to 55/45, 25 to 27 min: 55/45 to 95/5, 
27 to 35 min: 95/5. Afterwards, the reaction was stopped with 10 % aq. TFA (2.9 µL, 
corresponds to ≈ 160 eq of TFA) and the reaction mixture was purified with analytical 
HPLC (Figure 6.9a). Therefore, the reaction mixture was diluted with 0.1 % aq. TFA 
(350 µL) and the product was isolated (3 injections) using the conditions specified for 
the reaction control. For this purpose radiometric detection was not performed. The 
product was eluted at 18.8 to 19.3 min and collected in a 1.5 mL Eppendorf reaction 
vessel (screw top), which was put into the vacuum concentrator between the 
injections. The combined product fractions were evaporated to dryness in a vacuum 
concentrator, the residue was dissolved in 300 µL of ethanol containing TFA (100 µM) 
and transferred to a clean 3 mL Amersham glass vial together with the washings (2 × 
100 µL). 
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Figure  6.9. a) Analytical HPLC run for the isolation of radioligand 6.1; detection: UV (220 nm). b) HPLC analysis 
of the reaction mixture containing the non-purified radioligand 6.1; radiometric detection, tR = 19.30 min. 
Quantification: A five point calibration was performed with (S)-3.63 (0.25, 0.5, 1.0, 1.5 
and 3.0 µM, injection volume: 100 µL; Figure 6.10). Eluent: CH3CN + 0.05 % aq. TFA 
(A) and 0.05 % aq. TFA (B), gradient: 0 to 20 min: A/B 30/70 to 60/40, 20 to 20 min: 
60/40 to 95/5, 22 to 30 min: 95/5 (retention time: 15.72 min). The solutions for 
injection were prepared in CH3CN/0.05 % aq. TFA (20/80) less than 5 minutes prior to 
the injection. All standard solutions were prepared from a 40 µM solution of (S)-3.63 
(in CH3CN/0.05 % aq. TFA 20/80), which was freshly made from a 1 mM stock solution 
of (S)-3.63 in CH3CN. Two aliquots (2.0 µL) of the ethanolic solution (total volume: 
500 µL) of the product were diluted with 100 µL of CH3CN/0.05 % aq. TFA (20/80), 
and 100 µL were analyzed by HPLC. Whereas one sample was only used for 
quantification of the product by UV detection the second sample was additionally 
monitored radiometrically to determine radiochemical purity (Figure 6.1a and b). The 
molarity of the ethanolic solution of 6.1 was calculated from the mean of the peak 
areas and the linear calibration curve obtained from the peak areas of the standards. 
Yield: 9.1 µg (7.41 nmol, 31 %). 
Determination of the specific activity: 1.5 µL of the ethanolic solution were diluted 
with 448.5 µL of a mixture of CH3CN and water (50/50) in duplicate, and 9 µL of the 
1:300 dilutions were counted in RotiszintTM eco plus (3 mL). Calculated specific 
activity (as): 2.71 TBq · mmol–1 (73.3 Ci · mmol–1). The activity concentration (av) was 
adjusted to 9.25 MBq · mL–1 (0.25 mCi · mL–1) by addition of ethanol (1685 µL) 
containing TFA (100 µM) to the residual solution yielding a molarity of 3.42 µM. The 
radioligand 6.1 was stored at –20 °C. 
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Figure  6.10. Calibration line for the quantification of the 
molarity of the ethanolic solution of 6.1. Five point 
calibration was performed with (S)-3.63 (unlabeled 
analog of 6.1). Peak areas calculated from UV detection. 
Straight line equation: y = 430.963 AU · s · µM–1 · x – 
8.159 AU · s. Goodness of fit r2 = 0.9985. 
 
6.5.3 Pharmacology: Experimental Protocols 
General. The buffer for the Y2R binding studies of 6.1 was prepared by the addition of 
1 % BSA to a buffer (pH 7.4) consisting of HEPES (25 mM), CaCl2 × 2 H2O (2.5 mM) and 
MgCl2 × 6 H2O (1 mM). Bacitracin (100 µg/mL) was added for binding studies with 
pNPY. This HEPES buffer without the additives was used to wash the cells previous to 
and after radioligand binding. The loading buffer (pH 7.4) for the determination of 
intracellular Ca2+ mobilization in CHO cells was prepared by dissolving NaCl (120 mM), 
KCl (5 mM), MgCl2 × 6 H2O (2 mM), CaCl2 × 2 H2O (1.5 mM), HEPES (25 mM) and 
glucose (10 mM). The lysis solution for the radioligand binding assays consisted of 
urea (8 M), acetic acid (3 M), and Triton-X-100 (1 %) in water. Stock solutions of all 
compounds were prepared in DMSO (2 or 10 mM) and stored at –20 °C. Tritium 
counting was done in 3 mL of RotiszintTM eco plus with a Beckman LS 6500 beta-
counter. 
 
Cell culture. CHO cells were cultured as described elsewhere.23 
 
Radioligand binding assay. The radioligand binding assay was performed as 
essentially described.23 Cells were seeded in 24-well plates 2-3 days prior to the 
experiment. On the day of the experiment confluency of the cells was at least 70 %. 
The culture medium was removed by suction, the cells were washed with once with 
buffer (500 µL), and covered with binding buffer (200 µL). Binding buffer (25 µL) and 
binding buffer (25 µL) with 6.1 (10-fold concentrated) was added for total binding. 
For non-specific binding and displacement of 6.1 binding buffer (25 µL) with the 
competing agent (10-fold concentrated) and binding buffer (25 µL) with 6.1 (10-fold 
concentrated) was added. During incubation at room temperature the plates were 
gently shaken. After incubation (saturation experiments and competition with 
BIIE 0246, SF-11, (S)-3.50, (S)-3.53, (S)-3.63, 3.86, 5.4, 5.16: 30 min; competition with 
pNPY: 2 h) the binding buffer was removed, the cells were washed twice with buffer 
(500 µL, 4 °C, ≈ 30 s), covered with lysis solution (200 µL) and the plates were gently 
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shaken for at least 30 min. The lysates were transferred into scintillation vials filled 
with scintillator (3 mL) and the dishes were washed once with lysis solution (100 µL). 
In case of the investigation of dissociation kinetics the cells were incubated with 
binding buffer (250 µL) containing the competing agent (BIIE 0246, SF-11: 100-fold 
higher concentrated than the previously used radioligand; pNPY: 400-fold higher 
concentrated than the previously used radioligand) after incubation with radioligand 
6.1 (75 nM) and subsequent washing (twice 500 µL, 4 °C). After different periods of 
time the cells were washed again twice with buffer (500 µL, 4 °C) followed by the 
addition of lysis solution. For association kinetics cells were incubated with 6.1 
(75 nM) in binding buffer (250 µL). The supernatant was sucked off after different 
periods of time and the adherent cells were washed twice with cold buffer (500 µL, 4 
°C) before lysis solution was added. The non-specific binding was determined with 
BIIE 0246 (100 fold higher concentrated than the previously used radioligand) in 
kinetics. Assays were performed in triplicate. 
 
Fura-2 assay on CHO-cells (Schild analysis). The fura-2 assay was performed as 
previously described25 using a LS50 B spectrofluorimeter from Perkin Elmer 
(Überlingen, Germany). 
Concentration-response curves of pNPY were constructed in the presence of (S)-3.63 
at different concentrations. The signal intensities were related to the maximal 
intensity obtained from a pNPY effect curve in the absence of (S)-3.63. For Schild 
analysis, log10 (r-1) was plotted against log10 c (antagonist) with r = 10ΔpEC50. 
ΔpEC50: rightward shift of the concentration-response curves in the presence of 
different concentrations of antagonist. 
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Chapter 7 Summary 
Neuropeptide Y (NPY), a 36 amino acid peptide, is widely distributed in the central 
and peripheral nervous system, where it acts as a neurotransmitter and exhibits a 
large number of physiological functions, including the regulation of blood pressure, 
control of food intake, anxiety, pain and hormone secretion. In humans, these effects 
are mediated by four receptor subtypes (Y1, Y2, Y4, Y5), all belonging to class A of the 
superfamily of G-protein coupled receptors (GPCRs). The Y2R is expressed, e. g., in 
sympathetic nerve endings, in the renal tubules and in distinct brain regions such as 
the hippocampus and the hypothalamus. It is discussed to be involved in several 
human diseases, for instance, epilepsy, obesity and cancer, and therefore regarded as 
an attractive target in drug design. However, antagonistic pharmacological tools for 
the elucidation of the receptor´s function in health and disease are still missing. 
 
In 1999, the (S)-argininamide BIIE 0246, a C-terminal mimic of NPY, was reported the 
first highly potent and selective Y2R antagonist. NG-Acylation of BIIE 0246 was 
demonstrated to retain or even increase the Y2R affinity, thereby improving the 
pharmacokinetic properties. Thus, we prepared Nω-aminoacylated analogs as 
precursors towards radio- and fluorescence labeled as well as bivalent pharmacologi-
cal tools according to the guanidine-acylguanidine bioisosteric approach. Such 
derivatives, bearing a free amino group, exhibited the highest Y2R affinities (Ki < 
10 nM). Interestingly, masking the positive charge, e.g. by acylation, resulted in 
decreased affinities, presumably, due to the loss of an additional electrostatic 
interaction of the primary amine with the receptor. 
 
Bivalent ligands were synthesized starting from various amine precursors derived 
from BIIE 0246 by acylation with different aliphatic dicarboxylic acids. Only minor 
differences in affinities (Ki = 61-300 nM) were observed for the majority of the 
compounds, irrespective of the diversity in length and chemical nature of the spacer. 
However, bivalent ligand 4.6, constructed from an amine precursor bearing an 
additional amino group in the linker, showed a binding affinity (Ki = 21 nM) and 
antagonistic activity (KB = 15 nM) in the same range as the monovalent antagonists, 
corroborating the affinity-enhancing effect of a positive charge in the linker. 
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Fluorescence ligands were synthesized from the amine precursors by acylation with 
succinimidyl esters or by ring transformation of pyrylium dyes. In terms of retaining 
affinity, the pyrylium dyes were superior to the bulky cyanine, hemicyanine and 
Bodipy dyes. Whereas the majority of the cyanine and hemicyanine labeled 
fluorescent ligands proved to be suitable for the detection of Y2Rs at the cell 
membrane by confocal microscopy, rapid cellular uptake was observed for most of 
the Py-1 and Py-5 coupled antagonists. Based on the results from binding studies and 
confocal microscopy, four fluorescent Y2R antagonists (5.4, 5.15-5.17) were chosen 
for flow cytometric binding studies. These compounds turned out to be applicable as 
labeled standard ligands in saturation and competition binding experiments. 
Interestingly, kinetic studies revealed a pseudo-irreversible binding of 5.16 at the Y2R. 
The endogenous ligand NPY was not able to displace the novel red-fluorescent Y2R 
antagonists 5.4 and 5.16 even at very high concentrations. 
 
Acylation of the amine precursor (S)-3.48 with succinimidyl [2,3-3H]-propionate 
afforded the easily accessible, highly potent and selective tritiated Y2R antagonist 
[3H]-UR-PLN196 (A2: 43 nM, Ca2+ assay; KD: 43 nM, determined by kinetic studies), 
which was shown to be useful for the quantification of Y2R binding sites and for the 
radiochemical determination of Y2R binding affinities of small molecules. In addition, 
the novel radioligand was identified as an insurmountable antagonist against pNPY 
exhibiting pseudo-irreversible binding at the Y2R similar to the fluorescent labeled 
antagonist 5.16. 
 
 
In conclusion, this work presents a straight-forward synthetic route towards labeled 
argininamide-type Y2R antagonists related to BIIE 0246 with improved physico-
chemical properties. These compounds are useful pharmacological tools for the 
detection of the Y2R in vitro and for detailed investigations of the antagonistic binding 
mode, respectively, as well as for the identification and characterization of small 
molecule Y2R antagonists. Moreover, these tracers are suitable to replace labeled 
NPY standard ligands in binding assays due to their beneficial properties in terms of 
Y2 receptor subtype selectivity, antagonistic mode of action, stability and kinetics. 
 
Chapter 8 Appendix 
8.1 Abbreviations 
aq. aqueous 
Ar aryl 
as specific activity 
av activity concentration
BBB blood brain barrier
Bmax maximum number of binding sites
BIIE 0246 (2S)-N-[2-(3,5-Dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-Nα-[2-(1-{2-
oxo-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazine-1-
yl]ethyl}cyclopentyl)acetyl]argininamide
Bn benzyl 
Boc tert-butoxycarbonyl
Bq becquerel 
br broad singulet 
BSA bovine serum albumin
tBu tert-butyl 
Bz benzoyl 
c concentration 
[Ca2+]i intracellular calcium ion concentration
Cbz benzyloxycarbonyl
CD circular dichroism
CHO chinese hamster ovary
Ci curie
CI chemical ionization
CLSM confocal laser scanning microscopy
CNS central nervous system
COSY correlated spectroscopy
CRC concentration-response curve
d doublet 
δ chemical shift 
DCC N,N´-dicyclohexylcarbodiimide
DCU N,N´-dicyclohexylurea
DIPEA N,N´-diisopropyl-ethylamine
DMAP 4-(dimethylamino)pyridin
DMF dimethylformamide
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DMSO dimethylsulfoxide 
DMSO-d6 per-deuterated dimethylsulfoxide
EC50 agonist concentration which induces 50 % of maximum response 
EDC N-(3-dimethylaminopropyl)-N´-ethyldicarbodiimide
EI electron impact ionization
eq equivalent(s)
EtOH ethanol 
FAB fast atom bombardment 
FACS fluorescence activated cell sorter
FCS fetal calf serum 
Fmoc 9-fluorenylmethoxycarbonyl
FRET fluorescence-resonance energy transfer
GPCR G-protein coupled receptor
h hour(s)/human 
HEC-1B human endometrial carcinoma
HEL human erythroleukemia 
HEPES 2-(4-(2-hydroxyethyl)-1-piperazinyl)ethansulfonic acid
HMBC heteronuclear multiple bond correlation
HOBt 1-hydroxybenzotriazole 
HPLC high-pressure liquid chromatography
HR-MS high resolution mass spectrometry
HSQC heteronuclear single quantum coherence
HTS high throughput screening
IBCF isobutyl chloroformate 
IC50 antagonist concentration which suppresses 50 % of an agonist induced 
effect or displaces 50 % of a labeled ligand from the binding site 
IR infrared 
nJ coupling constant 
k retention (capacity) factor
KB dissociation constant derived from a functional assay
KD dissociation constant derived from a saturation experiment or kinetics 
Ki dissociation constant derived from a competition binding assay 
kob observed/macroscopic association rate constant
koff dissociation rate constant
kon association rate constant 
LSI-MS liquid secondary ion mass spectrometry
m multiplet 
M molar (mol/L) 
MeOH methanol 
mp melting point
MS mass spectrometry 
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MW microwave 
NHS N-hydroxysuccinimide
NMR nuclear magnetic resonance
NPY neuropeptide Y 
p quintet 
PBS phosphate buffered saline
PET positron emission tomography
Ph phenyl 
Pht phthaloyl 
ppm parts per million 
quat quartet 
QY quantum yield 
RP reversed phase 
rt room temperature
s singulet/second(s)
SAR structure-activity relationships
SEM standard error of the mean
t triplet/time 
t0 hold-up time 
tR retention time 
TBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate
TFA trifluoroacetic acid
THF tetrahydrofurane 
TM transmembrane domain
TMSI trimethylsilyl iodide
TMSOTf trimethylsilyl triflate
UV ultraviolet 
Yn NPY receptor subtypes, n = 1, 2, 4, 5, 6
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8.2 Flow Cytometric Saturation and Competition Binding Experiments 
Figure  8.1. Flow cytometric saturation binding experi-
ment with fluorescent ligand 5.15 on CHO-hY2R cells 
(mean values ± SEM, n = 2, experiments performed in 
triplicates). Non-specific binding was determined in 
the presence of BIIE 0246 (100-fold excess); 
incubation time: 30 min. 
 
Figure  8.2. Flow cytometric competition binding on CHO-hY2R cells; incubation time: 30 min; non-specific 
binding was determined with BIIE 0246 (c = 10 µM); mean values ± SEM (n = 2); measured in Fl-4. a) 
Displacement of 5.15 (c = 100 nM, KD = 143 nM). b) Displacement of 5.17 (c = 40 nM, KD = 42 nM). 
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8.3 Confocal Microscopy 
 
  
Total binding of 5.26 (c: 50 nM), 8 min Non-specific binding of 5.26 (c: 50 nM), 
11 min 
Figure  8.3. Binding of the fluorescent ligand 5.26 to Y2R expressed in the cell membrane of CHO-hY2R cells, 
visualized by confocal microscopy. Non-specific binding determined in the presence of BIIE 0246 at 100-fold 
excess. Cells were incubated with the fluorescent ligands at rt in Leibowitz L15 culture medium. All images were 
acquired with a Zeiss Axiovert 200 M microscope. 
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8.4 HPLC Stability Investigations 
Figure  8.4. HPLC analysis of the Y2R 
antagonist (S)-3.49 in buffer. BIIE 0246 
((S)-3.47) is formed by decomposition 
of the ligand. Incubation: 90 min in 
buffer, pH 7.4, 20 °C. Conditions: 
eluent: mixtures of acetonitrile (A) and 
0.05 % aq. TFA (B), gradient: 0 to 30 
min: A/B 20/80 to 95/5. 
Figure  8.5. HPLC analysis of the Y2R 
antagonist (S)-3.50 in buffer. BIIE 0246 
((S)-3.47) is formed by decomposition 
of the ligand. Incubation: 90 min in 
buffer, pH 7.4, 20 °C. Conditions: 
eluent: mixtures of acetonitrile (A) and 
0.05 % aq. TFA (B), gradient: 0 to 30 
min: A/B 20/80 to 95/5. 
Figure  8.6. HPLC analysis of the Y2R 
antagonist (S)-3.53 in buffer. BIIE 0246 
((S)-3.47) is formed by decomposition 
of the ligand. Incubation: 90 min in 
buffer, pH 7.4, 20 °C. Conditions: 
eluent: mixtures of acetonitrile (A) and 
0.05 % aq. TFA (B), gradient: 0 to 30 
min: A/B 20/80 to 95/5. 
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Figure  8.7. HPLC analysis of the Y2R 
antagonist (S)-3.55 in buffer. BIIE 0246 
((S)-3.47) is formed by decomposition 
of the ligand. Incubation: 90 min in 
buffer, pH 7.4, 20 °C. Conditions: 
eluent: mixtures of acetonitrile (A) and 
0.05 % aq. TFA (B), gradient: 0 to 30 
min: A/B 20/80 to 95/5. 
Figure  8.8. HPLC analysis of the Y2R 
antagonist (S)-3.57 in buffer. BIIE 0246 
((S)-3.47) is formed by decomposition 
of the ligand. Incubation: 90 min in 
buffer, pH 7.4, 20 °C. Conditions: 
eluent: mixtures of acetonitrile (A) and 
0.05 % aq. TFA (B), gradient: 0 to 30 
min: A/B 20/80 to 95/5. 
Figure  8.9. HPLC analysis of the Y2R 
antagonist (S)-3.58 in buffer. BIIE 0246 
((S)-3.47) is formed by decomposition 
of the ligand. Incubation: 90 min in 
buffer, pH 7.4, 20 °C. Conditions: 
eluent: mixtures of acetonitrile (A) and 
0.05 % aq. TFA (B), gradient: 0 to 30 
min: A/B 20/80 to 95/5. 
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Figure  8.10. HPLC analysis of the Y2R 
antagonist (S)-3.72 in buffer. BIIE 0246 
((S)-3.47) is formed by decomposition 
of the ligand. Incubation: 90 min in 
buffer, pH 7.4, 20 °C. Conditions: 
eluent: mixtures of acetonitrile (A) and 
0.05 % aq. TFA (B), gradient: 0 to 30 
min: A/B 20/80 to 95/5. 
Figure  8.11. HPLC analysis of the Y2R 
antagonist (S)-3.74 in buffer. BIIE 0246 
((S)-3.47) is formed by decomposition 
of the ligand. Incubation: 90 min in 
buffer, pH 7.4, 20 °C. Conditions: 
eluent: mixtures of acetonitrile (A) and 
0.05 % aq. TFA (B), gradient: 0 to 30 
min: A/B 20/80 to 95/5. 
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